

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/21, C07K 14/56, C12N 15/88, 15/24, C07K 14/54, C12N 15/85, A61K 48/00 // 9/127		A2	(11) International Publication Number: WO 99/47678
			(43) International Publication Date: 23 September 1999 (23.09.99)
(21) International Application Number: PCT/US99/05394		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 12 March 1999 (12.03.99)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 60/078,654 19 March 1998 (19.03.98) US			
(71) Applicant (for all designated States except US): GEN-EMEDICINE, INC. [US/US]; 8301 New Trials Drive, The Woodlands, TX 77381-4248 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): NORDSTROM, Jeff [US/US]; 1016 Puryear Drive, College Station, TX 77840 (US). PERICLE, Federica [IT/US]; 26001 Budde Road #2904, The Woodlands, TX 77380 (US). ROLLAND, Allain [FR/US]; 22 Drift oak Circle, The Woodlands, TX 77381 (US). RALSTON, Robert [US/US]; 6 Lake Leaf Place, The Woodlands, TX 77381 (US).			
(74) Agent: WARBURG, Richard J.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).			
(54) Title: INTERFERON ALPHA PLASMIDS AND DELIVERY SYSTEMS, AND METHODS OF MAKING AND USING THE SAME			
(57) Abstract			
<p>The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for expression of interferon alpha in a mammal, formulations for delivery that incorporate a nucleic acid construct for expression, and methods for preparing and using such constructs and formulations. In particular, this invention relates to plasmid constructs for delivery of therapeutic interferon alpha encoding nucleic acids to cells in order to modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as cytokines, preferably IL-12), as well as methods for preparing such constructs.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTIONInterferon Alpha Plasmids And Delivery Systems,
And Methods Of Making And Using The SameRelated Applications

5 This application relates to U.S. patent application Serial No. 08/949,160, filed October 10, 1997 and International patent application No. PCT/US97/18779, filed October 10, 1997, (Lyon & Lyon Docket Nos. 226/285 US and PCT, respectively), both of which are related to U.S. patent
10 application Serial No. 60/028,676, filed October 18, 1996, (Lyon & Lyon Docket No. 222/086 US), all three of which are entitled "IL-12 GENE EXPRESSION AND DELIVERY SYSTEMS AND USES" (by Nordstrom et al.).

This application is also related to U.S. patent
15 application Serial No. 08/798,974, filed February 11, 1997, (Lyon & Lyon Docket No. 224/084 US) and International patent application No. PCT/US95/17038, filed December 28, 1995, (Lyon & Lyon Docket No. 210/190 PCT), both of which are related to U.S. patent application Serial No. 08/372,213;
20 filed January 13, 1995, (Lyon & Lyon Docket No. 210/190 US), all three of which are entitled "FORMULATED NUCLEIC ACID COMPOSITIONS AND METHODS OF ADMINISTERING THE SAME FOR GENE THERAPY" (by Mumper Rolland).

Each of the above-mentioned applications are
25 incorporated herein by reference in their entirety, including any drawings.

Field Of The Invention

The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for
30 expression of interferon alpha in a mammal, formulations for delivery that incorporate a nucleic acid construct for expression, and methods for preparing and using such constructs and formulations. In particular, this invention

relates to plasmid constructs for delivery of therapeutic interferon alpha encoding nucleic acids to cells in order to modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as cytokines, preferably IL-12), as well as methods for preparing such constructs.

Background Of The Invention

The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention and is not admitted to describe or constitute prior art to the present invention.

Plasmids are an important element in genetic engineering and gene therapy. Plasmids are usually circular DNA molecules that can be introduced into bacterial cells by transformation which replicate autonomously in the cell. Plasmids typically allow for the amplification of cloned DNA. Some plasmids are present in 20 to 50 copies during cell growth, and after the arrest of protein synthesis, as many as 1000 copies per cell of a plasmid can be generated. Suzuki et al., *Genetic Analysis*, p. 404, 1989.

Current non-viral approaches to human gene therapy require that a potential therapeutic gene be cloned into plasmids. Large quantities of a bacterial host harboring the plasmid may be fermented and the plasmid DNA may be purified for subsequent use. Current human clinical trials using plasmids utilize this approach. Recombinant DNA Advisory Committee Data Management Report, December, 1994, *Human Gene Therapy* 6:535-548. Studies normally focus on the therapeutic gene and the elements that control its expression in the patient when designing and constructing gene therapy plasmids. Generally, therapeutic genes and regulatory elements are simply inserted into existing cloning vectors that are convenient and readily available.

Plasmid design and construction utilizes several key factors. First, plasmid replication origins determine

plasmid copy number, which affects production yields. Plasmids that replicate to higher copy number can increase plasmid yield from a given volume of culture, but excessive copy number can be deleterious to the bacteria and lead to undesirable effects (Fitzwater, et al., *Embo J.* 7:3289-3297 (1988); Uhlin, et al., *Mol. Gen. Genet.* 165:167-179 (1979)). Artificially constructed plasmids are sometimes unstably maintained, leading to accumulation of plasmid-free cells and reduced production yields.

10 To overcome this problem of plasmid-free cells, genes that code for antibiotic resistance phenotype are included on the plasmid and antibiotics are added to kill or inhibit plasmid-free cells. Most general purpose cloning vectors contain ampicillin resistance (β -lactamase, or *bla*) genes. Use of ampicillin can be problematic because of the potential for residual antibiotic in the purified DNA, which can cause an allergic reaction in a treated patient. In addition, β -lactam antibiotics are clinically important for disease treatment. When plasmids containing antibiotic resistance genes are used, the potential exists for the transfer of antibiotic resistance genes to a potential pathogen.

Other studies have used the *neo* gene which is derived from the bacterial transposon *Tn5*. The *neo* gene encodes resistance to kanamycin and neomycin (Smith, Vaccine 12:1515-1519 (1994)). This gene has been used in a number of gene therapy studies, including several human clinical trials (Recombinant DNA Advisory Committee Data Management Report, December, 1994, *Human Gene Therapy* 6:535-548). Due to the mechanism by which resistance is imparted, residual antibiotic and transmission of the gene to potential pathogens may be less of a problem than for β -lactams.

In addition to elements that affect the behavior of the plasmid within the host bacteria, such as *E. coli*, plasmid vectors have also been shown to affect transfection and expression in eukaryotic cells. Certain plasmid sequences

have been shown to reduce expression of eukaryotic genes in eukaryotic cells when carried in *cis* (Peterson, et al., *Mol. Cell. Biol.* 7:1563-1567 (1987); Yoder et al., *Mol. Cell. Biol.* 3:956-959 (1983); Lusky et al., *Nature* 293:79-81 (1981); and Leite, et al., *Gene* 82:351-356 (1989)). Plasmid sequences also have been shown to fortuitously contain binding sites for transcriptional control proteins (Ghersa, et al., *Gene* 151:331-332 (1994); Tully et al., *Biochem. Biophys. Res. Comm.* 144:1-10 (1987); and Kushner, et al., *Mol. Endocrinol.* 8:405-407 (1994)). This can cause inappropriate levels of gene expression in treated patients.

Interferon alpha is a gene product that has been proposed for use, either alone or in combination with other agents, in different delivery systems for the treatment of certain diseases, including particular cancers. International patent publication WO/97/00085, published January 3, 1997, proposes *ex vivo* transfection of tumor cells with interferon alpha and another immunomodulatory molecule, such as IL-12. None of the previously proposed treatments have proven entirely satisfactory, due in part to the high cost and technical difficulty involved in *ex vivo* approaches. Thus there still remains a need in the art for improved plasmids encoding interferon alpha as well as improved treatment protocols and technologies.

25 Summary

The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for expression of interferon alpha in a mammal, formulations for delivery that incorporate a nucleic acid construct for expression, and methods for preparing and using such constructs and formulations. In particular, this invention relates to plasmid constructs for delivery of therapeutic interferon alpha encoding nucleic acids to cells in order to modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as

cytokines, preferably IL-12), as well as methods for preparing such constructs. The pharmaceutical acceptable, cost effective and highly efficient delivery system presented herein represents an unanticipated improvement over the art.

Thus, in a first aspect, the invention features a plasmid that contains a CMV promoter and optionally a synthetic 5' intron transcriptionally linked with an interferon alpha coding sequence, and a 3'-untranslated region (UTR). Preferably the 3' UTR is a 3' growth hormone UTR.

As used herein, the term "plasmid" refers to a construct made up of genetic material (i.e., nucleic acids). It includes genetic elements arranged such that an inserted coding sequence can be transcribed in eukaryotic cells. Also, while the plasmid may include a sequence from a viral nucleic acid, such viral sequence does not cause the incorporation of the plasmid into a viral particle, and the plasmid is therefore a non-viral vector. Preferably a plasmid is a closed circular DNA molecule.

"Cytomegalovirus promoter" refers to one or more sequences from a cytomegalovirus which are functional in eukaryotic cells as a transcriptional promoter and an upstream enhancer sequence. The enhancer sequence allows transcription to occur at a higher frequency from the associated promoter.

In this context, "transcriptionally linked" means that in a system suitable for transcription, transcription will initiate under the direction of the control sequence(s) and proceed through sequences which are transcriptionally linked with that control sequence(s). Preferably no mutation is created in the resulting transcript, which would alter the resulting translation product.

The term "coding region" or "coding sequence" refers to a nucleic acid sequence which encodes a particular gene product for which expression is desired, according to the

normal base pairing and codon usage relationships. Thus, the coding sequence must be placed in such relationship to transcriptional control sequences (possibly including control elements and translational initiation and termination codons) that a proper length transcript will be produced and will result in translation in the appropriate reading frame to produce a functional desired product.

In a preferred embodiment the interferon alpha coding sequence is for human interferon alpha and preferably is a synthetic sequence having optimal codon usage, such as the nucleotide sequence of SEQ ID NO:11 or semi-optimal codon usage, such as the nucleotide sequence of SEQ ID NO:12.

A particular example of coding regions suitable for use in the plasmids of this invention are the natural sequences coding for human interferon alpha. Thus, in a preferred embodiment coding region has a nucleotide sequence which is the same as SEQ ID NO:10, which is the natural nucleotide sequence encoding human interferon alpha. However, it may be preferable to have an interferon alpha coding sequence which is a synthetic coding sequence. In a preferred embodiment, the interferon alpha coding sequence is a synthetic sequence utilizing optimal or semi-optimal codon usage, preferably the sequence shown in SEQ ID NO:11 or SEQ ID NO:12.

Thus, a "sequence coding for the human interferon alpha" or "a human interferon alpha coding sequence" is a nucleic acid sequence which encodes the amino acid sequence of human interferon alpha, based on the normal base pairing and translational codon usage relationships. It is preferable that the coding sequence encode the exact, full amino acid sequence of natural human interferon, but this is not essential. The encoded polypeptide may differ from natural human interferon alpha, so long as the polypeptide retains interferon alpha activity, preferably the polypeptide is at least 50%, 75%, 90%, or 97% as active as natural human interferon alpha, and more preferably fully as

active as natural human interferon alpha. Thus, the polypeptide encoded by the interferon alpha coding sequence may differ from a natural human interferon alpha polypeptide by a small amount, preferably less than a 15%, 10%, 5%, or 1% change. Such a change may be of one of more different types, such as deletion, addition, or substitution of one or more amino acids.

The term "transcriptional control sequence" refers to sequences which control the rate of transcription of a transcriptionally linked coding region. Thus, the term can include elements such as promoters, operators, and enhancers. For a particular transcription unit, the transcriptional control sequences will include at least a promoter sequence.

A "growth hormone 3' untranslated region" is a sequence located downstream (i.e., 3') of the region encoding material polypeptide and including at least part of the sequence of the natural 3' UTR/poly(a) signal from a growth hormone gene, preferably the human growth hormone gene. This region is generally transcribed but not translated. For expression in eukaryotic cells it is generally preferable to include sequence which signals the addition of a poly-A tail. As with other synthetic genetic elements a synthetic 3' UTR/poly(A) signal has a sequence which differs from naturally-occurring UTR elements.

The sequence may be modified, for example by the deletion of ALU repeat sequences. Deletion of such ALU repeat sequences acts to reduce the possibility of homologous recombination between the expression cassette and genomic material in a transfected cell.

The plasmid preferably includes a promoter, a TATA box, a Cap site and a first intron and intron/exon boundary in appropriate relationship for expression of the coding sequence. The plasmid may also include a 5' mRNA leader sequence inserted between the promoter and the coding sequence and/or an intron/5' UTR from a chicken skeletal α -

actin gene. Also, the plasmid may have a nucleotide sequence which is the same as the nucleotide sequence of plasmid pIF0921, as shown in Figure 5.

The plasmid may also include: (a) a first transcription unit containing a first transcriptional control sequence transcriptionally linked with a first 5'-untranslated region, a first intron, a first coding sequence, and a first 3'-untranslated region/poly(A) signal, wherein the first intron is between the control sequence and the first coding sequence; and (b) a second transcription unit containing a second transcriptional control sequence transcriptionally linked with a second 5'-untranslated region, a second intron, a second coding sequence, and a second 3'-untranslated region/poly(A) signal, wherein the second intron is between the control sequence and the second coding sequence; wherein the first and second coding sequences contain a sequence having the sequence of SEQ ID NO:2, 3, 4 or 25 coding for a human IL-12 p40 subunit, and a sequence having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for a human IL-12 p35 subunit.

The term "transcription unit" or "expression cassette" refers to a nucleotide sequence which contains at least one coding sequence along with sequence elements which direct the initiation and termination of transcription. A transcription unit may however include additional sequences, which may include sequences involved in post-transcriptional or post-translational processes. In preferred embodiments, the first transcriptional control sequence or the second transcriptional control sequence contain one or more cytomegalovirus promoter sequences. The first and second transcriptional control sequences can be the same or different.

A "5' untranslated region" or "5' UTR" refers to a sequence located 3' to promoter region and 5' of the downstream coding region. Thus, such a sequence, while transcribed, is upstream of the translation initiation codon

and therefore is not translated into a portion of the polypeptide product.

For the plasmids described herein, one or more of a promoter, 5' untranslated region (5' UTR), the 3' UTR/poly(A) signal, and introns may be a synthetic sequence. In this context the term "synthetic" means that the sequence is not provided directly by the sequence of a naturally occurring genetic element of that type but rather is an artificially created sequence (i.e., created by a person by molecular biological methods). While one or more portions of such a synthetic sequence may be the same as portions of naturally occurring sequences, the full sequence over the specified genetic element is different from a naturally occurring genetic element of that type. The use of such synthetic genetic elements allows the functional characteristics of that element to be appropriately designed for the desired function.

Thus, a "synthetic intron" refers to a sequence which is not a naturally occurring intron sequence but which will be removed from an RNA transcript during normal post transcriptional processing. Such introns can be designed to have a variety of different characteristics, in particular such introns can be designed to have a desired strength of splice site.

A "subunit" of a therapeutic molecule is a polypeptide or RNA molecule which combines with one or more other molecules to form a complex having the relevant pharmacologic activity. Examples of such complexes include homodimers and heterodimers as well as complexes having greater numbers of subunits. A specific example of a heterodimer is IL-12, having the p40 and p35 subunits.

The "p40 subunit" is the larger of the two subunits of the IL-12 heterodimer. Thus, it is capable of association with p35 subunit to form a molecule having activities characteristic of IL-12. Human p40 has the amino acid sequence of SEQ ID NO:1. Those skilled in the art will

recognize that the molecule may have a number of changes from that sequence, such as deletions, insertions or changes of one or a few amino acids, while still retaining IL-12 activity when associated with p35. Such active altered
5 molecules are also regarded as p40.

Conversely, the "p35 subunit" is the smaller of the two heterodimeric subunits of IL-12. For humans, p35 has the amino acid sequence of SEQ ID NO:5. As for p40, p35 may have a low level of alterations from that sequence while
10 still being regarded as p35.

A particular example of coding regions suitable for use in the plasmids of this invention are the natural sequences coding for the p40 and p35 subunits of human IL-12. Thus, in a preferred embodiment the first and second coding
15 regions are coding regions for those sequences and are preferably in the order p40 then p35 in the 5' to 3' direction.

Thus, a "sequence coding for the p40 subunit of human IL-12" is a nucleic acid sequence which encodes the human
20 p40 subunit as described above, based on the normal base pairing and translational codon usage relationships. The sequence coding for p35 subunit of human IL-12 is similarly defined.

In a preferred embodiment the sequence coding for the
25 p40 subunit of human IL-12 is 5' to the sequence coding for the p35 subunit of human IL-12. Those skilled in the art will appreciate that the interferon alpha, p35 subunit and p40 subunit may all be on a single transcription unit, that all three may be on separate transcription units, or that
30 any two coding sequences may be on one transcription unit and the other coding sequence on another transcription unit.

The plasmid may also contain an intron having variable splicing, a first coding sequence, and a second coding sequence, wherein the first and second coding sequences
35 include a sequence having the sequence of SEQ ID NO:2, 3, 4 or 25 coding for a human IL-12 p40 subunit, and a sequence

having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for a human IL-12 p35 subunit.

In a preferred embodiment, the plasmid also has: (a) a transcriptional control sequence transcriptionally linked
5 with a first coding sequence and a second coding sequence;
(b) a 5'-untranslated region; (c) an intron 5' to the first coding sequence; (d) an alternative splice site 3' to the first coding sequence and 5' to the second coding sequence;
and (e) a 3'-untranslated region/poly(A) signal. The
10 transcriptional control sequence preferably includes a cytomegalovirus promoter sequence.

In a preferred embodiment, the plasmid also has: (a) a transcriptional control sequence transcriptionally linked
15 with a first coding sequence, an IRES sequence, a second coding sequence, and a 3'-untranslated region/poly(A) signal, wherein the IRES sequence is between the first coding sequence and the second coding sequence; and (b) an intron between the promoter and the first coding sequence;
wherein the first and second coding sequences include a
20 sequence having the sequence of SEQ ID NO:2, 3, 4 or 25 coding for a human IL-12 p40 subunit, and a sequence having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for a human IL-12 p35 subunit. The transcriptional control sequence preferably includes a cytomegalovirus promoter sequence and
25 the IRES sequence preferably is from an encephalomyocarditis virus.

For delivery of coding sequences for gene expression, it is generally useful to provide a delivery composition or delivery system which includes one or more other components
30 in addition to the nucleic acid sequences. Such a composition can, for example, aid in maintaining the integrity of the DNA and/or in enhancing cellular uptake of the DNA and/or by acting as an immunogenic enhancer, such as by the non-DNA components having an immuno-stimulatory
35 effect of their own.

Thus, in another aspect, the invention features a composition containing a plasmid as described above and a protective, interactive non-condensing compound (PINC).

The PINC enhances the delivery of the nucleic acid molecule to mammalian cells *in vivo*, and preferably the nucleic acid molecule includes a coding sequence for a gene product to be expressed in the cell. In many cases, the relevant gene product is a polypeptide or protein. Preferably the PINC is used under conditions so that the PINC does not form a gel, or so that no gel form is present at the time of administration at about 30-40°C. Thus, in these compositions, the PINC is present at a concentration of 30% (w/v) or less. In certain preferred embodiments, the PINC concentration is still less, for example, 20% or less, 10% or less, 5% or less, or 1% or less. Thus, these compositions differ in compound concentration and functional effect from uses of these or similar compounds in which the compounds are used at higher concentrations, for example in the ethylene glycol mediated transfection of plant protoplasts, or the formation of gels for drug or nucleic acid delivery. In general, the PINCs are not in gel form in the conditions in which they are used as PINCs, though certain of the compounds may form gels under some conditions.

In connection with the compounds and compositions of this invention, the term "protects" or "protective" refers to an effect of the interaction between such a compound and a nucleic acid such that the rate of degradation of the nucleic acid is decreased in a particular environment. Such degradation may be due to a variety of different factors, which specifically include the enzymatic action of a nuclease. The protective action may be provided in different ways, for example, by exclusion of the nuclease molecules or by exclusion of water.

Some compounds which protect a nucleic acid and/or prolong the bioavailability of a nucleic acid may also

- interact or associate with the nucleic acid by intermolecular forces and/or valence bonds such as: Van der Waals forces, ion-dipole interactions, ion-induced dipole interactions, hydrogen bonds, or ionic bonds. These interactions may serve the following functions: (1) Stereoselectively protect nucleic acids from nucleases by shielding; (2) facilitate the cellular uptake of nucleic acid by "piggyback endocytosis". Piggyback endocytosis is the cellular uptake of a drug or other molecule complexed to a carrier that may be taken up by endocytosis. CV Uglea and C Dumitriu-Medvichi, *Medical Applications of Synthetic Oligomers*, In: Polymeric Biomaterials, Severian Dumitriu ed., Marcel Dekker, Inc., 1993, incorporated herein by reference.
- To achieve the desired effects set forth it is desirable, but not necessary, that the compounds which protect the nucleic acid and/or prolong the bioavailability of a nucleic acid have amphiphilic properties; that is, have both hydrophilic and hydrophobic regions. The hydrophilic region of the compounds may associate with the largely ionic and hydrophilic regions of the nucleic acid, while the hydrophobic region of the compounds may act to retard diffusion of nucleic acid and to protect nucleic acid from nucleases.
- Additionally, the hydrophobic region may specifically interact with cell membranes, possibly facilitating endocytosis of the compound and thereby also of nucleic acid associated with the compound. This process may increase the pericellular concentration of nucleic acid.
- Agents which may have amphiphilic properties and are generally regarded as being pharmaceutically acceptable are the following: polyvinylpyrrolidones; polyvinylalcohols; polyvinylacetates; propylene glycol; polyethylene glycols; poloxamers (Pluronic); poloxamines (Tetronics); ethylene vinyl acetates; methylcelluloses, hydroxypropylcelluloses, hydroxypropylmethylcelluloses; heteropolysaccharides

(pectins); chitosans; phosphatidylcholines (lecithins);
migllyols; polylactic acid; polyhydroxybutyric acid; xanthan
gum. Also, copolymer systems such as polyethylene glycol-
polylactic acid (PEG-PLA), polyethylene glycol-
5 polyhydroxybutyric acid (PEG-PHB), polyvinylpyrrolidone-
polyvinylalcohol (PVP-PVA), and derivatized copolymers such
as copolymers of N-vinyl purine (or pyrimidine) derivatives
and N-vinylpyrrolidone. However, not all of the above
compounds are protective, interactive, non-condensing
10 compounds as described below.

In connection with the protective, interactive, non-
condensing compounds for these compositions, the term "non-
condensing" means that an associated nucleic acid is not
condensed or collapsed by the interaction with the PINC at
15 the concentrations used in the compositions. Thus, the
PINC's differ in type and/or use concentration from such
condensing polymers. Examples of commonly used condensing
polymers include polylysine, and cascade polymers (spherical
polycations).

Also in connection with such compounds and an
associated nucleic acid molecule, the term "enhances the
delivery" means that at least in conditions such that the
amounts of PINC and nucleic acid is optimized, a greater
20 biological effect is obtained than with the delivery of
nucleic acid in saline. Thus, in cases where the expression
25 of a gene product encoded by the nucleic acid is desired,
the level of expression obtained with the PINC:nucleic acid
composition is greater than the expression obtained with the
same quantity of nucleic acid in saline for delivery by a
30 method appropriate for the particular PINC/coding sequence
combination.

In preferred embodiments of the above compositions, the
PINC is polyvinyl pyrrolidone (PVP), polyvinyl alcohol
(PVA), a PVP-PVA co-polymer, N-methyl-2-pyrrolidone (NM2P),
35 ethylene glycol, or propylene glycol. In compositions in
which a Poloxamer (Pluronic) is used, the nucleic acid is

preferably not a viral vector, i.e., the nucleic acid is a non-viral vector.

In other preferred embodiments, the PINC is bound with a targeting ligand. Such targeting ligands can be of a variety of different types, including but not limited to galactosyl, residues, fucosal residues, mannosyl residues, carnitine derivatives, monoclonal antibodies, polyclonal antibodies, peptide ligands, and DNA-binding proteins. The targeting ligands may bind with receptors on cells such as antigen-presenting cells, hepatocytes, myocytes, epithelial cells, endothelial cells, and cancer cells.

In connection with the association of a targeting ligand and a PINC, the term "bound with" means that the parts have an interaction with each other such that the physical association is thermodynamically favored, representing at least a local minimum in the free energy function for that association. Such interaction may involve covalent binding, or non-covalent interactions such as ionic, hydrogen bonding, van der Waals interactions, hydrophobic interactions, and combinations of such interactions.

While the targeting ligand may be of various types, in one embodiment the ligand is an antibody. Both monoclonal antibodies and polyclonal antibodies may be utilized.

The nucleic acid may also be present in various forms. Preferably the nucleic acid is not associated with a compound(s) which alter the physical form, however, in other embodiments the nucleic acid is condensed (such as with a condensing polymer), formulated with cationic lipids, formulated with peptides, or formulated with cationic polymers.

In preferred embodiments, the protective, interactive non-condensing compound is polyvinyl pyrrolidone, and/or the plasmid is in a solution having between 0.5% and 50% PVP, more preferably about 5% PVP. The DNA preferably is at least about 80% supercoiled, more preferably at least about

90% supercoiled, and most preferably at least about 95% supercoiled.

In another aspect the invention features a composition containing a protective, interactive non-condensing compound and a plasmid containing an interferon alpha coding sequence.

In yet another aspect, the invention provides a composition containing a plasmid of the invention (or a plasmid containing an interferon alpha coding sequence) and a cationic lipid with a neutral co-lipid.

Preferably the cationic lipid is DOTMA and the neutral co-lipid is cholesterol (chol). DOTMA is 1,2-di-O-octadecenyl-3-trimethylammonium propane, which is described and discussed in Eppstein et al., U.S. Patent 4,897,355, issued January 30, 1990, which is incorporated herein by reference. However, other lipids and lipid combinations may be used in other embodiments. A variety of such lipids are described in Gao & Huang, 1995, *Gene Therapy* 2:710-722, which is hereby incorporated by reference.

As the charge ratio of the cationic lipid and the DNA is also a significant factor, in preferred embodiments the DNA and the cationic lipid are present in such amounts that the negative to positive charge ratio is about 1:3. While preferable, it is not necessary that the ratio be 1:3. Thus, preferably the charge ratio for the compositions is between about 1:1 and 1:10, more preferably between about 1:2 and 1:5.

The term "cationic lipid" refers to a lipid which has a net positive charge at physiological pH, and preferably carries no negative charges at such pH. An example of such a lipid is DOTMA. Similarly, "neutral co-lipid" refers to a lipid which has is usually uncharged at physiological pH. An example of such a lipid is cholesterol.

Thus, "negative to positive charge ratio" for the DNA and cationic lipid refers to the ratio between the net

negative charges on the DNA compared to the net positive charges on the cationic lipid.

As the form of the DNA affects the expression efficiency, the DNA preferably is at least about 80% supercoiled, more preferably at least about 90% supercoiled, and most preferably at least about 95% supercoiled. The composition preferably includes an isotonic carbohydrate solution, such as an isotonic carbohydrate solution that consists essentially of about 10% lactose. In preferred embodiments, the composition the cationic lipid and the neutral co-lipid are prepared as a liposome having an extrusion size of about 800 nanometers. Preferably the liposomes are prepared to have an average diameter of between about 20 and 800 nm, more preferably between about 50 and 400 nm, still more preferably between about 75 and 200 nm, and most preferably about 100 nm. Microfluidization is the preferred method of preparation of the liposomes.

In another aspect the invention features a composition containing: (a) a first component having a plasmid including an interferon alpha coding sequence and a cationic lipid with a neutral co-lipid, wherein the cationic lipid is DOTMA and the neutral co-lipid is cholesterol, wherein the DNA in the plasmid and the cationic lipid are present in amounts such that the negative to positive charge ratio is about 1:3; and (b) a second component including a protective, interactive non-condensing compound, wherein the first component is present within the second component.

In another aspect, the invention provides a composition having a protective, interactive non-condensing compound, a first plasmid including an interferon alpha coding sequence, and one or more other plasmids independently having an IL-12 p35 or IL-12 p40 subunit coding sequence.

In another aspect, the invention features a method for making any of the plasmids described above by inserting a CMV promoter transcriptionally linked with an interferon

alpha coding sequence, and a growth hormone 3'-untranslated region into a plasmid.

The invention also provides methods of making the compositions described above. The method may involve: (a) preparing a DNA molecule having a transcriptional unit, wherein the transcriptional unit contains an interferon alpha coding sequence; (b) preparing a protective, interactive non-condensing compound; and (c) combining the protective, interactive non-condensing compound with the DNA in conditions such that a composition capable of delivering a therapeutically effective amount of an interferon alpha coding sequence to a mammal is formed.

Preferably, the DNA molecule is a plasmid, wherein the plasmid includes a CMV promoter transcriptionally linked with an interferon alpha coding sequence, and a human growth hormone 3'-untranslated region/poly(A) signal.

The method may involve the steps of: (a) preparing a DNA having an interferon alpha coding sequence; (b) preparing a mixture of a cationic lipid and a neutral co-lipid, wherein the cationic lipid is DOTMA and the neutral co-lipid is cholesterol; and (c) combining the mixture with the DNA in amounts such that the cationic lipid and the DNA are present in a negative to positive charge ratio of about 1:3.

In another embodiment, the method involves the steps of: (a) preparing a first component having a plasmid containing an interferon alpha coding sequence and a cationic lipid with a neutral co-lipid, wherein the cationic lipid is DOTMA and the neutral co-lipid is cholesterol, wherein the DNA in the plasmid and the cationic lipid are present in amounts such that the negative to positive charge ratio is about 1:3; (b) preparing a second component having a protective, interactive non-condensing compound; and (c) combining the first and second components such that the resulting composition includes the first component within the second component.

In another embodiment, the method involves the steps of: (a) preparing a protective, interactive non-condensing compound, (b) preparing a first plasmid having an interferon alpha coding sequence, (c) preparing one or more other
5 plasmids independently having an IL-12 p35 or IL-12 p40 subunit coding sequence, and (d) combining the protective, interactive non-condensing compound, the plasmid having the interferon alpha coding sequence and the other plasmids.

In another aspect, the invention provides a method for
10 treatment of a mammalian condition or disease, by administering to a mammal suffering from the condition or disease a therapeutically effective amount of a plasmid as described herein.

A "therapeutically effective amount" of a composition
15 is an amount which is sufficient to cause at least temporary relief or improvement in a symptom or indication of a disease or condition. Thus, the amount is also sufficient to cause a pharmacological effect. The amount of the composition need not cause permanent improvement or
20 improvement of all symptoms or indications. A therapeutically effective amount of a cancer therapeutic would be one that reduces overall tumor burden in the case of metastatic disease (i.e., the number of metastases or their size) or one that reduces the mass of the tumor in
25 localized cancers.

The condition or disease preferably is a cancer, such as epithelial glandular cancer, including adenoma and adenocarcinoma; squamous and transitional cancer, including polyp, papilloma, squamous cell and transitional cell
30 carcinoma; connective tissue cancer, including tissue type positive, sarcoma and other (oma's); hematopoietic and lymphoreticular cancer, including lymphoma, leukemia and Hodgkin's disease; neural tissue cancer, including neuroma, sarcoma, neurofibroma and blastoma; mixed tissues of origin
35 cancer, including teratoma and teratocarcinoma. Other cancerous conditions that are applicable to treatment

include cancer of any of the following: adrenal gland, anus, bile duct, bladder, brain tumors: adult, breast, cancer of an unknown primary site, carcinoids of the gastrointestinal tract, cervix, childhood cancers, colon and rectum, esophagus, gall bladder, head and neck, islet cell and other
5 pancreatic carcinomas, Kaposi's sarcoma, kidney, leukemia, liver, lung: non-small cell, lung: small cell, lymphoma: AIDS-associated, lymphoma: Hodgkin's disease, Lymphomas: non-Hodgkin's disease, melanoma, mesothelioma, metastatic
10 cancer, multiple myeloma, ovary, ovarian germ cell tumors, pancreas, parathyroid, penis, pituitary, prostate, sarcomas of bone and soft tissue, skin, small intestine, stomach, testis, thymus, thyroid, trophoblastic disease, uterus: endometrial carcinoma, uterus: uterine sarcomas, vagina, or
15 vulva. The composition preferably is administered by injection, although the method may also be performed *ex vivo*.

In another aspect, the invention provides a method for transfection (i.e., the delivery and expression of a gene to
20 cells) of a cell *in situ*, by contacting the cell with a plasmid described herein for sufficient time to transfect the cell. Transfection of the cell preferably is performed *in vivo* and the contacting preferably is performed in the presence of about 5% PVP solution.

25 In another aspect, the invention features a method for delivery and expression of an interferon alpha gene in a plurality of cells, by: (a) transfecting the plurality of cells with a plasmid or composition of the invention; and (b) incubating the plurality of cells under conditions
30 allowing expression of a nucleic acid sequence in the vector, wherein the nucleic acid sequence encodes interferon alpha.

In preferred embodiments, the interferon alpha is human interferon alpha and the cells are human cells and/or the
35 contacting is performed in the presence of an about 5% PVP solution.

In another aspect, the invention features a method for treating a disease or condition, by transfecting a cell *in situ* with a plasmid or composition of the invention. The disease or condition can be a localized disease or condition or a systemic disease or condition.

In another aspect, the invention features a cell transfected with a plasmid or composition of the invention.

In yet another aspect, the invention features a method for treatment of a mammalian condition or disease, by administering to a mammal suffering from the condition or disease a therapeutically effective amount of a composition described herein.

As the compositions are useful for delivery of a nucleic acid molecule to cells *in vivo*, in a related aspect the invention provides a composition at an *in vivo* site of administration. In particular this includes at an *in vivo* site in a mammal.

In preferred embodiments the nucleic acid molecule includes a sequence encoding a gene product. Also in preferred embodiments, the site of administration is in an interstitial space or a tissue of an animal, particularly of a mammal.

The invention also provides methods for using the above compositions. Therefore, in further related aspects, methods of administering the compositions are provided in which the composition is introduced into a mammal, preferably into a tissue or an interstitial space.

Various methods of delivery may be utilized, such as are known in the art, but in preferred embodiments, the composition is introduced into the tissue or interstitial space by injection. The compositions may also be delivered to a variety of different tissues, but in preferred embodiments the tissue is muscle or tumor.

In another related aspect, the invention provides methods for treating a mammalian condition or disease by administering a therapeutically effective amount of a

composition as described above. In preferred embodiments, the disease or condition is a cancer.

The summary of the invention described above is non-limiting and other features and advantages of the invention will be apparent from the following detailed description of the preferred embodiments, as well as from the claims.

Brief Description Of The Drawings

Figure 1 shows the effects of interferon alpha in two cancer models.

Figure 2 shows a plasmid map and sequence (SEQ ID NO:18) for an exemplary IL-12 plasmid of the present invention.

Figure 3 shows optimal codon usage for highly expressed human genes.

Figure 4 shows a plasmid map and sequence (SEQ ID NO:19) for plasmid pIF0836, an exemplary interferon alpha plasmid of the present invention.

Figure 5 shows a plasmid map and sequence (SEQ ID NO:20) for pIN096, an exemplary IL-12 plasmid that can be used with the present invention.

Figure 6 shows the nucleic acid sequence (SEQ ID NO:21) of plasmid pIF0921, an exemplary interferon alpha plasmid of the present invention.

Figures 7A and 7B show a plasmid map and sequence (SEQ ID NO:22) for plasmid pIF0921.

Figure 8 shows an outline of a strategy that can be used to synthesize a pIF0921 plasmid.

Figure 9 shows interferon alpha and IL-12 gene medicine (combination therapy) in Renca model.

Detailed Description Of The Preferred Embodiments

The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for expression of interferon alpha in a mammal, formulations for delivery that incorporate a nucleic acid construct for

expression, and methods for preparing and using such constructs and formulations. In particular, this invention relates to plasmid constructs for delivery of therapeutic interferon alpha encoding nucleic acids to cells in order to
5 modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as cytokines, preferably IL-12), as well as methods for preparing such constructs.

I. General

10 As described, this invention concerns expression systems for the delivery and expression of interferon alpha coding sequences in mammalian cells, and formulations and methods for delivering such expression systems or other expression systems to a mammal.

15 Therefore, particular genetic constructs are described which includes nucleotide sequences coding for interferon alpha, preferably human interferon alpha. Such a construct can beneficially be formulated and administered as described herein, utilizing the expression systems of this invention.

20 To allow convenient production of such plasmids, it is generally preferable that the plasmid be capable of replication in a cell to high copy number. Generally such production is carried out in prokaryotic cells, particularly including *Escherichia coli* (*E.coli*) cells. Thus, the plasmid
25 preferably contains a replication origin functional in a prokaryotic cell, and preferably the replication origin is one which will direct replication to a high copy number.

It is also possible to utilize synthetic genetic elements in the plasmid constructs.

30 As described below, these elements affect post-transcriptional processing in eukaryotic systems. Thus, the use of synthetic sequences allows the design of processing characteristics as desired for the particular application. Commonly, the elements will be designed to provide rapid and
35 accurate processing.

For delivery of DNA encoding a desired expression product to a mammalian system, it is usually preferable to utilize a delivery system. Such a system can provide multiple benefits, notably providing stabilization to protect the integrity of the DNA, as well as assisting in cellular uptake.

In addition, the non-DNA components of the formulation may contribute to an immune system enhancement or activation. As a result, components of a delivery system can be selected in conjunction with a particular gene product to enhance or minimize the immuno-stimulatory effect.

The plasmids may also include elements for expression of IL-12 or one or more subunits thereof. Similarly, the treatment may involve administration of an interferon alpha coding sequence and one or more IL-12 coding sequences whether on a single plasmid or on separate plasmids. Such plasmids may be incorporated into compositions for delivery with a protective, interactive non-condensing compound, a cationic lipid and neutral co-lipid, or both.

While these are specific effective examples, other components may be utilized in formulations containing the interferon alpha expression vectors of the present invention to provide effective delivery and expression of interferon alpha or with other coding sequences for which manipulation of the activation of immune system components is desirable.

The selection of delivery system components and preparation methods in conjunction with the selection of coding sequences provides the ability to balance the specific effects of the encoded gene products and the immune system effects of the overall delivery system composition. This capacity to control the biological effects of delivery system formulation administration represents an aspect of the invention in addition to the interferon alpha encoding constructs and specific formulations of delivery systems. Co-selection of the encoded gene product and the delivery

system components and parameters provides enhanced desired effects rather than merely providing high level gene expression. In particular, such enhancement is described below for the antitumor effects of the exemplary PVP
5 containing compositions.

For systems in which IL-12 is also administered, the antitumor effect can be greater than merely additive (i.e., greater than merely the sum of the antitumor effects of interferon alpha alone and IL-12 alone). Enhancement of
10 immuno-stimulatory effects is also desirable in other contexts, for example, for vaccine applications.

In contrast, for certain applications, it is preferable to select a delivery systems which minimizes the immune system effects. For example, it is often preferred that the
15 immune system activation be minimized for compositions to be delivered to the lung in order to minimize lung tissue swelling.

A useful approach for selecting the delivery system components and preparation techniques for a particular coding sequence can proceed as follows, but is not limited
20 to these steps or step order.

1. Select a particular genetic construct which provides appropriate expression *in vitro*.
- 25 2. Select delivery system components based on desired immunostimulatory effects and/or on *in vivo* physiological effect. Such effects can be tested or verified in *in vivo* model systems.
- 30 3. Select the other delivery system parameters consistent with the desired immuno-stimulatory effects and/or consistent with enhancing the desired *in vivo* physiological effect. Such parameters can, for example, include the amount and ratio of DNA to one or more other composition components, the relative amounts of non-DNA
35 composition components, the size of delivery system formulation particles, the percent

supercoiled DNA for circular dsDNA vectors, and the specific method of preparation of delivery system formulation particles. The particular parameters relevant for specific types of formulations will be apparent or readily determined by testing.

The description below illustrates the selection of components and parameters in the context of interferon alpha encoding constructs. However, it should be recognized that the approach is applicable to constructs containing a variety of other coding sequences.

II. Plasmid Construct Expression Systems

A. Plasmid Design and Construction

For the methods and constructs of this invention, a number of different plasmids were constructed which are useful for delivery and expression of sequences encoding interferon alpha. Thus, these plasmids contain coding regions for interferon alpha, along with genetic elements necessary or useful for expression of those coding regions.

While these embodiments utilized interferon alpha cDNA clones or partial genomic sequences from a particular source, those skilled in the art could readily obtain interferon alpha coding sequences from other sources, or obtain a coding sequence by identifying a cDNA clone in a library using a probe(s) based on the published interferon alpha coding and/or flanking sequences. This also applies to the IL-12 coding sequences utilized in the embodiments described herein.

Coding sequences for interferon alpha were incorporated into an expression plasmid that contains eukaryotic and bacterial genetic elements. Eukaryotic genetic elements include the CMV immediate early promoter and 5' UTR, and a human growth hormone 3' UTR/poly(a) signal, which influence gene expression by controlling the accuracy and efficiency of RNA processing, mRNA stability, and translation.

The human growth hormone 3' UTR is from a human growth hormone gene, and preferably includes a poly(a) signal. This sequence can be linked immediately following the natural translation termination codon for a cDNA sequence, genomic sequence, modified genomic sequence, or synthetic sequence coding for interferon alpha.

An example of a human growth hormone 3' UTR/poly(a) signal is shown by the human growth hormone 3' UTR (nucleotides 1 - 100) and 3' flanking sequence (nucleotides 101 - 191; GenBank accession #J03071, HUMGHCSA) below. (SEQ ID NO:13)

```

1  GGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGT
                                     Poly (a) signal
15
51  TGCCACTCCAGTGCCCACCAGCCTTGTCTTAATAAAATTAAGTGCATCA
101 TTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTG
20 151 GTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGC

```

The 5' and 3' UTR and flanking regions can be further and more precisely defined by routine methodology, e.g., deletion or mutation analysis or their equivalents., and can be modified to provide other sequences having appropriate transcriptional and translational functions.

1. Construction of plasmid: Plasmid Backbone, human interferon alpha cDNA, Final Construct

A diagrammatic representation of the PCR products and plasmids involved in creation of an exemplary construct is shown below in Figure 8.

Plasmid pIF0921 was constructed from commercially available plasmids, and contains the TN5 gene encoding the kanamycin resistance gene, the pUC origin of replication, the CMV enhancer and promoter to base +112, a synthetic intron called IVS8, the human IFN- α 2b gene, and the human growth hormone 3' UTR. The plasmid construction descendency

for pIL0697 is shown in Figure 8. pIL0697 was cut with BamHI and Xba I and the hIFN-a2b PCR product, which had been amplified from human genomic DNA with BamHI and Xba I ends, was cloned into the pIL0697 backbone in place of the IL-2 coding region. The resulting plasmid was pIF0863. pIF0863 was cut with Nco I and intron IVS8 from pCT0828 was cloned in. The resulting plasmid was pIF0890. pIF0890 was cut with Nde I and Pac I and an additional region of the CMV 5' UTR to base +112 was cloned in from plasmid pLC0888.

10 B. Synthetic Genetic Elements

In some embodiments, some or all of the genetic elements can be synthetic, derived from synthetic oligonucleotides, and thus are not obtained directly from natural genetic sequences. These synthetic elements are appropriate for use in many different expression vectors.

15 A synthetic intron is designed with splice sites that ensure that RNA splicing is accurate and efficient. A synthetic 3' UTR/poly(A) signal is designed to facilitate mRNA 3' end formation and mRNA stability. A synthetic 5' UTR is designed to facilitate the initiation of translation. The design of exemplary synthetic elements is described in more detail below.

1. Summary of Synthetic Element Features

25 Exemplary synthetic 5'UTR, intron, and 3'UTR/poly(A) signal have the general features shown below:

5' UTR	Short.
	Lack of secondary structure.
	Kozak sequence.
	Site for intron insertion.

Intron

5' splice site sequence matches consensus.
5' splice site sequence is exactly complementary to 5' end of U1 snRNA.
Branch point sequence matches consensus.
Branch point sequence is complementary to U2 snRNA.
3' splice site matches consensus.
Polypyrimidine tract is 16 bases in length and contains 7 consecutive T's. (The tract preferably contains at least 5 consecutive T's.)
Contains internal restriction enzyme sites.
BbsI cleaves at the 5'ss, EarI cleaves at the 3'ss.

3' UTR/Poly(A) Based on rabbit β -globin 3' UTR/poly(A) signal.
Consists of two poly(A) signals in tandem.

2. Features of the Synthetic 5'UTR (UT6):

5 The 5' untranslated region (5'UTR) influences the translational efficiency of messenger RNA, and is therefore an important determinant of eukaryotic gene expression. The synthetic 5'UTR sequence (UT6) has been designed to maximize the translational efficiency of mRNAs encoded by vectors that express genes of therapeutic interest.

10 The sequence of the synthetic 5' UTR (UT6) is shown below. The Kozak sequence is in boldface and the initiation codon is double underlined. The location of the intron (between residues 48 and 49) is indicated by the filled

triangle and the sequences that form the exonic portion of consensus splice sites are single underlined. The restriction sites for HindIII and NcoI are overlined. (SEQ ID NO:14)

5

HindIIIV NcoI

AAGCTTACTCAACACAATAACAACTTACTTACAATCTTAATTAACAGGCCACCATGG

10 The 5' untranslated region (5' UTR), located between the cap site and initiation codon, is known to influence the efficiency of mRNA translation. Any features that influence the accessibility of the 5' cap structure to initiation factors, the binding and subsequent migration of the 43S preinitiation complex, or the recognition of the initiation
15 codon, will influence mRNA translatability. An efficient 5' UTR is expected to be one that is moderate in length, devoid of secondary structure, devoid of upstream initiation codons, and has an AUG within an optimal local context (Kozak, 1994, *Biochimie* 76:815-821; Jansen et al., 1994). A
20 5' UTR with these characteristics should allow efficient recognition of the 5' cap structure, followed by rapid and unimpeded ribosome scanning by the ribosome, thereby facilitating the translation initiation process.

25 The sequence of the synthetic 5'UTR was designed to be moderate in length (54 nucleotides (nts)), to be deficient in G but rich in C and A residues, to lack an upstream ATG, to place the intended ATG within the context of a optimal Kozak sequence (CCACCATGG), and to lack potential secondary structure. The synthetic 5' UTR sequence was also designed
30 to lack AU-rich sequences that target mRNAs to be rapidly degraded in the cytoplasm.

Experiments have demonstrated that introns increase gene expression from cDNA vectors, and that introns located in the 5' UTR are more effective than ones located in the 3' UTR (Huang and Gorman, 1990, *Mol. Cell. Biol.* 10:1805-1810; Evans and Scarpulla, 1989, *Gene* 84:135-142; Brinster et al.,
35

1988, *Proc. Natl. Acad. Sci. USA* 85:836-840; Palmiter et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:478-482; Choi et al., 1991, *Mol. Cell. Biol.* 11:3070-3074). Accordingly, the synthetic 5' UTR sequence was designed to accommodate an intron with consensus splice site sequences. The intron may, for example, be located between residues 48 and 49 (See intron sequence structure below). The CAG at position 46-48 is the exonic portion of a consensus 5' splice site. The G at position 49 is the exonic portion of a consensus 3' splice site.

To facilitate cloning manipulations, the synthetic 5' UTR sequence was designed to begin with a HindIII site and terminate with a NcoI site.

3. Features of the Synthetic Intron

RNA splicing is required for the expression of most eukaryotic genes. For optimal gene expression, RNA splicing must be highly efficient and accurate. A synthetic intron, termed OPTIVS8B, was designed to be maximally efficient and accurate.

The structure of the exemplary synthetic intron, OPTIVS8 is shown below. Sequences for the 5' splice site (5'ss), branch point (bp), and 3' splice site (3'ss) are double underlined. The recognition sequences for the restriction enzymes BbsI and EarI are overlined. The cleavage site for BbsI corresponds to the 5'ss, and the cleavage site for EarI corresponds to the 3'ss.

5'ss		bp		3'ss
	<u>BbsI</u>		<u>EarI</u>	
30	5' <u>CAG GTAAGTGTCTTC</u> ---	(77)---	<u>TACTAACGGTTCTTTTTTCTCTTCACAG</u>	G 3'
	(SEQ ID NO.15)		(SEQ ID NO.16)	

The 5' splice site (5'ss) sequence matches the established consensus sequence, MAG □ GTRAGT, where M = C or A, and R = G or A. Since the mechanism of splicing involves an interaction between the 5'ss of the pre-mRNA and U1

snRNA, the 5'ss sequence of OPTIVS8B was chosen to be exactly complementary to the 5' end of U1 snRNA.

```

5          5'ss      5' CAGGUAAGU 3'
                      |||||
          U1 RNA    3' GUCCAUUCA 5'

```

In mammals, the consensus sequence for branch points (YNYTRAY, where Y = C or T, R = A or G, N = any base, and the underlined A residue is the actual branch point) is very ambiguous. Since the mechanism of splicing involves an interaction between the branch point (bp) of the pre-mRNA and U2 snRNA, the branch point sequence of OPTIVS8B was chosen to maximize this interaction. (Note that the branch point itself is bulged out). The chosen sequence also matches the branch point sequence that is known to be obligatory for pre-mRNA splicing in yeast. The branch point is typically located 18-38 nts upstream of the 3' splice site. In OPTIVS8B, the branch point is located 24 nts upstream from the 3' splice site.

```

          BP          5' UACUAAC 3'
                      |||||
          U2 RNA      3' AUGAU G 5'

```

The sequence of the 3' splice site (3'ss) matches the established consensus sequence, Y₁₁NYAG ↓ G, where Y = C or T, and N = any base. In 3' splice sites, the polypyrimidine tract (Y₁₁) is the major determinant of splice site strength. For optimal splice site function in OPTIVS8B, the length of the polypyrimidine tract was extended to 16 bases, and its sequence was adjusted to contain 7 consecutive T residues. This feature was included because Roscigno et al. (1993) demonstrated that optimal splicing requires the presence of at least 5 consecutive T residues in the polypyrimidine tract.

Splicing *in vitro* is generally optimal when introns are >80 nts in length (Wieringa, et al., 1984; Ulfendahl et al., 1985, *Nucl. Acids Res.* 13:6299-6315). Although many introns may be thousands of bases in length, most naturally occurring introns are 90-200 nt in length (Hawkins, 1988, *Nucl. Acids Res.* 16:9893-9908). The length of the synthetic intron (118 nts) falls within this latter range.

OPTIVS8B was designed with three internal restriction enzyme sites, BbsI, NheI, and EarI. These restriction sites facilitate the screening and identification of genes that contain the synthetic intron sequence. In addition, the BbsI and EarI sites were placed so that their cleavage sites exactly correspond to the 5'ss (BbsI) or 3'ss (EarI). The sequence of the polypyrimidine tract was specifically designed to accommodate the EarI restriction site. Inclusion of the BbsI and EarI sites at these locations is useful because they permit the intron to be precisely deleted from a gene. They also permit the generation of an "intron cassette" that can be inserted at other locations within a gene.

The 77 bases between the BbsI site and the branch point sequence are random in sequence, except for the inclusion of the NheI restriction site.

4. Features of the Synthetic 3' UTR/poly(A)

25 Signal:

The 3' ends of eukaryotic mRNAs are formed by the process of polyadenylation. This process involves site specific site RNA cleavage, followed by addition of a poly(A) tail. RNAs that lack a poly(A) tail are highly unstable. Thus, the efficiency of cleavage/polyadenylation is a major determinant of mRNA levels, and thereby, of gene expression levels. 2XPA1 is a synthetic sequence, containing two efficient poly(A) signals, that is designed to be maximally effective in polyadenylation.

A poly(A) signal is required for the formation of the 3' end of most eukaryotic mRNA. The signal directs two RNA processing reactions: site-specific endonucleolytic cleavage of the RNA transcript, and stepwise addition of adenylates (approximately 250) to the newly generated 3' end to form the poly(A) tail. A poly(A) signal has three parts: hexanucleotide, cleavage site, and downstream element. The hexanucleotide is typically AAUAAA and cleavage sites are most frequently 3' to the dinucleotide CA (Sheets et al., 1987). Downstream elements are required for optimal poly(A) signal function and are located downstream of the cleavage site. The sequence requirement for downstream elements is not yet fully established, but is generally viewed as UG- or U-rich sequences (Wickens, 1990; Proudfoot, 1991, *Cell* 64:671-674; Wahle, 1992, *Bioessays* 14:113-118; Chen and Nordstrom, 1992, *Nucl. Acids Res.* 20:2565-2572).

Naturally occurring poly(A) signals are highly variable in their effectiveness (Peterson, 1992). The effectiveness of a particular poly(A) signal is mostly determined by the quality of the downstream element. (Wahle, 1992). In expression vectors designed to express genes of therapeutic interest, it is important to have a poly(A) signal that is as efficient as possible.

Poly(A) efficiency is important for gene expression, because transcripts that fail to be cleaved and polyadenylated are rapidly degraded in the nuclear compartment. In fact, the efficiency of polyadenylation in living cells is difficult to measure, since nonpolyadenylated RNAs are so unstable. In addition to being required for mRNA stability, poly(A) tails contribute to the translatability of mRNA, and may influence other RNA processing reactions such as splicing or RNA transport ((Jackson and Standart, 1990, *Cell* 62:15-24; Wahle, 1992).

Some eukaryotic genes have more than one poly(A) site, implying that if the cleavage/polyadenylation reaction fails to occur at the first site, it will occur at one of the

later sites. In COS cell transfection experiments, a gene with two strong poly(A) sites yielded approximately two-fold more mRNA than one with a single strong poly(A) site (Bordonaro, 1995). These data suggest that a significant fraction of transcripts remain unprocessed even with a single "efficient" poly(A) signal. Thus, it may be preferable to include more than one poly(A) site.

The sequence of the exemplary synthetic poly(A) signal is shown below. The sequence is named 2XPA. The hexanucleotide sequences and downstream element sequences are double underlined, and the two poly(A) sites are labeled as pA#1 and pA#2. Convenient restriction sites are overlined. The entire 2XPA unit may be transferred in cloning experiments as a XbaI-KpnI fragment. Deletion of the internal BspHI fragment results in the formation of a 1XPA unit. (SEQ ID NO. 17)

```

XbaI                                     BspHI
TCTAGAGCATTTTTCCCTCTGCCAAAATTATGGGGACATCATGAAGCCCTTGAGCATCTGACG
20                                     pA#1
      Hex                               |   Downstream element
TCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCCTCACT

                                     BspHI
25 CGGTACTAGAGCATTTTTCCCTCTGCCAAAATTATGGGGACATCATGAAGCCCTTGAGCATCT
                                     pA#2
      Hex                               |   Downstream element
GACGCTCGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCCTCT

30      KpnI
CACTCGGTACC

```

The sequence of the synthetic poly(A) site shown above is based on the sequence of the rabbit β -globin poly(A) signal, a signal that has been characterized in the literature as strong (Gil and Proudfoot, 1987, Cell 49:399-

406; Gil and Proudfoot, 1984, *Nature* 312:473-474). One of its key features is the structure of its downstream element, which contains both UG- and U-rich domains.

A double-stranded DNA sequence corresponding to the 1XPA sequence was constructed from synthetic oligonucleotides. Two copies of the 1XPA sequence were then joined to form the 2XPA sequence. The sequences were joined in such a way as to have a unique XbaI site at the 5' end of the first poly(A) signal containing fragment, and a unique KpnI site at the 3' end of the second poly(A) signal containing fragment.

C. Interferon Alpha and IL-12 Coding Sequences

The nucleotide sequence of a natural human interferon alpha coding sequences is known, and is provided below, along with a synthetic sequence which also codes for human interferon alpha. The same applies with respect to the IL-12 coding sequences.

In some cases, instead of the natural sequence coding for interferon alpha, it is advantageous to utilize synthetic sequences which encode interferon alpha. Such synthetic sequences have alternate codon usage from the natural sequence, and thus have dramatically different nucleotide sequences from the natural sequence. In particular, synthetic sequences can be used which have codon usage at least partially optimized for expression in a human. The natural sequences do not have such optimal codon usage. Preferably, substantially all the codons are optimized.

Optimal codon usage in humans is indicated by codon usage frequencies for highly expressed human genes, as shown in Fig. 3. The codon usage chart is from the program "Human_High.cod" from the Wisconsin Sequence Analysis Package, Version 8.1, Genetics Computer Group, Madison, WI. The codons which are most frequently used in highly expressed human genes are presumptively the optimal codons

for expression in human host cells, and thus form the basis for constructing a synthetic coding sequence. An example of a synthetic interferon alpha coding sequence is shown as the bottom sequence in the table below.

5 However, rather than a sequence having fully optimized codon usage, it may be desirable to utilize an interferon alpha encoding sequence which has optimized codon usage except in areas where the same amino acid is too close together or abundant to make uniform codon usage optimal.

10 In addition, other synthetic sequences can be used which have substantial portions of the codon usage optimized, for example, with at least 50%, 70%, 80% or 90% optimized codons as compared to a natural coding sequence. Other particular synthetic sequences for interferon alpha
15 can be selected by reference to the codon usage chart in Fig. 3. A sequence is selected by choosing a codon for each of the amino acids of the polypeptide sequences. DNA molecules corresponding to each of the polypeptides can then be constructed by routine chemical synthesis methods. For
20 example, shorter oligonucleotides can be synthesized, and then ligated in the appropriate relationships to construct the full-length coding sequences.

 The following sequences are provided in the sequence listing herein: interferon alpha amino acid sequence, SEQ
25 ID NO:9; interferon alpha wild type nucleic acid sequence, SEQ ID NO:10; interferon alpha synthetic nucleic acid sequence with optimized codon usage, SEQ ID NO:11; interferon alpha nucleic acid sequence with additional/semi-optimized codon usage, SEQ ID NO:12; IL-12 p40 subunit amino
30 acid sequence, SEQ ID NO:1; IL-12 p40 wild type nucleic acid sequence, SEQ ID NO:2; IL-12 p40 synthetic nucleic acid sequence with all codons optimized, SEQ ID NO:3; IL-12 p40 subunit nucleic acid sequence with all codons optimized except when same nucleic acids were too close/abundant, SEQ
35 ID NO:4; IL-12 p35 amino acid sequence, SEQ ID NO:5; IL-12 p35 wild type nucleic acid sequence, SEQ ID NO:6; IL-12 p35

- synthetic nucleic acid sequence with all codons optimized, SEQ ID NO:7; IL-12 p35 subunit nucleic acid sequence with all codons optimized except when same nucleic acids were too close/abundant, SEQ ID NO:8. Those skilled in the art will realize that various nucleic acid sequences with optimized codon usage can be constructed, for example based on the various combinations shown below, wherein optimal usage for each codon is shown below the IL-12 p35 and p40 subunit wild type sequences and the interferon alpha wild type sequence.

10 Sequences Encoding Human IL-12 p35

First line = natural sequence (SEQ ID NO. 6)

Second line = all codons optimized (SEQ ID NO. 7)

- Third line = all codons optimized except when same nucleic acids were too close/abundant (changes between second and third lines bolded) (SEQ ID NO. 8)

ATG TGT CCA GCG CGC AGC CTC CTC CTT GTG GCT ACC CTG GTC CTC CTG GAC CAC CTC ACT
 ATG TGC CCC GCC CGC AGC CTG CTG CTG GTG GCC ACC CTG GTG CTG CTG GAC CAC CTG AGC
 ATG TGC CCC GCC CGC AGC CTG CTG CTC GTG GCC ACC CTG GTG CTC CTG GAC CAC CTC AGC
 20 TTG GCC AGA AAC CTC CCC GTG GCC ACT CCA GAC CCA GGA ATG TTC CCA TGC CTT CAC CAC
 CTG GCC CGC AAC CTG CCC GTG GCC ACC CCC GAC CCC GGC ATG TTC CCC TGC CTG CAC CAC
 CTG GCC CGC AAC CTC CCC GTG GCC ACC CCA GAC CCC GGC ATG TTC CCA TGC CTG CAC CAC
 25 TCC CAA AAC CTG CTG AGG GCC GTC AGC AAC ATG CTC CAG AAG GCC AGA CAA ACT CTA GAA
 AGC CAG AAC CTG CTG GCG GCC GTG AGC AAC ATG CTG CAG AAG GCC GCG CAG ACC CTG GAG
 AGC CAG AAC CTG CTG GCG GCC GTG AGC AAC ATG CTG CAG AAG GCC GCG CAG ACC CTG GAG
 30 TTT TAC CCT TGC ACT TCT GAA GAG ATT GAT CAT GAA GAT ATC ACA AAA GAT AAA ACC AGC
 TTC TAC CCC TGC ACC AGC GAG GAG ATC GAC CAC GAG GAC ATC ACC AAG GAC AAG ACC AGC
 TTC TAC CCC TGC ACC AGC GAG GAG ATC GAC CAC GAG GAC ATC ACC AAG GAC AAG ACC AGC
 35 ACA GTG GAG GCC TGT TTA CCA TTG GAA TTA ACC AAG AAT GAG AGT TGC CTA AAT TCC AGA
 ACC GTG GAG GCC TGC CTG CCC CTG GAG CTG ACC AAG AAC GAG AGC TGC CTG AAC AGC CGC
 ACC GTG GAG GCC TGC CTG CCC CTC GAG TTA ACC AAG AAC GAG AGC TGC CTC AAC AGC CGC

- GAG ACC TCT TTC ATA ACT AAT GGG AGT TGC CTG GCC TCC AGA AAG ACC TCT TTT ATG ATG
 GAG ACC AGC TTC ATC ACC AAC GGC AGC TGC CTG GCC AGC CGC AAG ACC AGC TTC ATG ATG
 GAG ACC TCC TTC ATC ACC AAC GGC ACT TGC CTG GCC TCC CGC AAG ACC AGC TTC ATG ATG
 5
 GCC CTG TGC CTT AGT AGT ATT TAT GAA GAC TTG AAG ATG TAC CAG GTG GAG TTC AAG ACC
 GCC CTG TGC CTG AGC AGC ATC TAC GAG GAC CTG AAG ATG TAC CAG GTG GAG TTC AAG ACC
 GCC CTG TGC CTG AGC TCC ATC TAC GAG GAC CTG AAG ATG TAC CAG GTG GAG TTC AAG ACC
 10
 ATG AAT GCA AAG CTT CTG ATG GAT CCT AAG AGG CAG ATC TTT CTA GAT CAA AAC ATG CTG
 ATG AAC GCC AAG CTG CTG ATG GAC CCC AAG CTC CAG ATC TTC CTG GAC CAG AAC ATG CTG
 ATG AAC GCC AAG CTC CTG ATG GAC CCC AAG CTC CAG ATC TTC CTG GAC CAG AAC ATG CTG
 15
 GCA GTT ATT GAT GAG CTG ATG CAG GCC CTG AAT TTC AAC AGT GAG ACT GTG CCA CAA AAA
 GCC GTG ATC GAC GAG CTG ATG CAG GCC CTG AAC TTC AAC AGC GAG ACC GTG CCC CAG AAG
 GCC GTG ATC GAC GAG CTG ATG CAG GCC CTG AAC TTC AAC AGC GAG ACC GTG CCC CAG AAG
 20
 TCC TCC CTT GAA GAA CCG GAT TTT TAT AAA ACT AAA ATC AAG CTC TGC ATA CTT CTT CAT
 AGC AGC CTG GAG GAG CCC GAC TTC TAC AAG ACC AAG ATC AAG CTG TGC ATC CTG CTG CAC
 AGC AGC CTG GAG GAG CCC GAC TTC TAC AAG ACC AAG ATC AAG CTG TGC ATC CTG CTG CAC
 25
 GCT TTC AGA ATT CGG GCA GTG ACT ATT GAC AGA GTG ACG AGC TAT CTG AAT GCT TCC TAA
 GCC TTC CGC ATC CGC GCC GTG ACC ATC GAC CGC GTG ACC AGC TAC CTG AAC GCC ACC TGA
 GCC TTC CGC ATC CGG GCC GTG ACC ATC GAC CGC GTG ACC AGC TAC CTG AAC GCC ACG TGA
Additional Optimized Sequences Coding For IL-12 p35 Subunit
(Second Line = SEQ ID NO:24)
 10 20
 Met Cys Pro Ala Arg Ser Leu Leu Leu Val Ala Thr Leu Val Leu Leu Asp His Leu Ser
 ATG TGY CCN GCN MGN WSN YTN YTN YTN GTN GCN ACN YTN GTN YTN YTN GAY CAY YTN WSN
 30
 ATG TGT CCT GCT CGT TCT TTA TTA TTA GTT GCT ACT TTA GTT TTA TTA GAT CAT TTA TCT
 TGC CCC GCC CGC TCC TTG TTG TTG GTC GCC ACC TTG GTC TTG TTG GAC CAC TTG TCC
 CCA GCA CGA TCA CTT CTT CTT GTA GCA ACA CTT GTA CTT CTT CTT TCA
 CCG GCG CGG TCG CTC CTC CTC GTG GCG ACG CTC GTG CTC CTC CTC TCG

40

AGA AGT CTA CTA CTA

CTA

CTA CTA

CTA AGT

AGG AGC CTG CTG CTG

CTG

CTG CTG

CTG AGC

30

40

5 Leu Ala Arg Asn Leu Pro Val Ala Thr Pro Asp Pro Gly Met Phe Pro Cys Leu His His
 YTN GCN MGN AAY YTN CCN GTN GCN ACN CCN GAY CCN GGN ATG TTY CCN TGY YTN CAY CAY

TTA GCT CGT AAT TTA CCT GTT GCT ACT CCT GAT CCT GGT ATG TTT CCT TGT TTA CAT CAT
 TTG GCC CGC AAC TTG CCC GTC GCC ACC CCC GAC CCC GGC TTC CCC TGC TTG CAC CAC
 10 CTT GCA CGA CTT CCA GTA GCA ACA CCA CCA GGA CCA CTT
 CTC GCG CGG CTC CCG GTG GCG ACG CCG CCG GGG CCG CTC
 CTA AGA CTA CTA
 CTG AGG CTG CTG

15

50

60

Ser Gln Asn Leu Leu Arg Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu Glu
 WSN CAR AAY YTN YTN MGN GCN GTN WSN AAY ATG YTN CAR AAR GCN MGN CAR ACN YTN GAR

TCT CAA AAT TTA TTA CGT GCT GTT TCT AAT ATG TTA CAA AAA GCT CGT CAA ACT TTA GAA
 20 TCC CAG AAC TTG TTG CGC GCC GTC TCC AAC TTG CAG AAG GCC CGC CAG ACC TTG GAG
 TCA CTT CTT CGA GCA GTA TCA CTT GCA CGA ACA CTT
 TCG CTC CTC CGG GCG GTG TCG CTC GCG CGG ACG CTC
 AGT CTA CTA AGA AGT CTA AGA CTA
 AGC CTG CTG AGG AGC CTG AGG CTG

25

70

80

Phe Tyr Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys Thr Ser
 TTY TAY CCN TGY ACN WSN GAR GAR ATH GAY CAY GAR GAY ATH ACN AAR GAY AAR ACN WSN

TTT TAT CCT TGT ACT TCT GAA GAA ATT GAT CAT GAA GAT ATT ACT AAA GAT AAA ACT TCT
 30 TTC TAC CCC TGC ACC TCC GAG GAG ATC GAC CAC GAG GAC ATC ACC AAG GAC AAG ACC TCC
 CCA ACA TCA ATA ATA ACA ACA TCA
 CCG ACG TCG ACG ACG TCG
 AGT AGT
 35 AGC AGC

BNSDOCID: <WO 9947678A2 | >

42

150 160
Met Asn Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln Asn Met Leu
ATG AAY GCN AAR YTN YTN ATG GAY CCN AAR MGN CAR ATH TTY YTN GAY CAR AAY ATG YTN

5 ATG AAT GCT AAA TTA TTA ATG GAT CCT AAA CGT CAA ATT TTT TTA GAT CAA AAT ATG TTA
AAC GCC AAG TTG TTG GAC CCC AAG CGC CAG ATC TTC TTG GAC CAG AAC TTG
GCA CTT CTT CCA CGA ATA CTT CTT
GCG CTC CTC CCG CGG CTC CTC
CTA CTA AGA CTA CTA
10 CTG CTG AGG CTG CTG

170 180
Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn Ser Glu Thr Val Pro Gln Lys
GCN GTN ATH GAY GAR YTN ATG CAR GCN YTN AAY TTY AAY WSN GAR ACN GTN CCN CAR AAR

15 GCT GTT ATT GAT GAA TTA ATG CAA GCT TTA AAT TTT AAT TCT GAA ACT GTT CCT CAA AAA
GCC GTC ATC GAC GAG TTG CAG GCC TTG AAC TTC AAC TCC GAG ACC GTC CCC CAG AAG
GCA GTA ATA CTT GCA CTT TCA ACA GTA CCA
GCG GTG CTC GCG CTC TCG ACG GTG CCG
20 CTA AGT
CTG CTG AGC

190 200
Ser Ser Leu Glu Glu Pro Asp Phe Tyr Lys Thr Lys Ile Lys Leu Cys Ile Leu Leu His
WSN WSN YTN GAR GAR CCN GAY TTY TAY AAR ACN AAR ATH AAR YTN TGY ATH YTN YTN CAY

25 TCT TCT TTA GAA GAA CCT GAT TTT TAT AAA ACT AAA ATT AAA TTA TGT ATT TTA TTA CAT
TCC TCC TTG GAG GAG CCC GAC TTC TAC AAG ACC AAG ATC AAG TTG TGC ATC TTG TTG CAC
TCA TCA CTT CCA ACA ATA CTT ATA CTT CTT
30 TCG TCG CTC CCG ACG CTC CTC CTC
AGT AGT CTA CTA CTA CTA
AGC AGC CTG CTG CTG

210220

Ala Phe Arg Ile Arg Ala Val Thr Ile Asp Arg Val Thr Ser Tyr Leu Asn Ala Ser ***

GCN TTY MGN ATH MGN GCN GTN ACN ATH GAY MGN GTN ACN WSN TAY YTN AAY GCN WSN TRR

5 GCT TTT CGT ATT CGT GCT GTT ACT ATT GAT CGT GTT ACT TCT TAT TTA AAT GCT TCT TAA

GCC TTC CGC ATC CGC GCC GTC ACC ATC GAC CGC GTC ACC TCC TAC TTG AAC GCC TCC TAG

GCA CGA ATA CGA GCA GTA ACA ATA CGA GTA ACA TCA CTT GCA TCA TGA

GCG CGG CGG GCG GTG ACG CGG GTG ACG TCG CTC GCG TCG

AGA AGA AGA AGA AGT CTA AGT

10 AGG AGG AGG AGC CTG AGC

Sequences Encoding Human IL-12 p40

First line = natural sequence (SEQ ID NO. 2)

Second line = all codons optimized (SEQ ID NO. 3)

Third line = all codons optimized except when same
 15 nucleic acids were too close/abundant (changes between
 second and third lines bolded) (SEQ ID NO. 4)

ATG TGT CAC CAG CAG TTG GTC ATC TCT TGG TTT TCC CTG GTT TTT CTG GCA TCT CCC CTC

ATG TGC CAC CAG CAG CTG GTG ATC AGC TGG TTC AGC CTG GTG TTC CTG GCC AGC CCC CTG

ATG TGC CAC CAG CAG CTG GTG ATC AGC TGG TTC TCC CTG GTG TTT CTG GCC AGC CCC CTC

20 GTG GCC ATA TGG GAA CTG AAG AAA GAT GTT TAT GTC GTA GAA TTG GAT TGG TAT CCG GAT

GTG GCC ATC TGG GAG CTG AAG AAG GAC GTG TAC GTG GTG GAG CTG GAC TGG TAC CCC GAC

GTG GCC ATC TGG GAG CTG AAG AAA GAC GTG TAC GTG GTC GAG CTG GAC TGG TAC CCC GAC

25 GCC CCT GGA GAA ATG GTG GTC CTC ACC TGT GAC ACC CCT GAA GAA GAT GGT ATC ACC TGG

GCC CCC GGC GAG ATG GTG GTG CTG ACC TGC GAC ACC CCC GAG GAG GAC GGC ATC ACC TGG

GCC CCC GGC GAG ATG GTG GTC CTG ACC TGC GAC ACC CCC GAG GAA GAC GGC ATC ACC TGG

ACC TTG GAC CAG AGC AGT GAG GTC TTA GGC TCT GGC AAA ACC CTG ACC ATC CAA GTC AAA

30 ACC CTG GAC CAG AGC AGC GAG GTG CTG GGC AGC GGC AAG ACC CTG ACC ATC CAG GTG AAG

ACC CTG GAC CAG AGC AGT GAG GTG CTG GGC TCC GGC AAG ACC CTG ACC ATC CAG GTG AAG

GAG TTT GGA GAT GCT GGC CAG TAC ACC TGT CAC AAA GGA GGC GAG GTT CTA AGC CAT TCG

GAG TTC GGC GAC GCC GGC CAG TAC ACC TGC CAC AAG GGC GGC GAG GTG CTG AGC CAC AGC

35 GAG TTC GGC GAC GCC GGC CAG TAC ACC TGC CAC AAG GGA GGC GAG GTG CTG AGC CAC TCC

- CTC CTG CTG CTT CAC AAA AAG GAA GAT GGA ATT TGG TCC ACT GAT ATT TTA AAG GAC CAG
 CTG CTG CTG CTG CAC AAG AAG GAG GAC GGC ATC TGG AGC ACC GAC ATC CTG AAG GAC CAG
 CTC CTG CTG CTC CAC AAA AAG GAG GAC GGC ATC TGG AGC ACC GAC ATC CTG AAG GAC CAG
- 5 AAA GAA CCC AAA AAT AAG ACC TTT CTA AGA TGC GAG GCC AAG AAT TAT TCT GGA CGT TTC
 AAG GAG CCC AAG AAC AAG ACC TTC CTG CGC TGC GAG GCC AAG AAC TAC AGC GGC CGC TTC
 AAG GAG CCC AAG AAC AAG ACC TTC CTG CGC TGC GAG GCC AAG AAC TAC AGC GGC CGC TTC
- 10 ACC TGC TGG TGG CTG ACG ACA ATC AGT ACT GAT TTG ACA TTC AGT GTC AAA AGC AGC AGA
 ACC TGC TGG TGG CTG ACC ACC ATC AGC ACC GAC CTG ACC TTC AGC GTG AAG AGC AGC AGG
 ACC TGC TGG TGG CTG ACC ACG ATC AGC ACC GAC CTG ACC TTC AGT GTG AAG AGC AGC AGG
- 15 GGC TCT TCT GAC CCC CAA GGG GTG ACG TGC GGA GCT GCT ACA CTC TCT GCA GAG AGA GTC
 GGC AGC AGC GAC CCC CAG GGC GTG ACC TGC GGC GCC GCC ACC CTG AGC GCC GAG CGC GTG
 GGC TCC AGC GAC CCC CAG GGC GTG ACC TGC GGC GCT GCC ACC CTG AGC GCC GAG CGC GTG
- 20 AGA GGG GAC AAC AAG GAG TAT GAG TAC TCA GTG GAG TGC CAG GAG GAC AGT GCC TGC CCA
 CGC GGC GAC AAC AAG GAG TAC GAG TAC AGC GTG GAG TGC CAG GAG GAC AGC GCC TGC CCC
 CGC GGC GAC AAC AAG GAG TAC GAG TAC AGC GTG GAG TGC CAG GAA GAC TCC GCC TGC CCC
- 25 GCT GCT GAG GAG AGT CTG CCC ATT GAG GTC ATG GTG GAT GCC GTT CAC AAG CTC AAG TAT
 GCC GCC GAG GAG AGC CTG CCC ATC GAG GTG ATG GTG GAC GCC GTC CAC AAG CTG AAG TAC
 GCC GCT GAG GAG AGC CTG CCC ATC GAG GTG ATG GTG GAC GCC GTT CAC AAG CTG AAG TAC
- 30 GAA AAC TAC ACC AGC AGC TTC TTC ATC AGG GAC ATC ATC AAA CCT GAC CCA CCC AAG AAC
 GAG AAC TAC ACC AGC AGC TTC TTC ATC CGC GAC ATC ATC AAG CCC GAC CCC CCC AAG AAC
 GAG AAC TAC ACC AGC AGC TTC TTC ATC CGC GAC ATC ATC AAG CCT GAC CCA CCC AAG AAC
- 35 TTG CAG CTG AAG CCA TTA AAG AAT TCT CGG CAG GTG GAG GTC AGC TGG GAG TAC CCT GAC
 CTG CAG CTG AAG CCC CTG AAG AAC AGC CGC CAG GTG GAG GTG AGC TGG GAG TAC CCC GAC
 CTC CAG CTG AAG CCC CTC AAG AAC TCC CGC CAG GTG GAG GTG AGC TGG GAG TAC CCC GAC
 ACC TGG AGT ACT CCA CAT TCC TAC TTC TCC CTG ACA TTC TGC GTT CAG GTC CAG GGC AAG
 ACC TGG AGC ACC CCC CAC AGC TAC TTC AGC CTG ACC TTC TGC GTG CAG GTG CAG GGC AAG
 ACC TGG AGC ACG CCC CAC TCC TAC TTC TCC CTG ACC TTC TGC GTG CAG GTC CAG GGC AAG

AGC AAG AGA GAA AAG AAA GAT AGA GTC TTC ACG GAC AAG ACC TCA GCC ACG GTC ATC TGC
AGC AAG CGC GAG AAG AAG GAC CGC GTG TTC ACC GAC AAG ACC AGC GCC ACC GTG ATC TGC
AGC AAG CGC GAG AAG AAA GAC CGG GTG TTC ACC GAC AAG ACC AGC GCC ACC GTC ATC TGC

5 CGC AAA AAT GCC AGC ATT AGC GTG CGG GCC CAG GAC CGC TAC TAT AGC TCA TCT TGG AGC
CGC AAG AAC GCC AGC ATC AGC GTG CGC GCC CAG GAC CGC TAC TAC AGC AGC AGC TGG AGC
CGC AAG AAC GCC AGC ATC AGC GTG CGC GCC CAG GAC CGC TAC TAT AGC TCC TCT TGG AGC

GAA TGG GCA TCT GTG CCC TGC AGT TAG

10 GAG TGG GCC AGC GTG CCC TGC AGC TAG
GAG TGG GCC AGC GTG CCC TGC TCC TAG

Additional Optimized Sequences Coding For IL-12 p40 Subunit
(Second Line = SEQ ID NO:25)

[illegible]

46

50 60

Ala Pro Gly Glu Met Val Val Leu Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp
 GCN CCN GGN GAR ATG GTN GTN YTN ACN TGY GAY ACN CCN GAR GAR GAY GGN ATH ACN TGG

5 GCT CCT GGT GAA ATG GTT GTT TTA ACT TGT GAT ACT CCT GAA GAA GAT GGT ATT ACT TGG
 GCC CCC GGC GAG GTC GTC TTG ACC TGC GAC ACC CCC GAG GAG GAC GGC ATC ACC
 GCA CCA GGA GTA GTA CTT ACA ACA CCA GGA ATA ACA
 GCG CCG GGG GTG GTG CTC ACG ACG CCG GGG ACG

CTA
 CTG

10

70 80

Thr Leu Asp Gln Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys
 ACN YTN GAY CAR WSN WSN GAR GTN YTN GGN WSN GGN AAR ACN YTN ACN ATH CAR GTN AAR

15 ACT TTA GAT CAA TCT TCT GAA GTT TTA GGT TCT GGT AAA ACT TTA ACT ATT CAA GTT AAA
 ACC TTG GAC CAG TCC TCC GAG GTC TTG GGC TCC GGC AAG ACC TTG ACC ATC CAG GTC AAG
 ACA CTT TCA TCA GTA CTT GGA TCA GGA ACA CTT ACA ATA GTA
 ACG CTC TCG TCG GTG CTC GGG TCG GGG ACG CTC ACG GTG

20 CTA AGT AGT CTA AGT CTA
 CTG AGC AGC CTG AGC CTG

90 100

Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val Leu Ser His Ser
 GAR TTY GGN GAY GCN GGN CAR TAY ACN TGY CAY AAR GGN GGN GAR GTN YTN WSN CAY WSN

25 GAA TTT GGT GAT GCT GGT CAA TAT ACT TGT CAT AAA GGT GGT GAA GTT TTA TCT CAT TCT
 GAG TTC GGC GAC GCC GGC CAG TAC ACC TGC CAC AAG GGC GGC GAG GTC TTG TCC CAC TCC
 GGA GCA GGA ACA GGA GGA GTA CTT TCA TCA
 30 GGG GCG GGG ACG GGG GGG GTG CTC TCG TCG
 CTA AGT AGT
 CTG AGC AGC

BNSDOCID <WO 994767BA2 I >

48

170 180
 Gly Ser Ser Asp Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser Ala Glu Arg Val
 GGN WSN WSN GAY CCN CAR GGN GTN ACN TGY GGN GCN GCN ACN YTN WSN GCN GAR MGN GTN

 5 GGT TCT TCT GAT CCT CAA GGT GTT ACT TGT GGT GCT GCT ACT TTA TCT GCT GAA CGT GTT
 GGC TCC TCC GAC CCC CAG GGC GTC ACC TGC GGC GCC GCC ACC TTG TCC GCC GAG CGC GTC
 GGA TCA TCA CCA GGA GTA ACA GGA GCA GCA ACA CTT TCA GCA CGA GTA
 GGG TCG TCG CCG GGG GTG ACG GGG GCG GCG ACG CTC TCG GCG CGG GTG
 AGT AGT CTA AGT AGA
 10 AGC AGC CTG AGC AGG

190 200
 Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu Cys Gln Glu Asp Ser Ala Cys Pro
 MGN GGN GAY AAY AAR GAR TAY GAR TAY WSN GTN GAR TGY CAR GAR GAY WSN GCN TGY CCN

 15 CGT GGT GAT AAT AAA GAA TAT GAA TAT TCT GTT GAA TGT CAA GAA GAT TCT GCT TGT CCT
 CGC GGC GAC AAC AAG GAG TAC GAG TAC TCC GTC GAG TGC CAG GAG GAC TCC GCC TGC CCC
 CGA GGA TCA GTA TCA GCA CCA
 CGG GGG TCG GTG TCG GCG CCG
 20 AGA AGT AGT
 AGG AGC AGC

210 220
 Ala Ala Glu Glu Ser Leu Pro Ile Glu Val Met Val Asp Ala Val His Lys Leu Lys Tyr
 GCN GCN GAR GAR WSN YTN CCN ATH GAR GTN ATG GTN GAY GCN GTN CAY AAR YTN AAR TAY

 25 GCT GCT GAA GAA TCT TTA CCT ATT GAA GTT ATG GTT GAT GCT GTT CAT AAA TTA AAA TAT
 GCC GCC GAG GAG TCC TTG CCC ATC GAG GTC GTC GAC GCC GTC CAC AAG TTG AAG TAC
 GCA GCA TCA CTT CCA ATA GTA GTA GCA GTA CTT
 30 GCG GCG TCG CTC CCG GTG GTG GCG GTG CTC
 AGT CTA CTA
 AGC CTG CTG

10

250

260

15

270

280

25

30

50

290300

Ser Lys Arg Glu Lys Lys Asp Arg Val Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys
 WSN AAR MGN GAR AAR AAR GAY MGN GTN TTY ACN GAY AAR ACN WSN GCN ACN GTN ATH TGY

5 TCT AAA CGT GAA AAA AAA GAT CGT GTT TTT ACT GAT AAA ACT TCT GCT ACT GTT ATT TGT
 TCC AAG CGC GAG AAG AAG GAC CGC GTC TTC ACC GAC AAG ACC TCC GCC ACC GTC ATC TGC
 TCA CGA CGA GTA ACA ACA TCA GCA ACA GTA ATA
 TCG CGG CGG GTG ACG ACG TCG GCG ACG GTG
 AGT AGA AGA AGT
 10 AGC AGG AGG AGC

310320

Arg Lys Asn Ala Ser Ile Ser Val Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser
 MGN AAR AAY GCN WSN ATH WSN GTN MGN GCN CAR GAY MGN TAY TAY WSN WSN WSN TGG WSN

15 CGT AAA AAT GCT TCT ATT TCT GTT CGT GCT CAA GAT CGT TAT TAT TCT TCT TCT TGG TCT
 CGC AAG AAC GCC TCC ATC TCC GTC CGC GCC CAG GAC CGC TAC TAC TCC TCC TCC TCC
 CGA GCA TCA ATA TCA GTA CGA GCA CGA TCA TCA TCA TCA
 CGG GCG TCG TCG GTG CGG GCG CGG TCG TCG TCG TCG
 20 AGA AGT AGT AGA AGA AGT AGT AGT AGT
 AGG AGC AGC AGG AGG AGC AGC AGC AGC

Glu Trp Ala Ser Val Pro Cys Ser ***

25 GAR TGG GCN WSN GTN CCN TGY WSN TRR

GAA TGG GCT TCT GTT CCT TGT TCT TAA
 GAG GCC TCC GTC CCC TGC TCC TAG
 GCA TCA GTA CCA TCA TGA
 30 GCG TCG GTG CCG TCG
 AGT AGT
 AGC AGC

Wild Type Sequence Coding For Interferon Alpha

	9	18	27	36	45	54												
5'	ATG	GCC	TTG	ACC	TTT	GCT	TTA	CTG	GTG	GCC	CTC	CTG	GTG	CTC	AGC	TGC	AAG	TCA

5	M	A	L	T	F	A	L	L	V	A	L	L	V	L	S	C	K	S
	63	72	81	90	99	108												
	AGC	TGC	TCT	GTG	GGC	TGT	GAT	CTG	CCT	CAA	ACC	CAC	AGC	CTG	GGT	AGC	AGG	AGG

10	S	C	S	V	G	C	D	L	P	Q	T	H	S	L	G	S	R	R
	117	126	135	144	153	162												
	ACC	TTG	ATG	CTC	CTG	GCA	CAG	ATG	AGG	AGA	ATC	TCT	CTT	TTC	TCC	TGC	TTG	AAG

15	T	L	M	L	L	A	Q	M	R	R	I	S	L	F	S	C	L	K
	171	180	189	198	207	216												
	GAC	AGA	CAT	GAC	TTT	GGA	TTT	CCC	CAG	GAG	GAG	TTT	GGC	AAC	CAG	TTC	CAA	AAG

20	D	R	H	D	F	G	F	P	Q	E	E	F	G	N	Q	F	Q	K
	225	234	243	252	261	270												
	GCT	GAA	ACC	ATC	CCT	GTC	CTC	CAT	GAG	ATG	ATC	CAG	CAG	ATC	TTC	AAT	CTC	TTC

25	A	E	T	I	P	V	L	H	E	M	I	Q	Q	I	F	N	L	F
	279	288	297	306	315	324												
	AGC	ACA	AAG	GAC	TCA	TCT	GCT	GCT	TGG	GAT	GAG	ACC	CTC	CTA	GAC	AAA	TTC	TAC

30	S	T	K	D	S	S	A	A	W	D	E	T	L	L	D	K	F	Y
	333	342	351	360	369	378												
	ACT	GAA	CTC	TAC	CAG	CAG	CTG	AAT	GAC	CTG	GAA	GCC	TGT	GTG	ATA	CAG	GGG	GTG

35	T	E	L	Y	Q	Q	L	N	D	L	E	A	C	V	I	Q	G	V

52

387 396 405 414 423 432
 GGG GTG ACA GAG ACT CCC CTG ATG AAG GAG GAC TCC ATT CTG GCT GTG AGG AAA

 G V T E T P L M K E D S I L A V R K
 5
 441 450 459 468 477 486
 TAC TTC CAA AGA ATC ACT CTC TAT CTG AAA GAG AAG AAA TAC AGC CCT TGT GCC

 Y F Q R I T L Y L K E K K Y S P C A
 10
 495 504 513 522 531 540
 TGG GAG GTT GTC AGA GCA GAA ATC ATG AGA TCT TTT TCT TTG TCA ACA AAC TTG

 W E V V R A E I M R S F S L S T N L
 15
 549 558 567
 CAA GAA AGT TTA AGA AGT AAG GAA TGA 3'

 Q E S L R S K E *

20 Interferon Alpha Coding Sequence with All Codons Optimized
(SEQ ID NO:11)

ATG GCC CTG ACC TTC GCC CTG CTG GTG GCC CTG CTG GTG CTG AGC TGC AAG AGC AGC TGC
 25 TCC GTG GGG TGC GAC CTG CCC CAG ACC CAC AGC CTG GGG AGC CGG CGG ACC CTG ATG CTG
 CTG GCC CAG ATG CGG CGG ATC AGC CTG TTC AGC TGC CTG AAG GAC CGG CAC GAC TTC GGG
 30 TTC CCC CAG GAG GAG TTC GGG AAC CAG TTC CAG AAG GCC GAG ACC ATC CCC GTG CTG CAC
 GAG ATG ATC CAG CAG ATC TTC AAC CTG TTC AGC ACC AAG GAC AGC AGC GCC GCC TGG GAC
 GAG ACC CTG CTG GAC AAG TTC TAC ACC GAG CTG TAC CAG CAG CTG AAC GAC CTG GAG GCC
 35 TGC GTG ATC CAG GGG GTG GGG GTG ACC GAG ACC CCC CTG ATG AAG GAG GAC AGC ATC CTG

GCC GTG CGG AAG TAC TTC CAG CGG ATC ACC CTG TAC CTG AAG GAG AAG AAG TAC TCC CCC

TGC GCC TGG GAG GTG GTG CGG GCC GAG ATC ATG CGG AGC TTC AGC CTG AGC ACC AAC CTG

5

CAG GAG AGC CTG CGG AGC AAG GAG TGA

Additional/Semi Optimized Sequence Coding For Interferon
Alpha (Second Line = SEQ ID NO:12)

10

10

20

MET ALA LEU THR PHE ALA LEU LEU VAL ALA LEU LEU VAL LEU SER CYS LYS SER SER CYS
 ATG GCN YTN ACN TTY GCN YTN YTN GTN GCN YTN YTN GTN YTN WSN TGY AAR WSN WSN TGY

ATG GCT TTA ACT TTT GCT TTA TTA GTT GCT TTA TTA GTT TTA TCT TGT AAA TCT TCT TGT

15

GCC TTG ACC TTC GCC TTG TTG GTC GCC TTG TTG GTC TTG TCC TGC AAG TCC TCC TGC

GCA CTT ACA GCA CTT CTT GTA GCA CTT CTT GTA CTT TCA TCA TCA

GCG CTC ACG GCG CTC CTC GTG GCG CTC CTC GTG CTC TCG TCG TCG

CTA CTA CTA CTA CTA CTA CTA AGT AGT AGT

CTG CTG CTG CTG CTG CTG CTG AGC AGC AGC

20

30

40

SER VAL GLY CYS ASP LEU PRO GLN THR HIS SER LEU GLY SER ARG ARG THR LEU MET LEU
 WSN GTN GGN TGY GAY YTN CCN CAR ACN CAY WSN YTN GGN WSN MGN MGN ACN YTN ATG YTN

25

TCT GTT GGT TGT GAT TTA CCT CAA ACT CAT TCT TTA GGT TCT CGT CGT ACT TTA ATG TTA

TCC GTC GGC TGC GAC TTG CCC CAG ACC CAC TCC TTG GGC TCC CGC CGC ACC TTG TTG

TCA GTA GGA CTT CCA ACA TCA CTT GGA TCA CGA CGA ACA CTT CTT

TCG GTG GGG CTC CCG ACG TCG CTC GGG TCG CGG CGG ACG CTC CTC

AGT CTA AGT CTA AGT AGA AGA CTA CTA

30

AGC CTG AGC CTG AGC AGG AGG CTG CTG

54

50 60

LEU ALA GLN MET ARG ARG ILE SER LEU PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLY
 YTN GCN CAR ATG MGN MGN ATH WSN YTN TTY WSN TGY YTN AAR GAY MGN CAY GAY TTY GGN

5 TTA GCT CAA ATG CGT CGT ATT TCT TTA TTT TCT TGT TTA AAA GAT CGT CAT GAT TTT GGT
 TTG GCC CAG CGC CGC ATC TCC TTG TTC TCC TGC TTG AAG GAC CGC CAC GAC TTC GGC
 CTT GCA CGA CGA ATA TCA CTT TCA CTT CGA GGA
 CTC GCG CGG CGG TCG CTC TCG CTC CGG GGG
 CTA AGA AGA AGT CTA AGT CTA AGA
 10 CTG AGG AGG AGC CTG AGC CTG AGG

70 80

PHE PRO GLN GLU GLU PHE GLY ASN GLN PHE GLN LYS ALA GLU THR ILE PRO VAL LEU HIS
 TTY CCN CAR GAR GAR TTY GGN AAY CAR TTY CAR AAR GCN GAR ACN ATH CCN GTN YTN CAY

15 TTT CCT CAA GAA GAA TTT GGT AAT CAA TTT CAA AAA GCT GAA ACT ATT CCT GTT TTA CAT
 TTC CCC CAG GAG GAG TTC GGC AAC CAG TTC CAG AAG GCC GAG ACC ATC CCC GTC TTG CAC
 CCA GGA GCA ACA ATA CCA GTA CTT
 CCG GGG GCG ACG CCG GTG CTC
 20 CTA
 CTG

90 100

GLU MET ILE GLN GLN ILE PHE ASN LEU PHE SER THR LYS ASP SER SER ALA ALA TRP ASP
 25 GAR ATG ATH CAR CAR ATH TTY AAY YTN TTY WSN ACN AAR GAY WSN WSN GCN GCN TGG GAY

GAA ATG ATT CAA CAA ATT TTT AAT TTA TTT TCT ACT AAA GAT TCT TCT GCT GCT TGG GAT
 GAG ATC CAG CAG ATC TTC AAC TTG TTC TCC ACC AAG GAC TCC TCC GCC GCC GAC
 30 ATA ATA CTT TCA ACA TCA TCA GCA GCA
 CTC TCG ACG TCG TCG GCG GCG
 CTA AGT AGT AGT
 CTG AGC AGC AGC

BNSDOCID <WO 9547678A2 I >

```

                                170                                180
CYS ALA TRP GLU VAL VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER THR ASN LEU
TGY GCN TGG GAR GTN GTN MGN GCN GAR ATH ATG MGN WSN TTY WSN YTN WSN ACN AAY YTN
-----
5  TGT GCT TGG GAA GTT GTT CGT GCT GAA ATT ATG CGT TCT TTT TCT TTA TCT ACT AAT TTA
TGC GCC      GAG GTC GTC CGC GCC GAG ATC      CGC TCC TTC TCC TTG TCC ACC AAC TTG
      GCA      GTA GTA CGA GCA      ATA      CGA TCA      TCA CTT TCA ACA      CTT
      GCG      GTG GTG CGG GCG      CGG TCG      TCG CTC TCG ACG      CTC
                                AGA                                AGA AGT      AGT CTA AGT      CTA
10                                AGG                                AGG AGC      AGC CTG AGC      CTG

GLN GLU SER LEU ARG SER LYS GLU ***
CAR GAR WSN YTN MGN WSN AAR GAR TRR
15 -----
CAA GAA TCT TTA CGT TCT AAA GAA TAA
CAG GAG TCC TTG CGC TCC AAG GAG TAG
      TCA CTT CGA TCA      TGA
      TCG CTC CGG TCG
20      AGT CTA AGA AGT
      AGC CTG AGG AGC

```

Delivery and expression of nucleic acids in many formulations is limited due to degradation of the nucleic acids by components of organisms, such as nucleases. Thus, protection of the nucleic acids when delivered *in vivo* can greatly enhance the resulting expression, thereby enhancing a desired pharmacological or therapeutic effect. It was found that certain types of compounds which interact with a nucleic acid (e.g., DNA) in solution but do not condense the nucleic acid provide *in vivo* protection to the nucleic acid, and correspondingly enhance the expression of an encoded gene product.

We have described the use of delivery systems designed to interact with plasmids and protect plasmids from rapid extracellular nuclease degradation [Mumper, R.J., et al.,

1996, *Pharm. Res.* 13:701-709; Mumper, R.J., et al., 1997. Submitted to *Gene Therapy*]. A characteristic of the PINC systems is that they are non-condensing systems that allow the plasmid to maintain flexibility and diffuse freely throughout the muscle while being protected from nuclease degradation. While the PINC systems are primarily discussed below, it will be understood that cationic lipid based systems and systems utilizing both PINCS and cationic lipids are also within the scope of the present invention.

10 A common structural component of the PINC systems is that they are amphiphilic molecules, having both a hydrophilic and a hydrophobic portion. The hydrophilic portion of the PINC is meant to interact with plasmids by hydrogen bonding (via hydrogen bond acceptor or donor groups), Van der Waals interactions, or/and by ionic interactions. For example, PVP and N-methyl-2-pyrrolidone (NM2P) are hydrogen bond acceptors while PVA and PG are hydrogen bond donors.

20 All four molecules have been reported to form complexes with various (poly)anionic molecules [Buhler V., BASF Aktiengesellschaft Feinchemie, Ludwigshafen, pp 39-42; Galaev Y, et al., *J. Chrom. A.* 684:45-54 (1994); Tarantino R, et al. *J. Pharm. Sci.* 83:1213-1216 (1994); Zia, H., et al., *Pharm. Res.* 8:502-504 (1991);]. The hydrophobic portion of the PINC systems is designed to result in a coating on the plasmid rendering its surface more hydrophobic. Kabanov et al. have described previously the use of cationic polyvinyl derivatives for plasmid condensation designed to increase plasmid hydrophobicity, protect plasmid from nuclease degradation, and increase its affinity for biological membranes [Kabanov, A.V., and Kabanov, V.A., 1995, *Bioconj. Chem.* 6:7-20; Kabanov, A.V., et al., 1991, *Biopolymers* 31:1437-1443; Yaroslavov, A.A., et al., 1996, *FEBS Letters* 384:177-180].

35 Substantial protective effect is observed; up to at least a one log enhancement of gene expression in rat muscle

over plasmid formulated in saline has been demonstrated with these exemplary PINC systems. We have also found that the expression of reporter genes in muscle using plasmids complexed with the PINC systems was more reproducible than when the plasmid was formulated in saline. For example, the coefficient of variation for reporter gene expression in muscle using plasmid formulated in saline was $96 \pm 35\%$ ($n = 20$ studies; 8-12 muscles/study) whereas with coefficient of variation with plasmids complexed with PINC systems was $40 \pm 19\%$ ($n = 30$ studies; 8-12 muscles/study). The high coefficient of variation for reporter gene expression with plasmid formulated in saline has been described previously [Davis, H.L., et al., 1993, *Hum. Gene Ther.* 4:151-9]. In addition, in contrast with the results for DNA:saline, there was no significant difference in gene expression in muscle when plasmid with different topologies were complexed with polyvinyl pyrrolidone (PVP). This suggests that PVP is able to protect all forms of the plasmid from rapid nuclease degradation.

1. Summary of interactions between a PINC polymer (PVP) and plasmid

We have demonstrated using molecular modeling that an exemplary PINC polymer, PVP, forms hydrogen bonds with the base pairs of a plasmid within its major groove and results in a hydrophobic surface on the plasmid due to the vinyl backbone of PVP. These interactions are supported by the modulation of plasmid zeta potential by PVP as well as by the inhibition of ethidium bromide intercalation into complexed plasmid. We have correlated apparent binding between PVP and plasmid to pH and salt concentration and have demonstrated the effect of these parameters on β -gal expression after intramuscular injection of plasmid/PVP complexes [Mumper, R.J., et al., 1997. Submitted to *Gene Therapy*]. A summary of the physico-chemical properties of plasmid/PVP complexes is listed in Table I below.

Table I: Summary of the Physico-Chemical Properties of Plasmid/PVP Complexes

Method	Result
Molecular modeling	Hydrogen bonding and
Fourier-transformed	hydrophobic plasmid surface
Infra-red Hydrogen	observed bonding demonstrated
DNase I challenge	Decreased rate of plasmid
	degradation in the presence
	of PVP
Microtitration	Positive heats of reaction
Calorimetry	indicative of an endothermic
	process
Potentiometric titration	One unit pH drop when plasmid
	and PVP are complexed
Dynamic Dialysis	Rate of diffusion of PVP
	reduced in the presence of
	plasmid
Zeta potential	Surface charge of plasmid
modulation	decreased by PVP
Ethidium bromide	Ethidium bromide
Intercalation	intercalation reduced by
	plasmid/PVP complexation
Osmotic pressure	Hyper-osmotic formulation
	(i.e., 340 mOsm/kg H ₂ O)
Luminescence	Plasmid/PVP binding decreased
Spectroscopy	in salt and/or at pH 7

5

2. Histology of expression in muscle

Immunohistochemistry for β -gal using a slide scanning technology has revealed the uniform distribution of β -gal expression sites across the whole cross-sections of rat tibialis muscles. Very localized areas were stained positive for β -gal when CMV- β -gal plasmid was formulated in saline. β -gal positive cells were observed exclusively around the needle tract when plasmid was injected in saline. This is

in agreement with previously published results [Wolff, J.A., et al., 1990, *Science* 247:1465-68; Davis, H.L., et al., 1993, *Hum. Gene Ther.* 4:151-9; Davis, H.L., et al., 1993, *Hum. Gene Ther.* 4:733-40].

5 In comparison, immunoreactivity for β -gal was observed in a wide area of muscle tissue after intramuscular injection of CMV- β -gal plasmid/PVP complex (1:17 w/w) in 150 mM NaCl. It appeared that the majority of positive muscle fibers were located at the edge of muscle bundles. Thus, 10 staining for β -gal in rat muscle demonstrated that, using a plasmid/PVP complex, the number of muscle fibers stained positive for β -gal was approximately 8-fold greater than found using a saline formulation. Positively stained muscle fibers were also observed over a much larger area in 15 the muscle tissue using the plasmid/PVP complex providing evidence that the injected plasmid was widely dispersed after intramuscular injection.

We conclude that the enhanced plasmid distribution and expression in rat skeletal muscle was a result of both 20 protection from extracellular nuclease degradation due to complexation and hyper-osmotic effects of the plasmid/PVP complex. However, Dowty and Wolff et al. have demonstrated that osmolarity, up to twice physiologic osmolarity, did not significantly effect gene expression in muscle [Dowty, M.E., 25 and Wolff, J.A. In: J.A. Wolff (Ed.), 1994, *Gene Therapeutics: Methods and Applications of Direct Gene Transfer*. Birkhauser, Boston, pp. 82-98]. This suggests that the enhanced expression of plasmid due to PVP complexation is most likely due to nuclease protection and 30 less to osmotic effects. Further, the surface modification of plasmids by PVP (e.g., increased hydrophobicity and decreased negative surface charge) may also facilitate the uptake of plasmids by muscle cells.

3. Structure-activity relationship of PINC polymers

We have found a linear relationship between the structure of a series of co-polymers of vinyl pyrrolidone and vinyl acetate and the levels of gene expression in rat muscle. We have found that the substitution of some vinyl pyrrolidone monomers with vinyl acetate monomers in PVP resulted in a co-polymer with reduced ability to form hydrogen bonds with plasmids. The reduced interaction subsequently led to decreased levels of gene expression in rat muscle after intramuscular injection. The expression of β -gal decreased linearly ($R = 0.97$) as the extent of vinyl pyrrolidone monomer (VPM) content in the co-polymers decreased.

These data demonstrate that pH and viscosity are not the most important parameters effecting delivery of plasmid to muscle cells since these values were equivalent for all complexes. These data suggest that enhanced binding of the PINC polymers to plasmid results in increased protection and bioavailability of plasmid in muscle.

4. Additional PINC systems

The structure-activity relationship described above can be used to design novel co-polymers that will also have enhanced interaction with plasmids. It is expected that there is "an interactive window of opportunity" whereby enhanced binding affinity of the PINC systems will result in a further enhancement of gene expression after their intramuscular injection due to more extensive protection of plasmids from nuclease degradation. It is expected that there will be an optimal interaction beyond which either condensation of plasmids will occur or "triplex" type formation, either of which can result in decreased bioavailability in muscle and consequently reduced gene expression.

As indicated above, the PINC compounds are generally amphiphilic compounds having both a hydrophobic portion and a hydrophilic portion. In many cases the hydrophilic portion is provided by a polar group. It is recognized in the art that such polar groups can be provided by groups such as, but not limited to, pyrrolidone, alcohol, acetate, amine or heterocyclic groups such as those shown on pp. 2-73 and 2-74 of CRC Handbook of Chemistry and Physics (72nd Edition), David R. Lide, editor, including pyrroles, pyrazoles, imidazoles, triazoles, dithiols, oxazoles, (iso)thiazoles, oxadiazoles, oxatriazoles, diaoxazoles, oxathioles, pyrones, dioxins, pyridines, pyridazines, pyrimidines, pyrazines, piperazines, (iso)oxazines, indoles, indazoles, carpazoles, and purines and derivatives of these groups, hereby incorporated by reference.

Compounds also contain hydrophobic groups which, in the case of a polymer, are typically contained in the backbone of the molecule, but which may also be part of a non-polymeric molecule. Examples of such hydrophobic backbone groups include, but are not limited to, vinyls, ethyls, acrylates, acrylamides, esters, celluloses, amides, hydrides, ethers, carbonates, phosphazenes, sulfones, propylenes, and derivatives of these groups. The polarity characteristics of various groups are quite well known to those skilled in the art as illustrated, for example, by discussions of polarity in any introductory organic chemistry textbook.

The ability of such molecules to interact with nucleic acids is also understood by those skilled in the art, and can be predicted by the use of computer programs which model such intermolecular interactions. Alternatively or in addition to such modeling, effective compounds can readily be identified using one or more of such tests as 1) determination of inhibition of the rate of nuclease digestion, 2) alteration of the zeta potential of the DNA, which indicates coating of DNA, 3) or inhibition of the

ability of intercalating agents, such as ethidium bromide to intercalate with DNA.

5. Targeting Ligands

In addition to the nucleic acid/PINC complexes described above for delivery and expression of nucleic acid sequences, in particular embodiments it is also useful to provide a targeting ligand in order to preferentially obtain expression in particular tissues, cells, or cellular regions or compartments.

Such a targeted PINC complex includes a PINC system (monomeric or polymeric PINC compound) complexed to plasmid (or other nucleic acid molecule). The PINC system is covalently or non-covalently attached to (bound to) a targeting ligand (TL) which binds to receptors having an affinity for the ligand. Such receptors may be on the surface or within compartments of a cell. Such targeting provides enhanced uptake or intracellular trafficking of the nucleic acid.

The targeting ligand may include, but is not limited to, galactosyl residues, fucosal residues, mannosyl residues, carnitine derivatives, monoclonal antibodies, polyclonal antibodies, peptide ligands, and DNA-binding proteins. Examples of cells which may usefully be targeted include, but are not limited to, antigen-presenting cells, hepatocytes, myocytes, epithelial cells, endothelial cells, and cancer cells.

Formation of such a targeted complex is illustrated by the following example of covalently attached targeting ligand (TL) to PINC system:

TL-PINC + Plasmid -----> TL-PINC:::Plasmid

Formation of such a targeted complex is also illustrated by the following example of non-covalently attached targeting ligand (TL) to PINC system

TL:::PINC + Plasmid -----> TL:::PINC:::Plasmid

or alternatively,

PINC + Plasmid -----> PINC::::::::::Plasmid + TL ---
 -----> TL::::::::::PINC::::::::::Plasmid

In these examples :::::::::: is non-covalent interaction such as ionic, hydrogen-bonding, Van der Waals interaction, hydrophobic interaction, or combinations of such interactions.

A targeting method for cytotoxic agents is described in Subramanian et al., International Application No. PCT/US96/08852, International Publication No. WO 96/39124, hereby incorporated by reference. This application describes the use of polymer affinity systems for targeting cytotoxic materials using a two-step targeting method involving zip polymers, i.e., pairs of interacting polymers. An antibody attached to one of the interacting polymers binds to a cellular target. That polymer then acts as a target for a second polymer attached to a cytotoxic agent. As referenced in Subramanian et al., other two-step (or multi-step) systems for delivery of toxic agents are also described.

In another aspect, nucleic acid coding sequences can be delivered and expressed using a two-step targeting approach involving a non-natural target for a PINC system or PINC-targeting ligand complex. Thus, for example, a PINC-plasmid complex can target a binding pair member which is itself attached to a ligand which binds to a cellular target (e.g., a MAB). Binding pairs for certain of the compounds identified herein as PINC compounds as identified in Subramanian et al. Alternatively, the PINC can be complexed to a targeting ligand, such as an antibody. That antibody can be targeted to a non-natural target which binds to, for example, a second antibody.

III. Model Systems for Evaluation of Interferon Alpha Constructs and Formulations

In accord with the concept of using interferon alpha expressing plasmid constructs and formulations in anti-

cancer treatment, murine model systems were utilized based on murine tumor cell lines. The line primarily used was S.C. VII/SF, which is a cell line derived from murine squamous cell carcinoma (S.C.).

5 Squamous cell carcinoma of the head and neck begins with the cells lining the oral and pharyngeal cavities. Clinical disease progresses via infiltration and spreads into the underlying tissues and lymphatics. The undifferentiated, *in vivo* passage tumor line S.C. VII/SF
10 displays this typical growth pattern. In addition, its rapid growth rate provides a relatively short test period for individual experiments. Other murine tumor cell lines include another SCC line KLN-205, a keratinocyte line I-7, and a colon adenocarcinoma line MC-38.

15 An optimal model system preferably satisfies the criteria based on having tumor growth rate *in vivo* (i.e., tumors are ready for treatment in 4-10 days post implant), invasiveness, and local spread similar to those observed in clinical disease, and providing accessibility for
20 experimental treatment. As indicated, the SCC VII/SF cell line was utilized as the primary model system cell line. This cell line typically grows rapidly, resulting in death of untreated syngeneic mice 14-17 days after tumor cell implantation.

25 This cell line can be utilized in a variety of ways to provide model system suitable for a variety of different tests. Four such possibilities are described below.

First, SCCVII cells can be utilized in cell culture to provide an *in vitro* evaluation of interferon alpha
30 expression construct and formulation characteristics, such as expression levels and cellular toxicities.

Second, the cells can be implanted subcutaneously in mice. This system can be utilized in tests in which accessibility of the implant site is beneficial. As an
35 example, the method was utilized in evaluations of

expression efficiencies based on the expression of chloramphenicol acetyltransferase (CAT).

Third, the cells can be implanted transcutaneously into the fascia of digastric muscle.

5 Fourth, the cells can be implanted transcutaneously into digastric/mylohyoid muscles. The important features of models 3 and 4 are shown in the table below.

TABLE II: Comparison of submandibular tumor models

Feature	Mouse Tumor Model 3	Mouse Tumor Model 4
Tumor implant procedure	2-4 x 10 ⁵ cells transcutaneously into fascia of digastric muscle	5 x 10 ⁵ transcutaneously into digastric/mylohyoid muscles
Tumor growth and invasiveness characteristics	Prominent submandibular bulge; invasion of digastric/mylohyoid muscles and lymphatics	More variable, invasion of digastric/mylohyoid muscles and lymphatics
Treatment procedure (primary treatment)	Transcutaneous, needle inserted and moved within tumor to produce a 4 quadrant distribution of gene medicine	Lower jaw skin flap raised to expose tumor, needle inserted and moved within tumor to produce a 4 quadrant distribution of gene medicine
Days treated (post-implant)	Day 5, day 10 (both transcutaneously)	Day 5 (tumor exposed), day 8 (transcutaneously)
Measurement procedure	External calipering 2-3 x per week until death	First caliper when tumor exposed for treatment, second caliper at sacrifice

Feature	Mouse Tumor Model 3	Mouse Tumor Model 4
Advantages	Non-surgical, closed model allows larger experiments and more frequent treatments; Sacrifice unnecessary to caliper (=more time points)	Surgical, open model allows direct treatment of exposed tumor; Local inflammation from surgery may additionally stimulate immune response; More like clinical situation for protocol development
Disadvantages	Transcutaneous treatment is potentially less accurate and intensive; less like expected clinical treatments than surgical approaches	Labor intensive; Smaller, fewer experiments possible; Tumors deeper and more difficult to treat transcutaneously (for secondary treatments); Fewer treatments and caliperings possible

The tumor size treated in the mouse models is generally 20-50 mm³. A 50 mm³ mouse tumor is approximately equivalent to 150 cc³ human tumor having an average diameter of about 6.6 cm. This tumor size is approximately 10-fold larger than the size proposed to be treated in the phase I clinical trials. This indicates that the mouse models are strongly biased towards over estimating the expected tumor burden in human patients.

IV. Formulations for In Vivo Delivery

A. General

While expression systems such as those described above provide the potential for expression when delivered to an appropriate location, it is beneficial to provide the expression system construct(s) in a delivery system which

can assist both the delivery and the cellular uptake of the construct. Thus, this invention also provides particular formulations which include one or more expression system constructs (e.g., DNA plasmids as described above), and a
5 protective, interactive non-condensing compound.

An additional significant factor relating to the plasmid construct is the percentage of plasmids which are in a supercoiled (SC) form rather than the open circular (OC) form.

10 B. Delivery and Expression

A variety of delivery methods can be used with the constructs and formulations described above, in particular, delivery by injection to the site of a tumor can be used. The submandibular tumor models utilized injection into four
15 quadrants of the tumor being treated.

C. Anti-Cancer Efficacy of Human Interferon Alpha Formulations

The effects of the administration of the interferon alpha formulations described above were evaluated using the
20 S.C. VII mouse tumor models. Plasmid constructs as described above were incorporated in delivery formulations. The formulations were delivered by injection.

25 D. Synergistic Effects of Interferon Alpha plasmid and IL-12 Plasmid and Effect of Human Interferon Alpha Formulation Administration on Production of Secondary Cytokines

The effects of the expression of the human interferon alpha plasmids in tumor cells on the progress of the mouse tumors demonstrates that such interferon alpha expression is
30 effective against such tumors. However, it was also shown that IL-12 can act synergistically with the interferon alpha expression to exercise the antitumor effect (see Figure 9).

E. Toxicity Evaluation of Exemplary Formulations

The exemplary formulations do not show high cellular toxicity at the concentrations tested, suggesting that the formulations do not significantly kill cells by direct toxic action *in vivo*. Moreover, the anti-tumor activity induced by IFN α gene therapy is dependent upon activation of the immune system, which is demonstrated by depletion studies *in vivo*. Removal of a specific T lymphocyte population (CD8 $^{+}$) abrogates the anti-tumor activity elicited by IFN α gene therapy.

V. Administration

Administration as used herein refers to the route of introduction of a plasmid or carrier of DNA into the body. In addition to the methods of delivery described above, the expression systems constructs and the delivery system formulations can be administered by a variety of different methods.

Administration can be directly to a target tissue or by targeted delivery to the target tissue after systemic administration. In particular, the present invention can be used for treating disease by administration of the expression system or formulation to the body in order to establishing controlled expression of any specific nucleic acid sequence within tissues at certain levels that are useful for gene therapy.

The preferred means for administration of vector (plasmid) and use of formulations for delivery are described above. The preferred embodiments are by direct injection using needle injection.

The route of administration of any selected vector construct will depend on the particular use for the expression vectors. In general, a specific formulation for each vector construct used will focus on vector uptake with regard to the particular targeted tissue, followed by demonstration of efficacy. Uptake studies will include

uptake assays to evaluate cellular uptake of the vectors and expression of the DNA of choice. Such assays will also determine the localization of the target DNA after uptake, and establishing the requirements for maintenance of steady-state concentrations of expressed protein. Efficacy and cytotoxicity can then be tested. Toxicity will not only include cell viability but also cell function.

Muscle cells have the unique ability to take up DNA from the extracellular space after simple injection of DNA particles as a solution, suspension, or colloid into the muscle. Expression of DNA by this method can be sustained for several months.

Delivery of formulated DNA vectors involves incorporating DNA into macromolecular complexes that undergo endocytosis by the target cell. Such complexes may include lipids, proteins, carbohydrates, synthetic organic compounds, or inorganic compounds. Preferably, the complex includes DNA, a cationic lipid, and a neutral lipid in particular proportions. The characteristics of the complex formed with the vector (size, charge, surface characteristics, composition) determines the bioavailability of the vector within the body. Other elements of the formulation function as ligand which interact with specific receptors on the surface or interior of the cell. Other elements of the formulation function to enhance entry into the cell, release from the endosome, and entry into the nucleus.

Delivery can also be through use of DNA transporters. DNA transporters refers to molecules which bind to DNA vectors and are capable of being taken up by epidermal cells. DNA transporters contain a molecular complex capable of noncovalently binding to DNA and efficiently transporting the DNA through the cell membrane. It is preferable that the transporter also transport the DNA through the nuclear membrane. See, e.g., the following applications all of which (including drawings) are hereby incorporated by reference herein: (1) Woo et al., U.S. Serial No.

07/855,389, entitled "A DNA Transporter System and Method of Use,, filed March 20, 1992, now abandoned; (2) Woo et al., PCT/US93/02725, International Publ. WO93/18759, entitled "A DNA Transporter System and Method of Use", (designating the U.S. and other countries) filed March 19, 1993; (3) continuation-in-part application by Woo et al., entitled "Nucleic Acid Transporter Systems and Methods of Use", filed December 14, 1993, U.S. Serial No. 08/167,641; (4) Szoka et al., U.S. Serial No. 07/913,669, entitled "Self-Assembling Polynucleotide Delivery System", filed July 14, 1992 and (5) Szoka et al., PCT/US93/03406, International Publ. WO93/19768, entitled "Self-Assembling Polynucleotide Delivery System", (designating the U.S. and other countries) filed April 5, 1993. A DNA transporter system can consist of particles containing several elements that are independently and non-covalently bound to DNA. Each element consists of a ligand which recognizes specific receptors or other functional groups such as a protein complexed with a cationic group that binds to DNA. Examples of cations which may be used are spermine, spermine derivatives, histone, cationic peptides and/or polylysine. One element is capable of binding both to the DNA vector and to a cell surface receptor on the target cell. Examples of such elements are organic compounds which interact with the asialoglycoprotein receptor, the folate receptor, the mannose-6-phosphate receptor, or the carnitine receptor. A second element is capable of binding both to the DNA vector and to a receptor on the nuclear membrane. The nuclear ligand is capable of recognizing and transporting a transporter system through a nuclear membrane. An example of such ligand is the nuclear targeting sequence from SV40 large T antigen or histone. A third element is capable of binding to both the DNA vector and to elements which induce episomal lysis. Examples include inactivated virus particles such as adenovirus, peptides related to influenza virus hemagglutinin, or the GALA peptide described in the Szoka patent cited above.

Transfer of genes directly into a tumor has been very effective. Experiments show that administration by direct injection of DNA into tumor cells results in expression of the gene in the area of injection. Injection of plasmids containing human interferon alpha results in expression of the gene for 5 days following a single intra-tumoral injection. Human IFN α production was highest in tumors harvested 1 day post-tumor injection and steadily declined thereafter. The injected DNA appears to persist in an unintegrated extrachromosomal state. This means of transfer is a preferred embodiment.

Administration may also involve lipids as described in preferred embodiments above. The lipids may form liposomes which are hollow spherical vesicles composed of lipids arranged in unilamellar, bilamellar, or multilamellar fashion and an internal aqueous space for entrapping water soluble compounds, such as DNA, ranging in size from 0.05 to several microns in diameter. Lipids may be useful without forming liposomes. Specific examples include the use of cationic lipids and complexes containing DOPE which interact with DNA and with the membrane of the target cell to facilitate entry of DNA into the cell.

Gene delivery can also be performed by transplanting genetically engineered cells. For example, immature muscle cells called myoblasts may be used to carry genes into the muscle fibers. Myoblast genetically engineered to express recombinant human growth hormone can secrete the growth hormone into the animal's blood. Secretion of the incorporated gene can be sustained over periods up to 3 months.

Myoblasts eventually differentiate and fuse to existing muscle tissue. Because the cell is incorporated into an existing structure, it is not just tolerated but nurtured. Myoblasts can easily be obtained by taking muscle tissue from an individual who needs gene therapy and the genetically engineered cells can also be easily put back with out causing damage to the patient's muscle. Similarly,

keratinocytes may be used to delivery genes to tissues. Large numbers of keratinocytes can be generated by cultivation of a small biopsy. The cultures can be prepared as stratified sheets and when grafted to humans, generate
5 epidermis which continues to improve in histotypic quality over many years. The keratinocytes are genetically engineered while in culture by transfecting the keratinocytes with the appropriate vector. Although keratinocytes are separated from the circulation by the
10 basement membrane dividing the epidermis from the dermis, human keratinocytes secrete into circulation the protein produced.

The chosen method of delivery should result in expression of the gene product encoded within the nucleic
15 acid cassette at levels which exert an appropriate biological effect. The rate of expression will depend upon the disease, the pharmacokinetics of the vector and gene product, and the route of administration, but should be in the range 0.001-100 mg/kg of body weight /day, and
20 preferably 0.01-10 mg/kg of body weight/day. This level is readily determinable by standard methods. It could be more or less depending on the optimal dosing. The duration of treatment will extend through the course of the disease symptoms, possibly continuously. The number of doses will
25 depend upon the disease, delivery vehicle, and efficacy data from clinical trials.

Examples

The present invention will be more fully described in conjunction with the following specific examples which are
30 not to be construed in any way as limiting the scope of the invention. As shown below, mIFN- gene medicine reduces the growth of tumors in syngeneic murine tumor models. Lipid formulations of mIFN- gene medicine display anti tumor activity in both SCC-VII and MC-38 tumor models. PINC and
35 peptide formulations of mIFN- gene medicine display anti

tumor effects in the MC-38 tumor model. The anti tumor effects of mIFN- gene medicine are dose dependent. In addition, the examples demonstrate that treatment of tumors with the combination of IFN α and IL-12 gives an unanticipated more than additive (synergistic) anti-tumor activity using either a PINC or a lipid formulation.

Example 1

A plasmid expression system encoding murine IFN α 4 and formulated in a polymeric delivery system was used for in vivo immunotherapeutic activity against an immunogenic murine renal cell carcinoma, Renca, and a non-immunogenic mammary adenocarcinoma, TS/A. Mice bearing established tumors were treated with IFN α /polyvinyl-pyrrolidone (PVP) expression complexes via direct intra-tumoral injection. Up to 100 % tumor growth inhibition was observed in the treated mice. By using an optimal dose of 96 and 48 μ g of formulated IFN- α plasmid for the treatment of Renca and TS/A respectively, 30% (Renca) and 10% (TS/A) of the treated animals remained tumor-free. Tumor inhibition was dependent upon activation of the immune system. The anti-tumor activity elicited by IFN- α gene therapy was abrogated when mice were selectively depleted of CD8 $^{+}$ T cells. By contrast, removal of CD4 $^{+}$ resulted in increased tumor rejection following IFN- α /PVP treatments. Finally, mice that remained tumor-free following IFN- α gene therapy displayed immune resistance to a subsequent challenge of tumor. These data provide evidence that non-viral IFN α gene therapy can be used to induce an efficient anti-tumor response.

Local presence of cytokines in tumors can activate an immune response that in some cases leads to induction of specific long-lasting anti-tumor immunity. By direct intra-tumoral injection of plasmid encoding murine IFN α 4 and formulated in a polymeric delivery system, tumor-bearing mice develop an immune response, which leads to inhibition and eradication of the tumor. We have shown by depletion

studies in vivo that the immune response induced by IFN α is mainly CD8-mediated and that this treatment results in a long-term immunity in mice demonstrating complete tumor regression. Thus, non-viral IFN α gene therapy may be an effective alternative to IFN α protein therapy for human cancers.

Transduction of tumor cells with cytokine genes has proven to be a very efficient technique to induce cytokine-mediated anti-tumor immunity. In experimental models, the local presence of IL-2, IL-1, IL-4, IL-6, IL-7, IL-12, IFNs and CSFs (i.e., GM-CSF) at the site of the tumor can result in significant tumor growth inhibition (Colombo et al., "Local Cytokine Availability Elicits Tumor Rejection and Systemic Immunity Through Granulocyte-T-Lymphocyte Cross-Talk", Cancer Research, 52, 4853-4857 (1992)). In these systems, cytokines have limited effect on tumor proliferation directly but are capable of activating a rapid and potent anti-tumor immune response, which impedes tumor progression. Established parental tumors, however, are difficult to eradicate with ex vivo cytokine-transduced tumor cells because efficacy of vaccination is highly dependent on the size, growth rate and invasiveness of the tumor.

To overcome these problems, cytokine-based gene therapy approaches, which can deliver transgenic cytokines locally and induce an anti-tumor immune response, have been recently evaluated by a number of investigators (Forni et al., "Cytokine-Induced Immunogenicity: From Exogenous Cytokines to Gene Therapy", Journal of Immunotherapy, 14, 253-257, (1993); Pericle et al., "An Efficient Th2-type Memory Follows Cd8+ Lymphocyte-driven and Eosinophil-mediated Rejection of a Spontaneous Mouse Mammary Adenocarcinoma Engineered to Release Il-4", The Journal of Immunology, 153, 5660-5673. (1994); Pardoll et al., "Gene Modified Tumor Vaccines, In Cytokine-Induced Tumor Immunogenicity", eds. Academic Press, London, p. 71-86. (1994); and Musiani et

- al., "Cytokines, Tumor-cell Death and Immunogenicity: A Question of Choice", Immunology Today. 1, 32-36 (1997)). Technological breakthroughs in gene therapy using adenoviral, retroviral, and liposomal vectors have provided
- 5 powerful tools with which to study the biological effects of specific cytokine mediators as well as to develop novel and clinically applicable anti-tumor immunotherapies (Pardoll, "Paracrine Cytokine Adjuvants in Cancer Immunotherapy", Annu. Rev. Immunol. 13, 399-415 (1995); Bramson et al.,
- 10 "Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12", Hum. Gene Ther., 7, 1995-2002 (1996); Rao et al., "IL-12 Is an Effective Adjuvant to Recombinant
- 15 Vaccinia Virus-based Tumor Vaccines", J. Immunol. 156, 3357-3365. 1996; Rakhmilevich et al., "Gene Gun-mediated Skin Transfection with Interleukin 12 Gene Results in Regression of Established Primary and Metastatic Murine Tumors", Proc. Natl. Acad. Sci. USA. 93, 6291-6296 (1996);
- 20 and Rakhmilevich et al., "Cytokine Gene Therapy of Cancer Using Gene Gun Technology: Superior Antitumor Activity of Interleukin-12", Hum. Gene Ther. 8, 1303-1311, (1997)).
- A gene therapy approach utilizing an interactive polymeric gene delivery system that increases protein
- 25 expression by protecting plasmid DNA (pDNA) from nucleases and controlling the dispersion and retention of pDNA in muscle cells is described in Mumper et al., 1996. These polymeric interactive non-condensing (PINC) systems routinely result in a greater amount of gene expression from
- 30 tissues as compared to delivery of unformulated plasmid in saline (Mumper et al., 1996). By using a plasmid that encodes human insulin growth factor-1 (hIGF-1) and formulated as a PINC complex, production of biologically active h IGF-1 in vivo following intra-muscular injection
- 35 has been shown (Alila et al., "Expression of Biologically Active Human Insulin-Like Growth Factor-1 Following

Intramuscular Injection of a Formulated Plasmid in Rats", Human Gene Therapy, 8, 1785-1795 (1997)). The specific objective of this study was to determine whether a plasmid expression system encoding murine IFN α 4 and formulated as a complex with PVP could induce an anti-tumor immune response following direct injection into subcutaneous murine tumors.

The IFN family consists of three major glycoproteins, IFN α , IFN β and IFN γ . Although IFNs were first developed as antiviral agents, it is now clear that they also control cell growth and differentiation, and modulate various aspects of host immunity (Gresser et al., "Antitumor effects of interferon", Acta Oncol. 28, 347-353 (1989)). Clinical data concluded that systemic chronic administration of IFN α could produce regression of vascular tumors, including Kaposi's sarcoma, pulmonary hemangiomatosis, and hemangiomas (Singh et al., "Interferons A and B Down-regulate the Expression of Basic Fibroblast Growth Factor in Human Carcinomas", Proc. Natl. Acad. Sci. USA. 92, 4562-4566 (1995)). Although IFN α was the first cytokine to be used in clinical trials that proved to be effective against certain types of human cancer, only recently has this cytokine been considered as a candidate for gene therapy (Ogura et al. 1993, Belldegrun et al., "Human Renal Carcinoma Line Transfected With Interleukin-2 and/or Interferon α Gene(s): Implications for Live Cancer Vaccines, Journal of the National Cancer Institute, 85, 207-216 (1993)).

Initial studies have shown that the injection of genetically modified tumor cells producing IFN α into syngeneic mice induces tumor growth inhibition and elicits a tumor-specific immune memory (Ferrantini et al., Interferon Alpha-1-Interferon Gene Transfer into Metastatic Friend Lukemia Cells Abrogated Tumorigenicity in Immunocompetent Mice: Antitumor Therapy by Means of Interferon-Producing Cells; Cancer Res. 53, 1107-4615 (1993); Ferrantini et al., "Ifn- α 1 Gene Expression into a Metastatic Murine Adenocarcinoma (Ts/a) Results in Cd8+ T Cell-Mediated Tumor

Rejection and Development of Antitumor Immunity: Comparative Studies with Ifn- γ -producing Ts/a Cells" Journal of Immunology, 153, 4604-4615, (1994); Musiani et al. 1997). However, the real value of this potential form of vaccine in inducing the regression of established tumors remains to be demonstrated.

In this study we present evidence that direct injection of IFN α plasmid formulated in PVP into subcutaneous murine tumors results in a host-dependent tumor rejection, primarily mediated by CD8 $^{+}$ T cells, and elicits a protective immunity against subsequent tumor re-challenge.

Materials And Methods

Plasmid construction and formulation

A plasmid expression system containing an expression cassette for mIFN- α 4 was constructed as follows. The coding sequence of the murine IFN- α 4 gene (Genebank X01973 M15456 M23830 X01967) was amplified by PCR from mouse genomic DNA. The amplified mIFN- α 4 sequence was then subcloned into a plasmid backbone, and the sequence fidelity was verified by DNA sequence analysis (data not shown). The coding sequence for mIFN- α 4 was then subcloned as an XbaI-BamHI fragment into the expression plasmid pIL0697 to create the mIFN- α 4 expression system pIF0836. Plasmid pVC0612 (empty plasmid, EP) contains expression elements including the cytomegalovirus immediate early promoter and the 3' UTR/poly(A) signal from the bovine growth gene in the pVC0289 backbone described by Alila et al. (1997). Plasmid pVC0612 was used as a control plasmid in all in vivo experiments. Plasmids for intra-tumoral injection were grown under kanamycin selection in E. coli host strains DH5 α and purified using conventional alkaline lysis and chromatographic methods. Purified plasmid utilized for intra-tumoral injections had the following specifications: endotoxin (< 500 Eu/mg plasmid); protein (< 1%); and chromosomal DNA (< 20 %). Purified pIF0836 and control

plasmids were formulated at a concentration of 3 mg DNA/ml in a solution of 5 % w/v polyvinyl-pyrrolidone (Plasdone C-30, ISP Technologies, Wayne, NJ), 150 mM NaCl on the day of injection, as described previously (Mumper et al., 1996).

5 Western blot analysis and bioassay for mIFN α .

HeLa cells were plated in 6 well plates at 3×10^5 cells per well, and transfected using 1 μ g of mouse IFN α 4 plasmid pIF0836C and 3 μ g of Lipofectamine (Life Technologies, Inc., Gaithersburg, MD) in serum-free DMEM. Same supernatants
10 were harvested 24 hours later and immunoprecipitated using anti-mouse interferon α/β polyclonal antibody (BioSource International, Camarillo, CA) and protein A and G agarose (Boehringer Mannheim, Indianapolis, IN). Samples were run on a 12% Tris-glycine gel and electroblotted to Millipore
15 PVDF membrane. Anti-mouse interferon α/β polyclonal antibody was used at 1:1000, followed by anti-sheep Ig HRP (Boehringer Mannheim) at 1:1000. Biotinylated molecular weight markers were detected using Streptavidin-HRP (Amersham, Arlington Heights, IL). Detection was performed
20 using the Amersham ECL kit. Supernatants were also tested for IFN α biological activity using L929 cells treated with encephalomyocarditis virus, in parallel with a NIH mouse IFN α reference reagent (Access Biomedical, San Diego, CA).

Animals

25 Normal 8-week-old female BALB/c mice were purchased from Harlan Laboratories, Houston, TX. Mice were maintained on ad libitum rodent feed and water at 23 $^{\circ}$ C, 40% humidity, and a 12-h/12-h light-dark cycle. Animals were acclimated for at least 4 days before the start of the study.

30 Tumors

Three established mouse tumor models were used in this study. TS/A is a tumor cell line established by Dr. P. Nanni, University of Bologna, Italy, from the first in vivo

transplant of a moderately differentiated mammary adenocarcinoma that spontaneously arose in a BALB/c mouse (Nanni et al., 1983). A number of pre-immunization-challenge experiments suggested that TS/A does not elicit a long-lasting anti-tumor immunity (Forni et al., 1987). TS/A was generously provided by Dr. Guido Forni, University of Turin, Italy. Renca, a spontaneously arising murine renal cell carcinoma, and CT-26, a colon adenocarcinoma, were generously provided by Dr. Drew M. Pardoll, John Hopkins Hospital, Baltimore, MD. Tumor cell cultures were maintained in sterile disposable flasks from Corning (Corning, NY) at 37° C in a humidified 5% CO₂ atmosphere, using RPMI 1640 supplemented with 10% FBS, 100 U/ml penicillin, 100 U/ml streptomycin and 50 µg/ml gentamycin; all from Life Technologies.

In vivo evaluation of tumor growth and treatments

BALB/c mice were challenged s.c. in the middle of the left flank with 30 µl of a single-cell suspension contained the specified number of cells. Seven days later when the tumor size reached approximately 10 mm³, treatments with IFNα/PVP or EP/PVP started and were repeated at 1-2 day intervals for 2 weeks (total of 8 treatments: 4/week). Tumor volume was measured with electronic caliper in the two perpendicular diameters and in the depth. Measurements of the tumor masses (mm³) were performed twice a week for 40-50 days. All mice bearing tumor masses exceeding 1 cm³ volume were sacrificed for humane reasons. When depletion of immunocompetent cells in vivo was required, a group of mice received i.v. 0.5 ml of α-CD4 (GK1.5 hybridoma, 207-TIB, ATCC, Rockville, MD) ascite (1:10), or α-CD8 (2.43 hybridoma, 210-TIB, ATCC) ascite (1:100) or i.p. 100 µg α-GR1 (RB6-8C5 hybridoma, Pharmingen, San Diego, CA). Control mice received i.v. 0.5 ml isotype control IgG (Pharmingen). Antibody treatments were performed twice: first injection 1 day before starting the gene therapy

treatment and the second injection (i.p at the same dosage) 7 days later.

CTL assay

A standard 6-hour ^{51}Cr -release assay was performed following 5 days of in vitro effector cell stimulation. Single cell suspensions of splenocytes were prepared 3 weeks following tumor challenge by mashing the spleens in RPMI 1640 medium (Life Technologies) and passing the cells through 70 μm nylon mesh cell strainers (Falcon, Becton Dickinson, Lincoln Park, NJ) into 50ml centrifuge tubes (Falcon). After centrifugation, red blood cells were lysed with ACK Lysing Buffer (Biofluids, Inc., Rockville, MD) and the splenocytes washed twice with RPMI. In vitro stimulation cultures contained 3×10^6 splenocytes/effectors per ml with 6×10^5 mitomycin-C-treated Renca/stimulator cells per ml and 10 Units per ml recombinant murine IL-2 (Genzyme, Cambridge, MA) in RPMI containing 10% FBS, 22mM HEPES buffer (Research Organics Inc., Cleveland OH), Penn-Streptomycin, 5×10^{-5} M 2- β -mercapto-ethanol (Life Technologies), OPI media supplement (Sigma, St. Louis, MO), and essential and non-essential amino acids (Life Technologies) (for a 5 : 1 responder : stimulator ratio). Stimulators were prepared by incubating Renca cells at 3×10^7 per ml in RPMI with 30 μg per ml mitomycin-C (Sigma) at 37°C for 60 minutes, followed by four washes in HBSS with 2.5% FBS. After 5 days at 37°C , effector cells were pelleted, resuspended in complete RPMI, counted, and mixed with ^{51}Cr -labeled targets in a 96 well V-bottomed plate (Costar/Corning, Cambridge, MA). Renca and CT26 targets were labeled by incubating them at 2×10^6 cells per ml in complete RPMI with 150 μCi ^{51}Cr (Amersham) for 2.5 hours. Targets were washed 3 times in HBSS with 2.5% FBS and resuspended in complete RPMI before addition to the assay. After mixing effectors and targets (in triplicate wells) and a brief pelleting, plates were placed at 37°C for 6 hours.

Approximately 90% of the supernatants were then collected from each well with the Skatron Harvesting Press and Supernatant Collection System (Skatron Instruments, Norway). ^{51}Cr release was detected using a WALLAC 1470 Wizard automatic gamma counter (WALLAC Inc., Gaithersburg MD). Specific release was determined with the following equation:
$$\frac{(\text{experimental cpm} - \text{spontaneous cpm})}{(\text{total cpm} - \text{spontaneous cpm})} \times 100.$$
 Spontaneous release from the targets was less than 18%, and the standard error of the triplicate experimental counts was less than 14%.

Statistical analysis

Data for the effects of mIFN- α gene therapy on tumor growth were analyzed by repeated measures analysis. Individual treatment means were compared using Duncan's multiple range test when the main effect was significant. Data for the effect of mIFN- α gene therapy on tumor rejection were analyzed by ANOVA. In all cases a p value of less than 0.05 was considered to be statistically significant.

Results

Expression of mIFN- α

Murine IFN- α expression plasmid (pIF0836) was transfected into Cos-1 cells, and the resulting conditioned media was assayed for mIFN- α by Western blot and by bioassay. Western blot analysis of conditioned media indicated that the recombinant mIFN- α expressed from pIF0836 template was present as a single band with an approximate molecular weight of 23 kDa. This band was not observed in conditioned media from mock-transfected cells and likely represents a glycosylated form of mIFN- α . Recombinant mIFN- α ran with an approximate molecular weight of 18 kDa, which corresponds to the predicted molecular weight of non-glycosylated mIFN- α . Assay of conditioned media using an

anti-viral bioassay for mIFN- α indicated that approximately 175×10^3 IU/ml mIFN- α were present.

Anti-tumor activity of IFN- α gene therapy. The anti-tumor effect of murine IFN α 4 plasmid formulated as a complex with PVP (IFN α /PVP) was tested in a syngeneic murine renal cell carcinoma (Renca) and a mammary adenocarcinoma (TS/A) tumor model. BALB/c mice were challenged subcutaneously with 7×10^5 Renca or 1×10^5 CT26 cells, and IFN α /PVP injections were initiated 7 days later when tumors reached approximately 10 mm³ size. Each group of mice received at interval of 1-2 days 8 treatments (4 injections/week) of IFN α /PVP at scalar doses (from 12 to 96 μ g/mouse), EP/PVP (96 μ g/mouse) or no treatments for control (ctrl). Tumor size increased progressively in mice injected with EP/PVP (Renca, TS/A) or low doses of IFN α /PVP (TS/A), while tumors in mice injected with each dose of IFN α /PVP (Renca) or high dose of IFN α /PVP (TS/A) showed marked growth inhibition.

Tumor growth inhibition is associated to systemic immune response

Treatments of Renca and TS/A tumors with IFN α /PVP at 96 μ g/mouse and 48 μ g/mouse respectively, induced complete regression in 6 out of 20 (Renca) and 2 out of 20 (TS/A) of challenged mice. To test whether the rejection of these tumors leads to specific immune memory, mice with no tumors for 40-50 days following IFN α treatments were re-challenged with a greater number of fresh tumors in the right flank. All mice that rejected primary tumors displayed protection against the second tumor challenge whereas mice used as the control group and injected for the first time with same number of tumor cells (1×10^6 Renca or 2×10^5 TS/A) developed tumors.

To evaluate the requirements for the induction of anti-tumor immune memory, Renca and TS/A were injected into BALB/c rendered immunosuppressed by treatment with anti-CD4, anti-CD8 or anti-polymorphonuclear cells (PMN). Depletion

of CD8⁺ T cells allowed both Renca and TS/A to grow in all animals following IFN α /PVP treatments, showing that this population is crucial for the immune response induced by IFN α gene therapy. No increase in tumor growth was found in
5 mice treated with anti-PMN (α -GR1) monoclonal Ab (mAb). Increase in tumor rejection was observed in mice depleted of CD4⁺ T and treated with IFN α /PVP suggesting that depletion of CD4⁺ T cells can enhance the anti-tumor effect of IFN α gene therapy.

10 Expression of IFN- α within the tumor induces a CTL response. To assess whether CD8⁺ tumor specific CTL were induced in vivo by IFN α /PVP treatments, splenocytes from Renca tumor-challenged mice were tested for their cytolytic activity following IFN α gene therapy. Cytotoxic activity
15 against Renca, and not against CT26 cells used as control for tumor specificity, was found in 2 of 4 mice that had received IFN α gene therapy. Moreover, splenocytes from mice depleted of CD4⁺ T cells and treated with IFN α /PVP demonstrated potent CTL activity against Renca cells. By
20 contrast, little CTL activity against Renca cells was evident from splenocytes isolated from mice treated with EP/PVP.

Discussion

The data reported herein demonstrate that direct
25 administration of IFN α gene formulated in a polymeric delivery system into subcutaneous renal cell carcinoma and mammary adenocarcinoma inhibits tumor growth and induces a long-lasting immunity to secondary tumor challenges. Of considerable significance is the fact that the anti-tumor
30 response was observed against both an immunogenic carcinoma as well a more aggressive and poorly immunogenic adenocarcinoma, a phenotype which is similar to many spontaneously arising tumors in man.

A variety of genetic abnormalities arise in human
35 cancers that contribute to neoplastic transformation and

maligancy. Despite increasing understanding of the molecular basis of cancer, many malignancies remain resistant to established forms of treatment. More recently, molecular genetic interventions have been designed in an attempt to improve the efficacy of immunotherapy. While numerous experimental studies have been performed in murine models with tumor cells transduced with cytokine-gene ex vivo, a major limitation in the translation of this strategy to large-scale human tumor vaccine therapy is the labor intensity and variability of establishing each individual tumor in culture and transducing it with an appropriate vector (i.e., retrovirus). Our approach to this problem is to use a non-viral delivery system to modify tumor cells in vivo with cytokine cDNAs so that the tumor cells can supply the cytokine of interest in a paracrine fashion to the anti-tumor responder cells present within the tumor.

Using a plasmid containing IFN α 4 gene and formulated in PVP, we have shown that intra-tumoral injections of this DNA-PINC complex can lead to complete tumor regression in 30 % of the cases (Renca model) with an overall response rate of 100 % tumor growth inhibition. These results are in agreement with a recent study that described an anti-tumor activity elicited by genetically modified TS/A cells producing murine IFN α 1 (Ferrantini et al., 1994). Although the anti-tumor effect of IFN α using cytokine-gene transduced tumor cells has been described (Scarpa et al., "Extracellular Matrix Remodelling in a Murine Mammary Adenocarcinoma Transfected with the Interferon-alpha Gene", Journal of Pathology. 181, 116-123 1997), the real value of IFN α gene therapy in blocking or inhibiting advanced tumors remains to be explored. The advantage of using a non-viral IFN α gene delivery system over retrovirus is that tumor cells could be transduced directly in vivo without the need of first establishing tumor cells in vitro. Moreover, IFN α has a potent anti-viral activity limiting the use of this gene in combination with viral vectors.

Therapeutic levels of gene expression for IGF-I using a similar interactive PVP-based delivery system have previously been described (Alila et al., 1997). Direct intra-tumor injection of the same PINC delivery system as a complex with IFN α gene, resulted in dispersion in vivo of plasmid into target cells inducing an IFN α -specific anti-tumor activity. Tumors treated with the same plasmid but in the absence of IFN α coding region and formulated as a complex with PVP, did not respond to this treatment and grew in a similar rate to untreated tumors. By using an optimal dose of IFN α /PVP, tumor-bearing mice were able to reject the tumors mounting a specific long-lasting tumor immunity. Although, the numbers of mice rejecting a second tumor challenge was low, this observation indicates that a considerable portion of the activity of IFN α in inducing the rejection of established tumors is not anti-angiogenic or anti-proliferative but immunostimulatory. Our result demonstrating that IFN α -induced regression of advanced tumors was prevented by in vivo administration of anti-CD8 mAb provides direct evidence for a key role of CD8 $^{+}$ T cells in the anti-tumor effect of IFN α .

Depletion of CD4 $^{+}$ T cells in tumor-bearing mice treated with IFN α gene therapy significantly enhanced the therapeutic effect of IFN α , resulting in tumor regression and prolonged survival of up to 80% of treated mice. A CD4-mediated suppression during tumor progression has been previously reported and it has also been shown that depletion of CD4 $^{+}$ T cells in tumor-bearing mice results in augmentation of anti-tumor therapy with either IL-2 or IL-12 (Rackmilevich et al., 1994 and Martinotti et al., "Cd4 T Cells Inhibit in Vivo the Cd8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes", Eur. J. Immunol., 25, 137-146. (1995)). They have shown that depletion of CD4 $^{+}$ T cells in tumor-bearing mice in the absence of treatment did not affect the growth of tumor itself suggesting that removal of

CD4⁺ T cells does not deprive the tumor of growth factors (Rackmilevich et al., 1994). A possible explanation for this phenomenon is that depletion of CD4⁺ T cells from tumor-bearing mice augments the anti-tumor efficacy of IFN α -activated CD8⁺ T cells by releasing them from immunosuppression. The mechanism driving CD4 suppression is poorly understood, although Th2 type cytokines, directly or through B cell activation, may inhibit cell-mediated immunity (Mossman et al., 1989; Powrie et al., Eur-J-Immunol, 23(11):3043-9 (1993)). CTL can be generated in both CD4-depleted and non-depleted mice from lymphocytes obtained from spleens by in vitro re-stimulation with mitomycin-treated Renca cells and rIL-2. Thus, CD4-mediated suppression appears to be exerted on CD8 expansion and not priming. In accord with the in vivo results, stronger CTL activity was observed from mice depleted of CD4 and treated with IFN α /PVP suggesting CD4⁺ T cells inhibit an IFN α -mediated CD8⁺ T cell response in vivo. This study suggests that direct administration of cytokine genes, like IFN α , into tumors, which have been found to suppress malignancy growth, provide a new therapeutic option for the treatment of human cancers.

Example 2: Pharmacology of mIFN - Gene Medicine in Syngeneic Tumor Models

Gene expression systems encoding either mIFN-2 or mIFN-4 were tested for anti tumor activity when formulated in either cationic lipid, peptide, or PINC delivery systems and injected intratumorally into subcutaneous squamous cell carcinoma (SCC-VII) or adenocarcinoma (MC-38) tumors.

Experimental design and treatment regimen

Experiments to test the anti tumor activity of mIFN-gene medicine were conducted in either SCC-VII or MC-38 tumor models. Tumor cells (4×10^5) were injected subcutaneously into the flank region of mice, and treatment

was initiated when tumor volume reached approximately 50 mm³. Treatment was begun approximately 6 days (SCC-VII tumors) and 10 days (MC-38 tumors) after tumor initiation and repeated at 3 to 5 day intervals.

5 All formulations of mIFN- gene medicine were administered in a dose volume of 50 µl. The faster growing SCC-VII tumors typically received 3 treatments, whereas the relatively slower growing MC-38 tumors typically received 4 treatments. Experiments were terminated when lactose vehicle control tumors reached approximately 1000 mm³.

10 The anti-tumor effects of murine IFN gene medicine (IFNα/PVP) was tested in syngeneic murine renal cell carcinoma (Renca) and mammary adenocarcinoma (TS/A) tumor model. BALB/c mice were challenged subcutaneously with 7
15 X10⁵ or 1 X10⁵ CT26, and IFNα/PVP injections were initiated 7 days later when tumors reached approximately 10 mm³ size. Each group of mice received 8 treatments (4 injections for 2 weeks) of IFNα/PVP at scalar doses (from 12 to 96 µg/mouse), empty plasmid/PVP (EP/PVP, 96 µg/mouse) or no treatments for
20 control (ctrl). Tumor size increased progressively in mice injected with EP/PVP (Renca, TS/A) or low doses of IFNα/PVP (TS/A), while tumors in mice injected with each dose of IFNα/PVP (Renca) or high dose of IFNα/PVP (TS/A) showed marked growth inhibition.

25 Example 3: mIFN- Gene Medicine Formulated in Cationic lipid Reduces the Growth of SCC-VII Tumors

Experiments were conducted in the SCC-VII tumor model as described in the preceding example. mIFN- gene medicine formulated in cationic lipid, peptide, and PINC delivery
30 systems was tested. Results show that cationic lipid formulations significantly reduce the growth of SCC-VII tumors relative both to lactose vehicle injected tumors and to tumors injected with control (non coding) plasmid formulated in cationic lipid. The effect of mIFN- gene
35 medicine formulated in cationic lipid is dose dependent and

there is no effect of mIFN- gene medicine when formulated in PVA. In addition, analysis of tumors from this experiment using immunohistochemical methods revealed infiltration of CD8+ lymphocytes in tumors injected with cationic lipid formulations, but not in tumors injected with PVA formulations.

mIFN- gene medicine significantly reduces the growth of SCC-VII tumors as compared to control plasmid or lactose injected tumors. Differences between control plasmid and mIFN- plasmid were consistent across formulation. Plasmid dose was 46 µg/treatment. Growth of tumors injected with control plasmid was compared to that of tumors injected with mIFN- gene medicine using repeated measures analysis. mIFN- reduced SCC-VII tumor growth relative to control plasmid ($p=.035$).

Example 4: mIFN- Gene Medicine Reduces the Growth of MC-38 Tumors

Experiments were carried out as described in the preceding examples. The effects of various prototype formulations of mIFN- gene medicine on the growth of subcutaneous MC-38 tumors were compared. mIFN- gene medicine elicited reduced tumor growth in all formulations tested (cationic lipid, peptide, and PINC). Subsequent experiments in the MC-38 tumor model have shown similar results.

Example 5: Dose Responses

After demonstrating anti tumor effects of mIFN- gene medicine, the dose response for these effects was investigated in the MC-38 tumor model. Both cationic lipid (DOTMA:Chol) and PINC (PVA) delivery systems were evaluated. Results clearly show that mIFN- gene medicine elicited a dose dependent reduction in tumor growth. Tumor volume in this experiment was maximally reduced by approximately 50 % with mIFN- /DOTMA:Chol and 60 % with mIFN- /PVA after 4

treatments. Maximal reduction in tumor volume was observed at a plasmid dose of approximately 50 µg/treatment (cumulative dose of approximately 200 µg). These experiments will be conducted primarily in the MC-38 tumor model because it provides a broader treatment window than does the SCC-VII model.

Example 6: IFN-alpha Formulations

The formulations for the IFN-α are: (1) PVP 4 vial, (2) PVP three vial, (3) PVP two vial. The details are listed below:

PVP 4 vial

Materials: 25% PVP (50 kDa) stock solution, plasmid stock solution, 5 M NaCl stock solution, and water.

Method: Add in order of water, plasmid, 25% PVP and 5 M NaCl into a vial to make a plasmid in 5% PVP in saline formulation. The final concentration of PVP and NaCl are fixed (5% and 150 mM) and plasmid concentration could be varied (but based on the IGF-1 data, 3 mg DNA/ml in 5% PVP in saline should be the best formulation). The quality of the formulation is characterized by pH; DNA concentration, osmolality, and gel electrophoresis. The DNA concentration could be varied from 0.1-5 mg/ml. The pH may be varied from 3-5, osmolality may be 250 - 400 mOsm.

Three vial

Material: lyophilized PVP, plasmid stock solution (4 mg/ml), 115 mM Na-Citrate/5% NaCl stock buffer (pH = 4).

Method: Add in order of plasmid and buffer into the PVP to make final 3 mg DNA/ml in 5% PVP in 25 mM citrate/saline buffer (pH = 4). DNA expression is higher in saline than in the citrate buffer.

Two vial

Materials: Co-lyophilized plasmid and PVP, saline. Add saline into the co-lyophilized DNA and PVP to make final 3 mg/ml DNA in 5% PVP in saline.

- 5 The final formulation is 3mg/mL DNA, 5% PVP as a single vial. The formulation is prepared by adding (5%) PVP to (4mg/mL) DNA and recirculating the two components for a finite period of time (using static mixer). Then the formulation is lyophilized and rehydrated with 0.9% sodium chloride, to obtain a final composition of 3mg/mL, 5%PVP in saline.
- 10

Example 7: Treatment of Human Tumors

- The murine studies are predictive of the response of Human tumors to therapy using a plasmid construct encoding the human IFN alpha gene sequence such as that depicted in SEQ ID NO: 10, 11 or 12. A patient in need of anti-cancer therapy is injected with up to 3mg of plasmid formulation at daily intervals. The plasmid formulation may contain INF alpha plasmid alone or optionally a mixture of IFN-alpha encoding plasmid and an additional plasmid coding for a cytokine. The preferred cytokine is IL-12. The treatments are continued and the patient monitored as is the usual practice for anti-cancer chemotherapeutic regimes.
- 15
- 20

- 25 One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The molecular complexes and the methods, procedures, treatments, molecules, specific compounds described herein are presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention are
- 30
- 35 defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

5 All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically
10 ally and individually indicated to be incorporated by reference.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically
15 disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of" and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description
20 and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus,
25 it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and
30 variations are considered to be within the scope of this invention as defined by the appended claims.

In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby
35 described in terms of any individual member or subgroup of members of the Markush group. For example, if X is

described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described.

Other embodiments are within the following claims.

Claims

1. A plasmid comprising a CMV promoter transcriptionally linked with an interferon alpha coding sequence, and a growth hormone 3'-untranslated region.
- 5 2. The plasmid of claim 1, wherein said interferon alpha is human interferon alpha.
3. The plasmid of claim 2, wherein said human interferon alpha coding sequence is a synthetic sequence having optimal codon usage.
- 10 4. The plasmid of claim 3, wherein said interferon alpha coding sequence has the nucleotide sequence of SEQ ID NO:10, 11 or 12.
- 15 5. The plasmid of claim 1, wherein said growth hormone 3' untranslated region is from a human growth hormone gene.
6. The plasmid of claim 5, wherein an ALU repeat or ALU repeat-like sequence is deleted from said 3' untranslated region.
- 20 7. The plasmid of claim 1, wherein said plasmid includes a promoter, a TATA box, a Cap site and a first intron and intron/exon boundary in appropriate relationship for expression of said coding sequence.
- 25 8. The plasmid of claim 7, wherein said plasmid further comprises a 5' mRNA leader sequence inserted between said promoter and said coding sequence.

9. The plasmid of claim 1, wherein said plasmid further comprises an intron/5' UTR from a chicken skeletal α -actin gene.

10. The plasmid of claim 1, wherein said plasmid comprises a nucleotide sequence which is the same as the nucleotide sequence of plasmid pIF0921.

11. The plasmid of claim 1, further comprising:

a first transcription unit comprising a first transcriptional control sequence transcriptionally linked with a first 5'-untranslated region, a first intron, a first coding sequence, and a first 3'-untranslated region/poly(A) signal, wherein said first intron is between said control sequence and said first coding sequence; and

a second transcription unit comprising a second transcriptional control sequence transcriptionally linked with a second 5'-untranslated region, a second intron, a second coding sequence, and a second 3'-untranslated region/poly(A) signal, wherein said second intron is between said control sequence and said second coding sequence;

wherein said first and second coding sequences comprise a sequence having the sequence of SEQ ID NO:2, 3, 4 or 25 coding for human IL-12 p40 subunit, and a sequence having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for human IL-12 p35 subunit.

12. The plasmid of claim 11, wherein said first transcriptional control sequence or said second transcriptional control sequence comprise one or more cytomegalovirus promoter sequences.

13. The plasmid of claim 11, wherein said first and second transcriptional control sequences are the same.

14. The plasmid of claim 11, wherein said first and second transcriptional control sequences are different.

15. The plasmid of claim 14, wherein said sequence coding for the p40 subunit of human IL-12 is 5' to said sequence coding for the p35 subunit of human IL-12.

16. The plasmid of claim 1, further comprising an intron having variable splicing, a first coding sequence, and a second coding sequence,

wherein said first and second coding sequences comprise a sequence having the sequence of SEQ ID NO:2, 3, 4 or 25 coding for human IL-12 p40 subunit, and a sequence having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for human IL-12 p35 subunit.

17. The plasmid of claim 16, further comprising:

a transcriptional control sequence transcriptionally linked with a first coding sequence and a second coding sequence;

a 5'-untranslated region;

an intron 5' to said first coding sequence;

an alternative splice site 3' to said first coding sequence and 5' to said second coding sequence; and

a 3'-untranslated region/poly(A) signal.

18. The plasmid of claim 17, wherein said transcriptional control sequence comprises a cytomegalovirus promoter sequence.

19. The plasmid of claim 1, further comprising:

a transcriptional control sequence transcriptionally linked with a first coding sequence, an IRES sequence, a second coding sequence, and a 3'-untranslated region/poly(A) signal, wherein said IRES

sequence is between said first coding sequence and said second coding sequence; and

an intron between said promoter and said first coding sequence;

- 5 wherein said first and second coding sequences comprise a sequence having the sequence of SEQ ID NO:2, 3, 4 or 25 coding for human IL-12 p40 subunit, and a sequence having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for human IL-12 p35 subunit.

- 10 20. The plasmid of claim 19, wherein said transcriptional control sequence comprises a cytomegalovirus promoter sequence.

21. The plasmid of claim 19, wherein said IRES sequence is from an encephalomyocarditis virus.

- 15 22. A composition comprising the plasmid of anyone of claims 1-21, and a protective, interactive non-condensing compound.

23. The composition of claim 22, wherein said protective, interactive non-condensing compound is polyvinyl pyrrolidone.
- 20

24. The composition of claim 22, wherein said plasmid is in a solution having between 0.5% and 50% PVP.

25. The composition of claim 24, wherein said solution includes about 5% PVP.

- 25 26. The composition of claim 22, wherein said DNA is at least about 80% supercoiled.

27. The composition of claim 26, wherein said DNA is at least about 90% supercoiled.

28. The composition of claim 27, wherein said DNA is at least about 95% supercoiled.

29. A composition comprising a protective, interactive non-condensing compound and a plasmid comprising an interferon alpha coding sequence.

30. A composition comprising the plasmid of any one of claims 1-21 and a cationic lipid with a neutral co-lipid.

31. The composition of claim 30, wherein said cationic lipid is DOTMA.

32. The composition of claim 30, wherein said neutral co-lipid is cholesterol.

33. The composition of claim 30, wherein the DNA in said plasmid and said cationic lipid are present in such amounts that the negative to positive charge ratio is about 1:3.

34. The composition of claim 30, wherein said DNA is at least about 80% supercoiled.

35. The composition of claim 34, wherein said DNA is at least about 90% supercoiled.

36. The composition of claim 35, wherein said DNA is at least about 95% supercoiled.

37. The composition of claim 30, further comprising an isotonic carbohydrate solution.

38. The composition of claim 37, wherein said isotonic carbohydrate solution consists essentially of about 10% lactose.

39. The composition of claim 30 wherein said cationic lipid and said neutral co-lipid are prepared as a liposome having an extrusion size of about 800 nanometers.

40. A composition comprising:

a first component comprising a plasmid comprising an interferon alpha coding sequence and a cationic lipid with a neutral co-lipid, wherein said cationic lipid is DOTMA and said neutral co-lipid is cholesterol, wherein the DNA in said plasmid and said cationic lipid are present in amounts such that the negative to positive charge ratio is about 1:3; and

a second component comprising a protective, interactive non-condensing compound, wherein said first component is present within the second component.

41. A composition comprising a protective, interactive non-condensing compound, a first plasmid comprising an interferon alpha coding sequence, and one or more other plasmids independently comprising an IL-12 or IL-12 subunit coding sequence.

42. A composition comprising a plasmid comprising an interferon alpha coding sequence and a cationic lipid with a neutral co-lipid.

43. A method for making a plasmid of anyone of claims 1-21 comprising the step of inserting a CMV promoter transcriptionally linked with an interferon alpha coding sequence, and a growth hormone 3'-untranslated region into a plasmid.

44. A method for making a composition of claim 29, comprising the steps of:

- a. preparing a DNA molecule comprising a transcriptional unit, wherein said transcriptional unit comprises an interferon alpha coding sequence;
- b. preparing a protective, interactive non-condensing compound; and
- c. combining said protective, interactive non-condensing compound with said DNA in conditions such that a composition capable of delivering a therapeutically effective amount of an interferon alpha coding sequence to a mammal is formed.

45. The method of claim 44 wherein said DNA molecule is a plasmid, wherein said plasmid comprises a CMV promoter transcriptionally linked with an interferon alpha coding sequence, and a human growth hormone 3'-untranslated region/poly(A) signal.

46. A method of making a composition of claim 30, comprising the steps of:

- a. preparing a DNA comprising an interferon alpha coding sequence;
- b. preparing a mixture of a cationic lipid and a neutral co-lipid, wherein said cationic lipid is DOTMA and said neutral co-lipid is cholesterol; and
- c. combining said mixture with said DNA in amounts such that said cationic lipid and said DNA are present in a negative to positive charge ratio of about 1:3.

47. A method of making a composition of claim 40, comprising the steps of:

- a. preparing a first component comprising a plasmid comprising an interferon alpha coding sequence and a cationic lipid with a neutral co-lipid, wherein said cationic lipid is DOTMA and said neutral co-lipid is

cholesterol, wherein the DNA in said plasmid and said cationic lipid are present in amounts such that the negative to positive charge ratio is about 1:3;

5 b. preparing a second component comprising a protective, interactive non-condensing compound; and

 c. combining said first and second components such that the resulting composition comprises said first component within said second component.

48. A method of making a composition of claim 41,
10 comprising the steps of:

 a. preparing a protective, interactive non-condensing compound,

 b. preparing a first plasmid comprising an interferon alpha coding sequence,

15 c. preparing one or more other plasmids independently comprising an IL-12 p35 or IL-12 p40 subunit coding sequence, and

 d. combining said protective, interactive non-condensing compound, said plasmid comprising said interferon
20 alpha coding sequence and said other plasmids.

49. A method of making a composition of claim 42 comprising combining a plasmid comprising a interferonalpha coding sequence and a cationic lipid with a neutral co-lipid.

25 50. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount of a plasmid of anyone of claims 1-21.

51. The method of claim 50, wherein said condition or
30 disease is a cancer.

52. The method of claim 50, wherein said composition is administered by injection.

53. A method for transfection of a cell *in situ*, comprising the step of contacting said cell with a plasmid of anyone of claims 1-21 for sufficient time to transfect said cell.

54. The method of claim 53, wherein transfection of said cell is performed *in vivo*.

55. The method of claim 53, wherein said contacting is performed in the presence of an about 5% PVP solution.

56. A method for delivery and expression of an interferon alpha gene in a plurality of cells, comprising the steps of:

(a) transfecting said plurality of cells with a plasmid of anyone of claims 1-21; and

(b) incubating said plurality of cells under conditions allowing expression of a nucleic acid sequence in said vector, wherein said nucleic acid sequence encodes interferon alpha.

57. The method of claim 56, wherein said interferon alpha is human interferon alpha and said cells are human cells.

58. The method of claim 56, wherein said contacting is performed in the presence of an about 5% PVP solution.

59. A method for treating a disease or condition, comprising the steps of transfecting a cell *in situ* with a plasmid of any one of claims 1-21.

60. The method of claim 59, wherein said disease or condition is a localized disease or condition.

61. The method of claim 59, wherein said disease or condition is a systemic disease or condition.

5 62. A cell transfected with a plasmid of anyone of claims 1-21.

63. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount
10 of a composition of claim 22.

64. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount of a composition of claim 29.

15 65. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount of a composition of claim 30.


66. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount
20 of a composition of claim 40.


67. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from
25 said condition or disease a therapeutically effective amount of a composition of claim 41.

68. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from

said condition or disease a therapeutically effective amount of a composition of claim 42.

- 5 69. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount of a composition of a first plasmid comprising an interferon alpha coding sequence and a second plasmid comprising a IL-12 coding sequence.

FIGURE 1



**FIGURE 2 HUMAN IL-12
PLASMID pIN1143**

ccggccacagtcgatgaatccagaaaagcggccatttccaccatgatattcggcaagcaggcatcgccatcgctcagcagagatcctcgcgcgtgggc
atgcgcgccttgagcctggcgaaacagttcggctggcgagccctgatgctcttcgtccagatcatctgatcgacaagacggcttccatccgagtagct
gctcgtcgtgatgcgatgttctgcttggtgctgaatggcgagtagccggatcaagcgtatgcagccgccgattgcatcagccatgatggatacttctcg
gcaggagcaaggtgagatgacaggagatcctgccccggcacttggcccaatagcagccagtccttccgcttcagtgacaacgtcgagcacagctcg
caaggaaacggcgtcgtggccagccacgatagccgctgctcgtcctgcagttcattcagggcaccggacaggtcggtcttgacaaaaaagaccggg
cgccccctgcgtgacagccggaacacggcgcatcagagcagccgattgtctgttggtgccagtcataagcgaatagcctctccacccaagcggccgga
gaacctgcgtgcaatcattgttcaatcatgcgaacgatcctcctgctcttgcagatcttgatccctgcgccatcagatccttggcgcaagaaa
gccaatcagtttacttgcagggttcccaaccttaccagagggcgaaatcgagcttgcatgcttcaggtcgttacataacttacggtaaatggcccgcctg
gctgacccgccaacgacccccgccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatt
acggtaaaactgcccacttggcagatcatcaagtgtatcatatgccaaagtacgccccctattgacgtcaatgacggtaaatggcccgttgcattatgccag
tacctgaccttatgggacttctacttggcagtagatctacgtattatgcatcgtattaccatgggtgacgggttttggcagtagatcaatggcggtgatagc
ggtttgactcacggggaattccaaagtctccacccattgacgtcaatgggagttgttttggcaccaaaatcaacgggactttccaaatgtcgttaacaactcc
gcccattgacgcaaatgggggtgagcgtgtacggtgggaggtctataagcagagctcgtttagtgaaccgtcagatcgcttgagagccatccac
gctgtttgacctcatagaagacaccgggacgcatccgctcgcggcggaacgggtgattggaacgggattccccgtgttaaatcaacagtaagt
gtcttctctgttttcttccctgtatttctgctcaaccttccatcagaacctgcagatctgtatttttctagcagtaatacagggttttttttctctcacag
gccacattgggtccagcgcgcagcctcctctgtgtgtacccgtgtcctctgaccacctcagtttggcagaacctccccgtggccactccagaccc
aggaatgttccatgccttccacctcccaaaacctgtgaggcgctcagcaacatgctccagaaggccagacaaactctagaattttacccttgcacttct
gaagagattgatcatgaagatatacaaaagataaaaccagcacagtggagcgctgtttaccattggaattaaccaagaatgagattgcttaattccaga

gagacctcttcataactaattgggagttgcctggcctccagaaagaccctctttatgatggccctgtgccttagtagtattatgaagactgaagatgtaccagg
tggagttcaagaccatgaatgcaaagcctctgatggatcctaagaggcagatctttctagatcaaacatgctggcagttattgatgagctgagcggccctg
aattcaacagtgagactgtgccacaaaatcctccctgaagaaccggattttataaaactaaaaacagctctgcatactcttcagctttcagaattcggg
cagtgactattgatagtgatgactatcgaatgcttctaacaattctagaaaagccgaattctgcaggaattgggtggcaccctgtgacccctcccg
tgcctcctctggccctggaagttgccactccagtgcccaccagccttgctctaataaaatgaattgcatcatittgtctgactagggtgctcttataatattatgg
gggtggaggggggtggtatggagcaaggggcaagttgggaagacaacctgtagggtcgcagggggggccgggtacgggtgttacataactacggtaaa
tggcccgcttggtgacgcccaacgacccccgccattgacgtcaataatgacgtatgttcccatagtaacccaatagggacttccattgacgtcaatg
gggtggagtattacggtaaacgtcccacttggcagtcatacaagtgatcatatgccaaagtagcccccattgacgtcaatgacggtaaatggcccgctgg
cattatgcccatgacgttattgggactttcctacttggcagtcatactacgtattatgcatcgtattaccatgggtgatgggttttggcagtcataatg
gcgtggatagcgtttgactacggggatttcaagtctccacccctgacgtcaatgggagttgttttggcaccacaaatcaacgggacttccaaaatgtc
gtaacaactccgccccattgacgcaaatgggctgtaggggtgtacgggtggaggtctatataagcagagctcgtttagtgaaccgtcagatgcctggaga
cgccatccagctgtttgacctccatagaagacaccgggacggatccagcctccgcggccgggaacgggtgcaatgggaacgcgattccccgtgttaata
acaggtaagtgtctctctctgtttcttccccctgtattctgctcaaccttctatcagaaactgcagtatctgtattttgtgagaattgactaacgggtctttttc
tctcacaggcttaagtcatgggtcaccagcagttgtgctctctgttttccctggttttctggcatctccccctgtggccatattgggaactgaagaaagtgt
ttatgtcgtgaattgagttggtatccggatgccctggagaattgggtgtcctacctgtgacacccctgaagaagattggtatccctggaccttggaccag
agcagtgagctcttaggtctgcgcaaaacctgacctccaagtcgaagagtttggagatgtcggccagtagcacctgtcacaagaaggagcagggttctaag
ccattgcctctgtctgtccacaaaagggaagatggaattgttccactgataattttaaaggaccagaaagaccccaaaaataagaccttctaaagtgcgag
gccaagaattattctggagctttcactgtgtgtgtgacgacaatcagtagctgattgacattagttcacaagcagcagaggccttctgacccccaaag
gggtgacgtgcggagctgtactactctctcagagagagtcagaggggacaacaaggagtagtagtactcagttggaggtccaggaggaagcagtcctgc
ccagctgctgaggagagctgccccattgaggtcattgggtggtccgttcacaagctcaagtagaaaactacaccagcagcttcttcatcaggagacatc
aaacctgacccacccaagaacttcagctgaagccatgaagaattctcggcaggtggaggtcagctgggagtagcctgacacctggagtagtctccacattc
ctactctccctgacattctgcttcagggtccagggcaagagcaagagagaaaagaaagatagagttccaggacaagacctcagccagctcatctgcc
gcaaaaatgccagcattagcgtgcgggccaggaccgtactatagctcatcttggagcgaatgggcatctgtgcccgtgagtagacgcgtagaaaag
ccgaattctgcaggaattgggtggcatccctgtgacccctccccagtgccctctctggccctggaggttggcactccagtgcccaccagcctgtcctaata
aattaagttgcatattttgtctgactagggtgtcctctataatattgggggtggaggggggtggtatggagcaagggggaagttgggaagacaacctgtag
ggctcgaggggggggccgtaccagcttttgttccctttagtgagggttaatttcgagcttggcgtaatcatgtgcatagctgttctctgtgaaattgttacc
gtcacaattccacacaacatacagccgggaagcataaagtgaagcctgggggtgcttaatgagtagtaactcaacattaattgctgtgcctcactgcc
cgctttccagctgggaacctgtgtgtccagctgcattaatggaatggccaacgcgggggagaggcgggttgcattggggcgtcttccgcttccctgc
cactgactcgtctgcctgtgtgttgcgtgcggcgagcggtatcagctcactcaagggcgtaatacgggttatccacagaatacaggggataacgagga
aagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaggccgcttgcgttctccataggtccgccccctgacgagcatcac
aaaatcgacgtcgaagtcagaggtggcgaaacccgacaggactataaagatacaggcggtttccccctggaggtcctctgtgcgtctctgttccgac

cctgccgcttacggataacctgtccgccctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcgggtgtaggtcgttcgctc
caagctgggctgtgtgcacgaacccccgttcagcccgaccgctggccttatccggtactatcgtcttgagtcacccggtaagacacgacttatcgcc
actggcagcagccactggtaacaggattagcagagcgaggatgtaggcggtgtctacagagttcttgagtggtggcctaactacggctacactagaagg
acagtatttgggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaacaacaccaccgctgtagcggtgggttttt
gtttgcaagcagcagattacgcgcagaaaaaaggatctcaagaagatcctttgatctttctacggggtctgacgctcagaagaactcgtcaagaaggcga
tagaaggcgcgctgcgaatcgggagcggcgataccgtaaacgacgaggaagcggtcagccattcgccgccaagctcttcagcaatatcacgggta
gccaacgctatgtcctgatacggtccgccacaccag

FIGURE 3


Codon Frequency

human_high.doc

Codon usage for human(highly expressed) genes 1/31/91

AA	Codon	Mean	Std. Dev.	Fraction
Gly	GGT	441.00	9.14	0.12
Gly	GGC	1867.00	38.70	0.50
Glu	GAG	2420.00	50.16	0.75
Glu	GAA	792.00	16.42	0.25
Asp	GAT	592.00	12.27	0.25
Asp	GAC	1821.00	37.35	0.75
Val	GTG	1866.00	38.68	0.64
Val	GTA	134.00	2.78	0.05
Val	GTT	198.00	4.10	0.01
Val	GTC	728.00	15.09	0.25
Ala	GCG	652.00	13.51	0.17
Ala	GCA	488.00	10.12	0.13
Ala	GCT	654.00	13.56	0.17
Ala	GCC	2057.00	42.64	0.53
Arg	AGG	512.00	10.61	0.18
Arg	AGA	298.00	6.18	0.10
Ser	AGT	354.00	7.34	0.10
Ser	AGC	1171.00	24.27	0.34
Lys	AAG	2117.00	43.88	0.82
Lys	AAA	471.00	9.76	0.18
Asn	AAT	314.00	6.51	0.22
Asn	AAC	1120.00	23.22	0.78
Met	ATG	1077.00	22.32	1.00
Ile	ATA	84.00	1.82	0.05
Ile	ATT	315.00	6.53	0.18
Ile	ATC	1369.00	28.38	0.17
Thr	ACG	405.00	8.40	0.15
Thr	ACA	373.00	7.73	0.14
Thr	ACT	358.00	7.42	0.14
Thr	ACC	1502.00	31.13	0.57
Trp	TGG	652.00	13.51	1.00
End	TGA	109.00	2.26	0.55
Cys	TGT	325.00	6.74	0.32
Cys	TGC	706.00	14.63	0.68
End	TAG	42.00	0.87	0.21
End	TAA	46.00	0.95	0.23
Tyr	TAT	360.00	7.46	0.26
Tyr	TAC	1042.00	21.60	0.74

pIF0836




gaatcattgctgtaggctctgtgtcttctccatgatccttagaatgatgagctactactggtcagccctgttctctaggatgtgacctgcccacacttataaccttgg
gaacaagaggggccttgacagctcttggaagaatgagaagactccccctcttcttgcctgaaggacagggaaggtatttggattccccctggagaagggtgg
ataaccaacagatccagaaggctcaagccatcctgtgtctaaagagatcttaccacagagatttgaacctcttccatcaaaaagactgtctgtcctacttggaaatg
caactctctagactcattctgcaatgacctccatcagcagctcaatgatctcaaaagcctgtgtgatgcaggaaacctctctgaccagggaagactccctgct
gctgtgtgaggacatacttccacaggatcactgtgtacctgagaagaagaacacagccctctgtgctgggagggtgatcagagcgaagctctggagagacc
ctctcttcccaaccaacttgcgtgccaagactgagtgtaggagaaggagtgaictagaagccgaattctgcagggaatttggcatccctgtgacccctccca
gtgctctctgcccctggaaagtgcaccctcagctgccaccagccttgccttaataaataaagtgtgcatcattttgtctgactagggtccctctataataattg
gggtggagggggggtgtatggagcaaggggcccaagttgggaagacaacctgtagggtctcaggggggggcccggtaccagcttttgtcccttttagtga
gggttaatttcgagcttggcgttaatcatgtgtatcgtttctgtgtgaattgtttaccgctcacaaatccacacaacatacagccgggaagcataaagtgt
aggccctgggtgcttcaatgagtgtgactaactcattaatgtcggttcgctcactgccgcttccagctgggaaacctgtctgtgccagctgattaatgaat
cggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgttcttcgctcactgactcgtcgtcgtcgttcgttcggtcggcgagcgggtat
cagctcactcaaaaggcgttaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgacaaaaggccagcaaaaaggccaggaaacctg
aaaaaggccgcgtgttgcgttttccatagggctccgccccctgcagcagatcacaataacgcagctcgaagtacagagtggtggcgaaacccgacaggac
tataaagataccaggcggtttccccctggaagctccctcgtgcgctctctgttccgacctgcggctaccagataacctgtccgcttcttccccctgggaaac
gttggcgctttctatagctcacgctgtaggtatctcagttcgggttaggtcgttcgtccaagctgggctgtgtgcacgaacccccgttcagcccgaccgct
cgcccttatccggtaactatcgtcttgatgcccaaccggtaagacacgacttatcgccactggcagcagccactgtgaacggattagcagagcagggtat
tagggcggtgtacagagttcttgaaagtgggtgccttaactacggctacactagaaggacagattttgtatctgcgctctgtgaagccagttaaccttggaa

aaagagttggtagctctgatccggcaaaacaaccaccgtggtagcgggtgtttttgtttgcaagcagcagattacgcgcagaaaaaaggatctcaag
aagatccctttgatctttctacggggtctgacgctcagaagaactcgtcaagaaggcgalagaaggcgatgcgctgcgaatcgggagcggcgataccgtaa
agcacgagggaagcggtagcccatcgcgccaaagctcttcagcaatatcacgggtagccaacgctatgtcctgatacggctcgccacaccagccgg
ccacagtcgatgaatccagaaaagcggccatttccaccatgatattcggcaagcaggcatccatgcgtcacgacgagatcctcgcctcgggcatgc
gcgcttgagccctggcgaacagttcggctggcgcgagccctgatgctcttcgtccagatcatcctgatcgacaagaccgggttccatccgagtacgtctc
gctcgatgcgatgtttcgttgggtcgaatggcaggtagccggatcaagcgtatgcagccgccgcattgcatcagccatgatggatacttctcggcag
gagcaagggtgagatgacaggagatcctgcccggcacttcgcccaatagcagccagtccttcccgcttcagtgacaacgtgagcacagctgcgcaag
gaacgcccgctgctggccagccacgatagccgcgctgcctcgtcctgcaagttcattcaggggcacaggacaggtcgggtcttgacaaaaagaaccggcgcc
cctgcgtgacagccgggaacagcgggcgcatcagagcagccgattgtctgtgtgccagtcatagccgaatagcctctccaccaagcggccggagAAC
ctgctgcaatccatctgttcaatcatcggaacgatccctcatcctgtctcttgatcagatcttgatccctcgcgcacatccttgccggaagaaagcca
tccagtttactttgcagggttcccaaccttaccagaggcggaattcgagcttgcagctgcgttacataacttacggtaaatggcccgctcgtgctga
ccgcccaacgacccccgccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggaactttcattgacgtcaatgggtggagtatttacggt
aaactgccacttggcagtagatcaagtgtatcatatgccaaagtacgccccctattgacgtcaatgacggtaaatggcccgctgacattatgccagtagat
gaccttattgggaactttcctacttggcagtagatctacgtattatgctatcgtattaccatgggtgatggcgttttggcagtagatcaatggcggtgatacgggtt
gactcacgggatttccaagtctccacccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaatgtcgtacaactccgcccc
attgacgcaaatggcggtaggcgtgtacgggtgggaggtctatataagcagagctcgtttagtgaaccgtcagatcgccctggagacgccatccacgctgtt
tgacctccatagaagacaccgggaccgatccagcctccggactctagctagag

FIGURE 5 MOUSE IL-12

pIN0961



agcttcgagggggggcccggtaccagctctttgttcccttagtgagggttaattctgacgttggcgtaatcatggtcatagctgtttccgtgtgtaaatgttatcc
gctcacaattccacacacatacagccgggaagcataaagtgtaaagcctgggggtgcttaatgagtgagctaacacacataattgctgttgccgtcactgcc
cgctttccagtcgggaacctgtgctgcccagctgctaataatgaatcgcccaacgcgcggggagaggcggtttgctgtaattggcgctctcccgcttccctgct
cactgactcgctgcctgctgttcgctgctggcgctggcgagcggatcatcgtcactcaaaaggcggttaalacggttatccagaaatcagggggataacgcaggga
aagaacatgtgagcaaaaggccagcaaaaggccaggaaacctgaaaaaggccgctgttgcgtgctttttccataggtctccgcccccctgacgagcatcac
aaaaatcgacgctcaagtcagaggtggcgaaaccgacaggactataaagataccaggcgctttccccctggaagctccctctgctgcctctctgttccgac
cttgcctgcttaaccgatactgtccgcttctcccttgggaagcgtggcgctttctcatagctcacgctgtggtatctcagttcggtgtgagctgcttgcctc
caagctgggtctgtgtgacgaacccccctgttcagcccgaccgctgcgcttatccggttaatactcgtttagtccaacccggtaagacacgacttatcgcc
actggcagcagccactggttaacaggattagcagagcgagggtatgtaggcggtgctacagagttctgaagttgggtggcctaactacggctacactagaagg
acagtatttggtatctgcgtctgctgaaggccagttaaccttggaaaaagagttggttagctcttgatccggcaacaacaaccaccgctggtgagcgttggttttt
gtttgcaagcagcagattacgcgcagaaaaaaggatctcaagaagatccttgatctttctacggggtctgacgctcagaagaactcgtcaagaaggcgga
tagaaggcgatgcgtgcgaatcgggagcggcgataccgtaaaagcacgagggaagcgggtcagccattcgcgcgcaagctcttcagcaatatcacgggta
gccaacgctatgctctgatacggtccgccacaccgacccggccacagctgatgaatccagaaaaaggcgccatttccaccatgatattcggcaagcagg
catcgccatgcgtcacgacgagatctctcgccgtggcgatgcgcgccttgagcctggcgaaacgttcggctggcgcgagccctgatgctcttcgtccag
atcatcctgatgcagaagaccggttccatccgagtagctgtctcgtcgtatgcgatgtttcgttgggttggaatggggcaggtagccggatcaagcgtatg
cagccgcgcgcatgcatcagccatgatggatacttctcggcaggagcaaggtgagatgacaggagatcttccccggcacttcgcccaatagcagccag

RNSDOCID: <WO 9947678A2 | >

gatgctggccagtacacctgccacaaaggaggcgagactctgagccactcacatctgtctgccacaagaaggaaaatggaatttgccactgaaattta
aaaaatttcaaaaacaagacttctgaagtgtgaagcaccaaattactccggacggttcacgtgctcatggctgggcaaaagaacatggacttgaagtca
acatcaagagcagtagcagttccctgactctcgggcagtgacatgtggaatggcgtctctgtctgcagagaagggtcacactggaccaaaagggaactatgag
aagtattcagtgctctgccaggaggatgtcacctgcccaactgccgaggagaccctgccattgaactggcgttgggaagcacggcagcagaataaatatg
agaactacagcaccagcttctcatcaggacatcatcaaacagaccgcccaagaactgcagatgaagcctttgaagaactcacaggaggaggtcag
ctgggagtagccctgactcctggagcactcccatctacttctccctcaagttcttggcgaatccagcgcaagaagaaaagatgaaggagacagagga
gggggtgaaccagaaggtgcgttccctcgtagagaagacatctaccgaagtccaatgcaaggcggaatgtctgcgtgcaagctcaggatcgtattaca
attcctcatgcagcaagtgggcatgtgtccctgcagggtccgactcctagagctcgtgatcagcctcgtactgtgcccttagttgccagccatctgtgttgc
ccctcccccgtgccttcttgaccctggaagggtgccactcccactgtccttccataaaaaatgaggaaattgcatcgcattgtctgtaggtgtcattctattct
gggggggtgggtggggcaggacagcaaggggggaggattgggaagacaatagcaggcatgctggggatgcgggtgggtcttatggctctgaggcgga
agaaccaggctggggctcgagcatgca

FIGURE 6 HUMAN IFN

pIF0921

cgttacataacttacggttaaatggcccgctggctgaccgccaacgacccccgccattgacgtcaaatgacgtatgtcccatagtaacgccaatagg
 gactttccattgacgtcaaatgggtggagttattacggtaaactgccacttggcagtagatcaaggtatcatatgccaaagtagccccattgacgtcaatga
 cggtaaatggcccgctggcattatgccagtagacacatttgggactttcctacttggcagtagatcagctattatgctatcgtattaccagtggtatcg
 gttttggcagtagatcaaatggcggtgtagacgggtttgactcacgggatttcaagctccacccccattgacgtcaatgggagttgtttggcaccataatca
 acgggactttccaaaatgtcgtacaactcgcgccattgacgcaaatggcggttagcggtgtaggggaggtctatataagcagagctctgttagtgaa
 ccgtcagatcgctggagacgccatccacgtgtttgacctccatagaagacaccgggaccgacccagctcccgccggccgggaacgggtgattggaaac
 gcggattccccgtttaataacaggtaagtgtcttctctgtttcttccccgttatctgctcaaccttctcatcagaacctgcagtagtctgtattttgtagca
 gtaatactaacgggtttttttcttctcacagggccaccatggccttgaccttcttacttgggtggccctcctggtgctcagctgcaagtgactgtctgtggg
 ctgtgactgtcctcaaacccacagcctgggttagcaggagaccttgatgctctggcacagatgaggagaatctcttcttctgtctgaaggacagacat
 gactttggattccccagggaggtttggcaaccagttccaaaaggctgaaacatccctgtctccatgagatgacccagagatcttcaatctcttcagcac
 aaaggactcatctgctgctggatgagacccctctacacaaattctacactgaactctaccagcagctgaatgacctggaagcctgtgtgatacagggggt
 ggggggtgacagagactccccgtatgaaggaggactccattgctgtgaggaaatcttccaaagaatcactctctatctgaagagaaagaaatcacagcc
 ctgtgctgggaggtgtcagagcagaataatgagatcttttctgcaacaaactgcaagaagttaagaagaaagaaatgaatcagaagaccga
 attctgcaggaaattgggtgcatccctgtgacccctccccagtgctctcctgcccctgggaaggtgccactccagtgccaccagcctgtcctaataaata
 agttgcatcattttgtctgactagggtgctcttctataatattatgggggtgaggggggtggtatggagcaaggggcaagttgggaagacaacctgtagggtc
 gagggggggcccggtaccagctttgttcccttaagttaggggttaatttcagagcttggcgtaaatcatggtcatagctgttctgtgtgaaattgtatccgtca
 caattccacacaacatagcagccgggaagcatalaagtgtaaagctgggtgctaatgagtagtgaactacatcaataattgctgtcgctcactgcccgttt
 ccagtcgggaaacctgtcgtgccagctgcattaatgaatcgccaacgcgcggggagagggcggttgcgtattggcgctcttccgttctcgtcactg
 actcgtcgtcgtcgtgcttggctgctggcgtgagcggtatcagctcactcaaaaggcggttaatacagagaatcaggggataacgcaggaaagaa
 catgtgagcaaaaaggccagcaaaaaggccaggaaccgtaaaaaggccgctgtgctgctggtttccatagctccgccccctgacgagcatcacaaaaat
 cgacgtctcaagtcagaggtggcgaaacccgacagactataaagataccaggcgtttccccctggaaagctccctcgtgctgctctctgttccgacctgcc
 gcttaccgataacctgtccgcttcttcccttcgggaagcgtggcgctttctcatagctcacgctgtagggtatcagttcgtgtagggtcgttgcctcaagct
 gggctgtgtgacgaacccccgttcagcccgaccgtgctgcttaccggtactatcgtcttgaagtcacacccggtaagacacgactatcggcactgac
 agcagccactggtaacaggttagcagagcgggtatgtagggcgtgctacagagtttgaagttggtggcctaactacggctacactagaaggacagtat
 ttggtatctgcctctgtgtagccagttacctcggaaaaagagttggtagctcttgatccggcaacaaacccgctggtagcgggtgtttttttgttgca
 agcagcagattacgcgcagaaaaaaggatctcaagaagatcctttgacttttctacgggtctgacgctcagaagaactgtcaagaaggcgatagaag
 gcgatgcgtcgcgaatcgggagcggcgataccgtlaaagcacgaggaagcggtcagccattcggcgcaacgtcttcagcaataacagggttagccaa
 cgtatgtctgatagcggtccgccacccagcggccacagtcgatgaatccagaagaagcgccattttccacatgatattcggcaagcaggacatcgc
 catgctgcacgacgagatcctcctcgtcggcgatcgcgcccttgagcctggcgcaacagttcggctggcgagagccctgatgctcttcgtccagatcatcc

tgatcgacaagaccggcttccatccgagtacgtgctgctcgatcgcatgttctgcttggtggtcgaatggggcaggtagccggatcaagcgtatgcagccg
ccgcattgcatcagccatgatggatacttctcggcaggagcaaggtgagatgacaggagatcctgccccggcacttcgccaatagcagccagtccttc
ccgcttcagtgacaacgtcgagcacagctgcgcaagggaacgccgtcgtggccagccacgatagccgcgtgcctcgtcctgcagttcattcagggcac
cggacaggtcgggtttgacaaaaaagaaccgggcgccccctgctgacagccgggaacacggcgccatcagagcagccgattgtctgttgccagtc
agccgaatagcctctccaccaagcggcgggagaacctgcgtgcaatccattgttcaatcatcgaaacgatcctatcctgtctcttgatcagatcttgat
ccccgcgccatcagatccttggcggcaagaagccatccagtttactttgcagggttcccaaccttaccagagggcgaattcgagcttgcagtcctgcag
gt


Figure 7A IFN β las


Figure 7B IFNseq

DNA coding sequence for IFN- α 2b gene in pIF0921

ATGGCCTTGACCTTGCTTTACTGGTGGCCCTCCTGGTGCTCAGCTGCAAGTCAAGCTGCTCTGTGGGCTGTG
ATCTGCCTCAAACCCACAGCCTGGGTAGCAGGAGGACCTTGATGCTCCTGGCACAGATGAGGAGAATCTCTCT
TTTCTCCTGCTTGAAGGACAGACATGACTTTGGATTTCCCCAGGAGGAGTTTGGCAACCAGTTCCAAAAGGCT
GAAACCATCCCTGTCCTCCATGAGATGATCCAGCAGATCTTCAATCTCTTCAGCACAAAGGACTCATCTGCTG
CTTGGGATGAGACCCTCCTAGACAAATTCTACACTGAACTCTACCAGCAGCTGAATGACCTGGAAGCCTGTGT
GATACAGGGGGTGGGGGTGACAGAGACTCCCCTGATGAAGGAGGACTCCATTCTGGCTGTGAGGAAATACTTC
CAAAGAATCACTCTCTATCTGAAAGAGAAGAAATACAGCCCTTGTGCCTGGGAGGTTGTCAGAGCAGAAATCA
TGAGATCTTTTCTTTGTCAACAACTTGCAAGAAAGTTTAAGAAGTAAGGAATGA

IL-12 Gene Medicine (Combination Therapy) in Renca Model

FIGURE 9



* $p < 0.01$



GENENTECH INC.

IL-12/PVP (24 μ g)

IL-2/DC (6 μ g)

IFN- α (96 μ g)

EP= empty plasmid/PVP (96 μ g)

Sequence Listing Part

<110> NORDSTROM, JEFF; PERICLE, FEDERICA; ROLLAND,
 ALLAIN; RALSTON, ROBERT
 <120> INTERFERON ALPHA PLASMIDS AND DELIVERY SYSTEMS,
 5 AND METHODS OF MAKING AND USING THE SAME
 <150> US 08/949,160 and PCT/US97/18779
 <151> October 10, 1997
 <160> 25
 <210> 1
 10 <211> 328
 <212> amino acid
 <400> 1

Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu
 15 1 5 10 15
 Ala Ser Pro Leu Val Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val
 20 20 25 30
 Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu
 35 40 45
 Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln
 50 55 60
 25 Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys
 65 70 75 80
 Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val
 30 85 90 95
 Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp
 100 105 110
 35 Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe
 115 120 125
 Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp
 130 135 140
 40 Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg
 145 150 155 160
 Gly Ser Ser Asp Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser
 45 165 170 175
 Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu
 180 185 190

	Cys	Gln	Glu	Asp	Ser	Ala	Cys	Pro	Ala	Ala	Glu	Glu	Ser	Leu	Pro	Ile	
	195						200						205				
5	Glu	Val	Met	Val	Asp	Ala	Val	His	Lys	Leu	Lys	Tyr	Glu	Asn	Tyr	Thr	
	210						215					220					
	Ser	Ser	Phe	Phe	Ile	Arg	Asp	Ile	Ile	Lys	Pro	Asp	Pro	Pro	Lys	Asn	
10	225					230					235					240	
	Leu	Gln	Leu	Lys	Pro	Leu	Lys	Asn	Ser	Arg	Gln	Val	Glu	Val	Ser	Trp	
					245					250						255	
15	Glu	Tyr	Pro	Asp	Thr	Trp	Ser	Thr	Pro	His	Ser	Tyr	Phe	Ser	Leu	Thr	
				260					265						270		
	Phe	Cys	Val	Gln	Val	Gln	Gly	Lys	Ser	Lys	Arg	Glu	Lys	Lys	Asp	Arg	
			275					280					285				
20	Val	Phe	Thr	Asp	Lys	Thr	Ser	Ala	Thr	Val	Ile	Cys	Arg	Lys	Asn	Ala	
	290						295					300					
	Ser	Ile	Ser	Val	Arg	Ala	Gln	Asp	Arg	Tyr	Tyr	Ser	Ser	Ser	Trp	Ser	
25	305					310					315					320	
	Glu	Trp	Ala	Ser	Val	Pro	Cys	Ser									
					325												
	<210>					2											
30	<211>					987											
	<212>					nucleic acid											
	<400>					2											
35	ATGTGTCACC	AGCAGTTGGT	CATCTCTTGG	TTTTCCCTGG	TTTTTCTGGC	ATCTCCCCTC											60
	GTGGCCATAT	GGGAACGTAA	GAAAGATGTT	TATGTCGTAG	AATTGGATTG	GTATCCGGAT											120
	GCCCTGGAG	AAATGGTGGT	CCTCACCTGT	GACACCCCTG	AAGAAGATGG	TATCACCTGG											180
	ACCTTGGACC	AGAGCACTGA	GGTCTTAGGC	TCTGGCAAAA	CCCTGACCAT	CCAAGTCAAA											240
	GAGTTGGAG	ATGCTGGCCA	GTACACCTGT	CACAAAGGAG	GCGAGGTTCT	AAGCCATTGC											300
40	CTCCTGCTGC	TTTCAAAAAA	GGAAGATGGA	ATTTGGTCCA	CTGATATTTT	AAAGGACCAG											360
	AAAGAACCCA	AAAATAAGAC	CTTTCTAAGA	TGCGAGGCCA	AGAATTATTC	TGGACGTTTC											420
	ACCTGCTGGT	GGCTGACGAC	AATCAGTACT	GATTGACAT	TCAGTGTCAA	AAGCAGCAGA											480
	GGTCTTCTG	ACCCCAAGG	GGTGACGTGC	GGAGCTGCTA	CACCTCTCTC	AGAGAGAGTC											540
	AGAGGGGACA	ACAAGGAGTA	TGAGTACTCA	GTGGAGTGCC	AGGAGGACAG	TGCCTGCCCA											600
45	GCTGCTGAGG	AGAGTCTGCC	CATTGAGGTC	ATGGTGGATG	CCGTTACAAA	GCTCAAGTAT											660
	GAAACTACA	CCAGCAGCTT	CTTCATCAGG	GACATCATCA	AACCTGACCC	ACCCAAGAAC											720
	TTGCAGCTGA	AGCCATTAAA	GAATTCTCGG	CAGGTGGAGG	TCAGCTGGGA	GTACCCCTGAC											780
	ACCTGGAGTA	CTCCACATTC	CTACTCTCCC	CTGACATTCT	GCGTTCAGGT	CCAGGGCAAG											840
	AGCAAGAGAG	AAAAGAAAGA	TAGAGTCTTC	ACGGACAAGA	CCTCAGCCAC	GGTCATCTGC											900
50	CGCAAAAATG	CCAGCATTAG	CGTGCGGGCC	CAGGACCGCT	ACTATAGCTC	ATCTTGAGGC											960
	GAATGGGCAT	CTGTGCCCTG	CAGTTAG														987

3

<210> 3
 <211> 987
 <212> nucleic acid
 <400> 3

5

ATGTGCCACC	AGCAGCTGGT	GATCAGCTGG	TTCAGCCTGG	TGTTCTGGC	CAGCCCCCTG	60
GTGGCCATCT	GGGAGCTGAA	GAAGGACGTG	TACGTGGTGG	AGCTGGACTG	GTACCCCGAC	120
GCCCCCGGCG	AGATGGTGGT	GCTGACCTGC	GACACCCCGG	AGGAGGACGG	CATCACCTGG	180
ACCTTGAGCC	AGAGCAGCGA	GGTGTCTGGG	AGCGGCAAGA	CCCTGACCAT	CCAGGTGAAG	240
GAGTTCTGGG	ACGCCGGCCA	GTACACCTGC	CACAAGGGCG	GCGAGGTGCT	GAGCCACAGC	300
CTGCTGCTGC	TGCACAAGAA	GGAGGACGGC	ATCTGGAGCA	CCGACATCCT	GAAGGACCAG	360
AAGGAGCCCA	AGAACAAGAC	CTTCCTGCGC	TGCGAGGCCA	AGAACTACAG	CGGCCGCTTC	420
ACCTGCTGGT	GGCTGACCAC	CATCAGCACC	GACCTGACCT	TCAGCGTGAA	GAGCAGCAGG	480
GGCAGCAGCG	ACCCCCAGGG	CGTGACCTGC	GGCGCCGCCA	CCCTGAGCGC	CGAGCGCGTG	540
CGCGGGGACA	ACAAGGAGTA	CGAGTACAGC	GTGGAGTGCC	AGGAGGACAG	CGCCTGCCCC	600
CGCGCCGAGG	AGGCCCTGCC	CATCGAGGTG	ATGGTGGACG	CCGTCCACAA	CGTGAAGTAC	660
GAGAAGTACA	CCAGCAGCTT	CTTCATCCGC	GACATCATCA	AGCCCCGACC	CCCCAAGAAC	720
CTGCAGCTGA	AGCCCCCTGAA	GAACAGCCCG	CAGGTGGAGG	TGAGCTGGGA	GTACCCCGAC	780
ACCTGGAGCA	CCCCCAGCAG	CTACTTCAGC	CTGACCTTCT	GCGTGCAGGT	GCAGGGCAAG	840
AGCAAGCGCG	AGAGAGAGGA	CCGCGTGTTT	ACCGACAAGA	CCAGCGCCAC	CGTGATCTGC	900
CGCAAGAACG	CCAGCATCAG	CGTGCGCGCC	CAGGACCGCT	ACTACAGCAG	CAGCTGGAGC	960
GAGTGGGCCA	GCGTGCCCTG	CAGCTAG				987

<210> 4
 <211> 987
 <212> nucleic acid
 <400> 4

25

ATGTGCCACC	AGCAGCTGGT	GATCAGCTGG	TTCCTCCTGG	TGTTCTGGC	CAGCCCCCTC	60
GTGGCCATCT	GGGAGCTGAA	GAAGGACGTG	TACGTGGTGG	AGCTGGACTG	GTACCCCGAC	120
GCCCCCGGCG	AGATGGTGGT	CCTGACCTGC	GACACCCCGG	AGGAAGACGG	CATCACCTGG	180
ACCTTGAGCC	AGAGCAGTGA	GGTGTCTGGG	TCCGGCAAGA	CCCTGACCAT	CCAGGTGAAG	240
GAGTTCTGGG	ACGCCGGCCA	GTACACCTGC	CACAAGGGAG	GCGAGGTGCT	GAGCCATCTC	300
CTCCTGCTGC	TCCACAAAAA	GGAGGACGGC	ATCTGGAGCA	CCGACATCCT	GAAGGACCAG	360
AAGGAGCCCA	AGAACAAGAC	CTTCCTGCGC	TGCGAGGCCA	AGAACTACAG	CGGCCGCTTC	420
ACCTGCTGGT	GGCTGACCAC	GATCAGCACC	GACCTGACCT	TCAGTGTGAA	GAGCAGCAGG	480
GGCTCCAGCG	ACCCCCAGGG	CGTGACCTGC	GGCGCTGCCA	CCCTGAGCGC	CGAGCGCGTG	540
GCGCGGACCA	ACAAGGAGTA	CGAGTACAGC	GTGGAGTGCC	AGGAAGACTC	CGCCTGCCCC	600
GCGGCTGAGG	AGAGCCTGCC	CATCGAGGTG	ATGGTGGACG	CCGTTCACAA	GCTGAAGTAC	660
GAGAAGTACA	CCAGCAGCTT	CTTCATCCGC	GACATCATCA	AGCCTGACCC	ACCCAAGAAC	720
CTCCAGCTGA	AGCCCCCTCAA	GAATCCCCGC	CAGGTGGAGG	TGAGCTGGGA	GTACCCCGAC	780
ACCTGGAGCA	CGCCCCACTC	CTACTTCTCC	CTGACCTTCT	GCGTGCAGGT	CCAGGGCAAG	840
AGCAAGCGCG	AGAGAGAGGA	CCGCGTGTTT	ACCGACAAGA	CCAGGGCCAC	CGTATCTGTC	900
CGCAAGAACG	CCAGCATCAG	CGTGCGCGCC	CAGGACCGCT	ACTATAGCTC	CTCTTGGAGC	960
GAGTGGGCCA	GCGTGCCCTG	CTCCTAG				987

<210> 5
 <211> 219
 <212> amino acid
 <400> 5

50

Met	Cys	Pro	Ala	Arg	Ser	Leu	Leu	Leu	Val	Ala	Thr	Leu	Val	Leu	Leu
1				5					10					15	

	Asp	His	Leu	Ser	Leu	Ala	Arg	Asn	Leu	Pro	Val	Ala	Thr	Pro	Asp	Pro	
			20						25					30			
5	Gly	Met	Phe	Pro	Cys	Leu	His	His	Ser	Gln	Asn	Leu	Leu	Arg	Ala	Val	
			35					40					45				
	Ser	Asn	Met	Leu	Gln	Lys	Ala	Arg	Gln	Thr	Leu	Glu	Phe	Tyr	Pro	Cys	
			50				55					60					
10	Thr	Ser	Glu	Glu	Ile	Asp	His	Glu	Asp	Ile	Thr	Lys	Asp	Lys	Thr	Ser	
			65			70					75					80	
	Thr	Val	Glu	Ala	Cys	Leu	Pro	Leu	Glu	Leu	Thr	Lys	Asn	Glu	Ser	Cys	
15					85					90					95		
	Leu	Asn	Ser	Arg	Glu	Thr	Ser	Phe	Ile	Thr	Asn	Gly	Ser	Cys	Leu	Ala	
				100					105					110			
20	Ser	Arg	Lys	Thr	Ser	Phe	Met	Met	Ala	Leu	Cys	Leu	Ser	Ser	Ile	Tyr	
			115				120						125				
	Glu	Asp	Leu	Lys	Met	Tyr	Gln	Val	Glu	Phe	Lys	Thr	Met	Asn	Ala	Lys	
			130				135						140				
25	Leu	Leu	Met	Asp	Pro	Lys	Arg	Gln	Ile	Phe	Leu	Asp	Gln	Asn	Met	Leu	
			145			150					155					160	
	Ala	Val	Ile	Asp	Glu	Leu	Met	Gln	Ala	Leu	Asn	Phe	Asn	Ser	Glu	Thr	
30					165					170						175	
	Val	Pro	Gln	Lys	Ser	Ser	Leu	Glu	Glu	Pro	Asp	Phe	Tyr	Lys	Thr	Lys	
				180					185					190			
35	Ile	Lys	Leu	Cys	Ile	Leu	Leu	His	Ala	Phe	Arg	Ile	Arg	Ala	Val	Thr	
			195					200					205				
	Ile	Asp	Arg	Val	Thr	Ser	Tyr	Leu	Asn	Ala	Ser						
			210				215										
40	<210>		6														
	<211>		660														
	<212>		nucleic acid														
	<400>		6														
45	ATGTGTCCAG	CGGCGAGCCT	CCTCCTTGTC	GCTACCCCTGG	TCCTCCTGGA	CCACCTCACT											60
	TTGGCCAGAA	ACCTCCCGT	GGCCACTCCA	GACCCAGGAA	TGTTCCCATG	CCTTCACCAC											120
	TCCCAAAACC	TGCTGAGGGC	CGTCAGCAAC	ATGCTCCAGA	AGGCCAGACA	AACCTCTAGAA											180
	TTTACCCTT	GCACTTCTGA	AGAGATTGAT	CATGAAGATA	TCACAAAAGA	TAAAACCCAGC											240
50	ACAGTGGAGG	CCTGTTTACC	ATTGGAATTA	ACCAAGAATG	AGAGTTGCCT	AAATTCAGAA											300
	GAGACCTCTT	TCATAACTAA	TGGGAGTTGC	CTGGCCTCCA	GAAAGACCTC	TTTATGATG											360
	GCCTGTGCCC	TTAGTAGTAT	TTATGAAGAC	TTGAAGATGT	ACCAGGTGGA	GTTCAGAGACC											420
	ATGAATGCAA	AGCTTCTGAT	GGATCCTAAG	AGGCAGATCT	TCTAGATCA	AAACATGCTG											480
	GCAGTTATTG	ATGAGCTGAT	GCAGGCCCTG	AAATTCACAA	GTGAGACTGT	GCCACAAAAA											540
55	TCCTCCCTTG	AAGAACCCTG	TTTTTATAAA	ACTAAATCA	AGCTCTGCAT	ACTTCTTCAT											600
	GCTTTCAGAA	TTCGGGCAGT	GACTATTGAC	AGAGTGACGA	GCTATCTGAA	TGCTTCCTTAA											660

5

<210> 7
 <211> 660
 <212> nucleic acid
 <400> 7

5

ATGTGCCCGG CCCGAGCCT GCTGCTGGTG GCCACCTGG TGCTGCTGGA CCACCTGAGC 60
 CTGGCCCGCA ACCTGCCCGT GGCCACCCCG GACCCCGGCA TGTTCCTCTG CCTGCACCAC 120
 AGCCAGAACG TGCTGGCGGC CGTGAGCAAC ATGCTGCAGA AGGCCCGGCA GACCCCTGGAG 180
 TTCTACCCCT GCACCAGCGA GGAGATCGAC CACGAGGACA TCACCAAGGA CAAGACCAGC 240
 10 ACCGTGGAGG CCTGCCTGCC CTTGGAGCTG ACCAAGAAGC AGAGCTGCCT GAACAGCCGC 300
 GAGACCAGCT TCATCACCAG CGGCAGCTGC CTGGCCAGCC GCAAGACCAG CTTTATGATG 360
 GCCCTGTGCC TGAGCAGCAT CTACGAGGAC CTGAAGATGT ACCAGGTGGA GTTCAAGACC 420
 ATGAACGCCA AGCTGCTGAT GGACCCCAAG CTCAGATCT TCCTGGACCA GAACATGCTG 480
 15 GCGCTGATCG ACGAGCTGAT GCAGGCCCTG AACTTCAACA GCGAGACCGT GCCCCAGAAG 540
 AGCAGCTGG AGGAGCCCGA CTTCTACAAG ACCAAGATCA AGCTGTGCAT CCTGCTGCAC 600
 GCCTTCCGCA TCCGCGCCGT GACCATCGAC CGCGTGACCA GCTACCTGAA CGCCACCTGA 660

<210> 8
 <211> 660
 20 <212> nucleic acid
 <400> 8

ATGTGCCCGG CCCGAGCCT GCTGCTCGTG GCCACCTGG TGCTCCTGGA CCACCTCAGC 60
 CTGGCCCGCA ACCTGCCCGT GGCCACCCCA GACCCCGGCA TGTTCCTATG CCTGCACCAC 120
 25 AGCCAGAACG TGCTGGCGGC CGTGAGCAAC ATGCTGCAGA AGGCCCGGCA GACCCCTGGAG 180
 TTCTACCCCT GCACCAGCGA GGAGATCGAC CACGAGGACA TCACCAAGGA CAAGACCAGC 240
 ACCGTGGAGG CCTGCCTGCC CTTGAGTTA ACCAAGAAGC AGAGCTGCCT CAACAGCCGC 300
 GAGACCTCCT TCATCACCAG CGGCACCTGC CTGGCCTCCC GCAAGACCAG CTTTATGATG 360
 30 GCCCTGTGCC TGAGCTCCAT CTACGAGGAC CTGAAGATGT ACCAGGTGGA GTTCAAGACC 420
 ATGAACGCCA AGCTCCTGAT GGACCCCAAG CTCAGATCT TCCTGGACCA GAACATGCTG 480
 GCGCTGATCG ACGAGCTGAT GCAGGCCCTG AACTTCAACA GCGAGACCGT GCCCCAGAAG 540
 AGCAGCTGG AGGAGCCCGA CTTCTACAAG ACCAAGATCA AGCTGTGCAT CCTGCTGCAC 600
 GCCTTCCGCA TCCGGGCGCT GACCATCGAC CGCGTGACCA GCTACCTGAA CGCCACGTGA 660

35 <210> 9
 <211> 188
 <212> amino acid
 <400> 9

40 Met Ala Leu Thr Phe Ala Leu Leu Val Ala Leu Leu Val Leu Ser Cys
 1 5 10 15
 Lys Ser Ser Cys Ser Val Gly Cys Asp Leu Pro Gln Thr His Ser Leu
 20 25 30
 45 Gly Ser Arg Arg Thr Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser
 35 40 45
 50 Leu Phe Ser Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu
 50 55 60
 Glu Phe Gly Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His
 65 70 75 80

	Glu Met Ile Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser	85	90	95
5	Ala Ala Trp Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr	100	105	110
	Gln Gln Leu Asn Asp Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val	115	120	125
10	Thr Glu Thr Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys	130	135	140
15	Tyr Phe Gln Arg Ile Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro	145	150	155
	Cys Ala Trp Glu Val Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu	165	170	175
20	Ser Thr Asn Leu Gln Glu Ser Leu Arg Ser Lys Glu	180	185	
	<210>	10		
	<211>	567		
25	<212>	nucleic acid		
	<400>	10		
30	ATGGCCTTGA CCTTTGCTTT ACTGGTGGCC CTCCTGGTGC TCAGCTGCAA GTCAAGCTGC			60
	TCTGTGGGCT GTGATCTGCC TCAAACCCAC AGCCTGGGTA GCAGGAGGAC CTGTATGCTC			120
	CTGGCACAGA TGAGGAGAAT CTCTCTTTTC TCCTGCTTGA AGGACAGACA TGACTTTGGA			180
	TTTCCCCAGG AGGAGTTTGG CAACCACTTC CAAAAGGCTG AAACCATCCC TGTCCTCCAT			240
	GAGATGATCC AGCAGATCTT CAATCTCTTC AGCACAAAGG ACTCATCTGC TGCTTGGGAT			300
	GAGACCTCC TAGACAAATT CTACACTGAA CTCTACCAGC AGCTGAATGA CTGGAAGCC			360
35	TGTGTGATAC AGGGGGTGGG GGTGACAGAG ACTCCCCTGA TGAAGGAGGA CTCCATTCTG			420
	GCTGTGAGGA AATACTTCCA AAGAATCACT CTCTATCTGA AAGAGAAGAA ATACAGCCCT			480
	TGTGCCTGGG AGGTTGTGAG AGCAGAAATC ATGAGATCTT TTTCTTTGTC AACAACTTG			540
	CAAGAAAGTT TAAGAAGTAA GGAATGA			567
	<210>	11		
40	<211>	567		
	<212>	nucleic acid		
	<400>	11		
45	ATGGCCCTGA CCTTCGCCCT GCTGGTGGCC CTGCTGGTGC TGAGCTGCAA GAGCAGCTGC			60
	TCCGTGGGGT GCGACCTGCC CCAGACCCAC AGCCTGGGGA GCCGGCGGAC CCTGATGCTG			120
	CTGGCCACAGA TGCGGCGGAT CAGCCTGTTC AGCTGCCTGA AGGACCGGCA CGACTTCGGG			180
	TTCCCCAGG AGGAGTTTCGG GAACCACTTC CAGAAGGCCG AGACCATCCC CGTGCTGCAC			240
	GAGATGATCC AGCAGATCTT CAACCTGTTC AGCACCAAGG ACAGCAGCGC CGCCTGGGAC			300
	GAGACCTGC TGGACAAGTT CTACACCGAG CTGTACCAGC AGCTGAACGA CCTGGAGGCC			360
50	TGCGTGATCC AGGGGGTGGG GGTGACCGAG ACCCCCCTGA TGAAGGAGGA CAGCATCCTG			420
	GCCGTGCGGA AGTACTTCCA GCGGATCACC CTGTACCTGA AGGAGAAGAA GTACTCCCCC			480
	TGCGCCTGGG AGGTGGTGGC GGCCGAGATC ATGCGGAGCT TCAGCCTGAG CACCAACCTG			540
	CAGGAGAGCC TGCGGAGCAA GGAGTGA			567

7

- <210> 12
 <211> 567
 <212> nucleic acid
 <223> "Y" stands for C or T; "R" stands for A or G;
 5 "W" stands for T or A; "S" stands for C or G; "N"
 stands for any base.
 <400> 12
- 10 ATGGCNYTNA CNTTYGCNYT NYTNGTNGCN YTNYTNGTNY TNWSNTGYAA RWSNWSNTGY 60
 WSNGTNGGNT GYGAYYTNC NCARACNCAY WSNTYNGGNW SNMGNMGNAC NYTNATGYTN 120
 YTNGCNCARA TGMGNMGNAT HWSNYTNTTY WSNTGYTTNA ARGAYMGNCA YGAYTTYGGN 180
 TTYCCNCARG ARGARTTYGG NAAAYCARTTY CARAARGCNG ARACNATHCC NGTNYTNCAAY 240
 GARATGATHC ARCARTHTT YAAAYTNTTY WSNACNAARG AYWSNWSNGC NGCNTGGGAY 300
 GARACNYTNY TNGAYAARTT YTAYACNGAR YTNATYCARC ARYTNAAYGA YYTNGARGCN 360
 15 TGYGTNATHC ARGGNGTNGG NGTNACNGAR ACNCCNYTNA TGAARGARGA YWSNATHYTN 420
 GCNGTNMGNA ARTAYTTYCA RMGNATHACN YTNATYTTNA ARGARAARAA RTAYWSNCCN 480
 TGYGCNTGGG ARGTNGTNMG NGCNGARATH ATGMGNWSNT TYWSNYTNWS NACNAAYTNT 540
 CARGARWSNY TNMGNWSNAA RGARTTR 567
- 20 <210> 13
 <211> 191
 <212> nucleic acid
 <400> 13
- 25 GGGTGGCATC CCTGTGACCC CTCGCCAGTG CCTCTCCTGG CCTGGAAGT TGCCACTCCA 60
 GTGCCACCA GCCTTGTCCT AATAAAATTA AGTTGCATCA TTTTGTCTGA CTAGGTGTCC 120
 TTCTATAATA TTATGGGGTG GAGGGGGGTG GTATGGAGCA AGGGGCAAGT TGGGAAGACA 180
 ACCTGTAGGG C 191
- 30 <210> 14
 <211> 58
 <212> nucleic acid
 <400> 14
- 35 AAGCTTACTC AACACAATAA CAAACTTACT TACAATCTTA ATTAACAGGC CACCATGG 58
 <210> 15
 <211> 15
 <212> nucleic acid
 40 <400> 15
 CAGGTAAGTG TCTTC

15

	<210>	16		
	<211>	30		
	<212>	nucleic acid		
	<400>	16		
5			TACTAACGGT TCTTTTTTTC TCTTCACAGG	
	<210>	17		
	<211>	271		
10	<212>	nucleic acid		
	<400>	17		
15			TCTAGAGCAT TTTTCCCTCT GCCAAAAATT ATGGGGACAT CATGAAGCCC CTTGAGCATC	60
			TGACGCTCGG CTAATAAAGG AAATTTATTT TCATTGCAAT AGTGTGTTGG AATTTTTTGT	120
			GTCTCTCACT CGGTACTAGA GCATTTTCC CTCTGCCAAA AATTATGGGG ACATCATGAA	180
			GCCCTTGAG CATCTGAGCT CTGGCTAATA AAGGAAATTT ATTTTCATTG CAATAGTGTG	240
			TTGGAATTTT TGTGTCTCT CACTCGGTAC C	271
	<210>	18		
20	<211>	5686		
	<212>	nucleic acid		
	<400>	18		
25			CCGGCCACAG TCGATGAATC CAGAAAAGCG GCCATTTTCC ACCATGATAT TCGGCAAGCA	60
			GGCATCGCCA TGCCTCACGA CGAGATCCTC GCCGTCGGGC ATGCGCGCCT TGAGCCTGGC	120
			GAACAGTTGG GCTGGCGCGA GCCCTGATG CTCTTCGTCC AGATCATCCT GATCGACAAG	180
			ACCGGCTTCC ATCCGAGTAC GTGCTCGCTC GATGCGATGT TTCGCTTGGT GGTGCAATGG	240
			GCAGGTAGCC GGATCAAGCG TATGCAGCGC CCGCATTGCA TCAGCCATGA TGGATACTTT	300
30			CTCGGCAGGA GCAAGGTGAG ATGACAGGAG ATCCTGCCCC GGCACCTTCGC CCAATAGCAG	360
			CCAGTCCCTT CCGCTTCAG TGACAACGTC GAGCAGAGCT GCGCAAGGAA CGGCCGCTCGT	420
			GGCCAGCCAC GATAGCCGCG CTGCCTCGTC CTGCAGTTCA TTCAGGGCAC CGGACAGGTC	480
			GGTCTTGACA AAAAGAACCG GCGCCCCCTG CGCTGACAGC CGGAACACGG CGGCATCAGA	540
			GCAGCGGATT GTCTGTTGTG CCCAGTCAAT CTGTGTTCAAT CATGCGAAGC GATCCTCATC	600
35			AGAACCTGCG TGCAATCCAT CTTGTTCAAT CATGCGAAGC GATCCTCATC CTGTCTCTTG	660
			ATCAGATCTT GATCCCCGTC GCCATCAGAT CCTTGGCGGC AAGAAAGCCA TCCAGTTTAC	720
			TTTGCAGGCG TTCCCAACCT TACCAGAGGG CGAATTCGAG CTTGATGCC TGCAGGTCGT	780
			TACATAACTT ACGGTAAATG GCGCCGCTGG CTGACCGCCC AACGACCCCC GCGGCGCGG	840
			GTCAATAATG ACGTATGTTT CCATAGTAAC GCCAATAGGG ACTTCCCATT GACGTCAATG	900
40			GGTGGAGTAT TTACGGTAAA CTGCCCCACTT GGCAGTACAT CAAGTGTATC ATATGCCAAG	960
			TACGCCCCCT ATTGACGTCA ATGACGGTAA ATGGCCCGCC TGGCATTATG CCCAGTACAT	1020
			GACCTTATGG GACTTTCCTA CTTGGCAGTA CATCTACGTA TTAGTCATCG CTATTACCAT	1080
			GGTATGCGGG TTTTGGCAGT ACATCAATGG GCGTGGATAG CGGTTTGACT CACGGGGATT	1140
			TCCAAGTCTC CACCCCATGG ACGTCAATGG GAGTTTGTG TGGACCAAAA ATCAACGGGA	1200
45			CTTTCCAAAA TGTGTAACA ACTCCGCCCC ATTGACGCAA ATGGGCGGTA GCGGTGTAGC	1260
			GTGGAGGTC TATATAAGCA GAGCTCGTTT AGTGAACCGT CAGATCGCCT GGAGACGCCA	1320
			TCCACGCTGT TTTGACCTCC ATAGAAGACA CCGGGACCGA TCCAGCCTCC GCGGCGGGGA	1380
			ACGCTGCACT GGAACGCGGA TTCCCGGTGT TAATTAACAG GTAAGTGTCT TCCTCTCTGT	1440
			TCCTTCCCTT GCTATTCTGC TCAACCTTCC TATCAGAAAC TGCAGTATCT GTATTTTTCG	1500
50			TAGCAGTAAT ACTAAGCGTT CTTTTTTTCT CTTACAGGC CACCATGGGT CCAGCGCGCA	1560
			GCCTCTCTCT TGTGGCTACC CTGGTCTCTC TGGACCACTT CAGTTTGGCC AGAAACCTCC	1620
			CCGTGGCCAC TCCAGACCCA GGAATGTTCC CATGCCTCA CCACTCCCAA AACCTGCTGA	1680
			GGGCCGTCAG CACATGCTC CAGAAGGCCA GACAAACTCT AGAATTTTAC CCTTGCACCT	1740
			CTGAAGAGAT TGATCATGAA GATATACAA AAGATAAAAC CAGCAGAGT GAGGCGCTGT	1800
55			TACCATTGGA ATTAACCAA AATGAGAGTT GCCTAAATTC CAGAGAGACC TCTTTCATAA	1860
			CTAATGGGAG TTGCCTGGCC TCCAGAAAGA CCTCTTTTAT GATGGCCCTG TGCTTTAGTA	1920
			GTATTTATGA AGACTTGAAG ATGTACCAGG TGGAGTTCAA GACCATGAAT GCAAAGCTTC	1980
			TGATGGATCC TAAGAGGCAG ATCTTCTAG ATCAAAACAT GCTGGCAGTT ATTGATGAGC	2040

	TGATGCAGGC	CCTGAATTTC	AACAGTGAGA	CTGTGCCACA	AAAACTCCTCC	CTTGAAGAAC	2100
	CGGATTTTTA	TAAAACTAAA	ATCAAGCTCT	GCATACTTCT	TCATGCTTTC	AGAATTCCGGG	2160
	CAGTGACTAT	TGATAGAGTG	ATGAGCTATC	TGAATGCTTC	CTAACAAATTC	TAGAAAAGGCC	2220
	GAATTCTGCA	GGAAATGGGT	GGCATCCCTG	TGACCCCTCC	CCAGTGGCCTC	TCCTGGCCCT	2280
5	GGAAAGTTGCC	ACTCCAGTCT	CCACCAGCCT	TGCTCTAATA	AAATTAAGTT	GCATCATTTT	2340
	GTCCTGACTG	GTGTCCCTTG	ATAAATATTAT	GGGGTGGAGG	GGGGTGGTAT	GGAGCAAGGG	2400
	GCAAGTTGGG	AAGACAACTT	GTAGGGCTCG	AGGGGGGGGCC	CGGTACGGTC	GTTACATAAC	2460
	TTACGGTAAG	TGGCCCCGCT	GGCTGACCGC	CCAACGACCC	CCGCCCATTG	ACGTCAATAA	2520
	TGACGTATGT	TCCCATAGTA	ACGCCAATAG	GGACTTTCCA	TTGACGTCAA	TGGGTGGAGT	2580
10	ATTTACGGTA	AAC TGCCAC	TTGGCAGTAC	ATCAAGTGTA	TCATATGCCA	AGTACGCCCC	2640
	CTATTGACGT	CAATGACGGT	AAATGGCCCG	CCTGGCATTG	TGCCCAGTAC	ATGACCTTAT	2700
	GGGACTTTCC	TACTTTGGCAG	TACATCTACG	TATTAGTCAT	CGCTATTACC	ATGGTGATGC	2760
	GGTTTTGGCA	GTACATCAAT	GGGCGTGGAT	AGCGGTTTGA	CTCACGGGGA	TTTCCAAGTC	2820
	TCCACCCCAT	TGACGTCAAT	GGGAGTTTGT	TTTGCCACCA	AAATCAACGG	GACTTTCCAAC	2880
15	AATGTGTAAG	CAACTCCGCC	CCATTGACGC	AAATGGGCGG	TAGGCGTGTA	CGGTGGGAGG	2940
	TCTATATAAG	CAGAGCTCGT	TTAGTGAACC	GTGACATCGC	CTGGAGACGC	CATCCACGCT	3000
	GTTTTGACCT	CCATAGAGAA	CAACGGGACC	GATCCAGCCT	CCGCGGCGGG	GAACGGTGCA	3060
	TTGGAAACGG	GATTCGCCGT	GTTAATTAAAC	AGGTAAGTGT	CTTCCTCCTG	TTTCCTTCCC	3120
20	CTGCTATTCT	CTCAACCTT	CCTATCAGAA	ACTGCAGTAT	CTGTATTTTT	GCTAGAATTG	3180
	TACTAACGGT	CTTTTTTTTC	TCTTCACAGG	CTTAAGTCAT	GGGTACACAG	CAGTTGGTCA	3240
	TCTCTTGGTT	TTCCCTGGTT	TTTCTGGCAT	CTCCCTCGT	GGCCATATGG	GAACCTGAAGA	3300
	AAGATGTTTA	TGTCGTAGAA	TTGGATTGGT	ATCCGGATGC	CCCTGGAGAA	ATGTTGGTCC	3360
	TCACCTGTGA	CACCCCTGAA	GAAGATGTTA	TCACCTGGAC	CTTGAGCCAG	AGCAGTGAGG	3420
	TCTTAGGCTC	TGGCAAAACC	CTGACCATCC	AAGTCAAAGA	GTTTGGAGAT	GCTGGCCAGT	3480
25	ACACCTGTCA	CAAGGAGGCG	GAGGTTCTAA	GCCATTCGCT	CTGCTGCTT	CACAAAAGG	3540
	AAGATGGAAT	TTGGTCCACT	GATATTTTAA	AGGACCAAGAA	AGAACCACAA	AATAGACCT	3600
	TTCTAAGATG	CGAGGCCAAG	AATTATTCTG	GAGCTTTCAC	CTGCTGGTGG	CTGACGACAA	3660
	TCAGTACTGA	TTTGACATTG	AGTGTCAAAA	GCAGCAGAGG	CTCTCTGCAC	CCCCAGGGGG	3720
	TGACGTGGCG	AGCTGCTACA	CTCTCTGCA	AGAGAGTCAG	AGGGGACCAAC	AAGGAGTATG	3780
30	AGTACTCAGT	GGAGTCCGAG	GAGGACAGTG	CCTGCCCCAG	TGCTGAGGAG	AGTCTGCCCA	3840
	TTGAGGTGAT	GGTGGATGCC	GTTTCAACGC	TCAAGTATGA	AAACTACACC	AGCAGCTTCT	3900
	TCATCAGGGA	CATCATCAAA	CCTGACCCAC	CCAGAACTT	GCAGCTGAAG	CCATTAAAGA	3960
	ATTCTCGCGA	GGTGGAGGTG	AGCTGGGAGT	ACCTTGACAC	CTGGAGTACT	CCACATTCTCT	4020
	ACTTCTCCCT	GACATTCTGC	GTTCAAGTCC	AGGGCAAGAG	CAAGAGAGAA	AAGAAAAGATA	4080
35	GAGTCTTCAC	GGACAAAGCC	TCAGCCACGG	TCATCTGCCG	CAAAATGCCC	AGCATTAGGG	4140
	TGCGGGGCCA	GGACCGCTAC	TATAGCTCAT	CTTGGAGCGA	ATGGGCACTC	GTGCCCTGCA	4200
	GTTAGACGCG	CTAGAAAAGC	CGAATTCTGC	AGGAATTGGG	TGGCATCCCT	GTGACCCCTC	4260
	CCCAGTGCCT	CTCCTGGCCC	TGGAAGTTGC	CACCTCCAGTG	CCCAACGACC	TTGTCCTAAT	4320
40	AAAATTAAAT	TGCATCATTT	TGCTGACTA	GGTGCTCTTC	TATAATATTA	TGGGGTGGAG	4380
	GGGGGTGGTA	TGGAGCAAGG	GGCAAGTTGG	GAAGACAACC	TGTAGGGCTC	GAGGGGGGGG	4440
	CCGGTACCAG	CTTTTGTTC	CTTTAGTGAG	GGTTAATTTT	GAGCTTGGCG	TAATCATGGT	4500
	CATAGCTGTT	TCCTGTGTGA	AATTGTTATC	CGCTCACAAT	TCCACACCAAC	ATACGAGCCG	4560
	GAAGCATAAA	GTGTAAGGCC	TGGGGTCCCT	AATGAGTGAG	CTAACTCACA	TTAATTGCGT	4620
	TGCGCTCACT	GCCCGCTTTC	CAGTCGGGAA	ACCTGTCTGT	CCAGCTGCAT	TAATGAATCG	4680
45	GCCAAGCGCG	GGGGAGAGCG	GGTTTGCCTA	TTGGGGCGTC	TTCCGCTTCC	TCGCTCACTG	4740
	ACTCGCTCGG	CTCGGTCGTT	CGGCTGCGGC	GAGCGGTATC	AGCTCACTCA	AAGGCGGTAA	4800
	TACGGTTATC	CACAGATAAT	GGGGATAACG	CAGGAAAGAA	CATGTGAGCA	AAAGGCGCAG	4860
	AAAAGGCCAG	GAACCGTAAA	AAGGCCGCGT	TGCTGGCGTT	TTTCCATAGG	CTCCGCCCCC	4920
	CTGACGAGCA	TCACAAAAAT	CGACGCTCAA	GTGAGAGGTG	GCGAAACCCG	ACGAGACTAT	4980
50	AAAGATACCA	GGCGTTTCCC	CCTGGAAGCT	CCCTCGTGGG	CTCTCTGTTT	CCGACCCCTG	5040
	CGCTTACCGG	ATACCTGTCC	GCCTTTCTCC	CTTCGGGAAG	CGTGGCGCTT	TCTCATAGCT	5100
	CACGCTGTAG	GTATCTCAGT	TCGGTGTAGG	TCGTTGCGTC	CAAGCTGGGC	TGTGTGCACG	5160
	AACCCCGCGT	TCAGCCCGAC	CGCTGCGCCT	TATCCGGTAA	CTATCGTCTT	GAGTCCCAAC	5220
	CGCTAAGACA	CGACTTATCG	CCACTGGCAG	CAGCCACTGG	TAACAGGATT	ACGAGAGCGA	5280
55	GGTATGTAGG	CGGTGTCTCA	GAGTTCCTGA	AGTGGTGGCC	TAACCTAGCC	TACACTAGAA	5340
	GCCAGCATAT	TGGTATCTGC	GCTCTGCTGA	AGCCAGTTAC	CTTCGGAATA	AGAGTTGGTA	5400
	GCTCTTGATC	CGGCAAAACAA	ACCACCGCTG	GTAGCGGTGG	TTTTTTTGGT	TGCAAGCAGC	5460
	AGATTACCGG	CAGAAAAAAA	GGAATCTCAAG	AAGATCTCTT	GATCTTTTCT	ACGGGGTCTG	5520
	CGCTCAGAA	GAATCTGTCA	AGAAGGCGAT	AGAAGGCGAT	CGCGTGGGAA	TCGGGAGCGG	5580
60	ACGATACCGTA	AAGCACGAGG	AAGCGGTCAG	CCCATTCGCC	GCCAGAGCTT	TCAGCAATAT	5640
	CACGGGTAGC	CAACGCTATG	TCCTGATAGC	GGTCCGCCAC	ACCCAG		5686

10

	<210>	19	
	<211>	3426	
	<212>	nucleic acid	
	<400>	19	
5			
10			
15			
20			
25			
30			
35			
40			
45			
50			
55			
60			

BNSDOCID <WO 9947678A2 1 >

	GAAAGCTCAA	GGCCCTCTGC	CACAGCGCCC	TCCTCACACA	GATAGGAATT	CTGCAGATCC	3600
	TAGAGCTCGC	TGATCAGCCT	CGACTGTGCC	TTCTAGTTGC	CAGCCATCTG	TTGTTTGCCC	3660
	CTCCCCGTG	CCTTCCTTGA	CCCTGGGAAGG	TGCCACTCCC	ACTGTCTCTT	CCTAATAAAA	3720
5	TGAGGAAATT	GCATCGCAAT	GTCTGAGTAG	GTGTCTATTCT	ATTCTGGGGG	GTGGGGTGGG	3780
	GCAGGACAGC	AAGGGGGAGG	ATTGGGAAGA	CAATAGCAGG	CATGCTGGGG	ATGCCGTGGG	3840
	CTCTATGCTT	TCTGAGGCGG	AAAGAACACG	CTGGGGCTCG	AAATTCGAGC	TTGCATGCCT	3900
	GCAGGTCTGT	ACATAACTTA	CGGTAAATGG	CCCGCTGGC	TGACGCGCCA	ACGACCCCGC	3960
	CCCATTGAGC	TCAATAATGA	CGTATGTTC	CATAGTAACG	CCAATAGGGA	CTTTCCATTG	4020
10	ACGTCAATGG	GTGGAGTATT	TACGGTAAAC	TGCCCACTTG	GCAGTAGATC	AAGTGTATCA	4080
	TATGCCAAGT	ACGCCCCCTA	TTGACGTCAA	TGACGGTAAA	TGGCCCCGCT	GGCATTATGC	4140
	CCAGTACATG	ACCTTATGGG	ACTTTCCTAC	TTGGCAGTAC	ATCTACGTAT	TAGTCATCGC	4200
	TATTACCATG	GTGATCGGCT	TTTGGCAGTA	CATCAATGGG	CGTGGATAGC	GGTTTGACTC	4260
	ACGGGGATT	CCAAGTCTCC	ACCCATTGA	CGTCAATGGG	AGTTTGTGTT	GGCACCAAAA	4320
15	TCAACGGGAC	TTTCCAAAAAT	GTCTTAACAA	CTCCGCCCA	TTGACGCAAA	TGGGCGGTAG	4380
	CGGTGTACGG	TGGGAGGTCT	ATATAAGCAG	AGCTCGTTTA	GTGAACCGTC	AGATCGCGCT	4440
	GAGACGCCAT	CCACGCTGTT	TTGACCTCCA	TAGAAGACAC	CGGGACCGAT	CGACGCTCCG	4500
	CGGCCGGGAA	CGGTGCATTG	GAACCGGGAT	TCCCGGTGTT	AATTAACAGG	TAGTGTCTCT	4560
	CTCTCTGTTT	CCTTCCCTCT	CTATTCTGCT	CAACCTTCCT	ATCAGAAACT	GCAGTATCTG	4620
20	TATTTTGTCT	AGCAGTAATA	CTAACGGTTC	TTTTTTTCTC	TTCAACAGGC	ACGATGTGTC	4680
	CTCAGAAGCT	AACCATCTCC	TGGTTTGCCA	TCGTTTGTCT	GCTGTCTCCA	CATGTGCCCA	4740
	TGTGGGAGCT	GGAGAAAGAC	GTTTATGTTG	TAGAGGTGGA	CTGGACTCCC	GTATCGCCCTG	4800
	GAGAAACAGT	GAACCTCACCC	TGTGACACGC	CTGAAGAAGA	TGACATCTCT	TGGACCTCAG	4860
	ACCAGAGACA	TGGAGTCAATA	GGCTCTGGAA	AGACCTGAC	CATCACTGTC	CTGAGCCAC	4920
25	TAGATGCTGG	CCAGTACACC	TGCCACAAAG	GAGGCGAGAC	CTGAGCCAC	TCACATCTGC	4980
	TGCTCCACAA	GAAGGAAAAAT	GGAATTTGGT	CCACTGAAAT	TTTAAAAAAT	TTCAAAAAACA	5040
	AGACTTTCTT	GAAGTGTGAA	GCACCAAAAT	ACTCCGGACG	GTTCACGTGC	TCATGGCTGG	5100
	TGCAAGAAAA	CATGGGACTG	AAGTTCAACA	TCAAGAGCAG	TAGCAGTTCC	CCTGACTCTC	5160
	GGGCACTGAG	ATGTGGAATG	CGCTCTCTGT	CTGCAGAGAA	GGTCACACTG	GACCAAGGGG	5220
30	ACTATGAGAA	GTATTCACTG	TCTCTCCAGG	AGGATGTAC	CTGCCCAACT	GCCGAGGAGA	5280
	CCCTGCCCAT	TGAACCTGGC	TTGGAAGCAC	GGCAGCAGAA	TAAATATGAG	AACTACAGCA	5340
	CCAGTCTCTT	CATCAGGGAC	ATCATCAAA	CAGACCCGCC	CAAGAACTTG	CAGATGAAGC	5400
	CTTTGAAGAA	CTCAGAGGT	GAGGTCAGCT	GGGAGTACCC	TGACTCTCTG	AGCATCCCC	5460
	ATTCTCTACT	CTCCCTCAAG	TTCTTTGTTT	GAATCCAGCG	CAAGAAAGAA	AAGATGAAGG	5520
35	AGACAGAGGA	GGGGTGTAA	CAGAAAGGTG	CGTTCTCTGT	AGAGAAAGCA	TCTACCGAAG	5580
	TCCAAATGCA	AGGCGGGAAT	GTCTCGGTGC	AAGCTCAGGA	TCCGTATTAC	AATTCCTCAT	5640
	CGACAGAGTG	GGCATGTGTT	CCCTGCAGGG	TCCGATCCTA	GAGCTCGCTG	CTAGCCCTCG	5700
	ACTGTGCCCT	CTAGTTGCCA	GCATCTGTTT	GTTTGCCCTC	CCCCGTGGCC	TTCTTGACCC	5760
	CTGGAAGGTG	CCACTCCAC	TGCTCTTCC	TAATAAAATG	AGGAAATGCT	ATCGCATTTG	5820
40	CTGAGTAGGT	GTCATTCTAT	TCTGGGGGGT	GGGCTGGGGC	AGGACAGCAA	GGGGGAGGAT	5880
	TGGGAAGACA	ATAGCAGGCA	TGCTGGGGAT	CGGCTGGGCT	CTATGCTTC	TGAGGCGGAA	5940
	AGAACCAGCT	GGGGCTCGAG	CATGCA				5966

<210> 21

<211> 3589

45 <212> nucleic acid

<400> 21

	CGTTACATAA	CTTACGGTAA	ATGGCCCGCC	TGGCTGACCG	CCCAACGACC	CCGCGCCATT	60
50	GACGTCATAA	ATGACGTATG	TTCCCATAGT	AACGCCAATA	GGGACTTTCC	ATTGACGTCA	120
	ATGGGTGGAG	TATTTACGGT	AAACTGCCCA	CTTGCGAGTA	CATCAAGTGT	ATCATATGCC	180
	AAGTACGCC	CCTATTGACG	TCAATGACGG	TAAATGGCCC	CGCTGGCATT	ATGCCACAGTA	240
	CATGACCTTA	TGGGACTTTT	CTACTTGGCA	GTACATCTAC	GTATTAGTCA	TCGCTATTATC	300
	CATGGTGATG	CGGTTTGGG	AGTACATCAA	TGGGCGTGGTA	TAGCCGTTTG	ACTCACGGGG	360
55	ATTTCCAAAGT	CTCCACCCCA	TTGACGTCAA	TGGGAGTTTG	TTTTGGCACC	AAAATCAACG	420
	GGACTTTCCA	AAATGTGCTA	ACAACCTCCC	CCCATTGACG	CAARTGGGCG	CTAGCCGTGT	480
	ACGGTGGGAG	GTCTATATAA	GCAGAGCTCG	TTTATGTAAC	CGTCAGATCG	CCTGGAGACG	540
	CCATCCACGC	TGTTTGGACC	TCCATAGAA	ACACCGGGAC	CGATCCAGCC	TCCCGGGCCG	600
	GGAACGGTGC	ATTGGGAACG	GGATTCGCCG	TGTTAATTAA	CAGGTAAGTG	TCTTCTCTCT	660
60	GTTTCTCTTC	CCTGCTATTC	TGCTCAACCT	TCCTATCAGA	AACTGCAGTA	TCTGTATTTT	720
	TGCTTTTACT	GGTGGCCCTC	CTGGTGCTCA	GCTGCAAGTC	AAGCTGCTCT	GTGGGCTGTG	780
	ACGTGCCCTA	AACCCACAGC	CTGGGTAGCA	GGAGGACCTT	GATGCTCTTG	GCACAGATGA	840
	GGAGAATCTC	TGCTTTCTCC	TGCTTGAAGG	ACAGACATGA	CTTTGATGAT	CCCCGAGGAG	900
	AGTTTGGCAA	CCAGTTCCAA	AAGGCTGAAA	CCATCCCTGT	CCTCCATGAG	ATGATCCAGC	960
							1020

	AGATCTTCAA	TCTCTTCAGC	ACAAAGGACT	CATCTGCTGC	TTGGGATGAG	ACCCTCCTAG	1080
	ACAAATTCTA	CACTGAACCT	TACCAGCAGC	TGAATGACCT	GGAGGCTGTG	GTGATACAGG	1140
	GGGTGGGGGT	GACAGAGACT	CCCCTGATGA	AGGAGGACTC	CATTCTGGCT	GTGAGGAAAT	1200
5	ACTTCCAAAG	AATCACTCTC	TATCTGAAAG	AGAAGAAATA	CAGCCCTTGT	GCCTGGGAGG	1260
	TTGTGAGAGC	AGAAATCATG	AGATCTTTTT	CTTTGTCAAC	AAACTGTGCA	GAAGAGTTTAA	1320
	GAAGTAAGGA	ATGAATCTAG	AAAAGCCGAA	TTCTGCAGGA	ATTGGGTGGC	ATCCCTGTGA	1380
	CCCCCTCCCC	GTGCCCTCTC	TGGCCCTGGA	AGTTGCCACT	CCAGTGCCCA	CCAGCCCTTGT	1440
	CCTAATAAAA	TTAAGTTGCA	TCATTTTGTG	TGACTAGGTG	TCCTTCTATA	ATATTATTGGG	1500
	GTGGAGGGGG	GTGGTATGGA	GCAAGGGGCA	AGTTGGGAAG	ACAACCTGTA	GGGCTCGAGG	1560
10	GGGGGCCCGG	TACCAGCTTT	TGTTCCCTTT	AGTGAGGGTT	AATTTTCGAGC	TTGGCGTAAT	1620
	CATGTGTCAT	GGTGTTCCT	GTGTGAAAT	GTTATCCGCT	CACAATTCAC	CACAACATAC	1680
	GAGCCGGAAG	CATAAAGTGT	AAAGCCTGGG	GTGCCATAAT	AGTGAGCTAA	CTCACATTAA	1740
	TTCCGTTGGC	CTCACTGCCC	GCTTCCAGT	CGGGAACCT	GTCGTGCCAG	CTGCATTAA	1800
	GAATCGGCCA	ACGCGCGGGG	AGAGCGGTT	TGCGTATTGG	GCGCTCTTCC	GCTTCCCTCG	1860
15	TCACTGACTC	GCTGCGCTCG	GTGTTCCGGC	TGCGGCGAGC	GGTATCAGCT	CACTCAAAGG	1920
	CGGTAAATACG	GTATATCCACA	GAATCAGGGG	ATAACGCAGG	AAAGAACATG	TGAGCAAAAG	1980
	GCCACGAAAA	GGCCAGGAAC	CGTAAAAAGG	CCGCGTTGCT	GGCGTTTTTC	CATAGGCTCC	2040
	GCCCCCTCGA	CGAGCATCAC	AAAAATCGAC	GCTCAAGTCA	GAGGTGGCGA	AACCCGACAG	2100
	GACTATAAAG	ATACGAGCGC	TTTCCCCCTG	GAAGCTCCCT	CGTGCGCTCT	CCTGTTCCGA	2160
20	CCCTGCCGCT	TACCGGATAC	CTGTCCGCTT	TTCTCCCTTC	GGGAAGCGTG	GCGCTTTCTC	2220
	ATAGCTACCG	CTGTAGCTTG	CTCAGTTCCG	TGTAGGTCGT	TGCGTCCAAG	CTGGGCTGTG	2280
	TGCACGAACC	CCCCGTTTCA	CCCGACCGCT	GCGCCTTATC	CGGTAACTAT	CGTETTGAAT	2340
	CCAACCCGGT	AAGACACGAC	TTATCGCCAC	TGGCAGCAGC	CACCTGGTAA	AGGATTAGCA	2400
	GAGCCGAGTA	TGTAGGCGGT	GCTACAGAGT	TCTTGAAGTG	GTGGCCTAAC	TACGCGTACA	2460
25	CTAGAAGGAC	AGTATTTTGT	ATCTGCGCTC	TGCTGAAAGC	AGTTACCTTC	GGAAAAAGAG	2520
	TTGGTAGCTC	TTGATCCGGC	AAACAAACCA	CCGCTGGTAG	CGGTGGTTTT	TTTGTTTGCA	2580
	AGCAGCAGAT	TAGCGCGAGA	AAAAAAGGAT	CTCAAGAAGA	TCCTTTGATC	TTTTCTACGG	2640
	GGTCTGAGCG	TCAGAAGAAG	TCGTCAAGAA	GGCGATAGAA	GGCGATGCGC	TGCGAATCGG	2700
	GAGCGGCGAT	ACCGTAAAGC	ACGAGGAAGC	GGTCAGCCCA	TTCCGCCGCA	AGCTCTTCAG	2760
30	CAATATCACG	GGTAGCCAAAC	GCTATGTCTC	GATAGCGGTC	CGCCACACCC	AGCCGGGCCAC	2820
	AGTCGATGAA	TCCAGAAAAG	CGGCCATTTT	CCACCATGAT	ATTGCGCAAG	CAGGCATCGC	2880
	CATGCGTCAC	GACGAGATCC	TCGCCGTCGG	GCATGCGCGC	CTTGAGCAAG	CGGAACAGTT	2940
	CGGCTGGCGC	GAGCCCTCTG	TGCTCTTCGT	CCAGATCATC	CTGATCGACA	AGACCGGCTT	3000
	CCATCCGAGT	ACGTGCTCGC	TCGATGCGAT	GTTTCGCTTG	GTGGTCCGAAT	GGGCAGGTAG	3060
35	CCGGATCAAG	CGTATGCAGC	CGCCGCATTG	CATCAGCCAT	GATGGATACT	TTCTCGGCAG	3120
	GAGCAAGGTG	AGATGACAGG	AGATCCTGCC	CCGGCACTTC	CCCCAATAGC	AGCCAGTCCC	3180
	TTCCCGCTTC	AGTGACAAGC	TCGAGCACAG	CTGCGCAAGG	AACGCCCGTC	GTGGCCAGCC	3240
	ACGATGCGCG	CGCTGCCTCG	TCCTGCAGTT	CATTCAAGGG	ACCGGACAGG	TCGGTCTTGA	3300
	CAAAAAGAAC	CGGCCGCCCC	TGCGCTGACA	GCCGGAACAC	GGCGGCATCA	GAGCAGCCGA	3360
40	TTGTCTGTTG	TGCCCACTCA	TAGCCGAATA	GCCTCTCCAC	CCAAGCGGCC	GGAGAACCTG	3420
	CGTGCATATC	ATCTTGTTC	ATCATGCGAA	ACGATCTCTA	TCCTGTCTCT	TGATCAGATC	3480
	TTGATCCCCT	GCGCCATCAG	ATCCTTGGCG	GCAAGAAAGC	CATCCAGTTT	ACCTTGCAGG	3540
	GCTTCCCAAC	CTTACCAGAG	GGCGAATTCG	AGCTTGCAATG	CCTGCAGGT		3580
45	<210>	22					
	<211>	567					
	<212>	nucleic acid					
	<400>	22					
50	ATGGCCTTGA	CCTTTGCTTT	ACTGGTGGCC	CTCCTGGTGC	TCAGTGCAG	GTCAAGCTGC	60
	TCGTGGGGCT	GTGATCTGCC	TCAAACCCAC	AGCCTGGGTA	GCAGGAGGAC	CTTGATGCTC	120
	CTGGCACAGA	TGAGGAGAAT	CTCTCTTTTC	TCCTGCTTGA	AGGACAGACA	TGACTTTGGA	180
	TTTCCCCAGG	AGGAGTTTGG	CAACCACTTC	CAAAAGGCTG	AAACCATCCC	TGTCCTCCAT	240
	GAGATGATCC	AGCAGATCTT	CAATCTCTTC	AGCAAAAGG	ACTCATCTGC	TGCTTGGGAT	300
55	GAGACCTCC	TAGACAAAT	CTACACTGAA	CTCTACCGA	AGCTGAATGA	CCTGGAAGCC	360
	TGTGTATAC	AGGGGGTGGG	GGTGACAGAG	ACTCCCTGTA	TGAAGGAGGA	CTCCATTCTG	420
	GCTGTGAGGA	AATACTTCCA	AAGAATCACT	CTCTATCTGA	AAGAGAAGAA	ATACAGCCCT	480
	TGTCCCTGGG	AGGTTGTCTG	AGCAGAAATC	ATGAGATCTT	TTTCTTTGTC	AACAAACTTG	540
60	CAAGAAAGTT	TAAGAAAGTAA	GGAATGA				567

	<210>	23	
	<211>	16	
	<212>	nucleic acid	
	<223>	"Y" stands for C or T; "N" stands for any base.	
5	<400>	23	
	YYYYYYYYYY YNYAGG		
	<210>	24	
10	<211>	660	
	<212>	nucleic acid	
	<223>	"Y" stands for C or T; "R" stands for A or G; "W" stands for T or A; "S" stands for C or G; "N" stands for any base.	
15	<400>	24	
	ATGTGYCCNG	CNMGNWSNYT	NYTNYTNGTN
	YTNCGNMGNA	AYYTNCNGT	NGCNACNCCN
	WSNCARAAYY	TNYTNGMNGC	NGTNWSNAAY
20	TTYTAYCCNT	GYACNWSNGA	RGARATHGAY
	ACNGTNGARG	CNTGYTYTNC	NYTNGARYTN
	GARACNWSNT	TYATHACNAA	YGGNWSNTGY
	GCNYTNTGYY	TNWSNWSNAT	HTAYGARGAY
	ATGAAYGCNA	ARYTNYTNAT	GGAYCCNAAR
25	GCNGTNATHG	AYGARYTNAT	GCARGCNYTN
	WSNWSNYTNG	ARGARCCNGA	YTTYTAYAAR
	GCNTTYMGNA	THMGNGCNGT	NACNATHGAY
		MGNGTNACNW	SNTAYYTNA
		YGCNWSNTRR	660
	<210>	25	
	<211>	987	
	<212>	nucleic acid	
	<223>	"Y" stands for C or T; "R" stands for A or G; "W" stands for T or A; "S" stands for C or G; "N" stands for any base.	
35	<400>	25	
	ATGTGYCAYC	ARCARYTNGT	NATHWSNTGG
	GTNGCNATHT	GGGARYTNAA	RAARGAYGTN
40	GCNCCNGNGG	ARATGGTNGT	NYTNACNTGY
	ACNYTNGAYC	ARWSNWSNGA	RGTNYTNGGN
	GARTTYGGNG	AYGCNGGNC	RTAYACNTGY
	YTYNTYNTNY	TNCAYAAARA	RGARGAYGGN
	AARGARCCNA	ARAAYAAARAC	NTTYTYTNGM
45	ACNTGYTGGT	GGYTACNAC	NATHWSNACN
	GGNWSNWSNG	AYCCNARGG	NGTNACNTGY
	MGNGGNGAYA	AYAARGARTA	YGARTAYWSN
	GCNGCNGARG	ARWSNYTNC	NATHGARGTN
	GARAAYTAYA	CNWSNWSNTT	YTYATHMGN
50	YTNCARYTNA	ARCCSNYTAA	RAAYWSNMG
	ACNTGWSNA	CNCCNAYWS	NTAYTTYWSN
		YTNACNTTYT	GYGTNCARGT
		NCARGGNAAR	840

WSNAARMGNG	AAAAAARGA	YMGNGTNTTY	ACNGAYAARA	CNWSNGCNAC	NGTNATHTGY	900
MGNAARAAYG	CNWSNATHWS	NGTNMGNGCN	CARGAYMGNT	AYTAYWSNWS	NWSNTGGWSN	960
GARTGGGCNW	SNGTNCCNTG	YWSNTRR				987



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/21, C07K 14/56, C12N 15/88, 15/24, C07K 14/54, C12N 15/85, A61K 48/00, C12N 5/10 // A61K 9/127		A3	(11) International Publication Number: WO 99/47678 (43) International Publication Date: 23 September 1999 (23.09.99)
(21) International Application Number: PCT/US99/05394 (22) International Filing Date: 12 March 1999 (12.03.99) (30) Priority Data: 60/078,654 19 March 1998 (19.03.98) US (71) Applicant (for all designated States except US): GEN- EMEDICINE, INC. [US/US]; 8301 New Trials Drive, The Woodlands, TX 77381-4248 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): NORDSTROM, Jeff [US/US]; 1016 Puryear Drive, College Station, TX 77840 (US); PERICLE, Federica [IT/US]; 26001 Budde Road #2904, The Woodlands, TX 77380 (US). ROLLAND, Allain [FR/US]; 22 Drift oak Circle, The Woodlands, TX 77381 (US). RALSTON, Robert [US/US]; 6 Lake Leaf Place, The Woodlands, TX 77381 (US). (74) Agent: WARBURG, Richard J.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. (88) Date of publication of the international search report: 9 December 1999 (09.12.99)	
(54) Title: INTERFERON ALPHA PLASMIDS AND DELIVERY SYSTEMS, AND METHODS OF MAKING AND USING THE SAME			
(57) Abstract The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for expression of interferon alpha in a mammal, formulations for delivery that incorporate a nucleic acid construct for expression, and methods for preparing and using such constructs and formulations. In particular, this invention relates to plasmid constructs for delivery of therapeutic interferon alpha encoding nucleic acids to cells in order to modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as cytokines, preferably IL-12), as well as methods for preparing such constructs.			
		<p>Renca</p> <p>Tumor size (mm)</p> <p>Days</p> <p>Legend: 8 wt, 8 wt+IFN, 8 wt+IFN+IFN, 8 wt+IFN+IFN+IFN</p>	
		<p>TS/A</p> <p>Tumor size (mm)</p> <p>Days after tumor challenge</p> <p>Legend: 8 wt, 8 wt+IFN, 8 wt+IFN+IFN, 8 wt+IFN+IFN+IFN</p>	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 99/05394

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N15/21 C07K14/56 C12N15/88 C12N15/24 C07K14/54
 C12N15/85 A61K48/00 C12N5/10 //A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07K A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 96 17063 A (VICAL INC) 6 June 1996 (1996-06-06)</p> <p>the whole document especially page 46, line 1 - line 37; claims: figure 1</p> <p style="text-align: center;">--- -/--</p>	<p>1-10, 22-30, 33-36, 42-45, 49-66, 68</p>

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of the actual completion of the international search

12 October 1999

Date of mailing of the international search report

21/10/1999

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl
 Fax: (+31-70) 340-3016

Authorized officer

Le Cornec, N

Form PCT/ISA/210 (second sheet) (July 1992)

page 1 of 4

INTERNATIONAL SEARCH REPORT

International Application No

Pct/US 99/05394

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
Y	BELLDEGRUN A ET AL: "HUMAN RENAL CARCINOMA LINE TRANSFECTED WITH INTERLEUKIN-2 AND/OR INTERFERON ALPHA GENE(S): IMPLICATIONS FOR LIVE CANCER VACCINES" JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 85, no. 3, 3 February 1993 (1993-02-03), pages 207-216, XP002057839 ISSN: 0027-8874 cited in the application the whole document	1-10, 22-30, 33-36, 42-45, 49-66,68
Y	RUSSELL J. MUMPER ET AL: "Polyvinyl derivatives as novel interactive polymers for controlled Gene delivery to muscle" PHARMACEUTICAL RESEARCH, vol. 13, no. 5, May 1996 (1996-05), pages 701-709; XP002118167 the whole document	1-10, 22-30, 33-36, 42-45, 49-66,68
Y	H. ALILA ET AL: "Expression of biologically active human Insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats" HUMAN GENE THERAPY, vol. 8, no. 15, 10 October 1997 (1997-10-10), pages 1785-1795, XP002118452 cited in the application the whole document	1-10, 22-30, 33-36, 42-45, 49-66,68
Y	WO 97 33998 A (CHIOU HENRY C ;CARLO DENNIS J (US); IMMUNE RESPONSE CORP INC (US)) 18 September 1997 (1997-09-18) page 16, line 30 - line 35; example 1	1-10, 22-30, 42-45, 49-66,68
Y	R.J. MUMPER ET AL: "protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle" JOURNAL OF CONTROLLED RELEASE, vol. 52, 2 March 1998 (1998-03-02), pages 191-203, XP004113667 the whole document	1-10, 22-30, 33-36, 42-45, 49-66,68

-/--

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US 99/05394

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FERRANTINI M ET AL: "ALPHA1-INTERFERON GENE TRANSFER INTO METASTATIC FRIEND LEUKEMIA CELLS ABROGATED TUMORIGENICITY IN IMMUNOCOMPETENT MICE: ANTITUMOR THERAPY BY MEANS OF INTERFERON-PRODUCING CELLS" CANCER RESEARCH. vol. 53, 1 March 1993 (1993-03-01), pages 1107-1112, XP002015124 ISSN: 0008-5472 cited in the application the whole document	1-10, 22-30, 33-36, 42-45, 49-66,68
Y	WO 97 00085 A (UNIV MEDICINE & DENTISTRY OF N) 3 January 1997 (1997-01-03) cited in the application page 41 -page 52; claims: example 2	1-10, 22-30, 33-36, 42-45, 49-66,68
Y	WO 96 21470 A (ROLLAND ALAIN ;GENEMEDICINE INC (US); MUMPER RUSSELL J (US)) 18 July 1996 (1996-07-18) cited in the application page 14 -page 15, line 10; claims: examples 1.4	1-10, 22-30, 33-36, 42-45, 49-66,68
A	WO 97 00321 A (WOOD PAUL ;SEOW HENG FONG (AU); COMMW SCIENT IND RES ORG (AU)) 3 January 1997 (1997-01-03) page 31, line 11 -page 32, line 7; claims	11-21
A	M. FERRANTINI ET AL: "IFN-alpha gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity" JOURNAL OF IMMUNOLOGY, vol. 153, 1994, pages 4604-4615, XP002118168 the whole document	1-69
A	GAO X ET AL: "CATIONIC LIPOSOME-MEDIATED GENE TRANSFER" GENE THERAPY, vol. 2, no. 10, 1 December 1995 (1995-12-01), pages 710-722, XP000749400 ISSN: 0969-7128	

-/--

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

page 3 of 4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/05394

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
P,X	M. COLEMAN ET AL: "Nonviral Interferon alpha Gene therapy inhibits growth of established tumors by eliciting a systemic immune response" HUMAN GENE THERAPY, vol. 9, 10 October 1998 (1998-10-10), pages 2223-2230, XP002118169 the whole document	1-8, 22-30, 43-45, 50-65
P,A	---	40, 42, 46, 47, 49, 66-69
P,X	WO 98 34952 A (GENEMEDICINE INC) 13 August 1998 (1998-08-13) The whole document especially page 11, line 8 - line 33; claims; figure 2 page 47, line 1 -page 49, line 23 ---	1-8, 22-40, 42-46, 49-65, 68, 69
P,X	WO 98 17689 A (DESHPANDE DEEPA ;FREIMARK BRUCE (US); NORDSTROM JEFF (US); GENEMED) 30 April 1998 (1998-04-30) cited in the application	1-8, 30-39, 42, 43, 46, 49-62, 65, 68, 69
P,A	the whole document	11-21, 40, 41, 44, 45, 47, 48, 63, 66, 67
T	SK MENDIRATTA ET AL: "Intratumoral delivery of iL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity" GENE THERAPY, vol. 6, no. 5, May 1999 (1999-05), pages 83-839, XP002118170 -----	

1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/ 05394

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 50-55, 59-61, 63-69
are directed to a method of treatment of the human/animal
body, (rule 39.1 (IV) PCT, the search has been carried out and
based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/05394

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9617063	A	06-06-1996	US 5641665 A EP 0795015 A JP 10509877 T	24-06-1997 17-09-1997 29-09-1998
WO 9733998	A	18-09-1997	AU 2322397 A CA 2248538 A EP 0904373 A	01-10-1997 18-09-1997 31-03-1999
WO 9700085	A	03-01-1997	AU 6282896 A EP 0835130 A	15-01-1997 15-04-1998
WO 9621470	A	18-07-1996	AU 703419 B AU 4611096 A CA 2210132 A EP 0794798 A JP 11502507 T	25-03-1999 31-07-1996 18-07-1996 17-09-1997 02-03-1999
WO 9700321	A	03-01-1997	AU 5991796 A	15-01-1997
WO 9834952	A	13-08-1998	AU 6269298 A	26-08-1998
WO 9817689	A	30-04-1998	AU 5146898 A	15-05-1998

Form PCT/ISA/210 (patent family annex) (July 1992)




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C12N 15/21, C07K 14/56, C12N 15/88, 15/24, C07K 14/54, C12N 15/85, A61K 48/00, C12N 5/10 // A61K 9/127</p>	A3	<p>(11) International Publication Number: WO 99/47678</p> <p>(43) International Publication Date: 23 September 1999 (23.09.99)</p>
<p>(21) International Application Number: PCT/US99/05394</p> <p>(22) International Filing Date: 12 March 1999 (12.03.99)</p> <p>(30) Priority Data: 60/078,654 19 March 1998 (19.03.98) US</p> <p>(71) Applicant (for all designated States except US): GEN-EMEDICINE, INC. [US/US]; 8301 New Trials Drive, The Woodlands, TX 77381-4248 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): NORDSTROM, Jeff [US/US]; 1016 Puryear Drive, College Station, TX 77840 (US). PERICLE, Federica [IT/US]; 26001 Budde Road #2904, The Woodlands, TX 77380 (US). ROLLAND, Allain [FR/US]; 22 DriftOak Circle, The Woodlands, TX 77381 (US). RALSTON, Robert [US/US]; 6 Lake Leaf Place, The Woodlands, TX 77381 (US).</p> <p>(74) Agent: WARBURG, Richard J.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> <p>(88) Date of publication of the international search report: 9 December 1999 (09.12.99)</p>	

(54) Title: INTERFERON ALPHA PLASMIDS AND DELIVERY SYSTEMS, AND METHODS OF MAKING AND USING THE SAME

(57) Abstract

The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for expression of interferon alpha in a mammal, formulations for delivery that incorporate a nucleic acid construct for expression, and methods for preparing and using such constructs and formulations. In particular, this invention relates to plasmid constructs for delivery of therapeutic interferon alpha encoding nucleic acids to cells in order to modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as cytokines, preferably IL-12), as well as methods for preparing such constructs.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTIONInterferon Alpha Plasmids And Delivery Systems,
And Methods Of Making And Using The SameRelated Applications

5 This application relates to U.S. patent application
Serial No. 08/949,160, filed October 10, 1997 and
International patent application No. PCT/US97/18779, filed
October 10, 1997, (Lyon & Lyon Docket Nos. 226/285 US and
PCT, respectively), both of which are related to U.S. patent
10 application Serial No. 60/028,676, filed October 18, 1996,
(Lyon & Lyon Docket No. 222/086 US), all three of which are
entitled "IL-12 GENE EXPRESSION AND DELIVERY SYSTEMS AND
USES" (by Nordstrom et al.).

This application is also related to U.S. patent
15 application Serial No. 08/798,974, filed February 11, 1997,
(Lyon & Lyon Docket No. 224/084 US) and International patent
application No. PCT/US95/17038, filed December 28, 1995,
(Lyon & Lyon Docket No. 210/190 PCT), both of which are
related to U.S. patent application Serial No. 08/372,213,
20 filed January 13, 1995, (Lyon & Lyon Docket No. 210/190 US),
all three of which are entitled "FORMULATED NUCLEIC ACID
COMPOSITIONS AND METHODS OF ADMINISTERING THE SAME FOR GENE
THERAPY" (by Mumper Rolland).

Each of the above-mentioned applications are
25 incorporated herein by reference in their entirety,
including any drawings.

Field Of The Invention

The present invention relates to gene delivery and gene
therapy, and provides novel nucleic acid constructs for
30 expression of interferon alpha in a mammal, formulations for
delivery that incorporate a nucleic acid construct for
expression, and methods for preparing and using such
constructs and formulations. In particular, this invention

relates to plasmid constructs for delivery of therapeutic interferon alpha encoding nucleic acids to cells in order to modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as cytokines, preferably IL-12), as well as methods for preparing such constructs.

Background Of The Invention

The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention and is not admitted to describe or constitute prior art to the present invention.

Plasmids are an important element in genetic engineering and gene therapy. Plasmids are usually circular DNA molecules that can be introduced into bacterial cells by transformation which replicate autonomously in the cell. Plasmids typically allow for the amplification of cloned DNA. Some plasmids are present in 20 to 50 copies during cell growth, and after the arrest of protein synthesis, as many as 1000 copies per cell of a plasmid can be generated. Suzuki et al., *Genetic Analysis*, p. 404, 1989.

Current non-viral approaches to human gene therapy require that a potential therapeutic gene be cloned into plasmids. Large quantities of a bacterial host harboring the plasmid may be fermented and the plasmid DNA may be purified for subsequent use. Current human clinical trials using plasmids utilize this approach. Recombinant DNA Advisory Committee Data Management Report, December, 1994, *Human Gene Therapy* 6:535-548. Studies normally focus on the therapeutic gene and the elements that control its expression in the patient when designing and constructing gene therapy plasmids. Generally, therapeutic genes and regulatory elements are simply inserted into existing cloning vectors that are convenient and readily available.

Plasmid design and construction utilizes several key factors. First, plasmid replication origins determine

plasmid copy number, which affects production yields. Plasmids that replicate to higher copy number can increase plasmid yield from a given volume of culture, but excessive copy number can be deleterious to the bacteria and lead to undesirable effects (Fitzwater, et al., *Embo J.* 7:3289-3297 (1988); Uhlin, et al., *Mol. Gen. Genet.* 165:167-179 (1979)). Artificially constructed plasmids are sometimes unstably maintained, leading to accumulation of plasmid-free cells and reduced production yields.

10 To overcome this problem of plasmid-free cells, genes that code for antibiotic resistance phenotype are included on the plasmid and antibiotics are added to kill or inhibit plasmid-free cells. Most general purpose cloning vectors contain ampicillin resistance (β -lactamase, or *bla*) genes. 15 Use of ampicillin can be problematic because of the potential for residual antibiotic in the purified DNA, which can cause an allergic reaction in a treated patient. In addition, β -lactam antibiotics are clinically important for disease treatment. When plasmids containing antibiotic 20 resistance genes are used, the potential exists for the transfer of antibiotic resistance genes to a potential pathogen.

Other studies have used the *neo* gene which is derived from the bacterial transposon *Tn5*. The *neo* gene encodes 25 resistance to kanamycin and neomycin (Smith, *Vaccine* 12:1515-1519 (1994)). This gene has been used in a number of gene therapy studies, including several human clinical trials (Recombinant DNA Advisory Committee Data Management Report, December, 1994, *Human Gene Therapy* 6:535-548). Due 30 to the mechanism by which resistance is imparted, residual antibiotic and transmission of the gene to potential pathogens may be less of a problem than for β -lactams.

In addition to elements that affect the behavior of the plasmid within the host bacteria, such as *E. coli*, plasmid 35 vectors have also been shown to affect transfection and expression in eukaryotic cells. Certain plasmid sequences

have been shown to reduce expression of eukaryotic genes in eukaryotic cells when carried in *cis* (Peterson, et al., *Mol. Cell. Biol.* 7:1563-1567 (1987); Yoder et al., *Mol. Cell. Biol.* 3:956-959 (1983); Lusky et al., *Nature* 293:79-81 (1981); and Leite, et al., *Gene* 82:351-356 (1989)). Plasmid sequences also have been shown to fortuitously contain binding sites for transcriptional control proteins (Ghera, et al., *Gene* 151:331-332 (1994); Tully et al., *Biochem. Biophys. Res. Comm.* 144:1-10 (1987); and Kushner, et al., *Mol. Endocrinol.* 8:405-407 (1994)). This can cause inappropriate levels of gene expression in treated patients.

Interferon alpha is a gene product that has been proposed for use, either alone or in combination with other agents, in different delivery systems for the treatment of certain diseases, including particular cancers. International patent publication WO/97/00085, published January 3, 1997, proposes *ex vivo* transfection of tumor cells with interferon alpha and another immunomodulatory molecule, such as IL-12. None of the previously proposed treatments have proven entirely satisfactory, due in part to the high cost and technical difficulty involved in *ex vivo* approaches. Thus there still remains a need in the art for improved plasmids encoding interferon alpha as well as improved treatment protocols and technologies.

25 Summary

The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for expression of interferon alpha in a mammal, formulations for delivery that incorporate a nucleic acid construct for expression, and methods for preparing and using such constructs and formulations. In particular, this invention relates to plasmid constructs for delivery of therapeutic interferon alpha encoding nucleic acids to cells in order to modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as

cytokines, preferably IL-12), as well as methods for preparing such constructs. The pharmaceutical acceptable, cost effective and highly efficient delivery system presented herein represents an unanticipated improvement over the art.

Thus, in a first aspect, the invention features a plasmid that contains a CMV promoter and optionally a synthetic 5' intron transcriptionally linked with an interferon alpha coding sequence, and a 3'-untranslated region (UTR). Preferably the 3' UTR is a 3' growth hormone UTR.

As used herein, the term "plasmid" refers to a construct made up of genetic material (i.e., nucleic acids). It includes genetic elements arranged such that an inserted coding sequence can be transcribed in eukaryotic cells. Also, while the plasmid may include a sequence from a viral nucleic acid, such viral sequence does not cause the incorporation of the plasmid into a viral particle, and the plasmid is therefore a non-viral vector. Preferably a plasmid is a closed circular DNA molecule.

"Cytomegalovirus promoter" refers to one or more sequences from a cytomegalovirus which are functional in eukaryotic cells as a transcriptional promoter and an upstream enhancer sequence. The enhancer sequence allows transcription to occur at a higher frequency from the associated promoter.

In this context, "transcriptionally linked" means that in a system suitable for transcription, transcription will initiate under the direction of the control sequence(s) and proceed through sequences which are transcriptionally linked with that control sequence(s). Preferably no mutation is created in the resulting transcript, which would alter the resulting translation product.

The term "coding region" or "coding sequence" refers to a nucleic acid sequence which encodes a particular gene product for which expression is desired, according to the

normal base pairing and codon usage relationships. Thus, the coding sequence must be placed in such relationship to transcriptional control sequences (possibly including control elements and translational initiation and termination codons) that a proper length transcript will be produced and will result in translation in the appropriate reading frame to produce a functional desired product.

In a preferred embodiment the interferon alpha coding sequence is for human interferon alpha and preferably is a synthetic sequence having optimal codon usage, such as the nucleotide sequence of SEQ ID NO:11 or semi-optimal codon usage, such as the nucleotide sequence of SEQ ID NO:12.

A particular example of coding regions suitable for use in the plasmids of this invention are the natural sequences coding for human interferon alpha. Thus, in a preferred embodiment coding region has a nucleotide sequence which is the same as SEQ ID NO:10, which is the natural nucleotide sequence encoding human interferon alpha. However, it may be preferable to have an interferon alpha coding sequence which is a synthetic coding sequence. In a preferred embodiment, the interferon alpha coding sequence is a synthetic sequence utilizing optimal or semi-optimal codon usage, preferably the sequence shown in SEQ ID NO:11 or SEQ ID NO:12.

Thus, a "sequence coding for the human interferon alpha" or "a human interferon alpha coding sequence" is a nucleic acid sequence which encodes the amino acid sequence of human interferon alpha, based on the normal base pairing and translational codon usage relationships. It is preferable that the coding sequence encode the exact, full amino acid sequence of natural human interferon, but this is not essential. The encoded polypeptide may differ from natural human interferon alpha, so long as the polypeptide retains interferon alpha activity, preferably the polypeptide is at least 50%, 75%, 90%, or 97% as active as natural human interferon alpha, and more preferably fully as

active as natural human interferon alpha. Thus, the polypeptide encoded by the interferon alpha coding sequence may differ from a natural human interferon alpha polypeptide by a small amount, preferably less than a 15%, 10%, 5%, or 1% change. Such a change may be of one of more different types, such as deletion, addition, or substitution of one or more amino acids.

The term "transcriptional control sequence" refers to sequences which control the rate of transcription of a transcriptionally linked coding region. Thus, the term can include elements such as promoters, operators, and enhancers. For a particular transcription unit, the transcriptional control sequences will include at least a promoter sequence.

A "growth hormone 3' untranslated region" is a sequence located downstream (i.e., 3') of the region encoding material polypeptide and including at least part of the sequence of the natural 3' UTR/poly(a) signal from a growth hormone gene, preferably the human growth hormone gene. This region is generally transcribed but not translated. For expression in eukaryotic cells it is generally preferable to include sequence which signals the addition of a poly-A tail. As with other synthetic genetic elements a synthetic 3' UTR/poly(A) signal has a sequence which differs from naturally-occurring UTR elements.

The sequence may be modified, for example by the deletion of ALU repeat sequences. Deletion of such ALU repeat sequences acts to reduce the possibility of homologous recombination between the expression cassette and genomic material in a transfected cell.

The plasmid preferably includes a promoter, a TATA box, a Cap site and a first intron and intron/exon boundary in appropriate relationship for expression of the coding sequence. The plasmid may also include a 5' mRNA leader sequence inserted between the promoter and the coding sequence and/or an intron/5' UTR from a chicken skeletal α -

actin gene. Also, the plasmid may have a nucleotide sequence which is the same as the nucleotide sequence of plasmid pIF0921, as shown in Figure 5.

The plasmid may also include: (a) a first transcription
5 unit containing a first transcriptional control sequence
transcriptionally linked with a first 5'-untranslated
region, a first intron, a first coding sequence, and a first
3'-untranslated region/poly(A) signal, wherein the first
10 intron is between the control sequence and the first coding
sequence; and (b) a second transcription unit containing a
second transcriptional control sequence transcriptionally
linked with a second 5'-untranslated region, a second
intron, a second coding sequence, and a second 3'-
15 untranslated region/poly(A) signal, wherein the second
intron is between the control sequence and the second coding
sequence; wherein the first and second coding sequences
contain a sequence having the sequence of SEQ ID NO:2, 3, 4
or 25 coding for a human IL-12 p40 subunit, and a sequence
20 having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for a
human IL-12 p35 subunit.

The term "transcription unit" or "expression cassette"
refers to a nucleotide sequence which contains at least one
coding sequence along with sequence elements which direct
the initiation and termination of transcription. A
25 transcription unit may however include additional sequences,
which may include sequences involved in post-transcriptional
or post-translational processes. In preferred embodiments,
the first transcriptional control sequence or the second
transcriptional control sequence contain one or more
30 cytomegalovirus promoter sequences. The first and second
transcriptional control sequences can be the same or
different.

A "5' untranslated region" or "5' UTR" refers to a
sequence located 3' to promoter region and 5' of the
35 downstream coding region. Thus, such a sequence, while
transcribed, is upstream of the translation initiation codon

and therefore is not translated into a portion of the polypeptide product.

For the plasmids described herein, one or more of a promoter, 5' untranslated region (5' UTR), the 3' UTR/poly(A) signal, and introns may be a synthetic sequence. In this context the term "synthetic" means that the sequence is not provided directly by the sequence of a naturally occurring genetic element of that type but rather is an artificially created sequence (i.e., created by a person by molecular biological methods). While one or more portions of such a synthetic sequence may be the same as portions of naturally occurring sequences, the full sequence over the specified genetic element is different from a naturally occurring genetic element of that type. The use of such synthetic genetic elements allows the functional characteristics of that element to be appropriately designed for the desired function.

Thus, a "synthetic intron" refers to a sequence which is not a naturally occurring intron sequence but which will be removed from an RNA transcript during normal post transcriptional processing. Such introns can be designed to have a variety of different characteristics, in particular such introns can be designed to have a desired strength of splice site.

A "subunit" of a therapeutic molecule is a polypeptide or RNA molecule which combines with one or more other molecules to form a complex having the relevant pharmacologic activity. Examples of such complexes include homodimers and heterodimers as well as complexes having greater numbers of subunits. A specific example of a heterodimer is IL-12, having the p40 and p35 subunits.

The "p40 subunit" is the larger of the two subunits of the IL-12 heterodimer. Thus, it is capable of association with p35 subunit to form a molecule having activities characteristic of IL-12. Human p40 has the amino acid sequence of SEQ ID NO:1. Those skilled in the art will

recognize that the molecule may have a number of changes from that sequence, such as deletions, insertions or changes of one or a few amino acids, while still retaining IL-12 activity when associated with p35. Such active altered
5 molecules are also regarded as p40.

Conversely, the "p35 subunit" is the smaller of the two heterodimeric subunits of IL-12. For humans, p35 has the amino acid sequence of SEQ ID NO:5. As for p40, p35 may have a low level of alterations from that sequence while
10 still being regarded as p35.

A particular example of coding regions suitable for use in the plasmids of this invention are the natural sequences coding for the p40 and p35 subunits of human IL-12. Thus, in a preferred embodiment the first and second coding
15 regions are coding regions for those sequences and are preferably in the order p40 then p35 in the 5' to 3' direction.

Thus, a "sequence coding for the p40 subunit of human IL-12" is a nucleic acid sequence which encodes the human
20 p40 subunit as described above, based on the normal base pairing and translational codon usage relationships. The sequence coding for p35 subunit of human IL-12 is similarly defined.

In a preferred embodiment the sequence coding for the
25 p40 subunit of human IL-12 is 5' to the sequence coding for the p35 subunit of human IL-12. Those skilled in the art will appreciate that the interferon alpha, p35 subunit and p40 subunit may all be on a single transcription unit, that all three may be on separate transcription units, or that
30 any two coding sequences may be on one transcription unit and the other coding sequence on another transcription unit.

The plasmid may also contain an intron having variable splicing, a first coding sequence, and a second coding sequence, wherein the first and second coding sequences
35 include a sequence having the sequence of SEQ ID NO:2, 3, 4 or 25 coding for a human IL-12 p40 subunit, and a sequence

having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for a human IL-12 p35 subunit.

In a preferred embodiment, the plasmid also has: (a) a transcriptional control sequence transcriptionally linked with a first coding sequence and a second coding sequence; (b) a 5'-untranslated region; (c) an intron 5' to the first coding sequence; (d) an alternative splice site 3' to the first coding sequence and 5' to the second coding sequence; and (e) a 3'-untranslated region/poly(A) signal. The transcriptional control sequence preferably includes a cytomegalovirus promoter sequence.

In a preferred embodiment, the plasmid also has: (a) a transcriptional control sequence transcriptionally linked with a first coding sequence, an IRES sequence, a second coding sequence, and a 3'-untranslated region/poly(A) signal, wherein the IRES sequence is between the first coding sequence and the second coding sequence; and (b) an intron between the promoter and the first coding sequence; wherein the first and second coding sequences include a sequence having the sequence of SEQ ID NO:2, 3, 4 or 25 coding for a human IL-12 p40 subunit, and a sequence having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for a human IL-12 p35 subunit. The transcriptional control sequence preferably includes a cytomegalovirus promoter sequence and the IRES sequence preferably is from an encephalomyocarditis virus.

For delivery of coding sequences for gene expression, it is generally useful to provide a delivery composition or delivery system which includes one or more other components in addition to the nucleic acid sequences. Such a composition can, for example, aid in maintaining the integrity of the DNA and/or in enhancing cellular uptake of the DNA and/or by acting as an immunogenic enhancer, such as by the non-DNA components having an immuno-stimulatory effect of their own.

Thus, in another aspect, the invention features a composition containing a plasmid as described above and a protective, interactive non-condensing compound (PINC).

- The PINC enhances the delivery of the nucleic acid molecule to mammalian cells *in vivo*, and preferably the nucleic acid molecule includes a coding sequence for a gene product to be expressed in the cell. In many cases, the relevant gene product is a polypeptide or protein. Preferably the PINC is used under conditions so that the PINC does not form a gel, or so that no gel form is present at the time of administration at about 30-40°C. Thus, in these compositions, the PINC is present at a concentration of 30% (w/v) or less. In certain preferred embodiments, the PINC concentration is still less, for example, 20% or less, 10% or less, 5% or less, or 1% or less. Thus, these compositions differ in compound concentration and functional effect from uses of these or similar compounds in which the compounds are used at higher concentrations, for example in the ethylene glycol mediated transfection of plant protoplasts, or the formation of gels for drug or nucleic acid delivery. In general, the PINCs are not in gel form in the conditions in which they are used as PINCs, though certain of the compounds may form gels under some conditions.
- In connection with the compounds and compositions of this invention, the term "protects" or "protective" refers to an effect of the interaction between such a compound and a nucleic acid such that the rate of degradation of the nucleic acid is decreased in a particular environment. Such degradation may be due to a variety of different factors, which specifically include the enzymatic action of a nuclease. The protective action may be provided in different ways, for example, by exclusion of the nuclease molecules or by exclusion of water.
- Some compounds which protect a nucleic acid and/or prolong the bioavailability of a nucleic acid may also

interact or associate with the nucleic acid by intermolecular forces and/or valence bonds such as: Van der Waals forces, ion-dipole interactions, ion-induced dipole interactions, hydrogen bonds, or ionic bonds. These interactions may serve the following functions: (1) Stereoselectively protect nucleic acids from nucleases by shielding; (2) facilitate the cellular uptake of nucleic acid by "piggyback endocytosis". Piggyback endocytosis is the cellular uptake of a drug or other molecule complexed to a carrier that may be taken up by endocytosis. CV Uglea and C Dumitriu-Medvichi, *Medical Applications of Synthetic Oligomers*, In: Polymeric Biomaterials, Severian Dumitriu ed., Marcel Dekker, Inc., 1993, incorporated herein by reference.

To achieve the desired effects set forth it is desirable, but not necessary, that the compounds which protect the nucleic acid and/or prolong the bioavailability of a nucleic acid have amphiphilic properties; that is, have both hydrophilic and hydrophobic regions. The hydrophilic region of the compounds may associate with the largely ionic and hydrophilic regions of the nucleic acid, while the hydrophobic region of the compounds may act to retard diffusion of nucleic acid and to protect nucleic acid from nucleases.

Additionally, the hydrophobic region may specifically interact with cell membranes, possibly facilitating endocytosis of the compound and thereby also of nucleic acid associated with the compound. This process may increase the pericellular concentration of nucleic acid.

Agents which may have amphiphilic properties and are generally regarded as being pharmaceutically acceptable are the following: polyvinylpyrrolidones; polyvinylalcohols; polyvinylacetates; propylene glycol; polyethylene glycols; poloxamers (Pluronic); poloxamines (Tetronics); ethylene vinyl acetates; methylcelluloses, hydroxypropylcelluloses, hydroxypropylmethylcelluloses; heteropolysaccharides

(pectins); chitosans; phosphatidylcholines (lecithins); miglyols; polylactic acid; polyhydroxybutyric acid; xanthan gum. Also, copolymer systems such as polyethylene glycol-poly-lactic acid (PEG-PLA), polyethylene glycol-polyhydroxybutyric acid (PEG-PHB), polyvinylpyrrolidone-polyvinylalcohol (PVP-PVA), and derivatized copolymers such as copolymers of N-vinyl purine (or pyrimidine) derivatives and N-vinylpyrrolidone. However, not all of the above compounds are protective, interactive, non-condensing compounds as described below.

In connection with the protective, interactive, non-condensing compounds for these compositions, the term "non-condensing" means that an associated nucleic acid is not condensed or collapsed by the interaction with the PINC at the concentrations used in the compositions. Thus, the PINCs differ in type and/or use concentration from such condensing polymers. Examples of commonly used condensing polymers include polylysine, and cascade polymers (spherical polycations).

Also in connection with such compounds and an associated nucleic acid molecule, the term "enhances the delivery" means that at least in conditions such that the amounts of PINC and nucleic acid is optimized, a greater biological effect is obtained than with the delivery of nucleic acid in saline. Thus, in cases where the expression of a gene product encoded by the nucleic acid is desired, the level of expression obtained with the PINC:nucleic acid composition is greater than the expression obtained with the same quantity of nucleic acid in saline for delivery by a method appropriate for the particular PINC/coding sequence combination.

In preferred embodiments of the above compositions, the PINC is polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), a PVP-PVA co-polymer, N-methyl-2-pyrrolidone (NM2P), ethylene glycol, or propylene glycol. In compositions in which a Poloxamer (Pluronics) is used, the nucleic acid is

preferably not a viral vector, i.e., the nucleic acid is a non-viral vector.

In other preferred embodiments, the PINC is bound with a targeting ligand. Such targeting ligands can be of a variety of different types, including but not limited to galactosyl, residues, fucosal residues, mannosyl residues, carnitine derivatives, monoclonal antibodies, polyclonal antibodies, peptide ligands, and DNA-binding proteins. The targeting ligands may bind with receptors on cells such as antigen-presenting cells, hepatocytes, myocytes, epithelial cells, endothelial cells, and cancer cells.

In connection with the association of a targeting ligand and a PINC, the term "bound with" means that the parts have an interaction with each other such that the physical association is thermodynamically favored, representing at least a local minimum in the free energy function for that association. Such interaction may involve covalent binding, or non-covalent interactions such as ionic, hydrogen bonding, van der Waals interactions, hydrophobic interactions, and combinations of such interactions.

While the targeting ligand may be of various types, in one embodiment the ligand is an antibody. Both monoclonal antibodies and polyclonal antibodies may be utilized.

The nucleic acid may also be present in various forms. Preferably the nucleic acid is not associated with a compound(s) which alter the physical form, however, in other embodiments the nucleic acid is condensed (such as with a condensing polymer), formulated with cationic lipids, formulated with peptides, or formulated with cationic polymers.

In preferred embodiments, the protective, interactive non-condensing compound is polyvinyl pyrrolidone, and/or the plasmid is in a solution having between 0.5% and 50% PVP, more preferably about 5% PVP. The DNA preferably is at least about 80% supercoiled, more preferably at least about

90% supercoiled, and most preferably at least about 95% supercoiled.

In another aspect the invention features a composition containing a protective, interactive non-condensing compound and a plasmid containing an interferon alpha coding sequence.

In yet another aspect, the invention provides a composition containing a plasmid of the invention (or a plasmid containing an interferon alpha coding sequence) and a cationic lipid with a neutral co-lipid.

Preferably the cationic lipid is DOTMA and the neutral co-lipid is cholesterol (chol). DOTMA is 1,2-di-O-octadecenyl-3-trimethylammonium propane, which is described and discussed in Eppstein et al., U.S. Patent 4,897,355, issued January 30, 1990, which is incorporated herein by reference. However, other lipids and lipid combinations may be used in other embodiments. A variety of such lipids are described in Gao & Huang, 1995, *Gene Therapy* 2:710-722, which is hereby incorporated by reference.

As the charge ratio of the cationic lipid and the DNA is also a significant factor, in preferred embodiments the DNA and the cationic lipid are present in such amounts that the negative to positive charge ratio is about 1:3. While preferable, it is not necessary that the ratio be 1:3. Thus, preferably the charge ratio for the compositions is between about 1:1 and 1:10, more preferably between about 1:2 and 1:5.

The term "cationic lipid" refers to a lipid which has a net positive charge at physiological pH, and preferably carries no negative charges at such pH. An example of such a lipid is DOTMA. Similarly, "neutral co-lipid" refers to a lipid which has is usually uncharged at physiological pH. An example of such a lipid is cholesterol.

Thus, "negative to positive charge ratio" for the DNA and cationic lipid refers to the ratio between the net

negative charges on the DNA compared to the net positive charges on the cationic lipid.

As the form of the DNA affects the expression efficiency, the DNA preferably is at least about 80% supercoiled, more preferably at least about 90% supercoiled, and most preferably at least about 95% supercoiled. The composition preferably includes an isotonic carbohydrate solution, such as an isotonic carbohydrate solution that consists essentially of about 10% lactose. In preferred embodiments, the composition the cationic lipid and the neutral co-lipid are prepared as a liposome having an extrusion size of about 800 nanometers. Preferably the liposomes are prepared to have an average diameter of between about 20 and 800 nm, more preferably between about 50 and 400 nm, still more preferably between about 75 and 200 nm, and most preferably about 100 nm. Microfluidization is the preferred method of preparation of the liposomes.

In another aspect the invention features a composition containing: (a) a first component having a plasmid including an interferon alpha coding sequence and a cationic lipid with a neutral co-lipid, wherein the cationic lipid is DOTMA and the neutral co-lipid is cholesterol, wherein the DNA in the plasmid and the cationic lipid are present in amounts such that the negative to positive charge ratio is about 1:3; and (b) a second component including a protective, interactive non-condensing compound, wherein the first component is present within the second component.

In another aspect, the invention provides a composition having a protective, interactive non-condensing compound, a first plasmid including an interferon alpha coding sequence, and one or more other plasmids independently having an IL-12 p35 or IL-12 p40 subunit coding sequence.

In another aspect, the invention features a method for making any of the plasmids described above by inserting a CMV promoter transcriptionally linked with an interferon

alpha coding sequence, and a growth hormone 3'-untranslated region into a plasmid.

The invention also provides methods of making the compositions described above. The method may involve: (a) preparing a DNA molecule having a transcriptional unit, wherein the transcriptional unit contains an interferon alpha coding sequence; (b) preparing a protective, interactive non-condensing compound; and (c) combining the protective, interactive non-condensing compound with the DNA in conditions such that a composition capable of delivering a therapeutically effective amount of an interferon alpha coding sequence to a mammal is formed.

Preferably, the DNA molecule is a plasmid, wherein the plasmid includes a CMV promoter transcriptionally linked with an interferon alpha coding sequence, and a human growth hormone 3'-untranslated region/poly(A) signal.

The method may involve the steps of: (a) preparing a DNA having an interferon alpha coding sequence; (b) preparing a mixture of a cationic lipid and a neutral co-lipid, wherein the cationic lipid is DOTMA and the neutral co-lipid is cholesterol; and (c) combining the mixture with the DNA in amounts such that the cationic lipid and the DNA are present in a negative to positive charge ratio of about 1:3.

In another embodiment, the method involves the steps of: (a) preparing a first component having a plasmid containing an interferon alpha coding sequence and a cationic lipid with a neutral co-lipid, wherein the cationic lipid is DOTMA and the neutral co-lipid is cholesterol, wherein the DNA in the plasmid and the cationic lipid are present in amounts such that the negative to positive charge ratio is about 1:3; (b) preparing a second component having a protective, interactive non-condensing compound; and (c) combining the first and second components such that the resulting composition includes the first component within the second component.

In another embodiment, the method involves the steps of: (a) preparing a protective, interactive non-condensing compound, (b) preparing a first plasmid having an interferon alpha coding sequence, (c) preparing one or more other
5 plasmids independently having an IL-12 p35 or IL-12 p40 subunit coding sequence, and (d) combining the protective, interactive non-condensing compound, the plasmid having the interferon alpha coding sequence and the other plasmids.

In another aspect, the invention provides a method for
10 treatment of a mammalian condition or disease, by administering to a mammal suffering from the condition or disease a therapeutically effective amount of a plasmid as described herein.

A "therapeutically effective amount" of a composition
15 is an amount which is sufficient to cause at least temporary relief or improvement in a symptom or indication of a disease or condition. Thus, the amount is also sufficient to cause a pharmacological effect. The amount of the composition need not cause permanent improvement or
20 improvement of all symptoms or indications. A therapeutically effective amount of a cancer therapeutic would be one that reduces overall tumor burden in the case of metastatic disease (i.e., the number of metastases or their size) or one that reduces the mass of the tumor in
25 localized cancers.

The condition or disease preferably is a cancer, such as epithelial glandular cancer, including adenoma and adenocarcinoma; squamous and transitional cancer, including polyp, papilloma, squamous cell and transitional cell
30 carcinoma; connective tissue cancer, including tissue type positive, sarcoma and other (oma's); hematopoietic and lymphoreticular cancer, including lymphoma, leukemia and Hodgkin's disease; neural tissue cancer, including neuroma, sarcoma, neurofibroma and blastoma; mixed tissues of origin
35 cancer, including teratoma and teratocarcinoma. Other cancerous conditions that are applicable to treatment

include cancer of any of the following: adrenal gland, anus, bile duct, bladder, brain tumors: adult, breast, cancer of an unknown primary site, carcinoids of the gastrointestinal tract, cervix, childhood cancers, colon and rectum, esophagus, gall bladder, head and neck, islet cell and other
5 pancreatic carcinomas, Kaposi's sarcoma, kidney, leukemia, liver, lung: non-small cell, lung: small cell, lymphoma: AIDS-associated, lymphoma: Hodgkin's disease, Lymphomas: non-Hodgkin's disease, melanoma, mesothelioma, metastatic
10 cancer, multiple myeloma, ovary, ovarian germ cell tumors, pancreas, parathyroid, penis, pituitary, prostate, sarcomas of bone and soft tissue, skin, small intestine, stomach, testis, thymus, thyroid, trophoblastic disease, uterus: endometrial carcinoma, uterus: uterine sarcomas, vagina, or
15 vulva. The composition preferably is administered by injection, although the method may also be performed *ex vivo*.

In another aspect, the invention provides a method for transfection (i.e., the delivery and expression of a gene to
20 cells) of a cell *in situ*, by contacting the cell with a plasmid described herein for sufficient time to transfect the cell. Transfection of the cell preferably is performed *in vivo* and the contacting preferably is performed in the presence of about 5% PVP solution.

25 In another aspect, the invention features a method for delivery and expression of an interferon alpha gene in a plurality of cells, by: (a) transfecting the plurality of cells with a plasmid or composition of the invention; and (b) incubating the plurality of cells under conditions
30 allowing expression of a nucleic acid sequence in the vector, wherein the nucleic acid sequence encodes interferon alpha.

In preferred embodiments, the interferon alpha is human interferon alpha and the cells are human cells and/or the
35 contacting is performed in the presence of an about 5% PVP solution.

In another aspect, the invention features a method for treating a disease or condition, by transfecting a cell *in situ* with a plasmid or composition of the invention. The disease or condition can be a localized disease or condition or a systemic disease or condition.

In another aspect, the invention features a cell transfected with a plasmid or composition of the invention.

In yet another aspect, the invention features a method for treatment of a mammalian condition or disease, by administering to a mammal suffering from the condition or disease a therapeutically effective amount of a composition described herein.

As the compositions are useful for delivery of a nucleic acid molecule to cells *in vivo*, in a related aspect the invention provides a composition at an *in vivo* site of administration. In particular this includes at an *in vivo* site in a mammal.

In preferred embodiments the nucleic acid molecule includes a sequence encoding a gene product. Also in preferred embodiments, the site of administration is in an interstitial space or a tissue of an animal, particularly of a mammal.

The invention also provides methods for using the above compositions. Therefore, in further related aspects, methods of administering the compositions are provided in which the composition is introduced into a mammal, preferably into a tissue or an interstitial space.

Various methods of delivery may be utilized, such as are known in the art, but in preferred embodiments, the composition is introduced into the tissue or interstitial space by injection. The compositions may also be delivered to a variety of different tissues, but in preferred embodiments the tissue is muscle or tumor.

In another related aspect, the invention provides methods for treating a mammalian condition or disease by administering a therapeutically effective amount of a

composition as described above. In preferred embodiments, the disease or condition is a cancer.

The summary of the invention described above is non-limiting and other features and advantages of the invention will be apparent from the following detailed description of the preferred embodiments, as well as from the claims.

Brief Description Of The Drawings

Figure 1 shows the effects of interferon alpha in two cancer models.

Figure 2 shows a plasmid map and sequence (SEQ ID NO:18) for an exemplary IL-12 plasmid of the present invention.

Figure 3 shows optimal codon usage for highly expressed human genes.

Figure 4 shows a plasmid map and sequence (SEQ ID NO:19) for plasmid pIF0836, an exemplary interferon alpha plasmid of the present invention.

Figure 5 shows a plasmid map and sequence (SEQ ID NO:20) for pIN096, an exemplary IL-12 plasmid that can be used with the present invention.

Figure 6 shows the nucleic acid sequence (SEQ ID NO:21) of plasmid pIF0921, an exemplary interferon alpha plasmid of the present invention.

Figures 7A and 7B show a plasmid map and sequence (SEQ ID NO:22) for plasmid pIF0921.

Figure 8 shows an outline of a strategy that can be used to synthesize a pIF0921 plasmid.

Figure 9 shows interferon alpha and IL-12 gene medicine (combination therapy) in Renca model.

Detailed Description Of The Preferred Embodiments

The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for expression of interferon alpha in a mammal, formulations for delivery that incorporate a nucleic acid construct for

expression, and methods for preparing and using such constructs and formulations. In particular, this invention relates to plasmid constructs for delivery of therapeutic interferon alpha encoding nucleic acids to cells in order to
5 modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as cytokines, preferably IL-12), as well as methods for preparing such constructs.

I. General

10 As described, this invention concerns expression systems for the delivery and expression of interferon alpha coding sequences in mammalian cells, and formulations and methods for delivering such expression systems or other expression systems to a mammal.

15 Therefore, particular genetic constructs are described which includes nucleotide sequences coding for interferon alpha, preferably human interferon alpha. Such a construct can beneficially be formulated and administered as described herein, utilizing the expression systems of this invention.

20 To allow convenient production of such plasmids, it is generally preferable that the plasmid be capable of replication in a cell to high copy number. Generally such production is carried out in prokaryotic cells, particularly including *Escherichia coli* (*E.coli*) cells. Thus, the plasmid
25 preferably contains a replication origin functional in a prokaryotic cell, and preferably the replication origin is one which will direct replication to a high copy number.

It is also possible to utilize synthetic genetic elements in the plasmid constructs.

30 As described below, these elements affect post-transcriptional processing in eukaryotic systems. Thus, the use of synthetic sequences allows the design of processing characteristics as desired for the particular application. Commonly, the elements will be designed to provide rapid and
35 accurate processing.

For delivery of DNA encoding a desired expression product to a mammalian system, it is usually preferable to utilize a delivery system. Such a system can provide multiple benefits, notably providing stabilization to protect the integrity of the DNA, as well as assisting in cellular uptake.

In addition, the non-DNA components of the formulation may contribute to an immune system enhancement or activation. As a result, components of a delivery system can be selected in conjunction with a particular gene product to enhance or minimize the immuno-stimulatory effect.

The plasmids may also include elements for expression of IL-12 or one or more subunits thereof. Similarly, the treatment may involve administration of an interferon alpha coding sequence and one or more IL-12 coding sequences whether on a single plasmid or on separate plasmids. Such plasmids may be incorporated into compositions for delivery with a protective, interactive non-condensing compound, a cationic lipid and neutral co-lipid, or both.

While these are specific effective examples, other components may be utilized in formulations containing the interferon alpha expression vectors of the present invention to provide effective delivery and expression of interferon alpha or with other coding sequences for which manipulation of the activation of immune system components is desirable.

The selection of delivery system components and preparation methods in conjunction with the selection of coding sequences provides the ability to balance the specific effects of the encoded gene products and the immune system effects of the overall delivery system composition. This capacity to control the biological effects of delivery system formulation administration represents an aspect of the invention in addition to the interferon alpha encoding constructs and specific formulations of delivery systems. Co-selection of the encoded gene product and the delivery

system components and parameters provides enhanced desired effects rather than merely providing high level gene expression. In particular, such enhancement is described below for the antitumor effects of the exemplary PVP
5 containing compositions.

For systems in which IL-12 is also administered, the antitumor effect can be greater than merely additive (i.e., greater than merely the sum of the antitumor effects of
10 interferon alpha alone and IL-12 alone). Enhancement of immuno-stimulatory effects is also desirable in other contexts, for example, for vaccine applications.

In contrast, for certain applications, it is preferable to select a delivery systems which minimizes the immune system effects. For example, it is often preferred that the
15 immune system activation be minimized for compositions to be delivered to the lung in order to minimize lung tissue swelling.

A useful approach for selecting the delivery system components and preparation techniques for a particular
20 coding sequence can proceed as follows, but is not limited to these steps or step order.

1. Select a particular genetic construct which provides appropriate expression *in vitro*.
2. Select delivery system components based on desired
25 immunostimulatory effects and/or on *in vivo* physiological effect. Such effects can be tested or verified in *in vivo* model systems.
3. Select the other delivery system parameters consistent with the desired immuno-stimulatory
30 effects and/or consistent with enhancing the desired *in vivo* physiological effect. Such parameters can, for example, include the amount and ratio of DNA to one or more other composition components, the relative amounts of non-DNA
35 composition components, the size of delivery system formulation particles, the percent

supercoiled DNA for circular dsDNA vectors, and the specific method of preparation of delivery system formulation particles. The particular parameters relevant for specific types of formulations will be apparent or readily determined by testing.

The description below illustrates the selection of components and parameters in the context of interferon alpha encoding constructs. However, it should be recognized that the approach is applicable to constructs containing a variety of other coding sequences.

II. Plasmid Construct Expression Systems

A. Plasmid Design and Construction

For the methods and constructs of this invention, a number of different plasmids were constructed which are useful for delivery and expression of sequences encoding interferon alpha. Thus, these plasmids contain coding regions for interferon alpha, along with genetic elements necessary or useful for expression of those coding regions.

While these embodiments utilized interferon alpha cDNA clones or partial genomic sequences from a particular source, those skilled in the art could readily obtain interferon alpha coding sequences from other sources, or obtain a coding sequence by identifying a cDNA clone in a library using a probe(s) based on the published interferon alpha coding and/or flanking sequences. This also applies to the IL-12 coding sequences utilized in the embodiments described herein.

Coding sequences for interferon alpha were incorporated into an expression plasmid that contains eukaryotic and bacterial genetic elements. Eukaryotic genetic elements include the CMV immediate early promoter and 5' UTR, and a human growth hormone 3' UTR/poly(a) signal, which influence gene expression by controlling the accuracy and efficiency of RNA processing, mRNA stability, and translation.

The human growth hormone 3' UTR is from a human growth hormone gene, and preferably includes a poly(a) signal. This sequence can be linked immediately following the natural translation termination codon for a cDNA sequence, 5 genomic sequence, modified genomic sequence, or synthetic sequence coding for interferon alpha.

An example of a human growth hormone 3' UTR/poly(a) signal is shown by the human growth hormone 3' UTR (nucleotides 1 - 100) and 3' flanking sequence (nucleotides 101 - 191; GenBank accession #J03071, HUMGHCSA) below. (SEQ ID NO:13)

```

1  GGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCTGGCCCTGGAAGT
                                Poly (a)signal
15
51  TGCCACTCCAGTGCCCAACCAGCCTTGTCTCTAATAAAATTAAGTGCATCA
101 TTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTG
20 151 GTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGC
    The 5' and 3' UTR and flanking regions can be further
    and more precisely defined by routine methodology, e.g.,
    deletion or mutation analysis or their equivalents., and can
    be modified to provide other sequences having appropriate
25 transcriptional and translational functions.
    1. Construction of plasmid: Plasmid Backbone, human
    interferon alpha cDNA, Final Construct
    A diagrammatic representation of the PCR products and
    plasmids involved in creation of an exemplary construct is
30 shown below in Figure 8.
    Plasmid pIF0921 was constructed from commercially
    available plasmids, and contains the TN5 gene encoding the
    kanamycin resistance gene, the pUC origin of replication,
    the CMV enhancer and promoter to base +112, a synthetic
35 intron called IVS8, the human IFN-a2b gene, and the human
    growth hormone 3' UTR. The plasmid construction descendency

```

for pIL0697 is shown in Figure 8. pIL0697 was cut with BamHI and Xba I and the hIFN- α 2b PCR product, which had been amplified from human genomic DNA with BamHI and Xba I ends, was cloned into the pIL0697 backbone in place of the IL-2 coding region. The resulting plasmid was pIF0863. pIF0863 was cut with Nco I and intron IVS8 from pCT0828 was cloned in. The resulting plasmid was pIF0890. pIF0890 was cut with Nde I and Pac I and an additional region of the CMV 5' UTR to base +112 was cloned in from plasmid pLC0888.

10 B. Synthetic Genetic Elements

In some embodiments, some or all of the genetic elements can be synthetic, derived from synthetic oligonucleotides, and thus are not obtained directly from natural genetic sequences. These synthetic elements are appropriate for use in many different expression vectors.

15 A synthetic intron is designed with splice sites that ensure that RNA splicing is accurate and efficient. A synthetic 3' UTR/poly(A) signal is designed to facilitate mRNA 3' end formation and mRNA stability. A synthetic 5' UTR is designed to facilitate the initiation of translation. The design of exemplary synthetic elements is described in more detail below.

1. Summary of Synthetic Element Features

25 Exemplary synthetic 5'UTR, intron, and 3'UTR/poly(A) signal have the general features shown below:

5' UTR	Short.
	Lack of secondary structure.
	Kozak sequence.
	Site for intron insertion.

Intron	5' splice site sequence matches consensus. 5' splice site sequence is exactly complementary to 5' end of U1 snRNA. Branch point sequence matches consensus. Branch point sequence is complementary to U2 snRNA. 3' splice site matches consensus. Polypyrimidine tract is 16 bases in length and contains 7 consecutive T's. (The tract preferably contains at least 5 consecutive T's.) Contains internal restriction enzyme sites. BbsI cleaves at the 5'ss, EarI cleaves at the 3'ss.
3' UTR/Poly(A)	Based on rabbit β -globin 3' UTR/poly(A) signal. Consists of two poly(A) signals in tandem.

2. Features of the Synthetic 5'UTR (UT6):

The 5' untranslated region (5'UTR) influences the translational efficiency of messenger RNA, and is therefore an important determinant of eukaryotic gene expression. The synthetic 5'UTR sequence (UT6) has been designed to maximize the translational efficiency of mRNAs encoded by vectors that express genes of therapeutic interest.

The sequence of the synthetic 5' UTR (UT6) is shown below. The Kozak sequence is in boldface and the initiation codon is double underlined. The location of the intron (between residues 48 and 49) is indicated by the filled

triangle and the sequences that form the exonic portion of consensus splice sites are single underlined. The restriction sites for HindIII and NcoI are overlined. (SEQ ID NO:14)

5

HindIII▽ NcoI

AAGCTTACTCAACACAATAACAACTTACTTACAATCTTAATTAACAGGCCACCATGG

10 The 5' untranslated region (5' UTR), located between the cap site and initiation codon, is known to influence the efficiency of mRNA translation. Any features that influence the accessibility of the 5' cap structure to initiation factors, the binding and subsequent migration of the 43S preinitiation complex, or the recognition of the initiation
15 codon, will influence mRNA translatability. An efficient 5' UTR is expected to be one that is moderate in length, devoid of secondary structure, devoid of upstream initiation codons, and has an AUG within an optimal local context (Kozak, 1994, *Biochimie* 76:815-821; Jansen et al., 1994). A
20 5' UTR with these characteristics should allow efficient recognition of the 5' cap structure, followed by rapid and unimpeded ribosome scanning by the ribosome, thereby facilitating the translation initiation process.

25 The sequence of the synthetic 5'UTR was designed to be moderate in length (54 nucleotides (nts)), to be deficient in G but rich in C and A residues, to lack an upstream ATG, to place the intended ATG within the context of a optimal Kozak sequence (CCACCATGG), and to lack potential secondary structure. The synthetic 5' UTR sequence was also designed
30 to lack AU-rich sequences that target mRNAs to be rapidly degraded in the cytoplasm.

Experiments have demonstrated that introns increase gene expression from cDNA vectors, and that introns located in the 5' UTR are more effective than ones located in the 3' UTR (Huang and Gorman, 1990, *Mol. Cell. Biol.* 10:1805-1810; Evans and Scarpulla, 1989, *Gene* 84:135-142; Brinster et al.,
35

To facilitate cloning manipulations, the synthetic 5' UTR sequence was designed to begin with a HindIII site and terminate with a NcoI site.

15 RNA splicing is required for the expression of most eukaryotic genes. For optimal gene expression, RNA splicing must be highly efficient and accurate. A synthetic intron, termed OPTIVS8B, was designed to be maximally efficient and accurate.

5' ss bp 3' ss

| BbsI | EarI |

The 5' splice site (5'ss) sequence matches the established consensus sequence, MAG □ GTRAGT, where M = C or A, and R = G or A. Since the mechanism of splicing involves an interaction between the 5'ss of the pre-mRNA and U1

snRNA, the 5'ss sequence of OPTIVS8B was chosen to be exactly complementary to the 5' end of U1 snRNA.

```

5          5'ss      5' CAGGUAAGU 3'
              |||||
          U1 RNA    3' GUCCAUCUA 5'
  
```

In mammals, the consensus sequence for branch points (YNYTRAY, where Y = C or T, R = A or G, N = any base, and the underlined A residue is the actual branch point) is very ambiguous. Since the mechanism of splicing involves an interaction between the branch point (bp) of the pre-mRNA and U2 snRNA, the branch point sequence of OPTIVS8B was chosen to maximize this interaction. (Note that the branch point itself is bulged out). The chosen sequence also matches the branch point sequence that is known to be obligatory for pre-mRNA splicing in yeast. The branch point is typically located 18-38 nts upstream of the 3' splice site. In OPTIVS8B, the branch point is located 24 nts upstream from the 3' splice site.

```

          BP          5' UACUAAC 3'
                      |||||
          U2 RNA      3' AUGAU G 5'
  
```

The sequence of the 3' splice site (3'ss) matches the established consensus sequence, Y₁₁NYAG ↓ G, where Y = C or T, and N = any base. In 3' splice sites, the polypyrimidine tract (Y₁₁) is the major determinant of splice site strength. For optimal splice site function in OPTIVS8B, the length of the polypyrimidine tract was extended to 16 bases, and its sequence was adjusted to contain 7 consecutive T residues. This feature was included because Roscigno et al. (1993) demonstrated that optimal splicing requires the presence of at least 5 consecutive T residues in the polypyrimidine tract.

Splicing *in vitro* is generally optimal when introns are >80 nts in length (Wieringa, et al., 1984; Ulfendahl et al., 1985, *Nucl. Acids Res.* 13:6299-6315). Although many introns may be thousands of bases in length, most naturally occurring introns are 90-200 nt in length (Hawkins, 1988, *Nucl. Acids Res.* 16:9893-9908). The length of the synthetic intron (118 nts) falls within this latter range.

OPTIVS8B was designed with three internal restriction enzyme sites, BbsI, NheI, and EarI. These restriction sites facilitate the screening and identification of genes that contain the synthetic intron sequence. In addition, the BbsI and EarI sites were placed so that their cleavage sites exactly correspond to the 5'ss (BbsI) or 3'ss (EarI). The sequence of the polypyrimidine tract was specifically designed to accommodate the EarI restriction site. Inclusion of the BbsI and EarI sites at these locations is useful because they permit the intron to be precisely deleted from a gene. They also permit the generation of an "intron cassette" that can be inserted at other locations within a gene.

The 77 bases between the BbsI site and the branch point sequence are random in sequence, except for the inclusion of the NheI restriction site.

4. Features of the Synthetic 3' UTR/poly(A)

Signal:

The 3' ends of eukaryotic mRNAs are formed by the process of polyadenylation. This process involves site specific site RNA cleavage, followed by addition of a poly(A) tail. RNAs that lack a poly(A) tail are highly unstable. Thus, the efficiency of cleavage/polyadenylation is a major determinant of mRNA levels, and thereby, of gene expression levels. 2XPA1 is a synthetic sequence, containing two efficient poly(A) signals, that is designed to be maximally effective in polyadenylation.

A poly(A) signal is required for the formation of the 3' end of most eukaryotic mRNA. The signal directs two RNA processing reactions: site-specific endonucleolytic cleavage of the RNA transcript, and stepwise addition of adenylates (approximately 250) to the newly generated 3' end to form the poly(A) tail. A poly(A) signal has three parts: hexanucleotide, cleavage site, and downstream element. The hexanucleotide is typically AAUAAA and cleavage sites are most frequently 3' to the dinucleotide CA (Sheets et al., 1987). Downstream elements are required for optimal poly(A) signal function and are located downstream of the cleavage site. The sequence requirement for downstream elements is not yet fully established, but is generally viewed as UG- or U-rich sequences (Wickens, 1990; Proudfoot, 1991, *Cell* 64:671-674; Wahle, 1992, *Bioessays* 14:113-118; Chen and Nordstrom, 1992, *Nucl. Acids Res.* 20:2565-2572).

Naturally occurring poly(A) signals are highly variable in their effectiveness (Peterson, 1992). The effectiveness of a particular poly(A) signal is mostly determined by the quality of the downstream element. (Wahle, 1992). In expression vectors designed to express genes of therapeutic interest, it is important to have a poly(A) signal that is as efficient as possible.

Poly(A) efficiency is important for gene expression, because transcripts that fail to be cleaved and polyadenylated are rapidly degraded in the nuclear compartment. In fact, the efficiency of polyadenylation in living cells is difficult to measure, since nonpolyadenylated RNAs are so unstable. In addition to being required for mRNA stability, poly(A) tails contribute to the translatability of mRNA, and may influence other RNA processing reactions such as splicing or RNA transport ((Jackson and Standart, 1990, *Cell* 62:15-24; Wahle, 1992).

Some eukaryotic genes have more than one poly(A) site, implying that if the cleavage/polyadenylation reaction fails to occur at the first site, it will occur at one of the

later sites. In COS cell transfection experiments, a gene with two strong poly(A) sites yielded approximately two-fold more mRNA than one with a single strong poly(A) site (Bordonaro, 1995). These data suggest that a significant
 5 fraction of transcripts remain unprocessed even with a single "efficient" poly(A) signal. Thus, it may be preferable to include more than one poly(A) site.

The sequence of the exemplary synthetic poly(A) signal is shown below. The sequence is named 2XPA. The
 10 hexanucleotide sequences and downstream element sequences are double underlined, and the two poly(A) sites are labeled as pA#1 and pA#2. Convenient restriction sites are overlined. The entire 2XPA unit may be transferred in cloning experiments as a XbaI-KpnI fragment. Deletion of
 15 the internal BspHI fragment results in the formation of a 1XPA unit. (SEQ ID NO. 17)

	<u>XbaI</u>		<u>BspHI</u>
	TCTAGAGCATTTTTCCCTCTGCCAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACG		
20		pA#1	
	Hex		Downstream element
	TCTGGCT <u>ATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTGTG</u> TCTCTCACT		
			<u>BspHI</u>
25	CGGTACTAGAGCATTTTTCCCTCTGCCAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCT		
		pA#2	
	Hex		Downstream element
	GACGTCTGGCT <u>ATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTGTG</u> TCTCTCT		
30	<u>KpnI</u>		
	CACTCGGTACC		

The sequence of the synthetic poly(A) site shown above is based on the sequence of the rabbit β -globin poly(A)
 35 signal, a signal that has been characterized in the literature as strong (Gil and Proudfoot, 1987, Cell 49:399-

406; Gil and Proudfoot, 1984, *Nature* 312:473-474). One of its key features is the structure of its downstream element, which contains both UG- and U-rich domains.

5 A double-stranded DNA sequence corresponding to the 1XPA sequence was constructed from synthetic oligonucleotides. Two copies of the 1XPA sequence were then joined to form the 2XPA sequence. The sequences were joined in such a way as to have a unique XbaI site at the 5' end of the first poly(A) signal containing fragment, and a
10 unique KpnI site at the 3' end of the second poly(A) signal containing fragment.

C. Interferon Alpha and IL-12 Coding Sequences

The nucleotide sequence of a natural human interferon alpha coding sequences is known, and is provided below,
15 along with a synthetic sequence which also codes for human interferon alpha. The same applies with respect to the IL-12 coding sequences.

In some cases, instead of the natural sequence coding for interferon alpha, it is advantageous to utilize
20 synthetic sequences which encode interferon alpha. Such synthetic sequences have alternate codon usage from the natural sequence, and thus have dramatically different nucleotide sequences from the natural sequence. In particular, synthetic sequences can be used which have codon
25 usage at least partially optimized for expression in a human. The natural sequences do not have such optimal codon usage. Preferably, substantially all the codons are optimized.

Optimal codon usage in humans is indicated by codon
30 usage frequencies for highly expressed human genes, as shown in Fig. 3. The codon usage chart is from the program "Human_High.cod" from the Wisconsin Sequence Analysis Package, Version 8.1, Genetics Computer Group, Madison, WI. The codons which are most frequently used in highly
35 expressed human genes are presumptively the optimal codons

for expression in human host cells, and thus form the basis for constructing a synthetic coding sequence. An example of a synthetic interferon alpha coding sequence is shown as the bottom sequence in the table below.

5 However, rather than a sequence having fully optimized codon usage, it may be desirable to utilize an interferon alpha encoding sequence which has optimized codon usage except in areas where the same amino acid is too close together or abundant to make uniform codon usage optimal.

10 In addition, other synthetic sequences can be used which have substantial portions of the codon usage optimized, for example, with at least 50%, 70%, 80% or 90% optimized codons as compared to a natural coding sequence. Other particular synthetic sequences for interferon alpha
15 can be selected by reference to the codon usage chart in Fig. 3. A sequence is selected by choosing a codon for each of the amino acids of the polypeptide sequences. DNA molecules corresponding to each of the polypeptides can then be constructed by routine chemical synthesis methods. For
20 example, shorter oligonucleotides can be synthesized, and then ligated in the appropriate relationships to construct the full-length coding sequences.

 The following sequences are provided in the sequence listing herein: interferon alpha amino acid sequence, SEQ
25 ID NO:9; interferon alpha wild type nucleic acid sequence, SEQ ID NO:10; interferon alpha synthetic nucleic acid sequence with optimized codon usage, SEQ ID NO:11; interferon alpha nucleic acid sequence with additional/semi-optimized codon usage, SEQ ID NO:12; IL-12 p40 subunit amino
30 acid sequence, SEQ ID NO:1; IL-12 p40 wild type nucleic acid sequence, SEQ ID NO:2; IL-12 p40 synthetic nucleic acid sequence with all codons optimized, SEQ ID NO:3; IL-12 p40 subunit nucleic acid sequence with all codons optimized except when same nucleic acids were too close/abundant, SEQ
35 ID NO:4; IL-12 p35 amino acid sequence, SEQ ID NO:5; IL-12 p35 wild type nucleic acid sequence, SEQ ID NO:6; IL-12 p35

synthetic nucleic acid sequence with all codons optimized, SEQ ID NO:7; IL-12 p35 subunit nucleic acid sequence with all codons optimized except when same nucleic acids were too close/abundant, SEQ ID NO:8. Those skilled in the art will realize that various nucleic acid sequences with optimized codon usage can be constructed, for example based on the various combinations shown below, wherein optimal usage for each codon is shown below the IL-12 p35 and p40 subunit wild type sequences and the interferon alpha wild type sequence.

10 Sequences Encoding Human IL-12 p35

First line = natural sequence (SEQ ID NO. 6)

Second line = all codons optimized (SEQ ID NO. 7)

Third line = all codons optimized except when same nucleic acids were too close/abundant (changes between second and third lines bolded) (SEQ ID NO. 8)

ATG TGT CCA GCG CGC AGC CTC CTC CTT GTG GCT ACC CTG GTC CTC CTG GAC CAC CTC ACT
 ATG TGC CCC GCC CGC AGC CTG CTG CTG GTG GCC ACC CTG GTG CTG CTG GAC CAC CTG AGC
 ATG TGC CCC GCC CGC AGC CTG CTG CTC GTG GCC ACC CTG GTG CTC CTG GAC CAC CTC AGC
 TTG GCC AGA AAC CTC CCC GTG GCC ACT CCA GAC CCA GGA ATG TTC CCA TGC CTT CAC CAC
 CTG GCC CGC AAC CTG CCC GTG GCC ACC CCC GAC CCC GGC ATG TTC CCC TGC CTG CAC CAC
 CTG GCC CGC AAC CTC CCC GTG GCC ACC CCA GAC CCC GGC ATG TTC CCA TGC CTG CAC CAC
 TCC CAA AAC CTG CTG AGG GCC GTC AGC AAC ATG CTC CAG AAG GCC AGA CAA ACT CTA GAA
 AGC CAG AAC CTG CTG GCG GCC GTG AGC AAC ATG CTG CAG AAG GCC GCG CAG ACC CTG GAG
 AGC CAG AAC CTG CTG GCG GCC GTG AGC AAC ATG CTG CAG AAG GCC GCG CAG ACC CTG GAG
 TTT TAC CCT TGC ACT TCT GAA GAG ATT GAT CAT GAA GAT ATC ACA AAA GAT AAA ACC AGC
 TTC TAC CCC TGC ACC AGC GAG GAG ATC GAC CAC GAG GAC ATC ACC AAG GAC AAG ACC AGC
 TTC TAC CCC TGC ACC AGC GAG GAG ATC GAC CAC GAG GAC ATC ACC AAG GAC AAG ACC AGC
 ACA GTG GAG GCC TGT TTA CCA TTG GAA TTA ACC AAG AAT GAG AGT TGC CTA AAT TCC AGA
 ACC GTG GAG GCC TGC CTG CCC CTG GAG CTG ACC AAG AAC GAG AGC TGC CTG AAC AGC CGC
 ACC GTG GAG GCC TGC CTG CCC CTC GAG TTA ACC AAG AAC GAG AGC TGC CTC AAC AGC CGC

- GAG ACC TCT TTC ATA ACT AAT GGG AGT TGC CTG GCC TCC AGA AAG ACC TCT TTT ATG ATG
 GAG ACC AGC TTC ATC ACC AAC GGC AGC TGC CTG GCC AGC CGC AAG ACC AGC TTC ATG ATG
 GAG ACC TCC TTC ATC ACC AAC GGC ACT TGC CTG GCC TCC CGC AAG ACC AGC TTC ATG ATG
- 5
 GCC CTG TGC CTT AGT AGT ATT TAT GAA GAC TTG AAG ATG TAC CAG GTG GAG TTC AAG ACC
 GCC CTG TGC CTG AGC AGC ATC TAC GAG GAC CTG AAG ATG TAC CAG GTG GAG TTC AAG ACC
 GCC CTG TGC CTG AGC TCC ATC TAC GAG GAC CTG AAG ATG TAC CAG GTG GAG TTC AAG ACC
- 10
 ATG AAT GCA AAG CTT CTG ATG GAT CCT AAG AGG CAG ATC TTT CTA GAT CAA AAC ATG CTG
 ATG AAC GCC AAG CTG CTG ATG GAC CCC AAG CTC CAG ATC TTC CTG GAC CAG AAC ATG CTG
 ATG AAC GCC AAG CTC CTG ATG GAC CCC AAG CTC CAG ATC TTC CTG GAC CAG AAC ATG CTG
- 15
 GCA GTT ATT GAT GAG CTG ATG CAG GCC CTG AAT TTC AAC AGT GAG ACT GTG CCA CAA AAA
 GCC GTG ATC GAC GAG CTG ATG CAG GCC CTG AAC TTC AAC AGC GAG ACC GTG CCC CAG AAG
 GCC GTG ATC GAC GAG CTG ATG CAG GCC CTG AAC TTC AAC AGC GAG ACC GTG CCC CAG AAG
- 20
 TCC TCC CTT GAA GAA CCG GAT TTT TAT AAA ACT AAA ATC AAG CTC TGC ATA CTT CTT CAT
 AGC AGC CTG GAG GAG CCC GAC TTC TAC AAG ACC AAG ATC AAG CTG TGC ATC CTG CTG CAC
 AGC AGC CTG GAG GAG CCC GAC TTC TAC AAG ACC AAG ATC AAG CTG TGC ATC CTG CTG CAC
- GCT TTC AGA ATT CGG GCA GTG ACT ATT GAC AGA GTG ACG AGC TAT CTG AAT GCT TCC TAA
 GCC TTC CGC ATC CGC GCC GTG ACC ATC GAC CGC GTG ACC AGC TAC CTG AAC GCC ACC TGA
 GCC TTC CGC ATC CGG GCC GTG ACC ATC GAC CGC GTG ACC AGC TAC CTG AAC GCC ACG TGA
- 25 Additional Optimized Sequences Coding For IL-12 p35 Subunit
(Second Line = SEQ ID NO:24)
- 10 20
- Met Cys Pro Ala Arg Ser Leu Leu Leu Val Ala Thr Leu Val Leu Leu Asp His Leu Ser
 ATG TGY CCN GCN MGN WSN YTN YTN YTN GTN GCN ACN YTN GTN YTN YTN GAY CAY YTN WSN
- 30

 ATG TGT CCT GCT CGT TCT TTA TTA TTA GTT GCT ACT TTA GTT TTA TTA GAT CAT TTA TCT
 TGC CCC GCC CGC TCC TTG TTG TTG GTC GCC ACC TTG GTC TTG TTG GAC CAC TTG TCC
 CCA GCA CGA TCA CTT CTT CTT GTA GCA ACA CTT GTA CTT CTT CTT TCA
 CCG GCG CGG TCG CTC CTC CTC GTG GCG ACG CTC GTG CTC CTC CTC TCG

40

AGA AGT CTA CTA CTA	CTA	CTA CTA	CTA AGT
AGG AGC CTG CTG CTG	CTG	CTG CTG	CTG AGC

30

40

5 Leu Ala Arg Asn Leu Pro Val Ala Thr Pro Asp Pro Gly Met Phe Pro Cys Leu His His
 YTN GCN MGN AAY YTN CCN GTN GCN ACN CCN GAY CCN GGN ATG TTY CCN TGY YTN CAY CAY

 TTA GCT CGT AAT TTA CCT GTT GCT ACT CCT GAT CCT GGT ATG TTT CCT TGT TTA CAT CAT
 TTG GCC CGC AAC TTG CCC GTC GCC ACC CCC GAC CCC GGC TTC CCC TGC TTG CAC CAC
 10 CTT GCA CGA CTT CCA GTA GCA ACA CCA CCA GGA CCA CTT
 CTC GCG CGG CTC CCG GTG GCG ACG CCG CCG GGG CCG CTC
 CTA AGA CTA
 CTG AGG CTG
 CTG

15

50

60

Ser Gln Asn Leu Leu Arg Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu Glu
 WSN CAR AAY YTN YTN MGN GCN GTN WSN AAY ATG YTN CAR AAR GCN MGN CAR ACN YTN GAR

 TCT CAA AAT TTA TTA CGT GCT GTT TCT AAT ATG TTA CAA AAA GCT CGT CAA ACT TTA GAA
 20 TCC CAG AAC TTG TTG CGC GCC GTC TCC AAC TTG CAG AAG GCC CGC CAG ACC TTG GAG
 TCA CTT CTT CGA GCA GTA TCA CTT GCA CGA ACA CTT
 TCG CTC CTC CGG GCG GTG TCG CTC GCG CGG ACG CTC
 AGT CTA CTA AGA AGT CTA AGA CTA
 AGC CTG CTG AGG AGC CTG AGG CTG

25

70

80

Phe Tyr Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys Thr Ser
 TTY TAY CCN TGY ACN WSN GAR GAR ATH GAY CAY GAR GAY ATH ACN AAR GAY AAR ACN WSN

 TTT TAT CCT TGT ACT TCT GAA GAA ATT GAT CAT GAA GAT ATT ACT AAA GAT AAA ACT TCT
 30 TTC TAC CCC TGC ACC TCC GAG GAG ATC GAC CAC GAG GAC ATC ACC AAG GAC AAG ACC TCC
 CCA ACA TCA ATA ATA ACA ACA TCA
 CCG ACG TCG ACG ACG TCG
 AGT
 35 AGC
 AGC

41

90100

Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr Lys Asn Glu Ser Cys Leu Asn Ser Arg
 ACN GTN GAR GCN TGY YTN CCN YTN GAR YTN ACN AAR AAY GAR WSN TGY YTN AAY WSN MGN
 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

5 ACT GTT GAA GCT TGT TTA CCT TTA GAA TTA ACT AAA AAT GAA TCT TGT TTA AAT TCT CGT
 ACC GTC GAG GCC TGC TTG CCC TTG GAG TTG ACC AAG AAC GAG TCC TGC TTG AAC TCC CGC
 ACA GTA GCA CTT CCA CTT CTT ACA TCA CTT TCA CGA
 ACG GTG GCG CTC CCG CTC CTC ACG TCG CTC TCG CGG
 CTA CTA CTA AGT CTA AGT AGA
 10 CTG CTG CTG AGC CTG AGC AGG

110120

Glu Thr Ser Phe Ile Thr Asn Gly Ser Cys Leu Ala Ser Arg Lys Thr Ser Phe Met Met
 GAR ACN WSN TTY ATH ACN AAY GGN WSN TGY YTN GCN WSN MGN AAR ACN WSN TTY ATG ATG
 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

15 GAA ACT TCT TTT ATT ACT AAT GGT TCT TGT TTA GCT TCT CGT AAA ACT TCT TTT ATG ATG
 GAG ACC TCC TTC ATC ACC AAC GGC TCC TGC TTG GCC TCC CGC AAG ACC TCC TTC
 ACA TCA ATA ACA GGA TCA CTT GCA TCA CGA ACA TCA
 ACG TCG ACG GGG TCG CTC GCG TCG CGG ACG TCG
 20 AGT AGT CTA AGT AGA AGT
 AGC AGC CTG AGC AGG AGC

130140

Ala Leu Cys Leu Ser Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys Thr
 GCN YTN TGY YTN WSN WSN ATH TAY GAR GAY YTN AAR ATG TAY CAR GTN GAR TTY AAR ACN
 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

25 GCT TTA TGT TTA TCT TCT ATT TAT GAA GAT TTA AAA ATG TAT CAA GTT GAA TTT AAA ACT
 GCC TTG TGC TTG TCC TCC ATC TAC GAG GAC TTG AAG TAC CAG GTC GAG TTC AAG ACC
 GCA CTT CTT TCA TCA ATA CTT GTA ACA
 30 GCG CTC CTC TCG TCG CTC GTG ACG
 CTA CTA AGT AGT CTA
 CTG CTG AGC AGC CTG

10

15

25

30

210220

Ala Phe Arg Ile Arg Ala Val Thr Ile Asp Arg Val Thr Ser Tyr Leu Asn Ala Ser ***

GCN TTY MGN ATH MGN GCN GTN ACN ATH GAY MGN GTN ACN WSN TAY YTN AAY GCN WSN TRR

5 GCT TTT CGT ATT CGT GCT GTT ACT ATT GAT CGT GTT ACT TCT TAT TTA AAT GCT TCT TAA

GCC TTC CGC ATC CGC GCC GTC ACC ATC GAC CGC GTC ACC TCC TAC TTG AAC GCC TCC TAG

GCA CGA ATA CGA GCA GTA ACA ATA CGA GTA ACA TCA CTT GCA TCA TGA

GCG CGG CGG GCG GTG ACG CGG GTG ACG TCG CTC GCG TCG

AGA AGA AGA AGT CTA AGT

10 AGG AGG AGG AGC CTG AGC

Sequences Encoding Human IL-12 p40

First line = natural sequence (SEQ ID NO. 2)

Second line = all codons optimized (SEQ ID NO. 3)

Third line = all codons optimized except when same
 15 nucleic acids were too close/abundant (changes between
 second and third lines bolded) (SEQ ID NO. 4)

ATG TGT CAC CAG CAG TTG GTC ATC TCT TGG TTT TCC CTG GTT TTT CTG GCA TCT CCC CTC

ATG TGC CAC CAG CAG CTG GTG ATC AGC TGG TTC AGC CTG GTG TTC CTG GCC AGC CCC CTG

ATG TGC CAC CAG CAG CTG GTG ATC AGC TGG TTC TCC CTG GTG TTT CTG GCC AGC CCC CTC

20 GTG GCC ATA TGG GAA CTG AAG AAA GAT GTT TAT GTC GTA GAA TTG GAT TGG TAT CCG GAT

GTG GCC ATC TGG GAG CTG AAG AAG GAC GTG TAC GTG GTG GAG CTG GAC TGG TAC CCC GAC

GTG GCC ATC TGG GAG CTG AAG AAA GAC GTG TAC GTG GTC GAG CTG GAC TGG TAC CCC GAC

25 GCC CCT GGA GAA ATG GTG GTC CTC ACC TGT GAC ACC CCT GAA GAA GAT GGT ATC ACC TGG

GCC CCC GGC GAG ATG GTG GTG CTG ACC TGC GAC ACC CCC GAG GAG GAC GGC ATC ACC TGG

GCC CCC GGC GAG ATG GTG GTC CTG ACC TGC GAC ACC CCC GAG GAA GAC GGC ATC ACC TGG

ACC TTG GAC CAG AGC AGT GAG GTC TTA GGC TCT GGC AAA ACC CTG ACC ATC CAA GTC AAA

30 ACC CTG GAC CAG AGC AGC GAG GTG CTG GGC AGC GGC AAG ACC CTG ACC ATC CAG GTG AAG

ACC CTG GAC CAG AGC AGT GAG GTG CTG GGC TCC GGC AAG ACC CTG ACC ATC CAG GTG AAG

GAG TTT GGA GAT GCT GGC CAG TAC ACC TGT CAC AAA GGA GGC GAG GTT CTA AGC CAT TCG

GAG TTC GGC GAC GCC GGC CAG TAC ACC TGC CAC AAG GGC GGC GAG GTG CTG AGC CAC AGC

35 GAG TTC GGC GAC GCC GGC CAG TAC ACC TGC CAC AAG GGA GGC GAG GTG CTG AGC CAC TCC

- CTC CTG CTG CTT CAC AAA AAG GAA GAT GGA ATT TGG TCC ACT GAT ATT TTA AAG GAC CAG
CTG CTG CTG CTG CAC AAG AAG GAG GAC GGC ATC TGG AGC ACC GAC ATC CTG AAG GAC CAG
CTC CTG CTG CTC CAC AAA AAG GAG GAC GGC ATC TGG AGC ACC GAC ATC CTG AAG GAC CAG
- 5
AAA GAA CCC AAA AAT AAG ACC TTT CTA AGA TGC GAG GCC AAG AAT TAT TCT GGA CGT TTC
AAG GAG CCC AAG AAC AAG ACC TTC CTG CGC TGC GAG GCC AAG AAC TAC AGC GGC CGC TTC
AAG GAG CCC AAG AAC AAG ACC TTC CTG CGC TGC GAG GCC AAG AAC TAC AGC GGC CGC TTC
- 10
ACC TGC TGG TGG CTG ACG ACA ATC AGT ACT GAT TTG ACA TTC AGT GTC AAA AGC AGC AGA
ACC TGC TGG TGG CTG ACC ACC ATC AGC ACC GAC CTG ACC TTC AGG GTG AAG AGC AGC AGG
ACC TGC TGG TGG CTG ACC ACG ATC AGC ACC GAC CTG ACC TTC AGT GTG AAG AGC AGC AGG
- 15
GGC TCT TCT GAC CCC CAA GGG GTG ACG TGC GGA GCT GCT ACA CTC TCT GCA GAG AGA GTC
GGC AGC AGC GAC CCC CAG GGC GTG ACC TGC GGC GCC GCC ACC CTG AGC GCC GAG CGC GTG
GGC TCC AGC GAC CCC CAG GGC GTG ACC TGC GGC GCT GCC ACC CTG AGC GCC GAG CGC GTG
- 20
AGA GGG GAC AAC AAG GAG TAT GAG TAC TCA GTG GAG TGC CAG GAG GAC AGT GCC TGC CCA
CGC GGC GAC AAC AAG GAG TAC GAG TAC AGC GTG GAG TGC CAG GAG GAC AGC GCC TGC CCC
CGC GGC GAC AAC AAG GAG TAC GAG TAC AGC GTG GAG TGC CAG GAA GAC TCC GCC TGC CCC
- 25
GCT GCT GAG GAG AGT CTG CCC ATT GAG GTC ATG GTG GAT GCC GTT CAC AAG CTC AAG TAT
GCC GCC GAG GAG AGC CTG CCC ATC GAG GTG ATG GTG GAC GCC GTC CAC AAG CTG AAG TAC
GCC GCT GAG GAG AGC CTG CCC ATC GAG GTG ATG GTG GAC GCC GTT CAC AAG CTG AAG TAC
- 30
GAA AAC TAC ACC AGC AGC TTC TTC ATC AGG GAC ATC ATC AAA CCT GAC CCA CCC AAG AAC
GAG AAC TAC ACC AGC AGC TTC TTC ATC CGC GAC ATC ATC AAG CCC GAC CCC CCC AAG AAC
GAG AAC TAC ACC AGC AGC TTC TTC ATC CGC GAC ATC ATC AAG CCT GAC CCA CCC AAG AAC
- 35
TTG CAG CTG AAG CCA TTA AAG AAT TCT CGG CAG GTG GAG GTC AGC TGG GAG TAC CCT GAC
CTG CAG CTG AAG CCC CTG AAG AAC AGC CGC CAG GTG GAG GTG AGC TGG GAG TAC CCC GAC
CTC CAG CTG AAG CCC CTC AAG AAC TCC CGC CAG GTG GAG GTG AGC TGG GAG TAC CCC GAC
ACC TGG AGT ACT CCA CAT TCC TAC TTC TCC CTG ACA TTC TGC GTT CAG GTC CAG GGC AAG
ACC TGG AGC ACC CCC CAC AGC TAC TTC AGC CTG ACC TTC TGC GTG CAG GTG CAG GGC AAG
ACC TGG AGC ACG CCC CAC TCC TAC TTC TCC CTG ACC TTC TGC GTG CAG GTC CAG GGC AAG

5 CGC AAA AAT GCC AGC ATT AGC GTG CGG *GCC* CAG GAC CGC TAC TAT AGC TCA TCT *TGG* AGC
CGC AAG AAC GCC AGC ATC AGC GTG *CGC* GCC CAG GAC CGC TAC TAC AGC AGC AGC TGG AGC
CGC AAG AAC GCC AGC ATC AGC GTG CGC *GCC* CAG GAC CGC TAC TAT AGC TCC TCT TGG AGC

GAG TGG GCC AGC GTG CCC TGC TCC TAG

Additional Optimized Sequences Coding For IL-12 p40 Subunit
(Second Line = SEQ ID NO:25)

[illegible]

70

80

90

100

	Glu	Phe	Gly	Asp	Ala	Gly	Gln	Tyr	Thr	Cys	His	Lys	Gly	Gly	Glu	Val	Leu	Ser	His	Ser
25	GAR	TTY	GGN	GAY	GCN	GGN	CAR	TAY	ACN	TGY	CAY	AAR	GGN	GGN	GAR	GTN	YTN	WSN	CAY	WSN
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---
	GAA	TTT	GGT	GAT	GCT	GGT	CAA	TAT	ACT	TGT	CAT	AAA	GGT	GGT	GAA	GTT	TTA	TCT	CAT	TCT
	GAG	TTC	GGC	GAC	GCC	GGC	CAG	TAC	ACC	TGC	CAC	AAG	GGC	GGC	GAG	GTC	TTG	TCC	CAC	TCC
			GGA		GCA	GGA			ACA				GGA	GGA		GTA	CTT	TCA		TCA
30			GGG		GCG	GGG			ACG				GGG	GGG		GTG	CTC	TCG		TCG
																	CTA	AGT		AGT
																	CTG	AGC		AGC

	130																		140	
	Lys	Glu	Pro	Lys	Asn	Lys	Thr	Phe	Leu	Arg	Cys	Glu	Ala	Lys	Asn	Tyr	Ser	Gly	Arg	Phe
15	AAR	GAR	CCN	AAR	AAV	AAR	ACN	TTY	YTN	MGN	TGY	GAR	GCN	AAR	AAV	TAY	WSN	GGN	MGN	TTY
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---
	AAA	GAA	CCT	AAA	AAT	AAA	ACT	TTT	TTA	CGT	TGT	GAA	GCT	AAA	AAT	TAT	TCT	GGT	CGT	TTT
	AAG	GAG	CCC	AAG	AAC	AAG	ACC	TTC	TTG	CGC	TGC	GAG	GCC	AAG	AAC	TAC	TCC	GGC	CGC	TTC
			CCA				ACA		CTT	CGA			GCA				TCA	GGA	CGA	
			CCG				ACG		CTC	CGG			GCG				TCG	GGG	CGG	
20									CTA	AGA							AGT		AGA	
									CTG	AGG							AGC		AGG	

		150																		160			
		Thr	Cys	Trp	Trp	Leu	Thr	Thr	Ile	Ser	Thr	Asp	Leu	Thr	Phe	Ser	Val	Lys	Ser	Ser	Arg		
25	ACN	TGY	TGG	TGG	YTN	ACN	ACN	ATH	WSN	ACN	GAY	YTN	ACN	TTY	WSN	GTN	AAR	WSN	WSN	MGN			
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---			
	ACT	TGT	TGG	TGG	TTA	ACT	ACT	ATT	TCT	ACT	GAT	TTA	ACT	TTT	TCT	GTT	AAA	TCT	TCT	CGT			
	ACC	TGC			TTG	ACC	ACC	ATC	TCC	ACC	GAC	TTG	ACC	TTC	TCC	GTC	AAG	TCC	TCC	CGC			
	ACA				CTT	ACA	ACA	ATA	TCA	ACA		CTT	ACA		TCA	GTA		TCA	TCA	CGA			
30	ACG				CTC	ACG	ACG		TCG	ACG		CTC	ACG		TCG	GTG		TCG	TCG	CGG			
					CTA				AGT			CTA			AGT			AGT	AGT	AGA			
					CTG				AGC			CTG			AGC			AGC	AGC	AGG			

[illegible]

[illegible]

50

290300

Ser Lys Arg Glu Lys Lys Asp Arg Val Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys
 WSN AAR MGN GAR AAR AAR GAY MGN GTN TTY ACN GAY AAR ACN WSN GCN ACN GTN ATH TGY
 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

5 TCT AAA CGT GAA AAA AAA GAT CGT GTT TTT ACT GAT AAA ACT TCT GCT ACT GTT ATT TGT
 TCC AAG CGC GAG AAG AAG GAC CGC GTC TTC ACC GAC AAG ACC TCC GCC ACC GTC ATC TGC
 TCA CGA CGA GTA ACA ACA TCA GCA ACA GTA ATA
 TCG CGG CGG GTG ACG ACG TCG GCG ACG GTG
 AGT AGA AGA AGT
 10 AGC AGG AGG AGC

310320

Arg Lys Asn Ala Ser Ile Ser Val Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser
 MGN AAR AAY GCN WSN ATH WSN GTN MGN GCN CAR GAY MGN TAY TAY WSN WSN WSN TGG WSN
 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

15 CGT AAA AAT GCT TCT ATT TCT GTT CGT GCT CAA GAT CGT TAT TAT TCT TCT TCT TGG TCT
 CGC AAG AAC GCC TCC ATC TCC GTC CGC GCC CAG GAC CGC TAC TAC TCC TCC TCC TCC
 CGA GCA TCA ATA TCA GTA CGA GCA CGA TCA TCA TCA TCA
 CGG GCG TCG TCG GTG CGG GCG CGG TCG TCG TCG TCG
 20 AGA AGT AGT AGA AGA AGT AGT AGT AGT
 AGG AGC AGC AGG AGG AGC AGC AGC AGC

330340

Glu Trp Ala Ser Val Pro Cys Ser ***
 25 GAR TGG GCN WSN GTN CCN TGY WSN TRR
 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

GAA TGG GCT TCT GTT CCT TGT TCT TAA
 GAG GCC TCC GTC CCC TGC TCC TAG
 GCA TCA GTA CCA TCA TGA
 30 GCG TCG GTG CCG TCG
 AGT AGT
 AGC AGC

Wild Type Sequence Coding For Interferon Alpha

	9	18	27	36	45	54
5'	ATG GCC TTG ACC TTT GCT TTA CTG GTG GCC CTC CTG GTG CTC AGC TGC AAG TCA					

5	M A L T F A L L V A L L V L S C K S					
	63	72	81	90	99	108
	AGC TGC TCT GTG GGC TGT GAT CTG CCT CAA ACC CAC AGC CTG GGT AGC AGG AGG					

10	S C S V G C D L P Q T H S L G S R R					
	117	126	135	144	153	162
	ACC TTG ATG CTC CTG GCA CAG ATG AGG AGA ATC TCT CTT TTC TCC TGC TTG AAG					

15	T L M L L A Q M R R I S L F S C L K					
	171	180	189	198	207	216
	GAC AGA CAT GAC TTT GGA TTT CCC CAG GAG GAG TTT GGC AAC CAG TTC CAA AAG					

20	D R H D F G F P Q E E F G N Q F Q K					
	225	234	243	252	261	270
	GCT GAA ACC ATC CCT GTC CTC CAT GAG ATG ATC CAG CAG ATC TTC AAT CTC TTC					

25	A E T I P V L H E M I Q Q I F N L F					
	279	288	297	306	315	324
	AGC ACA AAG GAC TCA TCT GCT GCT TGG GAT GAG ACC CTC CTA GAC AAA TTC TAC					

30	S T K D S S A A W D E T L L D K F Y					
	333	342	351	360	369	378
	ACT GAA CTC TAC CAG CAG CTG AAT GAC CTG GAA GCC TGT GTG ATA CAG GGG GTG					

35	T E L Y Q Q L N D L E A C V I Q G V					

52

387 396 405 414 423 432
 GGG GTG ACA GAG ACT CCC CTG ATG AAG GAG GAC TCC ATT CTG GCT GTG AGG AAA

 G V T E T P L M K E D S I L A V R K
 5

 441 450 459 468 477 486
 TAC TTC CAA AGA ATC ACT CTC TAT CTG AAA GAG AAG AAA TAC AGC CCT TGT GCC

 Y F Q R I T L Y L K E K K Y S P C A
 10

 495 504 513 522 531 540
 TGG GAG GTT GTC AGA GCA GAA ATC ATG AGA TCT TTT TCT TTG TCA ACA AAC TTG

 W E V V R A E I M R S F S L S T N L
 15

 549 558 567
 CAA GAA AGT TTA AGA AGT AAG GAA TGA 3'

 Q E S L R S K E *

20 Interferon Alpha Coding Sequence with All Codons Optimized
(SEQ ID NO:11)

ATG GCC CTG ACC TTC GCC CTG CTG GTG GCC CTG CTG GTG CTG AGC TGC AAG AGC AGC TGC
 25 TCC GTG GGG TGC GAC CTG CCC CAG ACC CAC AGC CTG GGG AGC CGG CGG ACC CTG ATG CTG
 CTG GCC CAG ATG CGG CGG ATC AGC CTG TTC AGC TGC CTG AAG GAC CGG CAC GAC TTC GGG
 TTC CCC CAG GAG GAG TTC GGG AAC CAG TTC CAG AAG GCC GAG ACC ATC CCC GTG CTG CAC
 30 GAG ATG ATC CAG CAG ATC TTC AAC CTG TTC AGC ACC AAG GAC AGC AGC GCC GCC TGG GAC
 GAG ACC CTG CTG GAC AAG TTC TAC ACC GAG CTG TAC CAG CAG CTG AAC GAC CTG GAG GCC
 35 TGC GTG ATC CAG GGG GTG GGG GTG ACC GAG ACC CCC CTG ATG AAG GAG GAC AGC ATC CTG

GCC GTG CGG AAG TAC TTC CAG CGG ATC ACC CTG TAC CTG AAG GAG AAG AAG TAC TCC CCC

TGC GCC TGG GAG GTG GTG CGG GCC GAG ATC ATG CGG AGC TTC AGC CTG AGC ACC AAC CTG

5

CAG GAG AGC CTG CGG AGC AAG GAG TGA

Additional/Semi Optimized Sequence Coding For Interferon
Alpha (Second Line = SEQ ID NO:12)

10

10

20

MET ALA LEU THR PHE ALA LEU LEU VAL ALA LEU LEU VAL LEU SER CYS LYS SER SER CYS
 ATG GCN YTN ACN TTY GCN YTN YTN GTN GCN YTN YTN GTN YTN WSN TGY AAR WSN WSN TGY

15

 ATG GCT TTA ACT TTT GCT TTA TTA GTT GCT TTA TTA GTT TTA TCT TGT AAA TCT TCT TGT
 GCC TTG ACC TTC GCC TTG TTG GTC GCC TTG TTG GTC TTG TCC TGC AAG TCC TCC TGC
 GCA CTT ACA GCA CTT CTT GTA GCA CTT CTT GTA CTT TCA TCA TCA
 GCG CTC ACG GCG CTC CTC GTG GCG CTC CTC GTG CTC TCG TCG TCG
 CTA CTA CTA CTA CTA AGT AGT AGT
 CTG CTG CTG CTG CTG AGC AGC AGC

20

30

40

SER VAL GLY CYS ASP LEU PRO GLN THR HIS SER LEU GLY SER ARG ARG THR LEU MET LEU
 WSN GTN GGN TGY GAY YTN CCN CAR ACN CAY WSN YTN GGN WSN MGN MGN ACN YTN ATG YTN

25

 TCT GTT GGT TGT GAT TTA CCT CAA ACT CAT TCT TTA GGT TCT CGT CGT ACT TTA ATG TTA
 TCC GTC GGC TGC GAC TTG CCC CAG ACC CAC TCC TTG GGC TCC CGC CGC ACC TTG TTG
 TCA GTA GGA CTT CCA ACA TCA CTT GGA TCA CGA CGA ACA CTT CTT
 TCG GTG GGG CTC CCG ACG TCG CTC GGG TCG CGG CGG ACG CTC CTC
 AGT CTA AGT CTA AGT AGA AGA CTA CTA
 AGC CTG AGC CTG AGC AGG AGG CTG CTG

30

60

80

100

	110																			120	
	GLU	THR	LEU	LEU	ASP	LYS	PHE	TYR	THR	GLU	LEU	TYR	GLN	GLN	LEU	ASN	ASP	LEU	GLU	ALA	
	GAR	ACN	YTN	YTN	GAY	AAR	TTY	TAY	ACN	GAR	YTN	TAY	CAR	CAR	YTN	AAY	GAY	YTN	GAR	GCN	
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	
5	GAA	ACT	TTA	TTA	GAT	AAA	TTT	TAT	ACT	GAA	TTA	TAT	CAA	CAA	TTA	AAT	GAT	TTA	GAA	GCT	
	GAG	ACC	TTG	TTG	GAC	AAG	TTC	TAC	ACC	GAG	TTG	TAC	CAG	CAG	TTG	AAC	GAC	TTG	GAG	GCC	
	ACA	CTT	CTT						ACA	CTT					CTT		CTT		CTT	GCA	
	ACG	CTC	CTC						ACG	CTC					CTC		CTC		CTC	GCG	
	CTA	CTA								CTA					CTA		CTA		CTA		
10	CTG	CTG								CTG					CTG		CTG		CTG		
	130																			140	
	CYS	VAL	ILE	GLN	GLY	VAL	GLY	VAL	THR	GLU	THR	PRO	LEU	MET	LYS	GLU	ASP	SER	ILE	LEU	
	TGY	GTN	ATH	CAR	GGN	GTN	GGN	GTN	ACN	GAR	ACN	CCN	YTN	ATG	AAR	GAR	GAY	WSN	ATH	YTN	
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	
15	TGT	GTT	ATT	CAA	GGT	GTT	GGT	GTT	ACT	GAA	ACT	CCT	TTA	ATG	AAA	GAA	GAT	TCT	ATT	TTA	
	TGC	GTC	ATC	CAG	GGC	GTC	GGC	GTC	ACC	GAG	ACC	CCC	TTG		AAG	GAG	GAC	TCC	ATC	TTG	
	GTA	ATA			GGA	GTA	GGA	GTA	ACA	ACA	CCA	CTT						TCA	ATA	CTT	
	GTG				GGG	GTG	GGG	GTG	ACG	ACG	CCG	CTC						TCG		CTC	
20															CTA			AGT		CTA	
															CTG			AGC		CTG	
	150																			160	
	ALA	VAL	ARG	LYS	TYR	PHE	GLN	ARG	ILE	THR	LEU	TYR	LEU	LYS	GLU	LYS	LYS	TYR	SER	PRO	
	GCN	GTN	MGN	AAR	TAY	TTY	CAR	MGN	ATH	ACN	YTN	TAY	YTN	AAR	GAR	AAR	AAR	TAY	WSN	CCN	
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	
25	GCT	GTT	CGT	AAA	TAT	TTT	CAA	CGT	ATT	ACT	TTA	TAT	TTA	AAA	GAA	AAA	AAA	TAT	TCT	CCT	
	GCC	GTC	CGC	AAG	TAC	TTC	CAG	CGC	ATC	ACC	TTG	TAC	TTG	AAG	GAG	AAG	AAG	TAC	TCC	CCC	
	GCA	GTA	CGA					CGA	ATA	ACA	CTT		CTT					TCA	CCA		
30	GCG	GTG	CGG					CGG	ACG	CTC		CTC						TCG	CGG		
	AGA							AGA		CTA		CTA						AGT			
	AGG							AGG		CTG		CTG						AGC			

```

                                170                                180
CYS ALA TRP GLU VAL VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER THR ASN LEU
TGY GCN TGG GAR GTN GTN MGN GCN GAR ATH ATG MGN WSN TTY WSN YTN WSN ACN AAY YTN
-----
5  TGT GCT TGG GAA GTT GTT CGT GCT GAA ATT ATG CGT TCT TTT TCT TTA TCT ACT AAT TTA
TGC GCC      GAG GTC GTC CGC GCC GAG ATC      CGC TCC TTC TCC TTG TCC ACC AAC TTG
      GCA      GTA GTA CGA GCA      ATA      CGA TCA      TCA CTT TCA ACA      CTT
      GCG      GTG GTG CGG GCG      CGG TCG      TCG CTC TCG ACG      CTC
                                AGA                                AGA AGT      AGT CTA AGT      CTA
10                                AGG                                AGG AGC      AGC CTG AGC      CTG

GLN GLU SER LEU ARG SER LYS GLU ***
CAR GAR WSN YTN MGN WSN AAR GAR TRR
15  ---
CAA GAA TCT TTA CGT TCT AAA GAA TAA
CAG GAG TCC TTG CGC TCC AAG GAG TAG
      TCA CTT CGA TCA      TGA
      TCG CTC CGG TCG
20  AGT CTA AGA AGT
      AGC CTG AGG AGC

```

Delivery and expression of nucleic acids in many formulations is limited due to degradation of the nucleic acids by components of organisms, such as nucleases. Thus, protection of the nucleic acids when delivered *in vivo* can greatly enhance the resulting expression, thereby enhancing a desired pharmacological or therapeutic effect. It was found that certain types of compounds which interact with a nucleic acid (e.g., DNA) in solution but do not condense the nucleic acid provide *in vivo* protection to the nucleic acid, and correspondingly enhance the expression of an encoded gene product.

We have described the use of delivery systems designed to interact with plasmids and protect plasmids from rapid extracellular nuclease degradation [Mumper, R.J., et al.,

1996, *Pharm. Res.* 13:701-709; Mumper, R.J., et al., 1997. Submitted to *Gene Therapy*]. A characteristic of the PINC systems is that they are non-condensing systems that allow the plasmid to maintain flexibility and diffuse freely throughout the muscle while being protected from nuclease degradation. While the PINC systems are primarily discussed below, it will be understood that cationic lipid based systems and systems utilizing both PINCS and cationic lipids are also within the scope of the present invention.

A common structural component of the PINC systems is that they are amphiphilic molecules, having both a hydrophilic and a hydrophobic portion. The hydrophilic portion of the PINC is meant to interact with plasmids by hydrogen bonding (via hydrogen bond acceptor or donor groups), Van der Waals interactions, or/and by ionic interactions. For example, PVP and N-methyl-2-pyrrolidone (NM2P) are hydrogen bond acceptors while PVA and PG are hydrogen bond donors.

All four molecules have been reported to form complexes with various (poly)anionic molecules [Buhler V., BASF Aktiengesellschaft Feinchemie, Ludwigshafen, pp 39-42; Galaev Y, et al., *J. Chrom. A.* 684:45-54 (1994); Tarantino R, et al. *J. Pharm. Sci.* 83:1213-1216 (1994); Zia, H., et al., *Pharm. Res.* 8:502-504 (1991);]. The hydrophobic portion of the PINC systems is designed to result in a coating on the plasmid rendering its surface more hydrophobic. Kabanov et al. have described previously the use of cationic polyvinyl derivatives for plasmid condensation designed to increase plasmid hydrophobicity, protect plasmid from nuclease degradation, and increase its affinity for biological membranes [Kabanov, A.V., and Kabanov, V.A., 1995, *Bioconj. Chem.* 6:7-20; Kabanov, A.V., et al., 1991, *Biopolymers* 31:1437-1443; Yaroslavov, A.A., et al., 1996, *FEBS Letters* 384:177-180].

Substantial protective effect is observed; up to at least a one log enhancement of gene expression in rat muscle

over plasmid formulated in saline has been demonstrated with these exemplary PINC systems. We have also found that the expression of reporter genes in muscle using plasmids complexed with the PINC systems was more reproducible than when the plasmid was formulated in saline. For example, the coefficient of variation for reporter gene expression in muscle using plasmid formulated in saline was $96 \pm 35\%$ ($n = 20$ studies; 8-12 muscles/study) whereas with coefficient of variation with plasmids complexed with PINC systems was $40 \pm 19\%$ ($n = 30$ studies; 8-12 muscles/study). The high coefficient of variation for reporter gene expression with plasmid formulated in saline has been described previously [Davis, H.L., et al., 1993, *Hum. Gene Ther.* 4:151-9]. In addition, in contrast with the results for DNA:saline, there was no significant difference in gene expression in muscle when plasmid with different topologies were complexed with polyvinyl pyrrolidone (PVP). This suggests that PVP is able to protect all forms of the plasmid from rapid nuclease degradation.

1. Summary of interactions between a PINC polymer (PVP) and plasmid

We have demonstrated using molecular modeling that an exemplary PINC polymer, PVP, forms hydrogen bonds with the base pairs of a plasmid within its major groove and results in a hydrophobic surface on the plasmid due to the vinyl backbone of PVP. These interactions are supported by the modulation of plasmid zeta potential by PVP as well as by the inhibition of ethidium bromide intercalation into complexed plasmid. We have correlated apparent binding between PVP and plasmid to pH and salt concentration and have demonstrated the effect of these parameters on β -gal expression after intramuscular injection of plasmid/PVP complexes [Mumper, R.J., et al., 1997. Submitted to *Gene Therapy*]. A summary of the physico-chemical properties of plasmid/PVP complexes is listed in Table I below.

Table I: Summary of the Physico-Chemical Properties of Plasmid/PVP Complexes

Method	Result
Molecular modeling	Hydrogen bonding and
Fourier-transformed	hydrophobic plasmid surface
Infra-red Hydrogen	observed bonding demonstrated
DNase I challenge	Decreased rate of plasmid degradation in the presence of PVP
Microtitration	Positive heats of reaction
Calorimetry	indicative of an endothermic process
Potentiometric titration	One unit pH drop when plasmid and PVP are complexed
Dynamic Dialysis	Rate of diffusion of PVP reduced in the presence of plasmid
Zeta potential modulation	Surface charge of plasmid decreased by PVP
Ethidium bromide	Ethidium bromide
Intercalation	intercalation reduced by plasmid/PVP complexation
Osmotic pressure	Hyper-osmotic formulation (i.e., 340 mOsm/kg H ₂ O)
Luminescence	Plasmid/PVP binding decreased
Spectroscopy	in salt and/or at pH 7

5 2. Histology of expression in muscle

Immunohistochemistry for β -gal using a slide scanning technology has revealed the uniform distribution of β -gal expression sites across the whole cross-sections of rat tibialis muscles. Very localized areas were stained positive for β -gal when CMV- β -gal plasmid was formulated in saline. β -gal positive cells were observed exclusively around the needle tract when plasmid was injected in saline. This is

in agreement with previously published results [Wolff, J.A., et al., 1990, *Science* 247:1465-68; Davis, H.L., et al., 1993, *Hum. Gene Ther.* 4:151-9; Davis, H.L., et al., 1993, *Hum. Gene Ther.* 4:733-40].

5 In comparison, immunoreactivity for β -gal was observed in a wide area of muscle tissue after intramuscular injection of CMV- β -gal plasmid/PVP complex (1:17 w/w) in 150 mM NaCl. It appeared that the majority of positive muscle fibers were located at the edge of muscle bundles. Thus, 10 staining for β -gal in rat muscle demonstrated that, using a plasmid/PVP complex, the number of muscle fibers stained positive for β -gal was approximately 8-fold greater than found using a saline formulation. Positively stained muscle fibers were also observed over a much larger area in 15 the muscle tissue using the plasmid/PVP complex providing evidence that the injected plasmid was widely dispersed after intramuscular injection.

We conclude that the enhanced plasmid distribution and expression in rat skeletal muscle was a result of both 20 protection from extracellular nuclease degradation due to complexation and hyper-osmotic effects of the plasmid/PVP complex. However, Dowty and Wolff et al. have demonstrated that osmolarity, up to twice physiologic osmolarity, did not significantly effect gene expression in muscle [Dowty, M.E., 25 and Wolff, J.A. In: J.A. Wolff (Ed.), 1994, *Gene Therapeutics: Methods and Applications of Direct Gene Transfer*. Birkhauser, Boston, pp. 82-98]. This suggests that the enhanced expression of plasmid due to PVP complexation is most likely due to nuclease protection and 30 less to osmotic effects. Further, the surface modification of plasmids by PVP (e.g., increased hydrophobicity and decreased negative surface charge) may also facilitate the uptake of plasmids by muscle cells.

3. Structure-activity relationship of PINC polymers

We have found a linear relationship between the structure of a series of co-polymers of vinyl pyrrolidone and vinyl acetate and the levels of gene expression in rat muscle. We have found that the substitution of some vinyl pyrrolidone monomers with vinyl acetate monomers in PVP resulted in a co-polymer with reduced ability to form hydrogen bonds with plasmids. The reduced interaction subsequently led to decreased levels of gene expression in rat muscle after intramuscular injection. The expression of β -gal decreased linearly ($R = 0.97$) as the extent of vinyl pyrrolidone monomer (VPM) content in the co-polymers decreased.

These data demonstrate that pH and viscosity are not the most important parameters effecting delivery of plasmid to muscle cells since these values were equivalent for all complexes. These data suggest that enhanced binding of the PINC polymers to plasmid results in increased protection and bioavailability of plasmid in muscle.

4. Additional PINC systems

The structure-activity relationship described above can be used to design novel co-polymers that will also have enhanced interaction with plasmids. It is expected that there is "an interactive window of opportunity" whereby enhanced binding affinity of the PINC systems will result in a further enhancement of gene expression after their intramuscular injection due to more extensive protection of plasmids from nuclease degradation. It is expected that there will be an optimal interaction beyond which either condensation of plasmids will occur or "triplex" type formation, either of which can result in decreased bioavailability in muscle and consequently reduced gene expression.

As indicated above, the PINC compounds are generally amphiphilic compounds having both a hydrophobic portion and a hydrophilic portion. In many cases the hydrophilic portion is provided by a polar group. It is recognized in the art that such polar groups can be provided by groups such as, but not limited to, pyrrolidone, alcohol, acetate, amine or heterocyclic groups such as those shown on pp. 2-73 and 2-74 of CRC Handbook of Chemistry and Physics (72nd Edition), David R. Lide, editor, including pyrroles, pyrazoles, imidazoles, triazoles, dithiols, oxazoles, (iso)thiazoles, oxadiazoles, oxatriazoles, diaoxazoles, oxathioles, pyrones, dioxins, pyridines, pyridazines, pyrimidines, pyrazines, piperazines, (iso)oxazines, indoles, indazoles, carpazoles, and purines and derivatives of these groups, hereby incorporated by reference.

Compounds also contain hydrophobic groups which, in the case of a polymer, are typically contained in the backbone of the molecule, but which may also be part of a non-polymeric molecule. Examples of such hydrophobic backbone groups include, but are not limited to, vinyls, ethyls, acrylates, acrylamides, esters, celluloses, amides, hydrides, ethers, carbonates, phosphazenes, sulfones, propylenes, and derivatives of these groups. The polarity characteristics of various groups are quite well known to those skilled in the art as illustrated, for example, by discussions of polarity in any introductory organic chemistry textbook.

The ability of such molecules to interact with nucleic acids is also understood by those skilled in the art, and can be predicted by the use of computer programs which model such intermolecular interactions. Alternatively or in addition to such modeling, effective compounds can readily be identified using one or more of such tests as 1) determination of inhibition of the rate of nuclease digestion, 2) alteration of the zeta potential of the DNA, which indicates coating of DNA, 3) or inhibition of the

ability of intercalating agents, such as ethidium bromide to intercalate with DNA.

5. Targeting Ligands

In addition to the nucleic acid/PINC complexes described above for delivery and expression of nucleic acid sequences, in particular embodiments it is also useful to provide a targeting ligand in order to preferentially obtain expression in particular tissues, cells, or cellular regions or compartments.

Such a targeted PINC complex includes a PINC system (monomeric or polymeric PINC compound) complexed to plasmid (or other nucleic acid molecule). The PINC system is covalently or non-covalently attached to (bound to) a targeting ligand (TL) which binds to receptors having an affinity for the ligand. Such receptors may be on the surface or within compartments of a cell. Such targeting provides enhanced uptake or intracellular trafficking of the nucleic acid.

The targeting ligand may include, but is not limited to, galactosyl residues, fucosal residues, mannosyl residues, carnitine derivatives, monoclonal antibodies, polyclonal antibodies, peptide ligands, and DNA-binding proteins. Examples of cells which may usefully be targeted include, but are not limited to, antigen-presenting cells, hepatocytes, myocytes, epithelial cells, endothelial cells, and cancer cells.

Formation of such a targeted complex is illustrated by the following example of covalently attached targeting ligand (TL) to PINC system:

TL-PINC + Plasmid -----> TL-PINC:::Plasmid

Formation of such a targeted complex is also illustrated by the following example of non-covalently attached targeting ligand (TL) to PINC system

TL:::PINC + Plasmid -----> TL:::PINC:::Plasmid

or alternatively,

PINC + Plasmid -----> PINC::::::::::Plasmid + TL ---
 -----> TL::::::::::PINC::::::::::Plasmid

In these examples :::::::::: is non-covalent interaction such as ionic, hydrogen-bonding, Van der Waals interaction, hydrophobic interaction, or combinations of such interactions.

A targeting method for cytotoxic agents is described in Subramanian et al., International Application No. PCT/US96/08852, International Publication No. WO 96/39124, hereby incorporated by reference. This application describes the use of polymer affinity systems for targeting cytotoxic materials using a two-step targeting method involving zip polymers, i.e., pairs of interacting polymers. An antibody attached to one of the interacting polymers binds to a cellular target. That polymer then acts as a target for a second polymer attached to a cytotoxic agent. As referenced in Subramanian et al., other two-step (or multi-step) systems for delivery of toxic agents are also described.

In another aspect, nucleic acid coding sequences can be delivered and expressed using a two-step targeting approach involving a non-natural target for a PINC system or PINC-targeting ligand complex. Thus, for example, a PINC-plasmid complex can target a binding pair member which is itself attached to a ligand which binds to a cellular target (e.g., a MAB). Binding pairs for certain of the compounds identified herein as PINC compounds as identified in Subramanian et al. Alternatively, the PINC can be complexed to a targeting ligand, such as an antibody. That antibody can be targeted to a non-natural target which binds to, for example, a second antibody.

III. Model Systems for Evaluation of Interferon Alpha Constructs and Formulations

In accord with the concept of using interferon alpha expressing plasmid constructs and formulations in anti-

cancer treatment, murine model systems were utilized based on murine tumor cell lines. The line primarily used was S.C. VII/SF, which is a cell line derived from murine squamous cell carcinoma (S.C.).

5 Squamous cell carcinoma of the head and neck begins with the cells lining the oral and pharyngeal cavities. Clinical disease progresses via infiltration and spreads into the underlying tissues and lymphatics. The undifferentiated, *in vivo* passage tumor line S.C. VII/SF
10 displays this typical growth pattern. In addition, its rapid growth rate provides a relatively short test period for individual experiments. Other murine tumor cell lines include another SCC line KLN-205, a keratinocyte line I-7, and a colon adenocarcinoma line MC-38.

15 An optimal model system preferably satisfies the criteria based on having tumor growth rate *in vivo* (i.e., tumors are ready for treatment in 4-10 days post implant), invasiveness, and local spread similar to those observed in clinical disease, and providing accessibility for
20 experimental treatment. As indicated, the SCC VII/SF cell line was utilized as the primary model system cell line. This cell line typically grows rapidly, resulting in death of untreated syngeneic mice 14-17 days after tumor cell implantation.

25 This cell line can be utilized in a variety of ways to provide model system suitable for a variety of different tests. Four such possibilities are described below.

First, SCCVII cells can be utilized in cell culture to provide an *in vitro* evaluation of interferon alpha
30 expression construct and formulation characteristics, such as expression levels and cellular toxicities.

Second, the cells can be implanted subcutaneously in mice. This system can be utilized in tests in which accessibility of the implant site is beneficial. As an
35 example, the method was utilized in evaluations of

expression efficiencies based on the expression of chloramphenicol acetyltransferase (CAT).

Third, the cells can be implanted transcutaneously into the fascia of digastric muscle.

5 Fourth, the cells can be implanted transcutaneously into digastric/mylohyoid muscles. The important features of models 3 and 4 are shown in the table below.

TABLE II: Comparison of submandibular tumor models

Feature	Mouse Tumor Model 3	Mouse Tumor Model 4
Tumor implant procedure	2-4 x 10 ⁵ cells transcutaneously into fascia of digastric muscle	5 x 10 ⁵ transcutaneously into digastric/mylohyoid muscles
Tumor growth and invasiveness characteristics	Prominent submandibular bulge; invasion of digastric/mylohyoid muscles and lymphatics	More variable, invasion of digastric/mylohyoid muscles and lymphatics
Treatment procedure (primary treatment)	Transcutaneous, needle inserted and moved within tumor to produce a 4 quadrant distribution of gene medicine	Lower jaw skin flap raised to expose tumor, needle inserted and moved within tumor to produce a 4 quadrant distribution of gene medicine
Days treated (post-implant)	Day 5, day 10 (both transcutaneously)	Day 5 (tumor exposed), day 8 (transcutaneously)
Measurement procedure	External calipering 2-3 x per week until death	First caliper when tumor exposed for treatment, second caliper at sacrifice

Feature	Mouse Tumor Model 3	Mouse Tumor Model 4
Advantages	Non-surgical, closed model allows larger experiments and more frequent treatments; Sacrifice unnecessary to caliper (=more time points)	Surgical, open model allows direct treatment of exposed tumor; Local inflammation from surgery may additionally stimulate immune response; More like clinical situation for protocol development
Disadvantages	Transcutaneous treatment is potentially less accurate and intensive; less like expected clinical treatments than surgical approaches	Labor intensive; Smaller, fewer experiments possible; Tumors deeper and more difficult to treat transcutaneously (for secondary treatments); Fewer treatments and caliperings possible

The tumor size treated in the mouse models is generally 20-50 mm³. A 50 mm³ mouse tumor is approximately equivalent to 150 cc³ human tumor having an average diameter of about 6.6 cm. This tumor size is approximately 10-fold larger than the size proposed to be treated in the phase I clinical trials. This indicates that the mouse models are strongly biased towards over estimating the expected tumor burden in human patients.

IV. Formulations for In Vivo Delivery

10 A. General

While expression systems such as those described above provide the potential for expression when delivered to an appropriate location, it is beneficial to provide the expression system construct(s) in a delivery system which

can assist both the delivery and the cellular uptake of the construct. Thus, this invention also provides particular formulations which include one or more expression system constructs (e.g., DNA plasmids as described above), and a
5 protective, interactive non-condensing compound.

An additional significant factor relating to the plasmid construct is the percentage of plasmids which are in a supercoiled (SC) form rather than the open circular (OC) form.

10 B. Delivery and Expression

A variety of delivery methods can be used with the constructs and formulations described above, in particular, delivery by injection to the site of a tumor can be used. The submandibular tumor models utilized injection into four
15 quadrants of the tumor being treated.

C. Anti-Cancer Efficacy of Human Interferon Alpha Formulations

The effects of the administration of the interferon alpha formulations described above were evaluated using the
20 S.C. VII mouse tumor models. Plasmid constructs as described above were incorporated in delivery formulations. The formulations were delivered by injection.

D. Synergistic Effects of Interferon Alpha plasmid and IL-12 Plasmid and Effect of Human Interferon Alpha Formulation Administration on Production of Secondary Cytokines
25

The effects of the expression of the human interferon alpha plasmids in tumor cells on the progress of the mouse tumors demonstrates that such interferon alpha expression is
30 effective against such tumors. However, it was also shown that IL-12 can act synergistically with the interferon alpha expression to exercise the antitumor effect (see Figure 9).

E. Toxicity Evaluation of Exemplary Formulations

The exemplary formulations do not show high cellular toxicity at the concentrations tested, suggesting that the formulations do not significantly kill cells by direct toxic
5 action *in vivo*. Moreover, the anti-tumor activity induced by IFN α gene therapy is dependent upon activation of the immune system, which is demonstrated by depletion studies *in vivo*. Removal of a specific T lymphocyte population (CD8⁺) abrogates the anti-tumor activity elicited by IFN α gene
10 therapy.

V. Administration

Administration as used herein refers to the route of introduction of a plasmid or carrier of DNA into the body. In addition to the methods of delivery described above, the
15 expression systems constructs and the delivery system formulations can be administered by a variety of different methods.

Administration can be directly to a target tissue or by targeted delivery to the target tissue after systemic
20 administration. In particular, the present invention can be used for treating disease by administration of the expression system or formulation to the body in order to establishing controlled expression of any specific nucleic acid sequence within tissues at certain levels that are
25 useful for gene therapy.

The preferred means for administration of vector (plasmid) and use of formulations for delivery are described above. The preferred embodiments are by direct injection using needle injection.

30 The route of administration of any selected vector construct will depend on the particular use for the expression vectors. In general, a specific formulation for each vector construct used will focus on vector uptake with regard to the particular targeted tissue, followed by
35 demonstration of efficacy. Uptake studies will include

uptake assays to evaluate cellular uptake of the vectors and expression of the DNA of choice. Such assays will also determine the localization of the target DNA after uptake, and establishing the requirements for maintenance of steady-state concentrations of expressed protein. Efficacy and cytotoxicity can then be tested. Toxicity will not only include cell viability but also cell function.

Muscle cells have the unique ability to take up DNA from the extracellular space after simple injection of DNA particles as a solution, suspension, or colloid into the muscle. Expression of DNA by this method can be sustained for several months.

Delivery of formulated DNA vectors involves incorporating DNA into macromolecular complexes that undergo endocytosis by the target cell. Such complexes may include lipids, proteins, carbohydrates, synthetic organic compounds, or inorganic compounds. Preferably, the complex includes DNA, a cationic lipid, and a neutral lipid in particular proportions. The characteristics of the complex formed with the vector (size, charge, surface characteristics, composition) determines the bioavailability of the vector within the body. Other elements of the formulation function as ligand which interact with specific receptors on the surface or interior of the cell. Other elements of the formulation function to enhance entry into the cell, release from the endosome, and entry into the nucleus.

Delivery can also be through use of DNA transporters. DNA transporters refers to molecules which bind to DNA vectors and are capable of being taken up by epidermal cells. DNA transporters contain a molecular complex capable of noncovalently binding to DNA and efficiently transporting the DNA through the cell membrane. It is preferable that the transporter also transport the DNA through the nuclear membrane. See, e.g., the following applications all of which (including drawings) are hereby incorporated by reference herein: (1) Woo et al., U.S. Serial No.

07/855,389, entitled "A DNA Transporter System and Method of Use,, filed March 20, 1992, now abandoned; (2) Woo et al., PCT/US93/02725, International Publ. WO93/18759, entitled "A DNA Transporter System and Method of Use", (designating the U.S. and other countries) filed March 19, 1993; (3) continuation-in-part application by Woo et al., entitled "Nucleic Acid Transporter Systems and Methods of Use", filed December 14, 1993, U.S. Serial No. 08/167,641; (4) Szoka et al., U.S. Serial No. 07/913,669, entitled "Self-Assembling Polynucleotide Delivery System", filed July 14, 1992 and (5) Szoka et al., PCT/US93/03406, International Publ. WO93/19768 entitled "Self-Assembling Polynucleotide Delivery System", (designating the U.S. and other countries) filed April 5, 1993. A DNA transporter system can consist of particles containing several elements that are independently and non-covalently bound to DNA. Each element consists of a ligand which recognizes specific receptors or other functional groups such as a protein complexed with a cationic group that binds to DNA. Examples of cations which may be used are spermine, spermine derivatives, histone, cationic peptides and/or polylysine. One element is capable of binding both to the DNA vector and to a cell surface receptor on the target cell. Examples of such elements are organic compounds which interact with the asialoglycoprotein receptor, the folate receptor, the mannose-6-phosphate receptor, or the carnitine receptor. A second element is capable of binding both to the DNA vector and to a receptor on the nuclear membrane. The nuclear ligand is capable of recognizing and transporting a transporter system through a nuclear membrane. An example of such ligand is the nuclear targeting sequence from SV40 large T antigen or histone. A third element is capable of binding to both the DNA vector and to elements which induce episomal lysis. Examples include inactivated virus particles such as adenovirus, peptides related to influenza virus hemagglutinin, or the GALA peptide described in the Szoka patent cited above.

Transfer of genes directly into a tumor has been very effective. Experiments show that administration by direct injection of DNA into tumor cells results in expression of the gene in the area of injection. Injection of plasmids containing human interferon alpha results in expression of the gene for 5 days following a single intra-tumoral injection. Human IFN α production was highest in tumors harvested 1 day post-tumor injection and steadily declined thereafter. The injected DNA appears to persist in an unintegrated extrachromosomal state. This means of transfer is a preferred embodiment.

Administration may also involve lipids as described in preferred embodiments above. The lipids may form liposomes which are hollow spherical vesicles composed of lipids arranged in unilamellar, bilamellar, or multilamellar fashion and an internal aqueous space for entrapping water soluble compounds, such as DNA, ranging in size from 0.05 to several microns in diameter. Lipids may be useful without forming liposomes. Specific examples include the use of cationic lipids and complexes containing DOPE which interact with DNA and with the membrane of the target cell to facilitate entry of DNA into the cell.

Gene delivery can also be performed by transplanting genetically engineered cells. For example, immature muscle cells called myoblasts may be used to carry genes into the muscle fibers. Myoblast genetically engineered to express recombinant human growth hormone can secrete the growth hormone into the animal's blood. Secretion of the incorporated gene can be sustained over periods up to 3 months.

Myoblasts eventually differentiate and fuse to existing muscle tissue. Because the cell is incorporated into an existing structure, it is not just tolerated but nurtured. Myoblasts can easily be obtained by taking muscle tissue from an individual who needs gene therapy and the genetically engineered cells can also be easily put back with out causing damage to the patient's muscle. Similarly,

keratinocytes may be used to delivery genes to tissues. Large numbers of keratinocytes can be generated by cultivation of a small biopsy. The cultures can be prepared as stratified sheets and when grafted to humans, generate
5 epidermis which continues to improve in histotypic quality over many years. The keratinocytes are genetically engineered while in culture by transfecting the keratinocytes with the appropriate vector. Although keratinocytes are separated from the circulation by the
10 basement membrane dividing the epidermis from the dermis, human keratinocytes secrete into circulation the protein produced.

The chosen method of delivery should result in expression of the gene product encoded within the nucleic
15 acid cassette at levels which exert an appropriate biological effect. The rate of expression will depend upon the disease, the pharmacokinetics of the vector and gene product, and the route of administration, but should be in the range 0.001-100 mg/kg of body weight /day, and
20 preferably 0.01-10 mg/kg of body weight/day. This level is readily determinable by standard methods. It could be more or less depending on the optimal dosing. The duration of treatment will extend through the course of the disease symptoms, possibly continuously. The number of doses will
25 depend upon the disease, delivery vehicle, and efficacy data from clinical trials.

Examples

The present invention will be more fully described in conjunction with the following specific examples which are
30 not to be construed in any way as limiting the scope of the invention. As shown below, mIFN- gene medicine reduces the growth of tumors in syngeneic murine tumor models. Lipid formulations of mIFN- gene medicine display anti tumor activity in both SCC-VII and MC-38 tumor models. PINC and
35 peptide formulations of mIFN- gene medicine display anti

tumor effects in the MC-38 tumor model. The anti tumor effects of mIFN- gene medicine are dose dependent. In addition, the examples demonstrate that treatment of tumors with the combination of IFN α and IL-12 gives an unanticipated more than additive (synergistic) anti-tumor activity using either a PINC or a lipid formulation.

Example 1

A plasmid expression system encoding murine IFN α 4 and formulated in a polymeric delivery system was used for in vivo immunotherapeutic activity against an immunogenic murine renal cell carcinoma, Renca, and a non-immunogenic mammary adenocarcinoma, TS/A. Mice bearing established tumors were treated with IFN α /polyvinyl-pyrrolidone (PVP) expression complexes via direct intra-tumoral injection. Up to 100 % tumor growth inhibition was observed in the treated mice. By using an optimal dose of 96 and 48 μ g of formulated IFN- α plasmid for the treatment of Renca and TS/A respectively, 30% (Renca) and 10% (TS/A) of the treated animals remained tumor-free. Tumor inhibition was dependent upon activation of the immune system. The anti-tumor activity elicited by IFN- α gene therapy was abrogated when mice were selectively depleted of CD8 $^{+}$ T cells. By contrast, removal of CD4 $^{+}$ resulted in increased tumor rejection following IFN- α /PVP treatments. Finally, mice that remained tumor-free following IFN- α gene therapy displayed immune resistance to a subsequent challenge of tumor. These data provide evidence that non-viral IFN α gene therapy can be used to induce an efficient anti-tumor response.

Local presence of cytokines in tumors can activate an immune response that in some cases leads to induction of specific long-lasting anti-tumor immunity. By direct intra-tumoral injection of plasmid encoding murine IFN α 4 and formulated in a polymeric delivery system, tumor-bearing mice develop an immune response, which leads to inhibition and eradication of the tumor. We have shown by depletion

studies in vivo that the immune response induced by IFN α is mainly CD8-mediated and that this treatment results in a long-term immunity in mice demonstrating complete tumor regression. Thus, non-viral IFN α gene therapy may be an effective alternative to IFN α protein therapy for human cancers.

Transduction of tumor cells with cytokine genes has proven to be a very efficient technique to induce cytokine-mediated anti-tumor immunity. In experimental models, the local presence of IL-2, IL-1, IL-4, IL-6, IL-7, IL-12, IFNs and CSFs (i.e., GM-CSF) at the site of the tumor can result in significant tumor growth inhibition (Colombo et al., "Local Cytokine Availability Elicits Tumor Rejection and Systemic Immunity Through Granulocyte-T-Lymphocyte Cross-Talk", Cancer Research, 52, 4853-4857 (1992)). In these systems, cytokines have limited effect on tumor proliferation directly but are capable of activating a rapid and potent anti-tumor immune response, which impedes tumor progression. Established parental tumors, however, are difficult to eradicate with ex vivo cytokine-transduced tumor cells because efficacy of vaccination is highly dependent on the size, growth rate and invasiveness of the tumor.

To overcome these problems, cytokine-based gene therapy approaches, which can deliver transgenic cytokines locally and induce an anti-tumor immune response, have been recently evaluated by a number of investigators (Forni et al., "Cytokine-Induced Immunogenicity: From Exogenous Cytokines to Gene Therapy", Journal of Immunotherapy, 14, 253-257, (1993); Pericle et al., "An Efficient Th2-type Memory Follows Cd8+ Lymphocyte-driven and Eosinophil-mediated Rejection of a Spontaneous Mouse Mammary Adenocarcinoma Engineered to Release Il-4", The Journal of Immunology, 153, 5660-5673. (1994); Pardoll et al., "Gene Modified Tumor Vaccines, In Cytokine-Induced Tumor Immunogenicity", eds. Academic Press, London, p. 71-86. (1994); and Musiani et

- al., "Cytokines, Tumor-cell Death and Immunogenicity: A Question of Choice", Immunology Today. 1, 32-36 (1997)). Technological breakthroughs in gene therapy using adenoviral, retroviral, and liposomal vectors have provided
- 5 powerful tools with which to study the biological effects of specific cytokine mediators as well as to develop novel and clinically applicable anti-tumor immunotherapies (Pardoll, "Paracrine Cytokine Adjuvants in Cancer Immunotherapy", Annu. Rev. Immunol. 13, 399-415 (1995); Bramson et al.,
- 10 "Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12", Hum. Gene Ther., 7, 1995-2002 (1996); Rao et al., "Il-12 Is an Effective Adjuvant to Recombinant
- 15 Vaccinia Virus-based Tumor Vaccines", J. Immunol. 156, 3357-3365. 1996; Rakhmilevich et al., "Gene Gun-mediated Skin Transfection with Interleukin 12 Gene Results in Regression of Established Primary and Metastatic Murine Tumors", Proc. Natl. Acad. Sci. USA. 93, 6291-6296 (1996);
- 20 and Rakhmilevich et al., "Cytokine Gene Therapy of Cancer Using Gene Gun Technology: Superior Antitumor Activity of Interleukin-12", Hum. Gene Ther. 8, 1303-1311, (1997)).

A gene therapy approach utilizing an interactive polymeric gene delivery system that increases protein

25 expression by protecting plasmid DNA (pDNA) from nucleases and controlling the dispersion and retention of pDNA in muscle cells is described in Mumper et al., 1996. These polymeric interactive non-condensing (PINC) systems routinely result in a greater amount of gene expression from

30 tissues as compared to delivery of unformulated plasmid in saline (Mumper et al., 1996). By using a plasmid that encodes human insulin growth factor-1 (hIGF-1) and formulated as a PINC complex, production of biologically active h IGF-1 in vivo following intra-muscular injection

35 has been shown (Alila et al., "Expression of Biologically Active Human Insulin-Like Growth Factor-1 Following

Intramuscular Injection of a Formulated Plasmid in Rats", Human Gene Therapy, 8, 1785-1795 (1997)). The specific objective of this study was to determine whether a plasmid expression system encoding murine IFN α 4 and formulated as a complex with PVP could induce an anti-tumor immune response following direct injection into subcutaneous murine tumors.

The IFN family consists of three major glycoproteins, IFN α , IFN β and IFN γ . Although IFNs were first developed as antiviral agents, it is now clear that they also control cell growth and differentiation, and modulate various aspects of host immunity (Gresser et al., "Antitumor effects of interferon", Acta Oncol. 28, 347-353 (1989)). Clinical data concluded that systemic chronic administration of IFN α could produce regression of vascular tumors, including Kaposi's sarcoma, pulmonary hemangiomatosis, and hemangiomas (Singh et al., "Interferons A and B Down-regulate the Expression of Basic Fibroblast Growth Factor in Human Carcinomas", Proc. Natl. Acad. Sci. USA. 92, 4562-4566 (1995)). Although IFN α was the first cytokine to be used in clinical trials that proved to be effective against certain types of human cancer, only recently has this cytokine been considered as a candidate for gene therapy (Ogura et al. 1993, Belldegrun et al., "Human Renal Carcinoma Line Transfected With Interleukin-2 and/or Interferon α Gene(s): Implications for Live Cancer Vaccines, Journal of the National Cancer Institute, 85, 207-216 (1993)).

Initial studies have shown that the injection of genetically modified tumor cells producing IFN α into syngeneic mice induces tumor growth inhibition and elicits a tumor-specific immune memory (Ferrantini et al., Interferon Alpha-1-Interferon Gene Transfer into Metastatic Friend Lukemia Cells Abrogated Tumorigenicity in Immunocompetent Mice: Antitumor Therapy by Means of Interferon-Producing Cells; Cancer Res. 53, 1107-4615 (1993); Ferrantini et al., "Ifn- α 1 Gene Expression into a Metastatic Murine Adenocarcinoma (Ts/a) Results in Cd8+ T Cell-Mediated Tumor

Rejection and Development of Antitumor Immunity: Comparative Studies with Ifn- γ -producing Ts/a Cells" Journal of Immunology, 153, 4604-4615, (1994); Musiani et al. 1997). However, the real value of this potential form of vaccine in inducing the regression of established tumors remains to be demonstrated.

In this study we present evidence that direct injection of IFN α plasmid formulated in PVP into subcutaneous murine tumors results in a host-dependent tumor rejection, primarily mediated by CD8 $^{+}$ T cells, and elicits a protective immunity against subsequent tumor re-challenge.

Materials And Methods

Plasmid construction and formulation

A plasmid expression system containing an expression cassette for mIFN- α 4 was constructed as follows. The coding sequence of the murine IFN- α 4 gene (Genebank X01973 M15456 M23830 X01967) was amplified by PCR from mouse genomic DNA. The amplified mIFN- α 4 sequence was then subcloned into a plasmid backbone, and the sequence fidelity was verified by DNA sequence analysis (data not shown). The coding sequence for mIFN- α 4 was then subcloned as an XbaI-BamHI fragment into the expression plasmid pIL0697 to create the mIFN- α 4 expression system pIF0836. Plasmid pVC0612 (empty plasmid, EP) contains expression elements including the cytomegalovirus immediate early promoter and the 3' UTR/poly(A) signal from the bovine growth gene in the pVC0289 backbone described by Alila et al. (1997). Plasmid pVC0612 was used as a control plasmid in all in vivo experiments. Plasmids for intra-tumoral injection were grown under kanamycin selection in E. coli host strains DH5 α and purified using conventional alkaline lysis and chromatographic methods. Purified plasmid utilized for intra-tumoral injections had the following specifications: endotoxin (< 500 Eu/mg plasmid); protein (< 1%); and chromosomal DNA (< 20 %). Purified pIF0836 and control

plasmids were formulated at a concentration of 3 mg DNA/ml in a solution of 5 % w/v polyvinyl-pyrrolidone (Plasdone C-30, ISP Technologies, Wayne, NJ), 150 mM NaCl on the day of injection, as described previously (Mumper et al., 1996).

5 Western blot analysis and bioassay for mIFN α .

HeLa cells were plated in 6 well plates at 3×10^5 cells per well, and transfected using 1 μ g of mouse IFN α 4 plasmid pIF0836C and 3 μ g of Lipofectamine (Life Technologies, Inc., Gaithersburg, MD) in serum-free DMEM. Same supernatants
10 were harvested 24 hours later and immunoprecipitated using anti-mouse interferon α/β polyclonal antibody (BioSource International, Camarillo, CA) and protein A and G agarose (Boehringer Mannheim, Indianapolis, IN). Samples were run on a 12% Tris-glycine gel and electroblotted to Millipore
15 PVDF membrane. Anti-mouse interferon α/β polyclonal antibody was used at 1:1000, followed by anti-sheep Ig HRP (Boehringer Mannheim) at 1:1000. Biotinylated molecular weight markers were detected using Streptavidin-HRP (Amersham, Arlington Heights, IL). Detection was performed
20 using the Amersham ECL kit. Supernatants were also tested for IFN α biological activity using L929 cells treated with encephalomyocarditis virus, in parallel with a NIH mouse IFN α reference reagent (Access Biomedical, San Diego, CA).

Animals

25 Normal 8-week-old female BALB/c mice were purchased from Harlan Laboratories, Houston, TX. Mice were maintained on ad libitum rodent feed and water at 23° C, 40% humidity, and a 12-h/12-h light-dark cycle. Animals were acclimated for at least 4 days before the start of the study.

30 Tumors

Three established mouse tumor models were used in this study. TS/A is a tumor cell line established by Dr. P. Nanni, University of Bologna, Italy, from the first in vivo

transplant of a moderately differentiated mammary adenocarcinoma that spontaneously arose in a BALB/c mouse (Nanni et al., 1983). A number of pre-immunization-challenge experiments suggested that TS/A does not elicit a long-lasting anti-tumor immunity (Forni et al., 1987). TS/A was generously provided by Dr. Guido Forni, University of Turin, Italy. Renca, a spontaneously arising murine renal cell carcinoma, and CT-26, a colon adenocarcinoma, were generously provided by Dr. Drew M. Pardoll, John Hopkins Hospital, Baltimore, MD. Tumor cell cultures were maintained in sterile disposable flasks from Corning (Corning, NY) at 37° C in a humidified 5% CO₂ atmosphere, using RPMI 1640 supplemented with 10% FBS, 100 U/ml penicillin, 100 U/ml streptomycin and 50 µg/ml gentamycin; all from Life Technologies.

In vivo evaluation of tumor growth and treatments

BALB/c mice were challenged s.c. in the middle of the left flank with 30 µl of a single-cell suspension contained the specified number of cells. Seven days later when the tumor size reached approximately 10 mm³, treatments with IFNα/PVP or EP/PVP started and were repeated at 1-2 day intervals for 2 weeks (total of 8 treatments: 4/week). Tumor volume was measured with electronic caliper in the two perpendicular diameters and in the depth. Measurements of the tumor masses (mm³) were performed twice a week for 40-50 days. All mice bearing tumor masses exceeding 1 cm³ volume were sacrificed for humane reasons. When depletion of immunocompetent cells in vivo was required, a group of mice received i.v. 0.5 ml of α-CD4 (GK1.5 hybridoma, 207-TIB, ATCC, Rockville, MD) ascite (1:10), or α-CD8 (2.43 hybridoma, 210-TIB, ATCC) ascite (1:100) or i.p. 100 µg α-GR1 (RB6-8C5 hybridoma, Pharmingen, San Diego, CA). Control mice received i.v. 0.5 ml isotype control IgG (Pharmingen). Antibody treatments were performed twice: first injection 1 day before starting the gene therapy

treatment and the second injection (i.p at the same dosage) 7 days later.

CTL assay

A standard 6-hour ^{51}Cr -release assay was performed following 5 days of in vitro effector cell stimulation. Single cell suspensions of splenocytes were prepared 3 weeks following tumor challenge by mashing the spleens in RPMI 1640 medium (Life Technologies) and passing the cells through 70 μm nylon mesh cell strainers (Falcon, Becton Dickinson, Lincoln Park, NJ) into 50ml centrifuge tubes (Falcon). After centrifugation, red blood cells were lysed with ACK Lysing Buffer (Biofluids, Inc., Rockville, MD) and the splenocytes washed twice with RPMI. In vitro stimulation cultures contained 3×10^6 splenocytes/effectors per ml with 6×10^5 mitomycin-C-treated Renca/stimulator cells per ml and 10 Units per ml recombinant murine IL-2 (Genzyme, Cambridge, MA) in RPMI containing 10% FBS, 22mM HEPES buffer (Research Organics Inc., Cleveland OH), Penn-Streptomycin, 5×10^{-5} M 2- β -mercapto-ethanol (Life Technologies), OPI media supplement (Sigma, St. Louis, MO), and essential and non-essential amino acids (Life Technologies) (for a 5 : 1 responder : stimulator ratio). Stimulators were prepared by incubating Renca cells at 3×10^7 per ml in RPMI with 30 μg per ml mitomycin-C (Sigma) at 37 $^{\circ}$ C for 60 minutes, followed by four washes in HBSS with 2.5% FBS. After 5 days at 37 $^{\circ}$ C, effector cells were pelleted, resuspended in complete RPMI, counted, and mixed with ^{51}Cr -labeled targets in a 96 well V-bottomed plate (Costar/Corning, Cambridge, MA). Renca and CT26 targets were labeled by incubating them at 2×10^6 cells per ml in complete RPMI with 150 uCi ^{51}Cr (Amersham) for 2.5 hours. Targets were washed 3 times in HBSS with 2.5% FBS and resuspended in complete RPMI before addition to the assay. After mixing effectors and targets (in triplicate wells) and a brief pelleting, plates were placed at 37 $^{\circ}$ C for 6 hours.

Approximately 90% of the supernatants were then collected from each well with the Skatron Harvesting Press and Supernatant Collection System (Skatron Instruments, Norway). ^{51}Cr release was detected using a WALLAC 1470 Wizard automatic gamma counter (WALLAC Inc., Gaithersburg MD). Specific release was determined with the following equation: $(\text{experimental cpm} - \text{spontaneous cpm}) / (\text{total cpm} - \text{spontaneous cpm}) \times 100$. Spontaneous release from the targets was less than 18%, and the standard error of the triplicate experimental counts was less than 14%.

Statistical analysis

Data for the effects of mIFN- α gene therapy on tumor growth were analyzed by repeated measures analysis. Individual treatment means were compared using Duncan's multiple range test when the main effect was significant. Data for the effect of mIFN- α gene therapy on tumor rejection were analyzed by ANOVA. In all cases a p value of less than 0.05 was considered to be statistically significant.

20 Results

Expression of mIFN- α

Murine IFN- α expression plasmid (pIF0836) was transfected into Cos-1 cells, and the resulting conditioned media was assayed for mIFN- α by Western blot and by bioassay. Western blot analysis of conditioned media indicated that the recombinant mIFN- α expressed from pIF0836 template was present as a single band with an approximate molecular weight of 23 kDa. This band was not observed in conditioned media from mock-transfected cells and likely represents a glycosylated form of mIFN- α . Recombinant mIFN- α ran with an approximate molecular weight of 18 kDa, which corresponds to the predicted molecular weight of non-glycosylated mIFN- α . Assay of conditioned media using an

anti-viral bioassay for mIFN- α indicated that approximately 175×10^3 IU/ml mIFN- α were present.

Anti-tumor activity of IFN- α gene therapy. The anti-tumor effect of murine IFN α 4 plasmid formulated as a complex with PVP (IFN α /PVP) was tested in a syngeneic murine renal cell carcinoma (Renca) and a mammary adenocarcinoma (TS/A) tumor model. BALB/c mice were challenged subcutaneously with 7×10^5 Renca or 1×10^5 CT26 cells, and IFN α /PVP injections were initiated 7 days later when tumors reached approximately 10 mm³ size. Each group of mice received at interval of 1-2 days 8 treatments (4 injections/week) of IFN α /PVP at scalar doses (from 12 to 96 μ g/mouse), EP/PVP (96 μ g/mouse) or no treatments for control (ctrl). Tumor size increased progressively in mice injected with EP/PVP (Renca, TS/A) or low doses of IFN α /PVP (TS/A), while tumors in mice injected with each dose of IFN α /PVP (Renca) or high dose of IFN α /PVP (TS/A) showed marked growth inhibition.

Tumor growth inhibition is associated to systemic immune response

Treatments of Renca and TS/A tumors with IFN α /PVP at 96 μ g/mouse and 48 μ g/mouse respectively, induced complete regression in 6 out of 20 (Renca) and 2 out of 20 (TS/A) of challenged mice. To test whether the rejection of these tumors leads to specific immune memory, mice with no tumors for 40-50 days following IFN α treatments were re-challenged with a greater number of fresh tumors in the right flank. All mice that rejected primary tumors displayed protection against the second tumor challenge whereas mice used as the control group and injected for the first time with same number of tumor cells (1×10^6 Renca or 2×10^5 TS/A) developed tumors.

To evaluate the requirements for the induction of anti-tumor immune memory, Renca and TS/A were injected into BALB/c rendered immunosuppressed by treatment with anti-CD4, anti-CD8 or anti-polymorphonuclear cells (PMN). Depletion

- of CD8⁺ T cells allowed both Renca and TS/A to grow in all animals following IFN α /PVP treatments, showing that this population is crucial for the immune response induced by IFN α gene therapy. No increase in tumor growth was found in mice treated with anti-PMN (α -GR1) monoclonal Ab (mAb). Increase in tumor rejection was observed in mice depleted of CD4⁺ T and treated with IFN α /PVP suggesting that depletion of CD4⁺ T cells can enhance the anti-tumor effect of IFN α gene therapy.
- Expression of IFN- α within the tumor induces a CTL response. To assess whether CD8⁺ tumor specific CTL were induced in vivo by IFN α /PVP treatments, splenocytes from Renca tumor-challenged mice were tested for their cytolytic activity following IFN α gene therapy. Cytotoxic activity against Renca, and not against CT26 cells used as control for tumor specificity, was found in 2 of 4 mice that had received IFN α gene therapy. Moreover, splenocytes from mice depleted of CD4⁺ T cells and treated with IFN α /PVP demonstrated potent CTL activity against Renca cells. By contrast, little CTL activity against Renca cells was evident from splenocytes isolated from mice treated with EP/PVP.

Discussion

- The data reported herein demonstrate that direct administration of IFN α gene formulated in a polymeric delivery system into subcutaneous renal cell carcinoma and mammary adenocarcinoma inhibits tumor growth and induces a long-lasting immunity to secondary tumor challenges. Of considerable significance is the fact that the anti-tumor response was observed against both an immunogenic carcinoma as well a more aggressive and poorly immunogenic adenocarcinoma, a phenotype which is similar to many spontaneously arising tumors in man.

- A variety of genetic abnormalities arise in human cancers that contribute to neoplastic transformation and

malignancy. Despite increasing understanding of the molecular basis of cancer, many malignancies remain resistant to established forms of treatment. More recently, molecular genetic interventions have been designed in an attempt to improve the efficacy of immunotherapy. While numerous experimental studies have been performed in murine models with tumor cells transduced with cytokine-gene *ex vivo*, a major limitation in the translation of this strategy to large-scale human tumor vaccine therapy is the labor intensity and variability of establishing each individual tumor in culture and transducing it with an appropriate vector (i.e., retrovirus). Our approach to this problem is to use a non-viral delivery system to modify tumor cells in vivo with cytokine cDNAs so that the tumor cells can supply the cytokine of interest in a paracrine fashion to the anti-tumor responder cells present within the tumor.

Using a plasmid containing IFN α 4 gene and formulated in PVP, we have shown that intra-tumoral injections of this DNA-PINC complex can lead to complete tumor regression in 30 % of the cases (Renca model) with an overall response rate of 100 % tumor growth inhibition. These results are in agreement with a recent study that described an anti-tumor activity elicited by genetically modified TS/A cells producing murine IFN- α 1 (Ferrantini et al., 1994). Although the anti-tumor effect of IFN α using cytokine-gene transduced tumor cells has been described (Scarpa et al., "Extracellular Matrix Remodelling in a Murine Mammary Adenocarcinoma Transfected with the Interferon-alpha Gene", Journal of Pathology. 181, 116-123 1997), the real value of IFN α gene therapy in blocking or inhibiting advanced tumors remains to be explored. The advantage of using a non-viral IFN α gene delivery system over retrovirus is that tumor cells could be transduced directly in vivo without the need of first establishing tumor cells in vitro. Moreover, IFN α has a potent anti-viral activity limiting the use of this gene in combination with viral vectors.

Therapeutic levels of gene expression for IGF-I using a similar interactive PVP-based delivery system have previously been described (Alila et al., 1997). Direct intra-tumor injection of the same PINC delivery system as a complex with IFN α gene, resulted in dispersion in vivo of plasmid into target cells inducing an IFN α -specific anti-tumor activity. Tumors treated with the same plasmid but in the absence of IFN α coding region and formulated as a complex with PVP, did not respond to this treatment and grew in a similar rate to untreated tumors. By using an optimal dose of IFN α /PVP, tumor-bearing mice were able to reject the tumors mounting a specific long-lasting tumor immunity. Although, the numbers of mice rejecting a second tumor challenge was low, this observation indicates that a considerable portion of the activity of IFN α in inducing the rejection of established tumors is not anti-angiogenic or anti-proliferative but immunostimulatory. Our result demonstrating that IFN α -induced regression of advanced tumors was prevented by in vivo administration of anti-CD8 mAb provides direct evidence for a key role of CD8 $^{+}$ T cells in the anti-tumor effect of IFN α .

Depletion of CD4 $^{+}$ T cells in tumor-bearing mice treated with IFN α gene therapy significantly enhanced the therapeutic effect of IFN α , resulting in tumor regression and prolonged survival of up to 80% of treated mice. A CD4-mediated suppression during tumor progression has been previously reported and it has also been shown that depletion of CD4 $^{+}$ T cells in tumor-bearing mice results in augmentation of anti-tumor therapy with either IL-2 or IL-12 (Rackmilevich et al., 1994 and Martinotti et al., "Cd4 T Cells Inhibit in Vivo the Cd8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes", Eur. J. Immunol., 25, 137-146. (1995)). They have shown that depletion of CD4 $^{+}$ T cells in tumor-bearing mice in the absence of treatment did not affect the growth of tumor itself suggesting that removal of

CD4⁺ T cells does not deprive the tumor of growth factors (Rackmilevich et al., 1994). A possible explanation for this phenomenon is that depletion of CD4⁺ T cells from tumor-bearing mice augments the anti-tumor efficacy of IFN α -activated CD8⁺ T cells by releasing them from immunosuppression. The mechanism driving CD4 suppression is poorly understood, although Th2 type cytokines, directly or through B cell activation, may inhibit cell-mediated immunity (Mossman et al., 1989; Powrie et al., Eur-J-Immunol, 23(11):3043-9 (1993)). CTL can be generated in both CD4-depleted and non-depleted mice from lymphocytes obtained from spleens by in vitro re-stimulation with mitomycin-treated Renca cells and rIL-2. Thus, CD4-mediated suppression appears to be exerted on CD8 expansion and not priming. In accord with the in vivo results, stronger CTL activity was observed from mice depleted of CD4 and treated with IFN α /PVP suggesting CD4⁺ T cells inhibit an IFN α -mediated CD8⁺ T cell response in vivo. This study suggests that direct administration of cytokine genes, like IFN α , into tumors, which have been found to suppress malignancy growth, provide a new therapeutic option for the treatment of human cancers.

Example 2: Pharmacology of mIFN - Gene Medicine in Syngeneic Tumor Models

Gene expression systems encoding either mIFN-2 or mIFN-4 were tested for anti tumor activity when formulated in either cationic lipid, peptide, or PINC delivery systems and injected intratumorally into subcutaneous squamous cell carcinoma (SCC-VII) or adenocarcinoma (MC-38) tumors.

Experimental design and treatment regimen

Experiments to test the anti tumor activity of mIFN-gene medicine were conducted in either SCC-VII or MC-38 tumor models. Tumor cells (4×10^5) were injected subcutaneously into the flank region of mice, and treatment

was initiated when tumor volume reached approximately 50 mm³. Treatment was begun approximately 6 days (SCC-VII tumors) and 10 days (MC-38 tumors) after tumor initiation and repeated at 3 to 5 day intervals.

5 All formulations of mIFN- gene medicine were administered in a dose volume of 50 µl. The faster growing SCC-VII tumors typically received 3 treatments, whereas the relatively slower growing MC-38 tumors typically received 4 treatments. Experiments were terminated when lactose
10 vehicle control tumors reached approximately 1000 mm³.

The anti-tumor effects of murine IFN gene medicine (IFNα/PVP) was tested in syngeneic murine renal cell carcinoma (Renca) and mammary adenocarcinoma (TS/A) tumor model. BALB/c mice were challenged subcutaneously with 7
15 X10⁵ or 1 X10⁵ CT26, and IFNα/PVP injections were initiated 7 days later when tumors reached approximately 10 mm³ size. Each group of mice received 8 treatments (4 injections for 2 weeks) of IFNα/PVP at scalar doses (from 12 to 96 µg/mouse), empty plasmid/PVP (EP/PVP, 96 µg/mouse) or no treatments for
20 control (ctrl). Tumor size increased progressively in mice injected with EP/PVP (Renca, TS/A) or low doses of IFNα/PVP (TS/A), while tumors in mice injected with each dose of IFNα/PVP (Renca) or high dose of IFNα/PVP (TS/A) showed marked growth inhibition.

25 Example 3: mIFN- Gene Medicine Formulated in Cationic lipid Reduces the Growth of SCC-VII Tumors

Experiments were conducted in the SCC-VII tumor model as described in the preceding example. mIFN- gene medicine formulated in cationic lipid, peptide, and PINC delivery
30 systems was tested. Results show that cationic lipid formulations significantly reduce the growth of SCC-VII tumors relative both to lactose vehicle injected tumors and to tumors injected with control (non coding) plasmid formulated in cationic lipid. The effect of mIFN- gene
35 medicine formulated in cationic lipid is dose dependent and

there is no effect of mIFN- gene medicine when formulated in PVA. In addition, analysis of tumors from this experiment using immunohistochemical methods revealed infiltration of CD8+ lymphocytes in tumors injected with cationic lipid formulations, but not in tumors injected with PVA formulations.

mIFN- gene medicine significantly reduces the growth of SCC-VII tumors as compared to control plasmid or lactose injected tumors. Differences between control plasmid and mIFN- plasmid were consistent across formulation. Plasmid dose was 46 µg/treatment. Growth of tumors injected with control plasmid was compared to that of tumors injected with mIFN- gene medicine using repeated measures analysis. mIFN- reduced SCC-VII tumor growth relative to control plasmid ($p=.035$).

Example 4: mIFN- Gene Medicine Reduces the Growth of MC-38 Tumors

Experiments were carried out as described in the preceding examples. The effects of various prototype formulations of mIFN- gene medicine on the growth of subcutaneous MC-38 tumors were compared. mIFN- gene medicine elicited reduced tumor growth in all formulations tested (cationic lipid, peptide, and PINC). Subsequent experiments in the MC-38 tumor model have shown similar results.

Example 5: Dose Responses

After demonstrating anti tumor effects of mIFN- gene medicine, the dose response for these effects was investigated in the MC-38 tumor model. Both cationic lipid (DOTMA:Chol) and PINC (PVA) delivery systems were evaluated. Results clearly show that mIFN- gene medicine elicited a dose dependent reduction in tumor growth. Tumor volume in this experiment was maximally reduced by approximately 50 % with mIFN- /DOTMA:Chol and 60 % with mIFN- /PVA after 4

treatments. Maximal reduction in tumor volume was observed at a plasmid dose of approximately 50 µg/treatment (cumulative dose of approximately 200 µg). These experiments will be conducted primarily in the MC-38 tumor model because it provides a broader treatment window than does the SCC-VII model.

Example 6: IFN-alpha Formulations

The formulations for the IFN-a are: (1) PVP 4 vial, (2) PVP three vial, (3) PVP two vial. The details are listed below:

PVP 4 vial

Materials: 25% PVP (50 kDa) stock solution, plasmid stock solution, 5 M NaCl stock solution, and water.

Method: Add in order of water, plasmid, 25% PVP and 5 M NaCl into a vial to make a plasmid in 5% PVP in saline formulation. The final concentration of PVP and NaCl are fixed (5% and 150 mM) and plasmid concentration could be varied (but based on the IGF-1 data, 3 mg DNA/ml in 5% PVP in saline should be the best formulation). The quality of the formulation is characterized by pH, DNA concentration, osmolality, and gel electrophoresis. The DNA concentration could be varied from 0.1-5 mg/ml. The pH may be varied from 3-5, osmolality may be 250 - 400 mOsm.

Three vial

Material: lyophilized PVP, plasmid stock solution (4 mg/ml), 115 mM Na-Citrate/5% NaCl stock buffer (pH = 4).

Method: Add in order of plasmid and buffer into the PVP to make final 3 mg DNA/ml in 5% PVP in 25 mM citrate/saline buffer (pH =4). DNA expression is higher in saline than in the citrate buffer.

Two vial

Materials: Co-lyophilized plasmid and PVP, saline. Add saline into the co-lyophilized DNA and PVP to make final 3 mg/ml DNA in 5% PVP in saline.

- 5 The final formulation is 3mg/mL DNA, 5% PVP as a single vial. The formulation is prepared by adding (5%) PVP to (4mg/mL) DNA and recirculating the two components for a finite period of time (using static mixer). Then the formulation is lyophilized and rehydrated with 0.9% sodium
10 chloride, to obtain a final composition of 3mg/mL, 5%PVP in saline.

Example 7: Treatment of Human Tumors

- The murine studies are predictive of the response of Human tumors to therapy using a plasmid construct encoding
15 the human IFN alpha gene sequence such as that depicted in SEQ ID NO: 10, 11 or 12. A patient in need of anti-cancer therapy is injected with up to 3mg of plasmid formulation at daily intervals. The plasmid formulation may contain INF
20 alpha plasmid alone or optionally a mixture of IFN-alpha encoding plasmid and an additional plasmid coding for a cytokine. The preferred cytokine is IL-12. The treatments are continued and the patient monitored as is the usual practice for anti-cancer chemotherapeutic regimes.

- 25 One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The molecular complexes and the methods, procedures, treatments, molecules, specific
30 compounds described herein are presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention are
35 defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

5 All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically
10 ally and individually indicated to be incorporated by reference.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically
15 disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of" and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the
20 use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus,
25 it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and
30 variations are considered to be within the scope of this invention as defined by the appended claims.

In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby
35 described in terms of any individual member or subgroup of members of the Markush group. For example, if X is

described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described.

Other embodiments are within the following claims.

Claims

1. A plasmid comprising a CMV promoter transcriptionally linked with an interferon alpha coding sequence, and a growth hormone 3'-untranslated region.
- 5 2. The plasmid of claim 1, wherein said interferon alpha is human interferon alpha.
3. The plasmid of claim 2, wherein said human interferon alpha coding sequence is a synthetic sequence having optimal codon usage.
- 10 4. The plasmid of claim 3, wherein said interferon alpha coding sequence has the nucleotide sequence of SEQ ID NO:10, 11 or 12.
5. The plasmid of claim 1, wherein said growth hormone 3' untranslated region is from a human growth
15 hormone gene.
6. The plasmid of claim 5, wherein an ALU repeat or ALU repeat-like sequence is deleted from said 3' untranslated region.
7. The plasmid of claim 1, wherein said plasmid
20 includes a promoter, a TATA box, a Cap site and a first intron and intron/exon boundary in appropriate relationship for expression of said coding sequence.
8. The plasmid of claim 7, wherein said plasmid further comprises a 5' mRNA leader sequence inserted between
25 said promoter and said coding sequence.

9. The plasmid of claim 1, wherein said plasmid further comprises an intron/5' UTR from a chicken skeletal α -actin gene.

10. The plasmid of claim 1, wherein said plasmid
5 comprises a nucleotide sequence which is the same as the nucleotide sequence of plasmid pIF0921.

11. The plasmid of claim 1, further comprising:
a first transcription unit comprising a first
transcriptional control sequence transcriptionally linked
10 with a first 5'-untranslated region, a first intron, a first
coding sequence, and a first 3'-untranslated region/poly(A)
signal, wherein said first intron is between said control
sequence and said first coding sequence; and
a second transcription unit comprising a second
15 transcriptional control sequence transcriptionally linked
with a second 5'-untranslated region, a second intron, a
second coding sequence, and a second 3'-untranslated
region/poly(A) signal, wherein said second intron is between
said control sequence and said second coding sequence;
20 wherein said first and second coding sequences
comprise a sequence having the sequence of SEQ ID NO:2, 3, 4
or 25 coding for human IL-12 p40 subunit, and a sequence
having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for
human IL-12 p35 subunit.

25 12. The plasmid of claim 11, wherein said first
transcriptional control sequence or said second
transcriptional control sequence comprise one or more
cytomegalovirus promoter sequences.

13. The plasmid of claim 11, wherein said first and
30 second transcriptional control sequences are the same.

14. The plasmid of claim 11, wherein said first and second transcriptional control sequences are different.

15. The plasmid of claim 14, wherein said sequence coding for the p40 subunit of human IL-12 is 5' to said
5 sequence coding for the p35 subunit of human IL-12.

16. The plasmid of claim 1, further comprising an intron having variable splicing, a first coding sequence, and a second coding sequence,

wherein said first and second coding sequences
10 comprise a sequence having the sequence of SEQ ID NO:2, 3, 4 or 25 coding for human IL-12 p40 subunit, and a sequence having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for human IL-12 p35 subunit.

17. The plasmid of claim 16, further comprising:
15 a transcriptional control sequence transcriptionally linked with a first coding sequence and a second coding sequence;
a 5'-untranslated region;
an intron 5' to said first coding sequence;
20 an alternative splice site 3' to said first coding sequence and 5' to said second coding sequence; and
a 3'-untranslated region/poly(A) signal.

18. The plasmid of claim 17, wherein said transcriptional control sequence comprises a cytomegalovirus
25 promoter sequence.

19. The plasmid of claim 1, further comprising:
a transcriptional control sequence transcriptionally linked with a first coding sequence, an IRES sequence, a second coding sequence, and a 3'-
30 untranslated region/poly(A) signal, wherein said IRES

sequence is between said first coding sequence and said second coding sequence; and

an intron between said promoter and said first coding sequence;

- 5 wherein said first and second coding sequences comprise a sequence having the sequence of SEQ ID NO:2, 3, 4 or 25 coding for human IL-12 p40 subunit, and a sequence having the sequence of SEQ ID NO:6, 7, 8 or 24 coding for human IL-12 p35 subunit.

- 10 20. The plasmid of claim 19, wherein said transcriptional control sequence comprises a cytomegalovirus promoter sequence.

21. The plasmid of claim 19, wherein said IRES sequence is from an encephalomyocarditis virus.

- 15 22. A composition comprising the plasmid of anyone of claims 1-21, and a protective, interactive non-condensing compound.

23. The composition of claim 22, wherein said protective, interactive non-condensing compound is polyvinyl pyrrolidone.
- 20

24. The composition of claim 22, wherein said plasmid is in a solution having between 0.5% and 50% PVP.

25. The composition of claim 24, wherein said solution includes about 5% PVP.

- 25 26. The composition of claim 22, wherein said DNA is at least about 80% supercoiled.

27. The composition of claim 26, wherein said DNA is at least about 90% supercoiled.

28. The composition of claim 27, wherein said DNA is at least about 95% supercoiled.

29. A composition comprising a protective, interactive non-condensing compound and a plasmid comprising an
5 interferon alpha coding sequence.

30. A composition comprising the plasmid of any one of claims 1-21 and a cationic lipid with a neutral co-lipid.

31. The composition of claim 30, wherein said cationic
10 lipid is DOTMA.

32. The composition of claim 30, wherein said neutral co-lipid is cholesterol.

33. The composition of claim 30, wherein the DNA in said plasmid and said cationic lipid are present in such
15 amounts that the negative to positive charge ratio is about 1:3.

34. The composition of claim 30, wherein said DNA is at least about 80% supercoiled.

35. The composition of claim 34, wherein said DNA is
20 at least about 90% supercoiled.

36. The composition of claim 35, wherein said DNA is at least about 95% supercoiled.

37. The composition of claim 30, further comprising an isotonic carbohydrate solution.

38. The composition of claim 37, wherein said isotonic carbohydrate solution consists essentially of about 10% lactose.

39. The composition of claim 30 wherein said cationic lipid and said neutral co-lipid are prepared as a liposome having an extrusion size of about 800 nanometers.

40. A composition comprising:

a first component comprising a plasmid comprising an interferon alpha coding sequence and a cationic lipid with a neutral co-lipid, wherein said cationic lipid is DOTMA and said neutral co-lipid is cholesterol, wherein the DNA in said plasmid and said cationic lipid are present in amounts such that the negative to positive charge ratio is about 1:3; and

a second component comprising a protective, interactive non-condensing compound, wherein said first component is present within the second component.

41. A composition comprising a protective, interactive non-condensing compound, a first plasmid comprising an interferon alpha coding sequence, and one or more other plasmids independently comprising an IL-12 or IL-12 subunit coding sequence.

42. A composition comprising a plasmid comprising an interferon alpha coding sequence and a cationic lipid with a neutral co-lipid.

43. A method for making a plasmid of any one of claims 1-21 comprising the step of inserting a CMV promoter transcriptionally linked with an interferon alpha coding sequence, and a growth hormone 3'-untranslated region into a plasmid.

44. A method for making a composition of claim 29, comprising the steps of:

a. preparing a DNA molecule comprising a transcriptional unit, wherein said transcriptional unit comprises an interferon alpha coding sequence;

b. preparing a protective, interactive non-condensing compound; and

c. combining said protective, interactive non-condensing compound with said DNA in conditions such that a composition capable of delivering a therapeutically effective amount of an interferon alpha coding sequence to a mammal is formed.

45. The method of claim 44 wherein said DNA molecule is a plasmid, wherein said plasmid comprises a CMV promoter transcriptionally linked with an interferon alpha coding sequence, and a human growth hormone 3'-untranslated region/poly(A) signal.

46. A method of making a composition of claim 30, comprising the steps of:

a. preparing a DNA comprising an interferon alpha coding sequence;

b. preparing a mixture of a cationic lipid and a neutral co-lipid, wherein said cationic lipid is DOTMA and said neutral co-lipid is cholesterol; and

c. combining said mixture with said DNA in amounts such that said cationic lipid and said DNA are present in a negative to positive charge ratio of about 1:3.

47. A method of making a composition of claim 40, comprising the steps of:

a. preparing a first component comprising a plasmid comprising an interferon alpha coding sequence and a cationic lipid with a neutral co-lipid, wherein said cationic lipid is DOTMA and said neutral co-lipid is

cholesterol, wherein the DNA in said plasmid and said cationic lipid are present in amounts such that the negative to positive charge ratio is about 1:3;

5 b. preparing a second component comprising a protective, interactive non-condensing compound; and

 c. combining said first and second components such that the resulting composition comprises said first component within said second component.

10 48. A method of making a composition of claim 41, comprising the steps of:

 a. preparing a protective, interactive non-condensing compound,

 b. preparing a first plasmid comprising an interferon alpha coding sequence,

15 c. preparing one or more other plasmids independently comprising an IL-12 p35 or IL-12 p40 subunit coding sequence, and

20 d. combining said protective, interactive non-condensing compound, said plasmid comprising said interferon alpha coding sequence and said other plasmids.

49. A method of making a composition of claim 42 comprising combining a plasmid comprising a interferonalph coding sequence and a cationic lipid with a neutral co-lipid.

25 50. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount of a plasmid of anyone of claims 1-21.

30 51. The method of claim 50, wherein said condition or disease is a cancer.

52. The method of claim 50, wherein said composition is administered by injection.

53. A method for transfection of a cell *in situ*, comprising the step of contacting said cell with a plasmid
5 of anyone of claims 1-21 for sufficient time to transfect said cell.

54. The method of claim 53, wherein transfection of said cell is performed *in vivo*.

55. The method of claim 53, wherein said contacting is
10 performed in the presence of an about 5% PVP solution.

56. A method for delivery and expression of an interferon alpha gene in a plurality of cells, comprising the steps of:

(a) transfecting said plurality of cells with a
15 plasmid of anyone of claims 1-21; and

(b) incubating said plurality of cells under conditions allowing expression of a nucleic acid sequence in said vector, wherein said nucleic acid sequence encodes interferon alpha.

57. The method of claim 56, wherein said interferon alpha is human interferon alpha and said cells are human cells.

58. The method of claim 56, wherein said contacting is performed in the presence of an about 5% PVP solution.

59. A method for treating a disease or condition, comprising the steps of transfecting a cell *in situ* with a plasmid of any one of claims 1-21.
25

60. The method of claim 59, wherein said disease or condition is a localized disease or condition.

61. The method of claim 59, wherein said disease or condition is a systemic disease or condition.

5 62. A cell transfected with a plasmid of anyone of claims 1-21.

63. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount
10 of a composition of claim 22.

64. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount of a composition of claim 29.

15 65. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount of a composition of claim 30.

20 66. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount of a composition of claim 40.


25 67. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from said condition or disease a therapeutically effective amount of a composition of claim 41.


68. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from

said condition or disease a therapeutically effective amount of a composition of claim 42.

69. A method for treatment of a mammalian condition or disease, comprising administering to a mammal suffering from
5 said condition or disease a therapeutically effective amount of a composition of a first plasmid comprising an interferon alpha coding sequence and a second plasmid comprising a IL-12 coding sequence.

Fig. 1



**Fig. 2A**

CCGGCCACAGTCGATGAATCCAGAAAGCGGCCATTTCCACCATGATATTTGGCAAGCAGGCGATCGCCATGCGTCAGACGAGATCCTCGCGTGGGC
 ATGCGGCCCTTGAGCCTGGCGAAACAGTTTCGGCTGGCGCGAGGCCCTGTAGTCTTTGTCCAGATCATCTTGATGCAAGACCGGCTCCATCCGAGTAGT
 GCTCGCTGATGGGATGTTTCGCTTGGTGGTGAATGGGACAGTAGCCGGATCAAGCGGATGCAAGCGCGCCGATTTGATCAGCCATGATGGATCTTCTCG
 GCAAGGACCAAGGTAGATGACAGGAGATCTCGCCCCGGCATTTCGCCCAATAGCAGCCAGTCCCTTCGCTTCAGTGACAACTGTGAGACAAAGAAACCGGG
 CAAAGAACCGCCCGTGTGGCCAGCCACGATAGCCGGCTGCTCGCTGACGTTCAATTCAGGGCACCAGACAGGTGGGTCTTGACAAAGAAAGAACCGGG
 CGCCCTGGGCTGACAGCGCGGAACACGGGGCATCAGACAGCCGATGTGTGTGTGGCCAGTCAIAGCCGGAATAGCTCTCCACCCAAAGCGGGGGA
 GAACCTCGGTGGCAATCCATCTTTTCAATCATGCGAAACGATCTCACTCGCTCTTGATCAGATCTTGATCTCCCTGCGCATCAGATCTTGGCGGCAAGAA
 GCCATCCAGTTACTTTGGACGGGCTTCCAACTTACCAAGGGGGAATTCGAGCTTGCAITGCTCGACGGTGTACATTAATCAATGCGTAATGGCCCGCTG
 GCTGACCGCCCAAGACCGCCCGCATTTGACGTCATTAATGACGTAATGACGTAATGTTTCCATAGTAACGCCAAIAGGACCTTCCATGACGTCATGGGTGGATATTT
 ACCGTAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCTTATGACGTCAATGACGTAATGGCGCTGGCATTTATGCCCCAG
 TACATGACCTTAATGGACTTTCTACTTGGCAGTACATACGATAGTATGCTATGCTATATCCATGGTGATGGGTTTGGCAGTACATCAATGGCGGTGGATAGC
 GGTTCGACTCAGGGGATTTCCAAGTCTCCACCCCATTTGACGTCAATGGGAGTTTGTGGCACCAGAAATCAACGGGACTTCCAAATGTCGTAACTACCTC
 GCCCATTTGACGCAAAATGGCGGTAGGCGGTACGGTGGGAGGTCTAATAGCAGAGCTCGTTAGTGAACCGTCAGATCGCTGGAGACGCCATCCAC
 GCTGTTTTCGACCTTCATAGAAAGACCGGGGACCGATCCAGCTCCGCGGCGGGGAACGGTGATTTGGAACGGGATTTCCCGGTGAATTAACAGGTAGT
 GCTTCTCTCTGTTTCTTCTCTGCTATTTCTGCTAACCTTCTCATAGAACTGAGATCTGATTTTGTAGCAGTAATACGATGCTTTTCTTCTTACAG
 GTCCTTCTCTGTTTCTTCTCTGCTATTTCTGCTAACCTTCTCATAGAACTGAGATCTGATTTTGTAGCAGTAATACGATGCTTTTCTTCTTACAG
 GCCCATTTGAGGTCCAGCGCGCAGCTCTCTCTTGTGGTACCTGGTCTCTCGAACCTCAAGTTGGCCAGAACTCTCCCGTGGCCACTCCAGACCC
 AGGAATGTTCCCATGCTTCACCACTCCCAAAACCTGCTGAAGGCGCTCAGCAACATGCTCCAGAAAGCCAGACAACTCTAGAAATTTACCTTGCACCTCT
 GAAAGATTTGATGATGAGATATCAGAAAGATAAACACGACAGTGGAGGCTGTTTACCATTGGAAATTAACCAAGATGAGAGTTGCCATAATTTCCAGA
 GAGACCTTTTCACTAACTAAATGGAGTGGCTGGCTCCAGAAAGACTTTTATGATGGCTGTGCTTAGTAGTATTTATGAAGCTTGAAGATGTACCAAG
 TGGAGTTGAAGACATGAATGCCAAAGCTTCATGATGATCTTAAGAGGAGATCTTTAGATCAAAACATGCTGGCAGTTATGATGAGCTGATGAGGCTG
 AATTTCACAGTGAAGCTGTGGCAGCAAAATCTCTCTTGAAGACCGGATTTTATAAACTAAATCAAGCTCTGATATCTTTCAATGCTTTCAAGATTTGGG
 CAGTGACTAATTGATAGAGTGAAGTATCTGAATGCTTCTTAACCAATTTAGAAAGCGGAATTCCTGACGGAATTTGGTGGCATCTCTGTGACCCCTCCCAAG

Fig. 2B

3/19

SUBSTITUTE SHEET (RULE 26)

TGCCCCCTCTGGCCTTGACCCGCCCAAGCACCCTTGCTCTAATAAATTAAGTTCGATCAATTTGTCTGACATAGGCTCTCTCTAATAATTAATAGG
GGTGGAGGGGGGGTGGTATGGAGCGAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCTCGAGGGGGGGGGGAGACGGCTGTTACATTAACCTTAGGTA
TGGCCCGCTTGCTGACCCGCCCAAGCACCCTTGCTGACGTCAATTAATGACGTATGTTCCCATAGTAACGCCAATAGGACCTTTCCATTGACGTCAATG
GGTGGAGTATTACGGTAACCTGCCCACTTGGGAGTACATCAAGTGATCATATGCCAAGTACGCCCTTATGACGTCAATAGCGTAATAGGCGCCCTGGG
CATATAGCCCAATAGCACTTATGGGACTTTCTACTTGGGAGTACATCTAGTATAGTCATGCTATTACATAGTGGTATGGGAGTACATCAATGG
GGTGGATAGGGGTTTGAATCAGCGGGGATTTCCAGCTCCACCCCATTAGCTCAATAGGAGTTGTTTGGACCAAAATCAACGGGACTTTCCAAATGTG
GTACAACTTCGCCCATTTGACGGCAATGGGCGGTGTAACGGTGGAGGCTATATAAGCAGAGCTCGTTAGTGAACCGTCAGATCGCTGGGGA
CGCCATCCACGCTGTTTGACCTCCATAGAAAGACACGGGACCCGATCCAGCCTCCGGCGCGGGAACGGTGCAATTGGAAACGGGATTCCTGTTAATTA
ACAAGTAACTGCTTCTCTCTGTTTCTTCTCCCTGCTATTGCTCAACCTCTATCAAGAACTGGAGTATGTAATTTTGTAGAAATTGACTAACGGTCTTTTTC
TCTTACAGGCTTAAGTCATGGGTACCAAGAGTTGGTACTCTTGGTTTTCCTGGTTTCTGGCATCTCCCTCGTGGCAATGGGAACGAAAGAAAGATGT
TTATGTCGTAGAAATTGGATTTGGTATCCGGATGCCCTGGAGAAATGGTGGTCTTACCTGTGACACCCCTGAAGAAAGATGGTATCACTTGACCTTGGACCA
AGCAGTGAAGGCTTAGGCTCTGGCAAAACCTTCACCATTCGAAGTCAAAAGATTGGAGATGCTGGCCAGTACACCTGTTCACAAAGAGGGGAGGTTCTAAG
CCATTCCCTCTGCTGCTTCACAAAAGAGAGAATGGAATTTGGTCCACTGATATTTTAAAGGACCAAGAAAGAACCCAAATAAGACCTTTCTAAGATGGAG
GCCAAGAAATTAATTTGAGCGTTTCACTGCTGGTGGTGAAGACAATCAGTACTGATTGACATTCGATGTCAAAAGCAGAGAGGCTTTCTGACCCCAAG
GGGTGACGCTGGGAGCTGTCTACACTCTCTCGAGAGAGAGTCAGAGGGGCAACAAGGAGTATGAGTACTCAAGTGGAGTGGCAGGAGGACAGTGGCTGC
CCAGTCTCTGAAGAGAGCTGCCCATTTGAGGTCATGGTGAATGCCGTTCAAGCTCAAGCTCAAGTATGAAGACTACACCAAGGCTTTCTATCAGGGAATATC
AAACTGACCCCAAGAACTTTGCACTGGAAGCCATTAAGAAATTTCTGGCAGGTGGAGGTGAGTGGAGTACCTGACACCTGGAGTACTCCCAATTC
CTACTTCTCCCTGACATTTCTGGTTCAAGTCCAGGGCAAGACCAAGAGAAAGAAAGATAGAGTTCACGGACAAAGACCTCAGCCAGGCTATCTGCC
GCAAAATAGCAAGCATTAGCGTGGGGGCCAGGACCCGCTACTATAGCTCATTTGGAGCGAATGGCGATCTGTGCCCTGCAAGTATAGACGGCTAGAAAG
CCGAATTTCTGAGGAATGGGTGGCATCCCTGTGACCCCTCCCAAGTGCCTCTCGGCCCCGGAAGTTGCCACTCGAGTGGCCACAGCCTTGCTCTAATAA
AATTAAGTTGCATCATTTTGTCTGAGTACAGTGTCTCTCTAATAATTAAGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACTGTAG
GGCTCGAGGGGGGGGGCCGATACAGCTTTGTCTCCCTTAGTGAAGGTTAATTTGCAGCTTGGCTAATCATGTGCTATAGCTGTTCTGTGTGAATTTGTTATCC

4/19

SUBSTITUTE SHEET (RULE 26)

Fig. 2C

GCTCACAAATCCACACACATACGAGCCGGAAGCAIAAGCTGTAAAGCCTGGGGTGCTTAATGAGTGAAGCTAACTCACATTAAATTGCGTTGGCTCACTGCC
 CGCTTTCAGTTCGGAAACCTGTCTGCCAGCTGCATTATGAATCGGCCAACGGCGGGGAGAGCGGTTTGGGTATTTGGCGCTCTTCCGCTTCTCGCT
 CACTGACTTCGCTGGCTCGGTCTGCTGGCTGGCGGAGGGTATCAGTCTCACTCAAGGGCGGTAAATACGGTTATCCACAGAAATCAGGGGAATAACCGAGGA
 AAGAACAATGTGAGCAAAAGGCCACAGCAAAAGGCCAGGAACCGTAAAGAGCGCGGTGTGCTGGCGTTTTCATAGGCTCCGCCCCCTGACGAGCATCAC
 AAAATTCAGCGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAGATACAGCGGTTTCCCCCTGGAACTCCCTCGTGGCTCTCTGTTCGAC
 CCTGCCGCTTACCGGATACCTGTCTGGCTTTCTCCCTTCGGGAAGCGTGGCGTTTCTCAAGCTCAAGCTGTAGGTATCTCAGTTCCGTTAGGTCTGCTC
 CAAGTGGGCTGTGTGCAGGAACCCCCGTTAGCCCCGAGCCGCTGGCTTATCCGGTAACTATCGTCTTGAAGTGGTGGCTAACTACGGCTACACTAGGAAG
 ACTGGCAGCAGCACTGGTAAACAGGATTAGCAGAGCGAGGTATGTAGCGGTGCTACAGAGTCTTTGAAGTGGTGGCTAACTACGGCTACACTAGGAAG
 ACAGTATTTGGTATCTGGCTCTGCTGAAGCCAGTTACCTTCGGAAAGAGGTGGTACCTTTGATTCGGCAACCAACCAACCGCTGGTAGCGGTGTTTTTTT
 GTTTGCAAGCAGCAGATTACGGCGCAAGAAAAAGGATCTCAAGAGATCTTTGATCTTTTCTACGGGCTTGACGCTCAGGAAGACTCGTCAAGAAAGCGA
 TAGAAGGCGATGGCTGGCAATCGGGAAGCGCGATACCGTAAAGCAGAGGAAGCGGTCAAGCCATTGCGCCCAAGCTCTTCAGCAATATCAGCGGTA
 GCCAAGGCTATGTCTTGATAGCGGTCCGCCACACCCAG

Fig. 2D

Codon Frequency

human_high.doc 143


Codon usag for human (highly xpressed) genes 1/24/91

AmAcid	Codon	Number	/1000	Fraction
Gly	GGG	905.00	18.76	0.24
Gly	GGT	441.00	9.14	0.12
Gly	GGC	1867.00	38.70	0.50
Glu	GAG	2420.00	50.16	0.75
Glu	GAA	792.00	16.42	0.25
Asp	GAT	592.00	12.27	0.25
Asp	GAC	1821.00	37.75	0.75
Val	GTG	1866.00	38.68	0.64
Val	GTA	134.00	2.78	0.05
Val	GTT	198.00	4.10	0.01
Val	GTC	728.00	15.09	0.25
Ala	GCG	652.00	13.51	0.17
Ala	GCA	488.00	10.12	0.13
Ala	GCT	654.00	13.56	0.17
Ala	GCC	2057.00	42.64	0.53
Arg	AGG	512.00	10.61	0.18
Arg	AGA	298.00	6.18	0.10
Ser	AGT	354.00	7.34	0.10
Ser	AGC	1171.00	24.27	0.34
Lys	AAG	2117.00	43.88	0.82
Lys	AAA	471.00	9.76	0.18
Asn	AAT	314.00	6.51	0.22
Asn	AAC	1120.00	23.22	0.78
Met	ATG	1077.00	22.32	1.00
Ile	ATA	88.00	1.82	0.05
Ile	ATT	315.00	6.53	0.18
Ile	ATC	1369.00	28.38	0.17
Thr	ACG	405.00	8.40	0.15
Thr	ACA	373.00	7.73	0.14
Thr	ACT	358.00	7.42	0.14
Thr	ACC	1502.00	31.13	0.57
Trp	TGG	652.00	13.51	1.00
End	TGA	109.00	2.26	0.55
Cys	TGT	325.00	6.74	0.32
Cys	TGC	706.00	14.63	0.68
End	TAG	42.00	0.87	0.21
End	TAA	46.00	0.95	0.23
Tyr	TAT	360.00	7.46	0.26
Tyr	TAC	1042.00	21.60	0.74

Fig. 3

6/19

SUBSTITUTE SHEET (RULE 26)

**Fig. 4A**

GATTCGATGGCTAGGCTCTGTGCTTTCTTCATGATCTCTAGTAATGATGAGCTACTACTGTGTCAGGCTGTCTCTTAGGATGTGACTTGGCTTCACACTTAATACCTGGG
GAACCAAGAGGGGCTTGACAGTCTCTGGAAGAAATGGAAGACTCCCCCTTTCTCTGCTGGAAGAACGGAAGATTTGGATTCCCTTGGAGAAAGGTGG
ATAACCAACAGATCCAGAAGGCTCAAGGCATCTCTGTGTAAGAGATTTACCCAGCAGATTTTGAACCTTTACATCAAAAGACTGTCTGTACTTGGAAATG
CAACTCTCTAGACTATTTCTGCATGACTCCATCAGAGCTCAATGATCTCAAGGCTGTGATGCAAGAACTCTCTGACCCAGGAAGACTCTCTGCT
GGCTGTGAGGACATACTTCCACAGGATACTGTGTGACTGAGGAAGAAAGAAACACAGGCTGTGTGCTGGGAGGTGATCAGAGCAAGAGTCTGGAAGAGCC
CTCTCTTCTCAACCAACTTGTGTCGAAGACTGAGTGAAGGAAGAGAGTGAATCAGAAAGCCGAATTTCTGAGGAATTTGGCATCTCCGTGACCCCTCCCA
GTGCTCTCTCTGGGCTTGGAAATTGCACTCCAGTGGCCCAAGCTTTGTCTTAATAATTAAATTGATGCATTTTGTCTGACTAGGTGTCTCTTAATAATTATG
GGGTGAGAGGGGGTGGTATGAGCAAGGGGGCCAAAGTTGGGAAGAACAACTGTAGGGCTCTGAGAGGGGGGGCCGGTACCAGCTTTTGTTCCTTTAGTGA
GGGTAAATTTTCAGCTTGGCGTAATCATGGTCAATAGCTGTCTCTGTGAAATTTATCCGCTCAAAATTCACACAAATACAGAGCCGGAAGCAATAAGTGT
AAAGCTGTGGGTGCTTAATGAGTGAAGTCACTACATAATTTGGGTGGGCTACTGCGGCTTCCAGTGGGAACCTGTGTGTCAGCTGCAATTAATGAAT
CGGGCAAGCGCGGGGAGAGGCGGTTTGGGTATTTGGGCTTTTCGCTTCTCTGCTACTGACTGCTGCTGCGCTCGGTCGTTCCGCTTGGCGGAGCGGTAH
CAGCTCACTCAAAAGCGGTAAATACGGTTATCCACAGAAATCAGGGGATAACGCAGGAAGAAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGGT
AAAAAGCGCGGCTGTGCGGCTTTTTCATAGGCTCCGCCCCCTTGACGAGCATCACAAAATTCAGCGTCAAGTCAAGAGGTGGCGAAACCCGACAGGAC
TATAAGATACCAAGCGTTTCCCCCTTGGAGCTCCCTCGTGCGCTCTCTGTTCCGACCTGCGCTTACCGGATACCTGTGCGCTTCTCCCTTCCGGAGC
GTGGGCTTTCTCATAGCTCAGCGTGTAGGATCTCAGTGGGTAGGTCGTTGCTTCCAAAGCTGGGCTGTGTGACGGAACCCCCCTTCAGCCCGACCGCT
CGGCTTATCCGGTAATATCGCTTTGAGTTCGAACCCGGTAAGACAGCACTTACGCACTGGCAGCAGCACTGTGAACAGGATTAGCAGAGCAGGATAT
GTAGGGGGTGTACAGAGTTCTTGAAGTGTGGCTTAATCTACGCTACACTAGAGGACAGTATTTGGTATCTGGGCTCTGCTGAGGCACTTACCTTCCGAA
AAAGAGTTGGTAGCTCTTATCCTCGGCAAAACAAACCAACCGCTGTAGCGGTGTTTTTTGTTCGAAGCAGCAGATTACGCCGAGAAAAAAAGATCTCAAG
AAGATCTTTGATCTTTTCTACGGGCTTGACGCTCAGGAAGAACTCGTCAAGAGGCGATAGAAAGCGATGCGCTGGAATTCGGAGCGCGGATACGTA
AGCAGAGGAAGCGGTAGGCCATTGCGCCCAAGCTCTTACGAAATATCAAGGATAGCCAAACGTATGTCTCTGATAGCGGTTCGCCACACCAAGCGGG
CCACAGTCGATGAATCCAGAAAGCGGCCATTTCACCAATGATATTCGCAAGCAGGATCGCCATGCTACGACGAGATCTCTGCGCTCGGGCATG
CGGCTTGAAGCTTGGCAACAGTTCGGCTGGCGGAGGCCCTTGATGCTCTGTCAGATCATCTTGATTCGACAAAGCGGCTTCATTCGAGTACGTGCTC

8/19

SUBSTITUTE SHEET (RULE 26)

GCTCGAATGCCAATGTTTCGTTGGTGGTGAATGGGCAGGTAGCCGGATCAAGCGTATGCGAGCCGCCGATTCGATCAGCCATGATGATACCTTCTCGGCAG
 GAGCAAGGTGAGATGACAGGAGATCCTGCCCCGGCACTTGGCCCAATAGCAGCCAGTCCCTTCCGCTTCAGTGACCAAGTGGAGCAGCTGGCCAG
 GAACGCCCCGTGCGGCCAGGCCAGATAGCCGCCCTGCTGCTGAGTTTCAATTCAGGGCAGCCGACAGGTGGTCTTGACAAAAAGAACCGGGGCC
 CCTGGCTGACAGCCGGAACACGGCGGCAICAGAGCAGCCGATTTGCTGTTGGCCAGTCAATAGCCGAATAGCTCTCCACCCAAAGCGGCCGGAAGAAC
 CTGGGTGCAATCCATCTTGTTCATTCATGCGAAGCATCTTCATCTGCTCTTGATCAGATCTTGATCCCTGCGCAACAGATCCTTGGCGGCAAGAAAGCA
 TCGGTGCAATCCATCTTGTTCATTCATGCGAAGCATCTTCATCTGCTCTTGATCAGATCTTGATCCCTGCGCAACAGATCCTTGGCGGCAAGAAAGCA
 TCGAGTTTACTTTGCGAGGCTTCCCAACCTTACCGAGGGCGAATTCGAGCTTGCATGCTTGCAGTGGTACATAACTTACGGTAATGGCCGCTGGCTGA
 CCGCCCAACGAGCCCCGCCAATGACGTCAATATGACGTATGTTCCCAATAGTAACGCCAATAGGACTTTTCATTTGACGTCAATGGGTGAGTATTTACGGT
 AACTGCCCCACTTGGCAGTACATCAAGTGTATCAATAGCAAGTACGCCCCCTAATGACGTCAATGACGGTAATGGCCGCTGGCATTTATGCCAGTACAT
 GACTTAATGGGACTTCTACTTGGCAGTACATCTACGTATAGTATGCTATACCAATGCTGATGCGGTTTGGCAGTACATCAATGGCGGTGAGTACGGTTT
 GACTCAGGGGATTTCCAGTCTCCAGCTTCAACCATTCAGGTCAATGGGAGTTTGTTTGGCACCAAAATCAACGGGACTTTCCAAAATGCTGTAACACTCCGCCC
 ATTGACGCAAAATGGGCGTAGGCGTAGCGGTGGAGGTCTAATTAAGCAGAGCTCGTTAGTGAAACCGTCAGATCGCTGGAGACGCCATCCACGCTGTTT
 TGACCTCCATAGAGACACCGGAGCCGATCCAGCTTCGGACTTAGCTAGAG

Fig. 4C




Fig. 5A

AGCTTCGAGGGGGGGCCCCGGTACGAGCTTTTGTTCCTTAGTGAAGGTTAATTTGAGCTTGGCGTAATCATGGTCATAGCTGTTCTCTGTGMAATTTGTAATCC
 GGTCAACAATTTCCACACACATACGAGCGCGGAGAGCATAAAGTGTAAAGCCCTGAGGCTGCTTAATGAGTGAGCTAACTACATTAATTTGGCTTGGCTCAGCTGCGC
 CGCTTTCAGTGTGGGAAACCTGTCTGTCCAGCTGCATTAATGAATGGCCAAAGCGCGGGGAGAGCGGTTTGGTATTTGGCGCTTTTCGGCTTCCTGCT
 CACTGACTCGCTGCGCTGTGCTGCTTCCGCTGCGGCGAGCGGTATCAGCTCACTCAAAAGGCGGTAATAGCGTTATCCAGAAATCAAGGGGATTAACGACGGA
 AAGAACATGTGAGCAAAAAGGCCAGCAAAAAGGCCAGGAACCTTAAAGAGGCCCGCTGTGCGGCTTTTTCATAGGCTCCGCCCCCTGACGAGCATCAC
 AAAAATTCAGCGCTCAAGTCAGAGGTGGCGAAACCCGACAGAGACTATAAGATACCAAGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCTGTTCGGAC
 CTTGCGCGTTACCGGATACCTGTCCGCTTTCTCCCTTGGGAAGCGTGGCGTTTCTATAGCTCAACGCTGAGGATCTCAGTTCCGCTGAGGTGCTTCCGCTC
 CAAGCTGGGCTGTGTGACGGAACCCCCCGTTTACGCCGAGCGCTGGCGCTTATCCGGTAATATCGTCTTGAGTCCAAACCGGTAAAGACAGACTTATGCCC
 ACTGGCAGCAGCCACTGGTAAACAGGATTAGCAGAGCGGAGGTATGTAGGCGGTGTCTACAGAGTTCTTGAACTGGTGGCTAACTACGGCTACACTAGAAGG
 ACAGTATTTGGTATCTGGCTGTGCTGAAGCCAGTTACTTTGGAAAGACAGTTGGTACTTTGATCCGGCAACCAACCAACCGCTGGTAGCGGTGTTT
 GTTGGCAAGCGACAGATTACCGCGACGAAAAAAGGATCTCAAGAGATCTTTGATCTTTTCTACGGGCTGTGACGCTCAGAGGAACTCGTCAAGAAAGCGCA
 TAGAAGCGGATGCGCTGCGAATCGGAGCGGGGATACCGTAAAGCACGAGGAAAGCGGTACGCCCATTCGCCCAAGCTTTACGCAATATACCGGTA
 GCCAAGCGTATGTTCTGATAGCGGTCGCCACACCCAGCGCGGCCACAGTGTGAATCCAGAAAGCGGCCATTTCCACATGATATTCGGCAAGCAGG
 CATCGGCATGGGTACGACGAGATCTTCGCCGTGGGCAATGGCGCTTGAAGCTGGCGGAACAGTTCCGGCTGGCGGAGGCCCTGATGCTTCGTCAG
 ATCATCTGATCGACAAAGCCGGCTTCATCTCGAGTAGTGTCTCGTCAATGCGATGTTTCGTTGGTGGTCCGAATGGGCAAGTAGCCGATCAAGCGTATG
 CAGCGCGCGCATTTGCATCAGCCATGATGATACTTTCTGGCAGGAGCAAGGTGAGTGAACAGGATCTTCGCCCGGACATTCGCCCAATAGCAGCCAG
 TCCCTTCCCGCTTACGTGACAAAGCTGTGACAAAGAGGCCCGGAGAACCTGGGTGCAATCCATTTGTTCAATCATGCGAAAGCATCTCATCTGTCTGTGATCA
 AGTCATAGCCGGAATAGCTCTCCACCCAAAGCGGCCGGAAGACTGGGTGCAATCCATTTGTTCAATCATGCGAAAGCATCTCATCTGTCTGTGATCA
 CTTGATCCCTGCGGCATCAGATCTTTGGGGGCAAGAAAGCATCCAGTTACTTTTGACAGGCTTCCCAACCTTACCAAGGCGGCCCAAGCTGGCAATTC
 GGTTCGCTTGTGTCAATAAAGCCGCCAGCTAGCAACTGTTGGGAAGGGCGGGGCTGACGAATTCGAGCTTGCATGCTTGCAGGTGTTACATTAACCTTA
 CGGTAATGGCGCGCTGCTGACCGGCCCAAGCAGACCCCGCCCATTTGACGTCATTAATGACGATGTTCCATAGTAACGCCAATAGGACCTTTCATTTGAC

11/19

Fig. 5B

GTCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGGCCCCCTATTGACGTCAATAGCGGTAAATGGCC
CGCTGGCATTATGCCCACTACATGACTTATGGGACTTCTACTTGGCAGTACATCTACGTAATTAGTCATCGTATTACATAGGTGATGGGTTTGGCAGTACAC
TCAATGGCGGTGGATAGCGGTTTGACTACAGGGGATTTTCAAGTCTCCACCCCAATTACGTCAATGGGAGTTGTTTGGCACCAAAATCAACGGGACTTTCCA
AAATGTCGTAAACAACTCCGCCCATTTAGCGGAATAGGGCGGTAGCGGTAGCGGTGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGG
CTGGAGACGCCATCCACCGTGTTTGACCTCCATAGAAGACACCGGAGCCATCCAGCGCTCCGGCGCGGGAACGGTGCAATGGAACGGGATTTCCCGT
GTTAATTAACAGGTAAGTGTCTCTCTGTTCTCTTCCCTGCTATTCTGTCAACTCTCTATAGAAATCGAGTATCTGTAATTTTGTACAGTAATACTAACGGGG
TTCTTTTTTCTTACAGGCCACGATGTCATATCAGTACCTCTCTTTTGGCCACCTTGCCCTCTAAACCACTCAGTTTGGCAGGGTATCTCAGCTC
TGACCTGCCAGGTGTTTACCGAGTCCGGAACCTGTGAAGACCAAGATGCAATGTTGAAGACCGCCAGAGAAAACTGAAACATTATCTTGCACTG
CTGAAGACATGCATGAGAACATACACGGGACCAACCCAGACATTTGAAGACCTGTTACACTTGAACCTACCAAGAAACGAGAGTTGCTGGTACT
AAGAGACTCTTCCACAACAAAGAGGAGCTGCTGCCCCCAGAGAAGCGTCTTGATGATGACCCTGTGCTTGGTAGCATATAGGACTTGAAGATG
TACCAAGCAAGATTCCAGGCCATCAACGGACACTTCAGAAATCAACCACTACAGCAATCATTTACAGCAAGGCAATGCTGGTGGCACTGATGAGCTGAT
GCACTCTTGATATCAATATGGCGGAGCTCTGCGCCAGAAACCTCTGTGGGAAGAGGAGCCCTACAGATGAAATGAAGCTCTGCATCTCGTCTACG
CCTTACGACCCCGCGTGTGACCAATCAACAGGAGTATGGGTATCTGAGCTCTCGCTTAACCTAGTGAAGCTCAAGGCCCTGCGCACAGCGCCCTCTAC
ACAGATAGGAATCTGCAGATCTTAGAGCTCGTGATAGCTCGACTGAGCTTCTAGTGGCAGCACTGTGTTTGGCCCTCCCGTGCTTCTTGAAC
CTGGAAGGTGCCACTCCCACTGTCTTCTTAATAAAATGAGGAATTTGATCTGCATGTGCTGATAGGTGTATTTCTGGGGGGTGGGTGGGGCAGGA
CAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCACTCTGGGGATGCGGTGGGCTCTATAGGCTTCTGAAGGGGAAGAACCACTGGGCTCGAAAT
TTCGAGCTTGCACTGCTGCAAGGTGTTACATAACTTACGGTAAATGGCCCCCTGGCTGACCGGCCCAACGCCCCCATTTAGCGTCAATAATGACGTA
TTCCCATAGTAAACCAATAGGAGCTTCCATTGACGTCAATGGGTGGAGTATTACGGTAACTGCCACTTGGCAGTACATCAAGTGTATCATATGCCAGTA
CGCCCTTATGACGTCAATGACGTAATAGGCCCGCTCGGACTATAGCCAGTACATGACTTATGGGACTTCTACTTGGCAGTACATCACTACGTAATTAGCA
TCGCTATTACATAGGTGATGGGTTTGGCAGTACATCAATGGGCGGTGATAGCGTTGACTACGGGATTTCAAGTCTCAACCCATGACGTCAATAGG
AGTTGTTTGGCACCAAAATCAACGGGACTTCCAAATAGTCTGAACAACTCCGCCCATTTAGCGCAAAATGGGCGGTAGGCGGTACGGTGGAGGTCTATA
TAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCTGGAGAGCCCATCCACCGCTGTTTGACTCCATAGAAGACACCGGAGCCGATCCAGCTCCGGGGC

12/19

CCGGAACGGTGCATTGGAAACCGCGGATTCCTCCGTTAATTACAGGTAAAGTGTCTCTCCCTGTTCTTCCCTGCTAATTCGTCAACCTTCCTATCAGAACT
 GCAGTATCTGTATTTTGGCTAGCAGTAATACTAACGGTCTTTTTTCTCTTCACAGGCGCAGCATGTGTCTCAGAACTAACCATCTCTGGTTGCCATCGTTTGTCT
 GGTGTCTCCACTCATGGCCATGTGGAGCTGGAAGAACGTTTATGTGTAGAGGTGGACTGGACTCCGATGCCCTGGAGAAACAGTGAACCTCACT
 GTGACACGCCCTGAAGAAAGATGACATCACTTGGACTCAGACCAGAGACATGGAGTCATAGGCTCTGGAAGACCTGACCATCACTGTCAAGAGTTTCTA
 GATGCTGGCCAGTACACCTGCCAAGAGGAGCGGAGACTCTGAGCCACTCACTCTGCTGCTCCACAGAAAGAAATGGAAATTTGGTCCACTGAATTTTA
 AAAAATTTCAAAAAACAAAGACTTTCTGAGGTGTGAAGCACCAATTAATTCGGAACGGTTCACGTGCTCATGGCTGGTGGCAAGAAACATGGACTTGAAGTTCA
 ACATCAAGAGCAGTAGCAGTTCCTGACTCTCGGGCAGTGACATGTGGATGGCGTCTGTCTGCAGAGAAAGGTCACTGGAACCAAGGAGCATAGAG
 AAGTATTCAGTGTCTGCCAGAGGAGTGTACCTGCCCCAACTGCCGAGGAGACCTTGCCATTGAACCTGGCGTTGGAAGCACGGCAGCAGAAATAATATG
 AGAAGTACAGCACAGCTTCTTCATCAGGGACATCATCAACAGAACCCGCCAAGAACTTGACATGAAGCTTTGAAGAACTCACAGGTGGAGGTGAG
 CTGGGAGTACCTTGACTCTCGAGGACCTCCCATTTCTACTTCTCTCAAGTCTTTGTTCGAATTCACCGCAAGAAAGAAAGATGAAGGAGACAGAGGA
 GGGGTGTAACCAAGAAAGGTGCGTTCCTGTAGAGAAAGACATCAACGAAGTCCAATGCCAAGGCGGGAAATGTCTGCGTGAAGCTCAAGATCGCTATTACA
 ATTCTCATGCAAGCAAGTGGGCAATGTTCCTCGAAGGCTCGATCTAGAGCTGCTGATCAGGCTGACTGTGCTTCTAGTTGCCAGCCATCTGTGTTGC
 CCTTCCCCCGTGCCTTCTTGACCTGGAAAGTGGCACTCCCACTGTCTTTCTTAATAAATGAGGAAATTGCAATGCAATGTCTGAGTAGGTGATTTATTTCT
 GGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATGGGAAAGACAATAGCAGGCAATGCTGGGATGGGGTGGGCTTATGGCTTCTGAGCGGGA
 AAGAACCAGCTGGGGCTCGAGCATGCA

Fig. 5D

HUMAN IFN pIF0921

CGTACATAACTTACGGTAATAGCCCGCTGGCTGACCGCCCAACGACCCCGCCCATTTGACCTCAATTAATGACGTATGTTCCCATAGTAACGCCCAATAGG
GACTTTCCATTGACGTCAATGGGTGGAGATATTACGGTAACACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCTTATGACGTCAATGA
CGGTAATAGCCCCCGCTGGCATTTATGCCAGTACATGACCTTATGGACTTCTTACTTGGCAGTACATCTACGTATAGTCAATGCCATTAACATGATGATGCC
GTTTGGCAGTACATCAATGGGCGTGATAGCGGTTTGACTCAGCGGGATTTCCAACTCCACCCCATTTGACGTCAATGGGAGTTGTTTGGCAACCAAAATCA
ACGGGACTTTCCAAATGTCGTAACCACTCCGCCCATTTGACCGCAATGGGCGTAGCGGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGTTAGTGA
CCGTGAGATCGCTGGAGAGCCCATCCAGCTGTTTGAACCTCATAGAAAGACACGGGACCGGATCCAGCTCCGCGGCCGGGAAACGGTGCAATTTGGAAC
GGGATTCCTGGTAAATTAACAGTAAGTGTCTCTCCCTGTTCTTCCCTGGTATTTCTGTCACCTTTCTATCAGAACTGACAGTATCTGATTTTGTAGCA
GTAACTAACGGTCTTTTCTTCTTCAACAGCCCAATGAGCTTGACCTTGACCTTGTCTTACTGGTGGCCCTCCGCTGCTGACGTGCAAGTCAAGCTGCTGTTGGG
CTGTGATCTGCTCAACCCACAGCTGGGTAGCAGAGGAGCTTGAATGCTCTGGCAGAGTGAAGGAATCTCTTTTCTGCTTGAAGGACAGACAT
GACTTTGATTTCCCAAGGAGAGGATTTGGCAACAGTTCAAAGGCTGAACCATCTCTGCTCTCAATGAGATGATCCAGCAGATCTTCAATCTCTTCAAGC
AAAGGACTCACTCTGCTGGATGGAGACCTCTAGACAAATTTCTACCTGAACTTACAGCAGCTGAATGACCTGGAAGCTGTGTGATACAGGGGGT
GGGGGTGACAGAGACTCCCCGTGATGAAGGAGACTCCATTTCTGGCTGTGAAGGAATCTTCCAAAGGAATCACTCTATCTGAAGAGAAATACAGCC
CTTGCTGAGGAGTGTGAGAGCAGAAATCATGAGATCTTTTCTTGTCAACAACTTGCAGAGAAATTTAAGAGTAAGGAATGAATCTAAGAAAGCCGA
ATTCTGAGGAATTTGGTGGCAATCCCTGTGACCTCCCTCCAGTGCCTCTCTGCTGGAAGTTGCCACTCCAGTGCCTCCAGCAGCTTGTCTTAATAATTA
AGTTGATCATTTTGTCTGACTAGGTGTCTTCTATAATATTAATGGGTGGAGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGCAACCTGTAGGGCTC
GAGGGGGGGGGGAGTACAGCTTTTGTCTTGTAGTGGGTAAATTTGAGCTTGGGTAATCATGATGATAGCTGTTTCTGTGTGAATTTGTTATCCGCTCA
CAATTCACACAAATACGAGCCGGGAAGCATAAAGTGTAAAGCTTGGGGTGCCTAATGAGTGAAGTCACTACATTAATTTGGGCTCACTGCCCCGTTT
CAAGTCCGGGAACCTGTGCTGCCAGCTGCATTAATGAATCGGCCCAACGCGGGGAGAGGCGGTTTGGCTATGGGCGCTCTCCGCTCACTG
ACTTGGCTGGCTCGCTGCTTGGCTGGGGGAGCGGATACAGTCACTCAAAAGCGGTAAATACGGTTATCCACAGAAATCAGGGGATTAACGACAGAAAGAA
CATGTGAGCAAAAGGCGCAGAAAGGCGCAGAACCCGTAAAGAGCGCGGTTGCTGGCGTTTTCATAGGCTCCGCCCCCTGACGAGCATCACAAAAT
CGAGCTCAAGTCAAGAGGTGGCGGAACCCGACAGAGCTAATAACATACAGGCTTTCCCTTGGAAAGCTCCCTGCTGCTGCTCCGAGCCCTGCC
GCTTACCGGATACCTGTCCGCTTCTCCCTTGGGGAAGGCTGGCGCTTCTCATAGCTACAGCTGTAGGTATCTCAAGTTGGGTAGAGTCTGCTTCCGCTCAAGCT


Fig. 6A

14/19

SUBSTITUTE SHEET (RULE 26)

GGGCTGTGTGACGAACCCCCGTTACGCCGACCGCTGCCCTTATCCGGTAACATCGTCTTGAGTCCAAACCGGTAAGACACGACTTATGCCACTGGC
 AGCAGCCACTGGTAAAGAGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCCTTGAAGTGGTGGCTTAACCTACGGCTACACTAGAAGGACAGTAT
 TTGGTATCTGCCCTCTGCTGAAGCCAGTTACCTTGGAAAAAGATTGTAAGTCTTGATCCGGCAACAAACCAACCGCTGTAGCGGTGTTTTTTTGGTTGCA
 AGCAGCAGATTACGGCGAAGAAAAAGGATCTCAAGAGATCTTTGATCTTTTCTACGGGGTCTGACGCTAGAAAGACTCGTCAAGAGGCGGATAGAAG
 GCGATGCCGTGCCGAATCGGAGCGGGGATACCGTAAAGCACGAGGAAGCGGTACGCCATTCCGCCGCAAGCTTTCAGCAATATCAGGGTAGCCAA
 CGTATGTCTTGATAAGCGGTCCGCCACACCCAGCCGGCCACAGTCGATGAATCCAGAAAAAGCGGCCATTTCACCATGATATTGGCAAGCAGGCAATCGC
 CATGGCTCACGACGAGATCCTCGCCGTCCGGCATCGCGCTTGAAGCTTGGCAAGTTCGGTGGCGGAGCCCCGTGATGCTCTTCGTCCAGATCATCC
 TGATCGACAAAGACCGGCTTCCATCCGAGTAGTGCTCGCTCGATGGGATGTTCCGCTTGGTGGTGAATGGGCAAGTAGCCGGATCAAGCGGATGCCAGCCG
 CCGCATTTGCAITCAGCCATGATGGATACCTTCTCGGCAAGGCAAGGTGAGATGACAGAGATCCCTGCCCGGCACTTTCGCCAATAGCAGCCAGTCCCTTC
 CCGCTTCAGTGACAAAGTCCGACACAGCTGGCGAAGGAACGCCCGTCTGTGGCCACGACAGATAGCCGCGTGCCTCGCTCGAGTTCAATTCAGGGGAC
 CGGACAGGTGGGCTTGGACAAAAAGAACCGGGGCCCTGGCGTGAACAGCCGGAACACGGCGGCATCAGAGCAGCGGATTTGCTGTTGTGCCCAT
 AGCCGAATAGCTCTCCACCCAAAGCGGCGGAGAACCTGGGTGCAATCCATCTTGAATCAATGCGAAAGCATCTCATCTGTCTTGTATCAGATCTTGAT
 CCGCTGCCCATCAGATCCCTTGGCGGCAAGAACCATCCAGTTACTTTGCAAGGGCTTCCCAACCTTACAGAGGGCGGAATTCGAGCTTGCAATGCCCTGCAG
 GT

Fig. 6B



DNA coding sequence for IFN- α 2b gene in pIF0921

ATGGCCCTGACCTTTGCTTACTGGTGGCCCTCCCTGGTGCCTCAGCTGCCAAGTCAAGCTGCTCTGTGGCTGTG
ATCTGCCCTCAAACCCACAGCCCTGGGTAGCAGGAGGACCTTGATGCTCCCTGGCACAGATGAGGAGAATCTCTCT
TTCTCTCGCTTGAAGGACAGACATGACTTTGGATTCCCCAGGAGGAGTTGGCAACCAAGTTCCAAAGGCT
GAAACCATCCCTGTCCCTCCATGAGATGATCCAGCAGATCTCAATCTCTCAGCACAAAGGACTCATCTGCTG
CTTGGGATGAGACCCCTCCTAGACAAATTTCTACACTGAACCTCTACCAGCAGCTGAATGACCTGGAAGCCGTGTG
GATACAGGGGGTGGGGGTGACAGAGACTCCCTGATGAAGGAGGACTCCATTCTGGCTGTGAGGAAATACCTTC
CAAGAAATCACTCTCTATCTGAAGAGAGAAATACAGCCCTTGTGCTGGGAGGTTGTCAAGCAGAAATCA
TGAGATCTTTTCTTTGTCAACAACCTTGCAAGAAAGTTAAGAAGTAAGGAATGA

Fig. 7B

17/19

SUBSTITUTE SHEET (RULE 26)




Fig. 8

IL-12 Gene Medicine (Combination Therapy) in Renca Model




Fig. 9

Sequence Listing Part

<110> NORDSTROM, JEFF; PERICLE, FEDERICA; ROLLAND,
ALLAIN; RALSTON, ROBERT

<120> INTERFERON ALPHA PLASMIDS AND DELIVERY SYSTEMS,
AND METHODS OF MAKING AND USING THE SAME

<150> US 08/949,160 and PCT/US97/18779

<151> October 10, 1997

<160> 25

<210> 1

<211> 328

<212> amino acid

<400> 1

Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu
1 5 10 15

Ala Ser Pro Leu Val Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val
20 25 30

Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu
35 40 45

Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln
50 55 60

Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys
65 70 75 80

Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val
85 90 95

Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp
100 105 110

Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe
115 120 125

Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp
130 135 140

Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg
145 150 155 160

Gly Ser Ser Asp Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser
165 170 175

Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu
180 185 190

Cys Gln Glu Asp Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile
 195 200 205
 5 Glu Val Met Val Asp Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr
 210 215 220
 Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn
 225 230 235 240
 10 Leu Gln Leu Lys Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp
 245 250 255
 15 Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr
 260 265 270
 Phe Cys Val Gln Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg
 275 280 285
 20 Val Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala
 290 295 300
 Ser Ile Ser Val Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser
 305 310 315 320
 25 Glu Trp Ala Ser Val Pro Cys Ser
 325

<210> 2

30 <211> 987

<212> nucleic acid

<400> 2

35 ATGTGTCAACC AGCAGTTGGT CATCTCTTGG TTTTCCCTGG TTTTCTGGC ATCTCCCTC 60
 GTGGCCATAT GGAAGCTGAA GAAAGATGTT TATGTCGTAG AATTGGATTG GTATCCGGAT 120
 GCCCCTGGAG AAATGGTGGT CCTCACCTGT GACACCCCTG AAGAAGATGG TATCACCTGG 180
 ACCTTGGACC AGAGCAGTGA GGTCTTAGGC TCTGGCAAAA CCTGACCAT CCAAGTCAAA 240
 GAGTTTGGAG ATGCTGGCCA GTACACCTGT CACAAAGGAG GCGAGGTTCT AAGCCATTCT 300
 CTCTCTGCTG TACACAAAAA GGAAGATGGA ATTTGGTCCA CTGATATTTT AAAGGACCAG 360
 40 AAAGAACCCA AAAATAAGAC CTTTCTAAGA TGCAGAGCCA AGAATTATTC TGGACGTTTC 420
 ACCTGCTGGT GGCTGACGAC AATCAGTACT GATTTGACAT TCAGTGTCAA AAGCAGCAGA 480
 GGCTCTTCTG ACCCCCAAGG GGTGACGTGC GGAGCTGCTA CACTCTCTGC AGAGAGAGTC 540
 AGAGGGGACA ACAAGGAGTA TGAGTACTCA GTGGAGTGCC AGGAGGACAG TGCCTGCCCA 600
 CTGCTGAGG AGAGTCTGCC CATTGAGGTC ATGGTGGATG CCGTTCACAA GCTCAAGTAT 660
 45 GAAAACTACA CCAGCAGCTT CTTTATCAGG GACATCATCA AACCTGACCC ACCCAAGAAC 720
 TTGCAGCTGA AGCCATTAAA GAATTCCTCG CAGGTGGAGG TCAGCTGGGA GTACCCTGAC 780
 ACCTGGAGTA CTCCACATT CTACTTCTCC CTGACATTCT GCGTTCAGGT CCAGGGCAAG 840
 AGCAAGAGAG AAAAGAAAGA TAGAGTCTTC ACGGACAAGA CCTCAGCCAC GGTCTATCTG 900
 CGCAAAAATG CCAGCATTAG CGTGCGGGCC CAGGACCGCT ACTATAGCTC ATCTTGGAGC 960
 50 GAATGGGCAT CTGTGCCCTG CAGTTAG 987

3

<210> 3
 <211> 987
 <212> nucleic acid
 <400> 3

5
 10
 15
 20

ATGTGCCACC	AGCAGCTGGT	GATCAGCTGG	TTCAGCCTGG	TGTTCTGGGC	CAGCCCCCTG	60
GTGGCCATCT	GGGAGCTGAA	GAAGGACGTG	TACGTGGTGG	AGCTGGACTG	GTACCCCGAC	120
GCCCCCGGCG	AGATGGTGGT	GCTGACCTGC	GACACCCCGG	AGGAGGACGG	CATCACCTGG	180
ACCTTGACC	AGAGCAGCGA	GGTGCTGGGC	AGCGGCAAGA	CCCTGACCAT	CCAGGTGAAG	240
GAGTTCCGGC	ACGCCGGCCA	GTACACCTGC	CACAAGGGCG	GCGAGGTGCT	GAGCCACAGC	300
CTGCTGCTGC	TGCACAAGAA	GGAGGACGGC	ATCTGGAGCA	CCGACATCCT	GAAGGACCAG	360
AAGGAGCCCA	AGAACAAGAC	CTTCCTGCGC	TGCGAGGCCA	AGAACTACAG	CGGCCGCTTC	420
ACCTGCTGGT	GGCTGACCAC	CATCAGCACC	GACCTGACCT	TCAGCGTGAA	GAGCAGCAGG	480
GGCAGCAGGT	ACCCCCAGGG	CGTGACCTGC	GGCGCCGCCA	CCCTGAGCGC	CGAGCGCGTG	540
CGCGCGGACA	ACAAGGAGTA	CGAGTACAGC	GTGGAGTGCC	AGGAGGACAG	CGCTGCCCTC	600
GCCGCCGAGG	AGAGCCTGCC	CATCGAGGTG	ATGGTGGACG	CCGTCCACAA	GCTGAAGTAC	660
GAGAACTACA	CCAGCAGCTT	CTTCATCCGC	GACATCATCA	AGCCCCGACC	CCCAAGAAGC	720
CTGCAGCTGA	AGCCCTTGAA	GAACAGCCGC	CAGGTGGAGG	TGAGCTGGGA	GTACCCCGAC	780
ACCTGGAGCA	CCCCCAGAG	CTACTTCAGC	CTGACCTTCT	GCGTGCAGGT	CGAGGGCAAG	840
AGCAAGCGCG	AGAAGAAGGA	CCGCGTGTTC	ACCGACAAGA	CCAGCGCCAC	CGTGATCTGC	900
CGCAAGAACG	CCAGCATCAG	CGTGCGCGCC	CAGGACCGCT	ACTACAGCAG	CAGCTGGAGC	960
GAGTGGGCCA	GCGTGCCCTG	CAGCTAG				987

<210> 4
 25 <211> 987
 <212> nucleic acid
 <400> 4

30
 35
 40
 45

ATGTGCCACC	AGCAGCTGGT	GATCAGCTGG	TTCTCCCTGG	TGTTTCTGGC	CAGCCCCCTC	60
GTGGCCATCT	GGGAGCTGAA	GAAAGACGTG	TACGTGGTGC	AGCTGGACTG	GTACCCCGAC	120
GCCCCCGGCG	AGATGGTGGT	CCTGACCTGC	GACACCCCGG	AGGAAGACGG	CATCACCTGG	180
ACCTTGACC	AGAGCAGTGA	GGTGCTGGGC	TCCGGCAAGA	CCCTGACCAT	CCAGGTGAAG	240
GAGTTCCGGC	ACGCCGGCCA	GTACACCTGC	CACAAGGGAG	GCGAGGTGCT	GAGCCACTCC	300
CTCCTGCTGC	TCCACAAAAA	GGAGGACGGC	ATCTGGAGCA	CCGACATCCT	GAAGGACCAG	360
AAGGAGCCCA	AGAACAAGAC	CTTCCTGCGC	TGCGAGGCCA	AGAACTACAG	CGGCCGCTTC	420
ACCTGCTGGT	GGCTGACCAC	GATCAGCACC	GACCTGACCT	TCAGTGTGAA	GAGCAGCAGG	480
GGCTCCAGCG	ACCCCCAGGG	CGTGACCTGC	GGCGCTGCCA	CCCTGAGCGC	CGAGCGCGTG	540
CGCGCGGACA	ACAAGGAGTA	CGAGTACAGC	GTGGAGTGCC	AGGAAGACTC	CGCCTGCCCT	600
GCCGCTGAGG	AGAGCCTGCC	CATCGAGGTG	ATGGTGGACG	CCGTTTCAAA	GCTGAAGTAC	660
GAGAACTACA	CCAGCAGCTT	CTTCATCCGC	GACATCATCA	AGCCTGACCC	ACCCAAGAAG	720
CTCCAGCTGA	AGCCCTTCAA	GAACCTCCGC	CAGGTGGAGG	TGAGCTGGGA	GTACCCCGAC	780
ACCTGGAGCA	CGCCCCACTC	CTACTTCTCC	CTGACCTTCT	GCGTGCAGGT	CCAGGGCAAG	840
AGCAAGCGCG	AGAAGAAGGA	CCGGGTGTTC	ACCGACAAGA	CCAGCGCCAC	CGTCACTCTC	900
CGCAAGAACG	CCAGCATCAG	CGTGCGCGCC	CAGGACCGCT	ACTATAGCTC	CTCTTGGAGC	960
GAGTGGGCCA	GCGTGCCCTG	CTCCTAG				987

<210> 5
 <211> 219
 <212> amino acid
 50 <400> 5

Met Cys Pro Ala Arg Ser Leu Leu Leu Val Ala Thr Leu Val Leu Leu
 1 5 10 15

4

	Asp	His	Leu	Ser	Leu	Ala	Arg	Asn	Leu	Pro	Val	Ala	Thr	Pro	Asp	Pro	
				20					25					30			
5	Gly	Met	Phe	Pro	Cys	Leu	His	His	Ser	Gln	Asn	Leu	Leu	Arg	Ala	Val	
			35					40					45				
	Ser	Asn	Met	Leu	Gln	Lys	Ala	Arg	Gln	Thr	Leu	Glu	Phe	Tyr	Pro	Cys	
		50					55					60					
10	Thr	Ser	Glu	Glu	Ile	Asp	His	Glu	Asp	Ile	Thr	Lys	Asp	Lys	Thr	Ser	
	65					70					75					80	
	Thr	Val	Glu	Ala	Cys	Leu	Pro	Leu	Glu	Leu	Thr	Lys	Asn	Glu	Ser	Cys	
					85					90					95		
15	Leu	Asn	Ser	Arg	Glu	Thr	Ser	Phe	Ile	Thr	Asn	Gly	Ser	Cys	Leu	Ala	
				100					105					110			
	Ser	Arg	Lys	Thr	Ser	Phe	Met	Met	Ala	Leu	Cys	Leu	Ser	Ser	Ile	Tyr	
20			115					120					125				
	Glu	Asp	Leu	Lys	Met	Tyr	Gln	Val	Glu	Phe	Lys	Thr	Met	Asn	Ala	Lys	
		130					135					140					
25	Leu	Leu	Met	Asp	Pro	Lys	Arg	Gln	Ile	Phe	Leu	Asp	Gln	Asn	Met	Leu	
	145					150					155					160	
	Ala	Val	Ile	Asp	Glu	Leu	Met	Gln	Ala	Leu	Asn	Phe	Asn	Ser	Glu	Thr	
					165					170					175		
30	Val	Pro	Gln	Lys	Ser	Ser	Leu	Glu	Glu	Pro	Asp	Phe	Tyr	Lys	Thr	Lys	
				180					185					190			
	Ile	Lys	Leu	Cys	Ile	Leu	Leu	His	Ala	Phe	Arg	Ile	Arg	Ala	Val	Thr	
35			195					200					205				
	Ile	Asp	Arg	Val	Thr	Ser	Tyr	Leu	Asn	Ala	Ser						
		210					215										
40	<210>		6														
	<211>		660														
	<212>		nucleic acid														
	<400>		6														
45	ATGTGTCCAG	CGCGCAGCCT	CCTCCTTGTG	GCTACCCTGG	TCCTCCTGGA	CCACCTCACT										60	
	TTGGCCAGAA	ACCTCCCGT	GGCCACTCCA	GACCCAGGAA	TGTTCCCATG	CCTTCAACCAC										120	
	TCCCAAACCC	TGCTGAGGGC	CGTCAGCAAC	ATGCTCCAGA	AGGCCAGACA	AACTCTAGAA										180	
	TTTTACCCTT	GCACTTCTGA	AGAGATTGAT	CATGAAGATA	TCACAAAAGA	TAAAACCCAGC										240	
	ACAGTGGAGG	CCTGTTTACC	ATTGGAATTA	ACCAAGAATG	AGAGTTGCCT	AAATTCCAGA										300	
50	GAGACCTCTT	TCATAACTAA	TGGGAGTTGC	CTGGCCTCCA	GAAAGACCTC	TTTATGATG										360	
	GCCCTGTGCC	TTAGTAGTAT	TTATGAAGAC	TTGAAGATGT	ACCAGGTGGA	GTTCAAGACC										420	
	ATGAATGCAA	AGCTTCTGAT	GGATCCTAAG	AGGCAGATCT	TTCTAGATCA	AAACATGCTG										480	
	GCAGTTATTG	ATGAGCTGAT	GCAGGCCCTG	AATTTCAACA	GTGAGACTGT	GCCACAAAAA										540	
	TCCTCCCTTG	AAGAACCGBA	TTTTTATAAA	ACTAAAATCA	AGCTCTGCAT	ACTTCTTCAT										600	
55	GCTTTCAGAA	TTCGGGCAGT	GACTATTGAC	AGAGTGACGA	GCTATCTGAA	TGCTTCTTAA										660	

5

<210> 7
 <211> 660
 <212> nucleic acid
 <400> 7

5
 10
 15
 ATGTGCCCCG CCGCAGCCT GCTGCTGGTG GCCACCCTGG TGCTGCTGGA CCACCTGAGC 60
 CTGGCCCCGA ACCTGCCCCG GGCCACCCCC GACCCCGGCA TGTTCCCCCTG CCTGCACCAC 120
 AGCCAGAACC TGCTGGCGGC CGTGAGCAAC ATGCTGCAGA AGGCCGCGCA GACCCTGGAG 180
 TTCTACCCCT GCACCAGCGA GGAGATCGAC CACGAGGACA TCACCAAGGA CAAGACCAGC 240
 ACCGTGGAGG CCTGCGCTGCC CTGGAGCTG ACCAAGAACG AGAGCTGCCT GAACAGCCGC 300
 GAGACCAGCT TCATCACCAA CGGCAGCTGC CTGGCCAGCC GCAAGACCAG CTTCATGATG 360
 GCCCTGTGCC TGAGCAGCAT CTACGAGGAC CTGAAGATGT ACCAGGTGGA GTTCAAGACC 420
 ATGAACGCCA AGCTGCTGAT GGACCCCAAG CTCCAGATCT TCCTGGACCA GAACATGCTG 480
 GCCGTGATCG ACGAGCTGAT GCAGGCCCTG AACTTCAACA GCGAGACCGT GCCCCAGAAG 540
 AGCAGCCTGG AGGAGCCCGA CTTCTACAAG ACCAAGATCA AGCTGTGCAT CCTGCTGCAC 600
 GCCTTCCGCA TCCGCGCCGT GACCATCGAC CGCGTGACCA GCTACCTGAA CGGCACCTGA 660

<210> 8
 <211> 660
 20 <212> nucleic acid
 <400> 8

25
 30
 ATGTGCCCCG CCGCAGCCT GCTGCTCGTG GCCACCCTGG TGCTCCTGGA CCACCTCAGC 60
 CTGGCCCCGA ACCTCCCCGT GGCCACCCCA GACCCCGGCA TGTTCCCATG CCTGCACCAC 120
 AGCCAGAACC TGCTGGCGGC CGTGAGCAAC ATGCTGCAGA AGGCCGCGCA GACCCTGGAG 180
 TTCTACCCCT GCACCAGCGA GGAGATCGAC CACGAGGACA TCACCAAGGA CAAGACCAGC 240
 ACCGTGGAGG CCTGCGCTGCC CTTCGAGTTA ACCAAGAACG AGAGCTGCCT CAACAGCCGC 300
 GAGACCTCCT TCATCACCAA CGGCACCTTGC CTGGCCTCCC GCAAGACCAG CTTCATGATG 360
 GCCCTGTGCC TGAGCTCCAT CTACGAGGAC CTGAAGATGT ACCAGGTGGA GTTCAAGACC 420
 ATGAACGCCA AGCTCCTGAT GGACCCCAAG CTCCAGATCT TCCTGGACCA GAACATGCTG 480
 GCCGTGATCG ACGAGCTGAT GCAGGCCCTG AACTTCAACA GCGAGACCGT GCCCCAGAAG 540
 AGCAGCCTGG AGGAGCCCGA CTTCTACAAG ACCAAGATCA AGCTGTGCAT CCTGCTGCAC 600
 GCCTTCCGCA TCCGGGCCGT GACCATCGAC CGCGTGACCA GCTACCTGAA CGGCACGTGA 660

35 <210> 9
 <211> 188
 <212> amino acid
 <400> 9

40 Met Ala Leu Thr Phe Ala Leu Leu Val Ala Leu Leu Val Leu Ser Cys
 1 5 10 15
 Lys Ser Ser Cys Ser Val Gly Cys Asp Leu Pro Gln Thr His Ser Leu
 20 25 30
 45 Gly Ser Arg Arg Thr Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser
 35 40 45
 Leu Phe Ser Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu
 50 50 55 60
 Glu Phe Gly Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His
 65 70 75 80

Glu Met Ile Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser
85 90 95

5 Ala Ala Trp Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr
100 105 110

Gln Gln Leu Asn Asp Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val
115 120 125

10 Thr Glu Thr Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys
130 135 140

15 Tyr Phe Gln Arg Ile Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro
145 150 155 160

Cys Ala Trp Glu Val Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu
165 170 175

20 Ser Thr Asn Leu Gln Glu Ser Leu Arg Ser Lys Glu
180 185

<210> 10

<211> 567

25 <212> nucleic acid

<400> 10

30 ATGGCCTTGA CCTTTGCTTT ACTGGTGGCC CTCCTGGTGC TCAGCTGCAA GTCAAGCTGC 60
TCTGTGGGCT GTGATCTGCC TCAAACCCAC AGCCTGGGTA GCAGGAGGAC CTTGATGCTC 120
CTGGCACAGA TGAGGAGAAT CTCTCTTTTC TCCTGCTTGA AGGACAGACA TGACTTTGGA 180
TTTCCCCAGG AGGAGTTTGG CAACCACTTC CAAAAGGCTG AAACCATCCC TGCTCTCCAT 240
GAGATGATCC AGCAGATCTT CAATCTCTTC AGCACAAAGG ACTCATCTGC TGCTTGGGAT 300
GAGACCTTCC TAGACAAATT CTACACTGAA CTCTACCAGC AGCTGAATGA CCTGGAAGCC 360
TGTGTGATAC AGGGGGTGGG GGTGACAGAG ACTCCCCTGA TGAAGGAGGA CTCATTCTG 420
35 GCTGTGAGGA AATACTTCCA AAGAATCACT CTCTATCTGA AAGAGAAGAA ATACAGCCCT 480
TGTGCCTGGG AGGTTGTGAG AGCAGAAATC ATGAGATCTT TTTCTTTGTC AACAACTTG 540
CAAGAAAGTT TAAGAAGTAA GGAATGA 567

<210> 11

40 <211> 567

<212> nucleic acid

<400> 11

45 ATGGCCCTGA CCTTCGCCCT GCTGGTGGCC CTGCTGGTGC TGAGCTGCAA GAGCAGCTGC 60
TCCGTGGGGT GCGACCTGCC CCAGACCCAC AGCCTGGGGA GCCGCGGAC CTTGATGCTG 120
CTGGCCCCAGA TCGGCGGGAT CAGCCTGTTC AGCTGCCTGA AGGACCGGCA CGACTTCGGG 180
TTCCCCAGG AGGAGTTCGG GAACCACTTC CAGAAGGCCG AGACCATCCC CGTCTGCAC 240
GAGATGATCC AGCAGATCTT CAACCTGTTC AGCACCAAGG ACAGCAGCGC CGCCTGGGAC 300
GAGACCTTGC TGGACAAGTT CTACACCGAG CTGTACCAGC AGCTGAACGA CCTGGAGGCC 360
50 TCCGTGATCC AGGGGGTGGG GGTGACCGAG ACCCCCCTGA TGAAGGAGGA CAGCATCTCTG 420
GCCGTGCGGA AGTACTTCCA GCGGATCACC CTGTACCTGA AGGAGAAGAA GTACTCCCCC 480
TGCGCCTGGG AGGTGGTGGC GGCAGAGATC ATGCGGAGCT TCAGCCTGAG CACCAACCTG 540
CAGGAGAGCC TCGGAGACAA GGAGTGA 567

7

- <210> 12
 <211> 567
 <212> nucleic acid
 <223> "Y" stands for C or T; "R" stands for A or G;
 5 "W" stands for T or A; "S" stands for C or G; "N"
 stands for any base.
 <400> 12
- | | | | | | | | |
|----|------------|------------|------------|------------|------------|------------|-----|
| 10 | ATGGCNYTNA | CNTTYGCNYT | NYTNGTNGCN | YTNYTNGTNY | TNWSNTGYAA | RWSNWSNTGY | 60 |
| | WSNGTNGGNT | GYGAYYTNC | NCARACNCAY | WSNYTNGGNW | SNMGNMGNAC | NYTNATGYTN | 120 |
| | YTNGCNCARA | TGMGMGNAT | HWSNYTNTTY | WSNTGYYTNA | ARGAYMGNCA | YGAYTTYGNN | 180 |
| | TTYCCNCARG | ARGARTTYGG | NAAYCARTTY | CARAARGCNG | ARACNATHCC | NGTNYTNCAY | 240 |
| | GARATGATHC | ARCARATHTT | YAAYYTNTTY | WSNACNAARG | AYWSNWSNGC | NGCNTGGGAY | 300 |
| | GARACNYTNY | TNGAYAARTT | YTAYACNGAR | YTNTAYCARC | ARYTNAAYGA | YTINGARGCN | 360 |
| 15 | TGYGTNATHC | ARGGNGTNGG | NGTNACNGAR | ACNCCNYTNA | TGAARGARGA | YWSNATHYTN | 420 |
| | GCNGTNMGNA | ARTAYTTYCA | RMGNATHACN | YTNTAYYTNA | ARGARAARAA | RTAYWSNCCN | 480 |
| | TGYGCNTGGG | ARGTNGTNMG | NGCNGARATH | ATGMGNWSNT | TYWSNYTNWS | NACNAAYYTN | 540 |
| | CARGARWSNY | TNMGNWSNAA | RGARTRR | | | | 567 |
- 20 <210> 13
 <211> 191
 <212> nucleic acid
 <400> 13
- | | | | | | | | |
|----|-------------|------------|------------|------------|-------------|-------------|-----|
| 25 | GGGTGGCATC | CCTGTGACCC | CTCCCCAGTG | CCTCTCCTGG | CCCTGGAAGT | TGCCACTCCA | 60 |
| | GTGCCCCACCA | GCCTTGTCTC | AATAAAATTA | AGTTGCATCA | TTTGTCTCTGA | CTAGGTGTGCC | 120 |
| | TTCTATAATA | TTATGGGGTG | GAGGGGGGTG | GTATGGAGCA | AGGGGCAAGT | TGGGAAGACA | 180 |
| | ACCTGTAGGG | C | | | | | 191 |
- 30 <210> 14
 <211> 58
 <212> nucleic acid
 <400> 14
- 35 AAGCTTACTC AACACAATAA CAAACTTACT TACAATCTTA ATTAACAGGC CACCATGG 58
- <210> 15
 <211> 15
 <212> nucleic acid
 40 <400> 15
- CAGGTAAGTG TCTTC

15

<210> 16
 <211> 30
 <212> nucleic acid
 <400> 16

5

TACTAACGGT TCTTTTTTTC TCTTCACAGG

30

<210> 17
 <211> 271
 <212> nucleic acid
 <400> 17

10

TCTAGAGCAT TTTCCCTCT GCCAAAATT ATGGGGACAT CATGAAGCCC CTTGAGCATC 60
 TGACGTCTGG CTAATAAAGG AATTTTATTT TCATTGCAAT AGTGTGTTGG AATTTTTTGT 120
 GTCTCTCACT CGGTACTAGA GCATTTTTCC CTCTGCCAAA AATTATGGGG ACATCATGAA 180
 GCCCCTTGAG CATCTGACGT CTGGCTAATA AAGGAAATTT ATTTTCATTG CAATAGTGTG 240
 TTGGAATTT TTGTGTCTCT CACTCGGTAC C 271

15

<210> 18
 <211> 5686
 <212> nucleic acid
 <400> 18

20

25

CCGGCCACAG TCGATGAATC CAGAAAAGCG GCCATTTTCC ACCATGATAT TCGGCAAGCA 60
 GGCAATGCCA TGCGTCACGA CGAGATCCTC GCCGTCGGGC ATGCGCGCCT TGAGCCTGGC 120
 GAACAGTTCC GCTGGCGCGA GCCCCTGATG CTCTTCGTCC AGATCATCCT CATGCAACAG 180
 ACCGGCTTCC ATCCGAGTAG GTGCTCGCTC GATGCGATGT TTCGCTTGGT GGTGCAATGG 240
 GCAGGTAGCC GGATCAAGCG TATGCAGCCG CGCATTTGCA TCAGCCATGA TGGATACTTT 300
 CTGGGACGGA GCAAGGTGAG ATGACAGGAG ATCCTGCCCC GGCACCTTCGC CCAATAGCAG 360
 CCAGTCCCTT CCCGCTTCAG TGACAAACGC GAGCACAGCT GCGCAAGGAA CGCCCGTCGT 420
 GGCACGCCAC GATAGCCGCG CTGCCTCGTC CTGCAGTTCA TTCAGGGCAC CGGACAGGTC 480
 GGTCTTGACA AAAAGAACC GCGCGCCCTG CGCTGACAGC CGGAACACGG CGGCATCAGA 540
 GCAGCCGATT GTCTGTTGTG CCCAGTCAAT GCGGAATAGC CTCTCCACCC AAGCGGCCGG 600
 AGAACCTGCG TGCAATCCAT CTGTTCATAT CATGCGAAAC GATCCTCATC CTGTCTCTTG 660
 ATCAGATCTT GATCCCTGCG GCCATCAGAT CCTTGGCGGC AAGAAAGCCA TCCAGTTTAC 720
 TTTGACGGGC TTCCCAACCT TACCAGAGGG CGAATTCGAG CTTGCATGCC TGCAGGTCGT 780
 TACATAATT ACGGTAATG GCGCGCTGCG CTGACCGCCC AACGACCCCC GCCCATTTGAC 840
 GTCAATAATG ACGTATGTT CCATAGTAAC GCCAATAGGG ACTTCCATT GACGTCATG 900
 GGTGGAGTAT TTACGGTAAA CTGCCCACTT GGCAATAGG CAAGTGTATC ATATGCCAAG 960
 TACGCGCCCT ATTGACGTCA ATGACGGTAA ATGGCCCGCC TGGCATATG CCCAGTACAT 1020
 GACCTTATGG GACTTTCCTA CTGCGCAGTA CATCTACGTA TTAGTCATCG CTATTACCAT 1080
 GGTGATGCGG TTTTGGCAGT ACATCAATGG GCGTGGATAG CGGTTTGACT CACGGGGATT 1140
 TCCAAGTCTC CACCCCATG ACGTCAATGG GAGTTTGTG TGGCACCATA ATCAACGGGA 1200
 CTTTCCAAAA TGTCGTAAGA ACTCCGCCCC ATTGACGCAA ATGGGCGGTA GCGGTGTACG 1260
 GTGGGAGGTC TATATAAGCA GAGCTCGTTT AGTGAACCGT CAGATCGCCT GGAGACGCCA 1320
 TCCACGCTGT TTTGACCTCC ATAGAAGACA CCGGGACCGA TCCAGCCTCC GCGGCCGGGA 1380
 ACCGTGCATT GGAACGCGGA TTCCCGGTGT TAATTAACAG GTAAGTGTCT TCCTCCTGTT 1440
 TCCTTCCCTT GCTATTCTGC TCAACCTTCC TATCAGAAAC TGCAGTATCT GTATTTTTCG 1500
 TAGCAATT ACTAAGCGTT CTTTTTTCT CTTCACAGGC CACCATGGGT CCAGCGCGCA 1560
 GCCTTCCTCT TGTGGCTACC CTGGCCTTCC TGGACCACCT CAGTTTGGCC AGAAACCTCC 1620
 CCGTGGCCAC TCCAGACCCA GGAATGTTCC CATGCCTTCA CCACTCCCAA AACCTGCTGA 1680
 GGGCCGTCAG CAACATGCTC CAGAAGGCCA GACAACTCT AGAATTTTAC CCTTGCATTT 1740
 CTGAAGAGAT TGATCATGAA GATATCAAA AAGATAAAAC CAGCACAGT GAGGCTGTTT 1800
 TACCATTTGA ATTAACCAAG AATGAGAGTT GCCTAAATTC CAGAGAGACC TCTTTCATAA 1860
 CTAATGGGAG TTGCTGGCC TCCAGAAAGA CCTCTTTTAT GATGGCCCTG TCCCTTAGTA 1920
 GTATTTATGA AGACTTGAAG ATGTACCAGG TGGAGTTCAA GACCATGAAT GCAAAGCTTC 1980
 TGATGGATCC TAAGAGGCAG ATCTTTCTAG ATCAAAACAT GCTGGCAGTT ATTGATGAG 2040

30

35

40

45

50

55

	TGATGCAGGC	CCTGAATTTT	AACAGTGAGA	CTGTGCCACA	AAAATCCTCC	CTTGAAGAAC	2100
	CGGATTTTTA	TAAACATAAA	ATCAAGCTCT	GCATACTTCT	TCATGCTTTC	AGAATTCGGG	2160
	CAGTGACTAT	TGATAGAGTG	ATGAGCTATC	TGAATGCTTC	CTAACCAATTC	TAGAAAAAGCC	2220
	GAATTCGTGA	GGAATTGGGT	GGCATCCCTG	TGACCCCTCC	CCAGTGCCCTC	TCCTGGCCCTT	2280
5	GGAAAGTTGCC	ACTCCAGTGC	CCACCAGCCT	TGTCCTAATA	AAATTAAGTT	GCATCATTTT	2340
	GTCTGACTAG	GTGCTCTTCT	ATAATATTAT	GGGGTGGAGG	GGGGTGGTAT	GGAGCAAGGG	2400
	GCAGGTTGGG	AAGACAACCT	GTAGGGCTCG	AGGGGGGGCC	CGGTACGGTC	GTTACATAAC	2460
	TTACGGTAAA	TGGCCCGCCT	GGCTGACCGC	CCAACGACCC	CCGCCCATTC	ACGTCAATAA	2520
	TGACGTATGT	TCCCATAGTA	ACGCCAATAG	GGACTTTCCA	TTGACGTCAA	TGGGTGGAGT	2580
10	ATTTACGGTA	AACCTGCCAC	TTGGCAGTAC	ATCAAGTGTA	TCATATGCCA	AGTACGCCCC	2640
	CTATTGACGT	CAATGACCGT	AAATGGCCCG	CCTGGCATT	TGCCCAGTAC	ATGACCTTAT	2700
	GGGACTTTCC	TACTTTGGCAG	TACATCTACG	TATTAGTCAT	CGCTATTACC	ATGGTGATGC	2760
	GGTTTGGCA	GTACATCAAT	GGGCGTGGAT	AGCGGTTTGA	CTCACGGGGA	TTTCCAAGTC	2820
	TCCACCCCAT	TGACGTCAAT	GGGAGTTTGT	TTTGGCACC	AAATCAACGG	GACTTTCCAA	2880
15	AATGTCCGTA	CAACTCCGCC	CCATTGACGC	AAATGGGCGG	TAGGCGTGTA	CGGTGGGAGG	2940
	TCTATATAAG	CAGAGCTCGT	TTAGTGAACC	GTCAGATCGC	CTGGAGACGC	CATCCACCGT	3000
	GTTTTGACCT	CCATAGAAGA	CACCGGAGCC	GATCCAGCCT	CCGCGGCGCG	GAACGGTGGA	3060
	TTTGAACCGG	GATTCCCGCT	TTTAATTAA	AGGTAAGTGT	CTTCTCCTG	TTTCTTCC	3120
	CTGCTATTCT	GCTCAACCTT	CCATCAGAA	ACTGCAGTAT	CTGTATTTT	GCTAGAAATT	3180
20	TACTAACCGT	TCCTTTTTTC	CTTTCACAGG	CTTAAGTCAT	GGGTCAACAG	CAGTTGGTCA	3240
	TCTCTTGGTT	TTCCCTGGTT	TTTCTGGCAT	CTCCCTCGT	GGCCATATGG	GAAGTGAAGA	3300
	AAGATGTTTA	TGTCGTAGAA	TTGGATTGGT	ATCCGGATGC	CCCTGGAGAA	ATGGTGGTCC	3360
	TCACCTGTGA	CACCCCTGAA	GAAGATGGTA	TCACCTGGAC	CTTGGACCAG	AGCAAGTGGG	3420
	TCTTAGGCTC	TGGCAAAACC	CTGACCATCC	AAGTCAAGA	GTTTGGAGAT	CTGGGCCAGT	3480
25	ACACCTGTCA	CAAAGGAGGC	GAGGTTCTAA	GCCATTCCGT	CCTGCTGCTT	CACAAAGAGG	3540
	AAGATGGAAT	TTGGTCCACT	GATATTTTAA	AGGACCAGAA	AGAAGCCAAA	AATAAGACCT	3600
	TCTTAAGATT	CGAGGCCAAG	AATATTCTG	GACGTTTCAC	CTGCTGGTGG	CTGACGACAA	3660
	TCAGTACTGA	TTTGACATTC	AGTGTCAAAA	GCAGCAGAGG	CTCTTCTGAC	CCCAAGGGG	3720
	TGACGTGCGG	AGCTGCTACA	CTCTCTGCAG	AGAGAGTCAG	AGGGGACAA	AGGAGTATG	3780
30	AGTACTCAGT	GGAGTGCCAG	GAGGACAGTG	CCTGCCACGC	TGCTGAGGAG	AGTCTGCCCA	3840
	TTGAGGTGAT	GGTGGATGCC	GTTTCAACAG	TCAAGTATGA	AAACTACACC	AGAGCTTCTT	3900
	TCATCAGGGA	CATCATCAAA	CCTGACCCAC	CCAAGAACTT	CGAGCTGAAG	CCATTAAAGA	3960
	ATTCTCGGCA	GGTGAGAGTG	AGCTGGGAGT	ACCTTGACAC	CTGGAGTACT	CCACATTCCT	4020
35	ACTTCTCCCT	GACATTCTGC	TGCTCAGTCC	AGGGCAAGAG	CAAGAGAGAA	AAGAAAGGAA	4080
	GAGTCTTAC	GGACAAGACC	TCAGCCACGG	TCATCTGCCG	CAAAAATGCC	AGCATTAGCG	4140
	TGCGGGCCCA	GGACCGCTAC	TATAGCTCAT	CTTGGAGCGA	ATGGGCATCT	GTGCCCTGCA	4200
	GTAGACGCG	CTAGAAAAGC	CGAATTCTGC	AGGAATTGGG	TGGCATCCCT	GTGACCCCTC	4260
	CCAGTGCCT	CTCCTGGCCC	TGGAAGTTGC	CACCTCCAGT	CCCACCAGCC	TTGTCTTAAT	4320
40	AAAATTAAGT	TGCATCATTT	TGCTGACTA	GGTGTCTTTC	TATAATATTA	TGGGGTGGAG	4380
	GGGGTGGSTA	TGGAGCAAGG	GGCAAGTTGG	GAAGACAACC	TGTAGGGCTC	GAGGGGGGGG	4440
	CCGGTACCAG	CTTTTGTTC	CTTTAGTGAG	GGTTAATTTT	GAGCTTGGCG	TAATCATGGT	4500
	CATAGCTGTT	TCCTGTGTGA	AATTGTTATC	CGCTCACAAT	TCCACACAAC	ATACGAGCCG	4560
	GAAGCATAAA	GTGTAAAGCC	TGGGGTGCTT	AATGAGTGAG	CTAACTCACA	TTAATTGCGT	4620
45	TGCGCTCACT	GCCCGCTTTC	CAGTCGGGAA	ACCTGTCTGT	CCAGCTGCAT	TAATGAATCG	4680
	GCCACGCGC	GGGGGAGGCG	GGTTTGCCTA	TTGGGCGCTC	TTCCGCTTCC	TGCTCACTG	4740
	ACTCGCTGCG	CTCGGTCTGT	GGGGATAACG	GAGCGGTATC	AGCTCACTCA	AAGGCGGTAA	4800
	TACGGTTATC	CACAGAATCA	AAGGCGCGCT	TGCTGGCGTT	TTTCCATAGG	CTCCGCCCCC	4860
	AAAAGGCCAG	GAACCGTAAA	GAGCGCTCAA	GTCAGAGGTG	GCGAAACCCG	ACAGGACTAT	4920
50	CTGACGAGCA	TCACAAAAAT	CCTGGAAGCT	CCCTCGTGCG	CTCTCCTGTT	CCGACCTGCG	4980
	AAAGATACCA	GGCGGTTTCC	GCTCTTCTCC	CTTCGGGAAG	CAAGCTGGGC	TGTGTGCAGG	5040
	CGTATTACCG	ATACCTGTCC	TGCGGTGAGG	TGCTTCCGCT	TATCCGGTAA	TGAGTCCAAC	5100
	CACGETGTAG	GTATCTCAGT	TCGGTGTAGG	TGCTTCCGCT	TAACAGGAGT	AGCAGAGCGA	5160
	AACCCCGCGT	TACGCCGCGT	CCACTGGCAG	GAGTCTCTGA	AGTGGTGSCC	TACACTAGAA	5220
55	CGGTAAGACA	CGACTTATCG	GAGTCTCTGA	AGTGGTGSCC	CTTCGGAAAA	AGAGTTGGTA	5280
	GGTATGTAGG	CGGTGTCTAC	TGGGTGTCTG	AGCCAGTTAC	TTTTTTTGT	TGCAAGCAGC	5340
	GGACAGTATT	CGGCAAAACAA	ACCACCGCTG	GATGCGGTGG	GATCTTTTCT	ACGGGGTCTG	5400
	GCTCTTGATC	CAGAAAAAAA	GATCTCAAG	AAGATCCTTT	GCGCTGCGAA	TCGGGAGCGG	5460
	AGATTACCGC	GAATCTGTCA	AGAAGCGCAT	AGAAGCGCAT	GCGCTGCGAA	TCGGGAGCGG	5520
	ACGCTCAGAA	AAGCAGCAGG	AAGCGGTGAG	CCCATTCGCT	GCCAAAGTCT	TCAGCAATAT	5580
60	CGATACCGTA	AAGCAGCAGG	AAGCGGTGAG	CCCATTCGCT	GCCAAAGTCT	TCAGCAATAT	5640
	CACGGGTAGC	CAACGCTATG	TACTGATAGC	GGTCCGCCAC	ACCCAG		5686

10

<210> 19
 <211> 3426
 <212> nucleic acid
 <400> 19

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60

GATCCATGGC TAGGCTCTGT GCTTCTCTCA TGATCCTAGT AATGATGAGC TACTACTGGT 60
 CAGCCTGTTC TCTAGGATGT GACCTGCCTC ACACCTTATAA CCTCGGGAAC AAGAGGGCCT 120
 TGACAGTCCT GGAAGAAATG AGAAGACTCC CCCCTCTTTC CTGCCTGAAG GACAGGAAGG 180
 ATTTTGGATT CCCCTTGGAG AAGGTGGATA ACCAACAGAT CCAGAAGGCT CAAGCCATCC 240
 TTGTGCTAAG AGATCTTACC CAGCAGATTT TGAACCTCTT CACATCAAAA GACTTGTCTG 300
 CTACTTGGAA TGCAACTCTC CTAGACTCAT TCTGCAATGA CCTCCATCAG CAGCTCAATG 360
 ATCTCAAAGC CTGTGTGATG CAGGAACCTC CTCTGACCCA GGAAGACTCC CTGCTGGCTG 420
 TGAGGACATA CTTCCACAGG ATCACTGTGT ACCTGAGAAA GAAGAAACAC AGCCTCTGTG 480
 CTTGGAGGT GATCAGAGCA GAAGTCTGGA GAGCCCTCTC TTCTCAACC AACTTGTCTG 540
 CAAGACTGAG TGAGGGAAGG GAGTGATCTA GAAAGCCGAA TTCTGCAGGA ATTTGGCATC 600
 CCTGTGACCC CTCCTCAGTG CCTCTCCTGG CCCTGGAAGT TGCCACTCCA GTGCCACCA 660
 GCCTTGTCTT AATAAAATTA AGTTGCATCA TTTTGTCTGA CTAGGTGTCC TTCTATAATA 720
 TTATGGGGTG GAGGGGGGTG GTATGGAGCA AGGGGGCCAA GTTGGGAAGA CAACCTGTAG 780
 GGCTCGAGGG GGGGGCCGGT ACCAGCTTTT GTTCCCTTTA GTGAGGGTTA ATTTGAGGT 840
 TGCGGTAACT ATGGTCATAG CTGTTTCTGT TGTGAAATTG TTATCCGCTC ACAATTCCAC 900
 ACAACATACG AGCCGGAAGC ATAAAGTGTA AAGCCTGGGG TGCCTAATGA GTGAGCTAAC 960
 TCACATTAAT TCGCTTGCCT TCACTGCCCG CTTTCCAGTC GGGAAACCTG CGCTCTTCCG 1020
 TGACATTAAT AATCGGCCAA CGCGCGGGA GAGGCGGTTT GCGTATTGGG CGCTCTTCCG 1080
 CTTCTCGCT CACTGACTCG CTGCGCTCGG TCGTTTCGGT CGCGCGAGCG GTATCAGCTC 1140
 25 ACTCAAAGGC GGTAAATACGG TTATCCACAG AATCAGGGGA TAACGCAGGA AAGAACATGT 1200
 GAGCAAAAGG CCAGCAAAAG GCCAGGAACC GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC 1260
 ATAGGCTCCG CCCCTCTGAC GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA 1320
 ACCCGACAGG ACTATAAAGA TACCAGGCGT TTCCCTCTGG AAGCTCCCTC GTGCGCTCTC 1380
 CTGTTCCGAC CCGTCCGCTT ACCGGATACC TGTCCGCTT TCTCCCTTCG GGAAGCGTGG 1440
 30 CGCTTTCTCA TAGCTCACG TGATAGTATC TCAGTTCGGT GTAGGTCTGT CGCTCCAAGC 1500
 TGCGCTGTGT GCACGAACCC CCCGTTACAG CCGACCGCTG CGCCTTATCC GGTAACATC 1560
 GTCTTGAGTC CAACCCGGTA AGACACGACT TATCGCCACT GGCAGCAGCG ACTGTAACA 1620
 GGATTAGCAG AGCGAGGTAT GTAGGCGGTG CTACAGAGTT CTTGAAGTGG GTGCCCTAAT 1680
 35 ACGGCTACAC TAGAAGGACA GTATTTGTA TCTGCGCTCT GCTGAAGCCA GTTGCTTCG 1740
 GAAAAAGAGT TGGTACTCTT TGTATCCGCA AACAAACCAC CGCTGGTAGC GGTGGTTTTT 1800
 TTGTTTGCAA GCAGCAGATT ACGCGCAGAA AAAAAAGGATC TCAAGAAAGT CCTTGTATCT 1860
 TTTCTACGGG GTCTGACGCT CAGAAAGACT CGTCAAGAA GCGATAGAAG GCGATCGCT 1920
 GCGAATCGGG AGCGCGGATA CCGTAAAGCA CGAGGAAGCG GTCAGCCCAT TCGCGCCAA 1980
 40 GCTCTTACAG AATATCACGG GTAGCCAACG CTATGTCCTG ATAGCGGTCC GCCACACCCA 2040
 GCCGCGCACA GTCGATGAAT CCAGAAAAGC GGCCATTTTC CACCATGATA TTCGGCAAGC 2100
 AGGCATCGCC ATGCGTCACG ACGAGATCCT CGCCGTCGGG CATGCGCGCG TTGAGCCTGG 2160
 GGAACAGTTC GGCTGGCGCG AGCCCTGTAT GCTCTTCGTC CAGATCATCC TGATCGACAA 2220
 GACCGGCTTC CATCCGAGTA CGTGCTCGCT CGATGCGATG TTTGCTTGG TTGTCGAATG 2280
 45 GGCAGGTAGC CGGATCAAGC GTATGCAGCC GCCGCATTGC ATCAGCCATG ATGGATACTT 2340
 TCTCGGAGG AGCAAGGTGA GATGCAGGA GATCCTGCC CGGCACTTCG CCAATAGCA 2400
 GCCAGTCCCT TCCCGCTTCA GTGACACAGT CGAGCACAGC TGGCGAAGGA ACGCCGCTCG 2460
 TGGCCAGCCA CGATAGCCCG CTGCGCTCGT CCTGCAGTTC ATTGAGGGCA CCGGACAGGT 2520
 CGGTCTTGAC AAAAAGAACC GGGCGGCCCT AGCCGAGTAT AGCCGAATAG CCTCTCCACC CAAGCGCGCC 2580
 50 AGCAGCCGAT TGCTGTGTTG GCCCAGTCAT AGCCGAATAG CGATCCTCAT CCGCTCTCTT 2640
 GAGAACCTGC GTGCAATCCA TCTTGTTCAT TCATGCGAAA CGATCCTCAT CCGCTCTCTT 2700
 GATCAGATCT TGATCCCTCG CGCCATCAGA TCCTTGGCGG CAAGAAAGCC ATCCAGTTTA 2760
 CTTTGCAGGG CTTTCCCAACC TTACCAGAGG GCGAATTGCA GCTTGCATGC CTCGAGGTG 2820
 TTACATAACT TACGGTAAAT GGCCGCGCTG GCTGACCGCC CAACGACCCC CGCCCATTA 2880
 55 GCTCAATAT GACGTATGTT CCCATAGTAA CGCCAATAGG GACTTTCCAT TGACGTCAAT 2940
 GGGTGGAGTA TTTACGGTAA ACTGCCACT TGGCAGTACA TCAAGTGTAT ATGATGCCAA 3000
 GTAGCCCCC TATTGACGCT AATGACGGTA AATGGCCCGC CTGGCATTAT GCCAGTACA 3060
 TGACCTTATG GACTTCTCTT ACATCTACGT ATTAGTTCAT GCTATTACCA 3120
 TGGTGATGCG GTTTTGGCAG TACATCAATG GCGTGGGATA GCGGTTTGAC TCACGGGGAT 3180
 60 TTCCAAGTCT CCACCCCAT GACGTCATG GGAGTTTGT TTGGCACCAA AATCACCGGG 3240
 ACTTCCAAAT ATGTCGTAAC SACTCCGCC CATTGACGCA AATGGGCGGT AGGCGTGTAC 3300
 GGTGGGAGGT CTATATAAGC AGAGTCGCTT TAGTGAACCG TCAGATCGCC TGGAGACGCC 3360
 ATCCAGCTG TTTTGACCTC CATAGAAGAC ACCGGGACCG ATCCAGCCTC CGGACTCTAG 3420
 CTAGAG 3426

<210> 20
 <211> 5966
 <212> nucleic acid
 <400> 20

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60

AGCTTCGAGG GGGGGCCCGG TACCAGCTTT TGTTCCCTTT AGTGAGGGTT AATTTCGAGC 60
 TTGGCGTAAT CATGGTCATA GCTGTTTCCT GTGTGAAATT GTTATCCGCT CACAATTCCA 120
 CACAACATAC GAGCCCGAAG CATAAAGTGT AAAGCCTGGG GTGCCTAATG AGTGAGCTAA 180
 CTCACATTAA TTGCGTTGCG CTCAGTCCCG GCTTTCCAGT CGGGAAACCT GTCGTGCCAG 240
 CTGCATTAAT GAATCGGCCA ACGCGCGGGG AGAGGCGGTT TCGGTATTGG GCGCTCTTTC 300
 GCTTCTCTCG TCACTGACTC GCTGCGCTCG GTCGTTCGGC TCGCGCGAGC GGTATCAGTT 360
 CACTCAAAGG CCGTAATACG GTTATCCACA GAATCAGGGG ATAACGCGAG AAAGAACATG 420
 TGAGCAAAAG GCCAGCAAAA GGCAGGAAC CGTAAAAGG CCGCGTTGCT GGCCTTTTTC 480
 CATAGGCTCC GCCCCCCGTA CGAGCATCAC AAAAAATCGAG GCTCAAGTCA GAGGTGGCGA 540
 AACCCGACAG GACTATAAAG ATACCAGGCG TTCCCCCTG GAAGCTCCCT CGTGCGCTCT 600
 CCTGTTCCGA CCCTGCCGCT TACCGGATAC CTGTCGCCCT TTCTCCCTTC GGGAGCGGTG 660
 GCGCTTCTCT ATAGCTCAGC CTGTAGGTAT CTCAGTTCGG TGTAGTTCGT TCGCTCCAAG 720
 CTGGGCTGTG TGCACGAACC CCCCCTTCAG CCGCAGCGCT GCGCCTTATC CGGTAACAT 780
 CGTCTTGAGT CCAACCCCGT AAGACACGAG TTATCGCCAC TGGCAGCAGC CACTGGTAAC 840
 AGGATTAGCA GAGCGAGGTA TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC 900
 TACGGCTACA CTAGAAGGAC AGTATTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC 960
 GGAAAAAGAG TTGGTAGCTC TTGATCCGGC AAACAACCA CCGCTGGTAG CGGTGGTTTT 1020
 TTTGTTTGCA ACGAGCAGAT TACGCGCAGA AAAAAAGGAT CTCAAGAAGA TCCTTTGATC 1080
 TTTTCTACGG GGTCTGACGC TCAGAAGAAC TCGTCAAGAA GGTCAGCCCA TCGCGCCGA 1140
 TCGCAATCGG GAGCGCGCAT ACCGTAAGC ACGAGGAAGC GGTCAAGCCCA TCGCGCCGA 1200
 AGCTCTTCAG CAATATCAGG GGTAGCCAAAC GCTATGTCTT GATAGCGCTC GCGCACACCC 1260
 AGCCGCGCAC AGTCGATGAA TCCAGAAAG CCGCCATTTT CCACCATGAT ATTCCGGCAG 1320
 CAGGCATCGC CATGCGTCA CAGCAGATCC TCGCCGTCGG GCATGCGCGC CTGAGCCTG 1380
 GCGAACAGTT CCGCTGGCGC GAGCCCTTGA TGCTCTTCGT CCAGATCATC CTGATCGACA 1440
 AGACCGGCTT CCATCCGAGT ACGTGCTCGC TCGATGCGAT GTTTCGCTTG GTGGTTCGAT 1500
 GGGCAGGTAG CCGGATCAAG CGTATGACAG CGCCGATTG CATCAGCCAT GATGATAC 1560
 TTCTCGCAG GAGCAAGGTG AGATGACAGG AGATCCTGCC CCGGCACCTT GCCCAATAGC 1620
 AGCCAGTCCC TTCCCCTCT AGTGACAACG TCGAGCACAG CTGCGCAAGG AACCCCGCTC 1680
 GTGGCAGCC GTGATAGCG CCGTCCCTCG TCCTGCGATT CATTAGGGG CACCGGACAG 1740
 TCGGCTCTGA CAAAAAGAAC CGGGCGCCCC TGCGCTGACA GCGCGAACAC GCGCGCATCA 1800
 GAGCAGCCGA TTGCTGTGTT GCCCAGTCA TAGCCGAATA GCCTCTCCAC CCAAGCGGCC 1860
 GGAGAACCTG CGTGCAATTC ATCTTGTTCA ATCATGCGAA ACGATCTCTA TCCTGTCTCT 1920
 TGATCAGATC TTGATCCCTT GCGCCATCAG ATCCTTGGCG GCAAGAAGC CATCCAGTTT 1980
 ACTTTGCAGG GCTTCCCAAC CTTACCAGAG GCGCCCCCAG CTGGCAATTC CGTTTCGCTT 2040
 GCTGTCCATA AAACCGCCCA GTCTAGCAAC TGTTGGGAAG GCGCGGGCTG CAGGAATTCG 2100
 AGCTTGCAAT CCTGCAAGTG GTTACATAAC TTACGGTAAA TGGCCCCCTT GGCTGACCGC 2160
 CCAACGACCC CCGCCCATTC ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAAATG 2220
 GGACTTTCCA TTGACGTCAA TGGGTGGAGT ATTTACGGTA AACTGCCCAT TTGGCAGTAC 2280
 ATCAAGTGTA TCRATGCCA AGTACGCCCC CTATTGACGT CAATGACGGT AAATGGCCCG 2340
 CTTGGCATT TGGCCAGTAC ATGACCTTAT GGGACTTTCC TACTTGGCAG TACATCTACG 2400
 TATTAGTCT CGCTATTACC ATGGTGATGC GGTTTTGCCA GTACATCAAT GGGCGTGGAT 2460
 AGCGGTTTGA CTCACGGGGA TTTCCAAGTC TCCACCCCAT TGACGTCAAT GGGAGTTTGT 2520
 TTTGGCACCA AAATCAACGG GACTTTCCAA AATGTCGTAA CAACTCCGCG CCATTGACGC 2580
 AAATGGGCGG TAGGCGTGTA CCGTGGGAGG TCTATATAAG CAGAGCTCGT TTAGTGAACC 2640
 GTCAGATCGC CTGGAGACGC CATCCACGCT GTTTTGACCT CATAGAAGA CACCGGGACC 2700
 GATCCAGCCT CCGCGCGCGG GAACGGTGCA TTGGAACCGG GATTCCCGCT GTTAATTAA 2760
 AGGTAAGTGT CTCTCTCTTG TTTCCTTCCC CTGCTATTCT GCTCAACCTT CCTATCAGAA 2820
 ACTGCAGTAT CTGTATTCTT GCTAGAGSTA ATACTAACGG TTCTTTTTTT CTCTTACAG 2880
 GCCACGATGT GTCAATCAGC CTACCTCTCT TTTTGGGCA CCCTTGCCCT CCTAAACCA 2940
 CTCAGTTTGG CCAGGTCAT TCCAGTCTCT GGACCTGCCA GGTGCTTAG CAGTCCCGA 3000
 AACCTGCTGA AGACCACAGA TGCATGGTG AAGACGGCCA GAGAAAACT GAAACATTAT 3060
 TCTGCACTG CTGAAGACAT CGATCATGAA GACATCACAC GGGACCAAC TAGCATTATG 3120
 AAGACCTGTT TACCATCGA ATACACAAG AACGAGAGTT GCCTGGCTAC CAGAGAGACT 3180
 TCTTCCACAA CAAGAGGGAG CTGCTGCCCC CCACAGAAGA CGTCTTTGAT GATGACCTG 3240
 TGCTTGGTA GCATCTATGA GGACTTGAAG ATGTACCAGA CAGAGTTCCA GGCATCAAC 3300
 GCAGCACTTC AGAATCAACA CCATCAGCAG ATCATTCTAG ACAAGGGCAT GCTGGTGGCC 3360
 ATCGATGAGC TGATGCACTT TCTGAATCAT AATGGCGAGA CTCTGCGCCA GAAACCTCCT 3420
 GTGGGAGAAG CAGAGCTTCA ATGAAGCTCT GCATCCTGCT TCACGCTTTC 3480
 AGCACCCGCG TCGTGACCAT CAACAGGGTG ATGGGCTATC TGAGTCCGCT CTTAACTAGT 3540

	GAAAGCTCAA	GGCCCTCTGC	CACAGCGCCC	TCCTCACACA	GATAGGAATT	CTGCAGATCC	3600
	TAGAGCTCGC	TGATCAGCCT	CGACTGTGCC	TTCTAGTTGC	CAGCCATCTG	TTGTTTGCCC	3660
	CTCCCCGCTG	CTTCTCTTGA	CCCTGGAAGG	TGCCACTCCC	ACTGTCCTTT	CCTAATAAAA	3720
5	TGAGGAAATT	GCATCGCATT	GTCTGAGTAG	GTGTCTATTCT	ATTCTGGGGG	GTGGGGTGGG	3780
	GCAGGACAGC	AAGGGGGAGG	ATTGGGAAGA	CAATAGCAGG	CATGCTGGGG	ATGCGGTGGG	3840
	CTCTATGGCT	TCTGAGCGGG	AAAGAACCAG	CTGGGGCTCG	AAATTTCGAGC	TTGCATGCTT	3900
	GCAGGTCGTT	ACATAACTTA	CGGTAAATGG	CCCGCTGGC	TGACCGCCCA	ACGACCCCGG	3960
	CCCATTGAGC	TCAATAATGA	CGTATGTTCC	CATAGTAACG	CCAATAGGGA	CTTTCCATTG	4020
10	ACGTCAATGG	GTGGAGTATT	TAGCGTAAAC	TGCCACTTG	GCAGTACATC	AAGTGATACA	4080
	TATGCCAAGT	ACGCCCCCTA	TTGACGTCAC	TGACGGTAAA	TGGCCCGCCT	GGCATTATGC	4140
	CCAGTACATG	ACCTTATGGG	ACTTTCCTAC	TTGGCAGTAC	ATCTACGTAT	TAGTCATCGC	4200
	TATTACCATG	GTGATGCGGT	TTTGGCAGTA	CATCAATGGG	CGTGGATAGC	GGTTTGACTC	4260
	ACGGGGATT	CCAAGTCTCC	ACCCCATGGA	CGTCAATGGG	AGTTTGTGTT	GGCACCAGAA	4320
15	TCAACGGGAC	TTTCCAAAT	GTCCGTAACA	CTCCGCCCA	TTGACGCAAA	TGGCGCGTAG	4380
	GCGGTGACGG	TGGGAGGTCT	ATATAAGCAG	AGCTCGTTTA	GTGAACCGTC	AGATCGCGCTG	4440
	GAGACGCCAT	CCACGCTGTT	TTGACCTCCA	TAGAAGACAC	CGGGACCGAT	CCAGCCTCCG	4500
	CGCCCGGGAA	CGGTGCATTG	GAACGCGGAT	TCCCGTGTT	AATTAACAGG	TAAGTGCTTT	4560
	CCTCTGTTT	CCTTCCCTTG	CTATTCTGCT	CAACCTTCCT	ATCAGAAACT	CGAGTATCTG	4620
20	TATTTTGTCT	AGCAGTAATA	CTAACGGTTC	TTTTTTTCTC	TTTACAGGCG	ACCATGTGTC	4680
	CTCAGAAGCT	AACCATCTCC	TGGTTTGCCA	TCGTTTGTCT	GGTGTCTCCA	CTCATGGCCA	4740
	TGTGGGAGCT	GGAGAAAGAC	GTTTATGTTG	TAGAGGTGGA	CTGGACTCCC	GATGCCCTCG	4800
	GAGAAACAGT	GAACTTCACC	TGTGACACGC	CTGAAGAAGA	TGACATCACC	TGGACCTCAG	4860
	ACCAGAGACA	TGAGTGCATA	GGCTCTGGAA	AGACCCCTGAC	CATCATCTGC	AAAGAGTTTC	4920
25	TAGATGCTGG	CCAGTACACC	TGCCACAAAG	GAGGCGAGAC	TCTGAGCCAC	TCACATCTGC	4980
	TGCTCCACAA	GAAGGAAAAT	GGAAATTTGT	CCACTGAAAT	TTTAAAAAAT	TTCAAAAAAC	5040
	AGACTTTCTC	GAAGTGTGAA	GCACCAAAAT	ACTCCGGACG	GTTCACGTGC	GACCAAGGGG	5100
	TGCAAGAAAT	CATGGACTTG	AAGTTCAACA	TCAAGAGCAG	TAGCAGTTCC	CCTGACTCTC	5160
	GGGCACTGAC	ATGTGGAATG	CGCTCTCTGT	CTGCAGAGAA	GGTCAACTG	GACCAAGGGG	5220
30	ACTATGAGAA	GTATTCAAGT	TCCCTGCCAG	AGGATGTGAC	CTGCCCAACT	GCCGAGGAGA	5280
	CCCTGCCCAT	TGGAGCTTTC	TGGAAGCAC	GGCAGCAGAA	TAAATATGAG	AACATACAGCA	5340
	CCAGCTTCTT	CATCAGGGAC	ATCATCAAAAC	CAGACCCGCC	CAAGAACTTC	CAGATGAAGC	5400
	CTTTGAAGAA	CTCACAGGTG	GAGGTGACGT	GGGAGTACCC	TGACTCCTGG	AGCACTCCCC	5460
35	ATTCCTACTT	CTCCCTCAAG	TCTTTGTTTC	GAATCCAGCG	CAAGAAAGAA	AAGATGAAGG	5520
	TCCAGAGGAA	GGGGTGTAAAC	CAGAAAGGTG	CGTTCCCTCGT	AGAGAAGACA	TCTACCGAAG	5580
	AGCAATGCAA	AGGGCGGAAAT	GTCTGCGTGC	AAGCTCAGGA	TCGCTATTAC	AATTCCTCAT	5640
	GCAGCAAGTG	GGCATGTGTT	CCCTGCAGGG	TCCGATCCTA	GAGCTCGCTG	ATCAGCCTCG	5700
	ACTGTGCTTT	CTAGTTGCCA	GCCATCTGTT	GTTTGCCCTT	CCCCCGTGCC	TTCTTGACCC	5760
	CTGGAAGGTG	CCACTCCAC	TGTCCTTTCC	TAATAAAATG	AGGAAATTCG	ATCGCATTTG	5820
40	CTGAGTAGGT	GTCATTCTAT	TCTGGGGGAT	GGGGTGGGGC	AGGACAGCAA	GGGGGAGGAT	5880
	TGGGAAGACA	ATAGCAGGCA	TGCTGGGGAT	GCGGTGGGCT	CTATGGCTTC	TGAGGCGGAA	5940
	AGAACCAGCT	GGGGCTCGAG	CATGCA				5960

<210> 21

<211> 3589

45 <212> nucleic acid

<400> 21

	CGTTACATAA	CTTACGGTAA	ATGGCCCGCC	TGGCTGACCG	CCCAACGACC	CCCGCCCAT	60
	GACGTCAATA	ATGACGTATG	TTCCCATAGT	AACGCCAATA	GGGACTTTCC	ATTGACGTCA	120
50	ATGGGTGGAG	TATTTACGGT	AAACTGCCCA	CTTGGCAGTA	CATCAAGTGT	ATCATATGCC	180
	AAGTACGCC	CCTATTGACG	TCAATGACGG	TAAATGGCCC	GCCTGGCATT	ATGCCACGTA	240
	CATGACCTTA	TGGGACTTTT	CTACTTGGCA	GTACATCTAC	GTATTAGTCA	TCGCTATTAC	300
	CATGTTGATG	CGGTTTTGGC	AGTACATCAA	TGGGCGTGGA	TAGCGGTTTG	ACTCACGGGG	360
55	ATTTCGAAGT	CTCCACCCCA	TTGAGTCAA	TGGGAGTTTG	TTTGGCACC	AAAATCAACG	420
	GGACTTTCCA	AAATGTCGTA	ACAACTCCGC	CCCATTTGACG	CAAATGGGCG	GATGGCGTGT	480
	ACGGTGGGAG	GTCTATATAA	CCAGAGCTCG	TTTAGTGAAC	CGTCAGATCG	CCTGGAGAGC	540
	CCATCCAGCG	TGTTTTGACC	TCCATAGAAG	ACACCGGGAC	CGATCCAGCC	TCCGCGCGCG	600
	GGAACGGTGC	ATTGGAACGC	GGATTCCCGG	TGTTAATTAA	CAGGTAAGTG	TCTTCTCTCT	660
60	GTTTCTTCC	CCTGCTATTG	TGCTCAACCT	TCCTATCAGA	AACTGCAGTA	TCTGTATTTT	720
	TGCTAGCAGT	AATACTAACG	GTTCTTTTTT	TCTCTTCACA	GGCCACCATG	GCCTTGACCT	780
	TGCTTTTACT	GGTGGCCCTC	CTGGTGCTCA	GCTGCAAGTC	AAGCTGCTCT	GTGGGCTGTG	840
	ATCTGCCTCA	AACCCACAGC	CTGGGTAGCA	GGAGGACCTT	GATGCTCCTG	GCACAGATGA	900
	GGAGAATCTC	TCTTTTCTCC	TGCTTGAAGG	ACAGACATGA	CTTTGGATT	CCCCAGGAGG	960
	AGTTTGGCAA	CCAGTTCCAA	AAGGCTGAAA	CCATCCCTGT	CCTCCATGAG	ATGATCCAGC	1020

	AGATCTTCAA	TCTCTTCAGC	ACAAAGGACT	CATCTGCTGC	TTGGGATGAG	ACCCTCCTAG	1080
	ACAAATTTCTA	CACGTGAACTC	TACCAGCAGC	TGAATGACCT	GGAAGCCTGT	GTGATACAGG	1140
	GGGTGGGGGT	GACAGAGACT	CCCCTGATGA	AGGAGGACTC	CATTCTGGCT	GTGAGGAAAT	1200
	ACTTCCAAAG	AATCACTCTC	TATCTGAAAG	AGAAGAAATA	CAGCCCTTGT	GCCTGGGAGG	1260
5	TTGTGAGAGC	AGAAATCATG	AGATCTTTTT	CTTTGTCAAC	AAACTTGCAA	GAAAGTTTAA	1320
	GAAGTAAGGA	ATGAATCTAG	AAAAGCCGAA	TTCTGCAGGA	ATTGGGTGGC	ATCCCTGTGA	1380
	CCCCTCCCCA	GTGCCCTCTC	TGGCCCTGGA	AGTTGCCACT	CCAGTGCCCA	CCAGCCTTGT	1440
	CCTAATAAAA	TTAAGTTGCA	TCATTTTGTG	TGACTAGGTG	TCCTTCTATA	ATATTATGGG	1500
	GTGGAGGGGG	GTGGTATGGA	GCAAGGGGCA	AGTTGGGAAG	ACAACCTGTA	GGGCTCGAGG	1560
10	GGGGGGCCGG	TACCAGCTTT	TGTTCCCTTT	AGTGAGGGTT	AATTTTCGAGC	TTGGCGTAAT	1620
	CATGGTCATA	GCTGTTTCTC	GTGTGAAATT	GTTATCCGCT	CACAATTCCA	CACAACATAC	1680
	GAGCCGGAAG	CATAAAGTGT	AAAGCCTGGG	GTGCCTAATG	AGTGAGCTAA	CTCACATTAA	1740
	TTGCGTTGCG	CTCACTGCCC	GCTTTCAGT	CGGGAACCTT	GTGCTGCCAG	CTGCATTAA	1800
	GAATCGGCCA	ACGCGCGGGG	AGAGGCGGTT	TGCGTATTGG	GCGCTCTTCC	GCTTCTCGC	1860
15	TCACTGACTC	GCTGCGCTCG	GTGCTTCGGC	TGCGGCGAGC	GGTATCAGCT	CACCTAAAGG	1920
	CGGTAATACG	GTTATCCACA	GAATCAGGGG	ATAACGCAGG	AAAGAACATC	TGAGCAAAAG	1980
	GCCAGCAAAA	GGCCAGGAAC	CGTAAAAAGG	CCGCGTTGCT	GGCGTTTTTC	CATAGGCTCC	2040
	GCCCCCTGA	CGAGCATCAC	AAAAATCGAC	GCTCAAGTCA	GAGGTGGCGA	AACCCGACAG	2100
	GACTATAAAG	ATACCAAGCG	TTTCCCCCTG	GAAAGCTCCCT	CGTGCCTCT	CCTGTTCCGA	2160
20	CCCTGCCGCT	TACCGGATAC	CTGTCCGCTT	TCTCCCTTC	GGGAAGCGTG	GCGCTTTCTC	2220
	ATAGCTCAGC	CTGTAGGTAT	CTCAGTTCCG	TGTAGTTCGT	TGCTCCAAAG	CTGGGCTGTG	2280
	TGCACGAACC	CCCCGTTTCA	CCCGACCGCT	GCGCCTTATC	CGGTAACAT	CGTCTTGAGT	2340
	CCAAACCGGT	AAGACACGAC	TTATCGCCAC	TGGCAGCAGC	CACCTGGTAA	AGGATTAGCA	2400
	GAGCGAGGTA	TGTAGGCGGT	GCTACAGAGT	TCTTGAAGTG	GTGGCCTAAC	TACGGCTACA	2460
25	CTAGAAGGAC	AGTATTGTGT	ATCTGCGCTC	TGCTGAAGCC	AGTTACCTTC	GGAAAAGAG	2520
	TTGTGATGTC	TTGATCCGGC	AAACAAACCA	CCGCTGGTAG	CGGTGGTTTT	TTTGTGTGCA	2580
	AGCAGCAGAT	TACGCGCAGA	AAAAAAGGAT	CTCAAGAAGA	TCCTTTGATC	TTTTCTACGG	2640
	GGCTGACGC	TCAGAAGAAC	TCGTCAAGAA	GGCGATAGAA	GGCGATCGCG	TGCGAATCGG	2700
	GAGCGGCGAT	ACCGTAAAGC	ACGAGGAAGC	GGTCAGCCCA	TTCGCCGCCA	AGCTCTTCAG	2760
30	CAATATCACG	GGTAGCCAAC	GCTATGTCCT	GATAGCGGTC	CGCCACACCC	AGCCGGCCAC	2820
	ATGCGATGAA	TCCAGAAAAA	CGGCCATTTT	CCACCATGAT	ATTGCGCAAG	CAGCGATCGC	2880
	CATCGCTCAC	GACGAGATCC	TGCGCGTCGG	GCAATGCGCG	CTTGAGCCTG	GCGAACAGTT	2940
	CGGCTGGGCG	GAGCCCCTGA	TGCTCTTCGT	CCAGATCATC	CTGATCGACA	AGACCGGCTT	3000
35	CCATCCGAGT	ACGTGCTCGC	TCGATGCGAT	GTTTTCGCTT	GTGGTTCGAT	GGGCGAGTAG	3060
	CCGGATCAAG	CTGATGTCAGC	CGCCGCATTG	CATCAGCCAT	GATGGATACT	TTCTCGGCAG	3120
	GAGCAAGGTG	AGATGACAGG	AGATCTCTGC	CCGGCACTTC	GCCCAATAGC	AGCCAGTCCC	3180
	TTCCCGCTTC	AGTGACAACG	TCGAGCACAG	CTGCGCAAGG	AACGCCCGTC	GTGGCCAGCC	3240
	ACGATAGCCG	CGCTGCCTCG	TCCTGCAGTT	CATTCAAGGG	ACCGGACAGG	TCGGTCTTGA	3300
	CAAAAAGAAC	CGGGCGCCCC	TGCGCTGACA	GCCGGAACAC	GGCGGCATCA	GAGCAGCCGA	3360
40	TTGTCTGTTG	TGCCCAGTCA	TAGCCGAATA	GCCTCTCCAC	CCAAGCGGCC	GGAGAACCTG	3420
	CGTGCAATCC	ATCTTGTTC	ATCATGCGAA	ACGATCTCA	TCCTGTCTCT	TGATCAGATC	3480
	TTGATCCCCC	GCGCCATCAG	ATCTTGGCG	GCAAGAAAGC	CATCCAGTTT	ACTTTGAGG	3540
	GCTTCCCAAC	CTTACCAGAG	GGCGAATTCT	AGCTTGCATG	CCTGCAGGT		3589
45	<210>	22					
	<211>	567					
	<212>	nucleic acid					
	<400>	22					
50	ATGGCCTTGA	CCTTTGCTTT	ACTGGTGGCC	CTCCTGGTGC	TCAGCTGCAA	GTCAAGCTGC	60
	TCGTGTTGGT	GTGATCTGCC	TCAAACCCAC	AGCCTGGGTA	GCAGGAGGAC	CTTGATGCTC	120
	CTGGCACAGA	TGAGGAGAAT	CTCTCTTTTC	TCCTGCTTGA	AGGACAGACA	TGACTTTGGA	180
	TTTCCCCAGG	AGGAGTTTGG	CAACCAAGTT	CAAAAGGCTG	AAACCATCCC	TGTCCTCCAT	240
	GAGATGATCC	AGCAGATCTT	CAATCTCTTC	AGCACAAAGG	ACTCATCTGC	TGCTTGGGAT	300
55	GAGACCTTCC	TAGACAAATT	CTACACTGAA	CTCTACCAGC	AGCTGAATGA	CCTGGAAGCC	360
	TGTGTGATAC	AGGGGGTGGG	GGTGACAGAG	ACTCCCTGTA	TGAAGGAGGA	CTGATTCTG	420
	GCTGTGAGGA	AATACTTCCA	AAGAACTACT	CTCTATCTGA	AAGAGAGAA	ATACAGCCCT	480
	TGTGCTTGGG	AGGTTGTCTAG	AGCAGAAATC	ATGAGATCTT	TTTCTTTGTC	AACAAACTTG	540
60	CAAGAAAGTT	TAAGAAGTAA	GGAATGA				567

<210> 23
 <211> 16
 <212> nucleic acid
 <223> "Y" stands for C or T; "N" stands for any base.
 5 <400> 23

YYYYYYYYYY YNYAGG

16

<210> 24
 10 <211> 660
 <212> nucleic acid
 <223> "y" stands for C or T; "R" stands for A or G;
 "W" stands for T or A; "S" stands for C or G; "N"
 stands for any base.

15 <400> 24

ATGTGYCCNG CNMGNWSNYT NYTNYTNGTN GCNACNYTNG TNYTNYTNGA YCAYYTNSWN 60
 YTNCGNMGNA AYYTNCNGT NGCNACNCCN GAYCCNGGNA TGTTYCCNTG YYTNCAYCAY 120
 20 WSNCARAAYY TNYTNMGNGC NGTNWSNAAAY ATGYTNCARA ARGCNMGNCA RACNYTNGAR 180
 TTYTAYCCNT GYACNWSNGA RGARATHGAY CAYGARGAYA THACNAARGA YAARACNWSN 240
 ACNGTNGARG CNTGYTNC NNTNGARYTN ACNAARAAYG ARWSNTGYT NAAYWSNMGN 300
 GARACNWSNT TYATHACNAA YGGNWSNTGY YTNCGNWSNM GNAARACNWS NTTYATGATG 360
 GCNYTNTGY TNSNWSNAT HTAYGARGAY YTNAAATGT AYCARGTNGA RTTYAARACN 420
 25 ATGAAYGCNA ARYNYTNAT GGAYCCNAAR MGNCARATH TTYTNGAYCA RAAATGYTN 480
 GCNGTNATHG AYGARYTNAT GCARGCNYTN AAYTTYAAW SNGARACNGT NCCNCARAAR 540
 WSNWSNYTNG ARGARCCNGA YTTYTAYAAR ACNAARATHA ARYTNTGYAT HYTNYTNCAY 600
 GCNTTYMGNA THMGNGCNGT NACNATHGAY MGNGTNACNW SNTAYYTNA YGCNWSNTRR 660

30 <210> 25

<211> 987

<212> nucleic acid

<223> "Y" stands for C or T; "R" stands for A or G; "W"
 stands for T or A; "S" stands for C or G; "N"
 stands for any base.

35 <400> 25

ATGTGYCAYC ARCARYTNGT NATHWSNTGG TTYWSNYTNG TNTTYTNGC NWSNCCNYTN 60
 GTNGCNATHT GGGARYTNAA RAARGAYTN TAYGTNGTNG ARYTNGAYTG GTAYCCNGAY 120
 40 GCNCCNGGNG ARATGGTNGT NYTNACNTGY GAYACNCCNG ARGARGAYGG NATHACNTGG 180
 ACNYTNGAYC ARWSNWSNGA RGTYNTNGGN WSNGGNAARA CNYTNACNAT HCARGTNAAR 240
 GARTTYGGNG AYGCCNGGNA RTAYACNTGY CAYAARGGGNG GNGARGTNYT NWSNCAIYWSN 300
 YTYNYTYNY TNCAYAAARA RGARGAYGGN ATHTGGWSNA CNGAYATHYT NAARGAYCAR 360
 45 AARGARCCNA ARAAYAAAR NTTYTNMGN TGYGARGCNA ARAAYTAYWS NGGNMGNTTY 420
 ACNTGYTGGT GGYTNACNAC NATHWSNACN GAYYTACNT TYWSNGTNAA RWSNWSNMGN 480
 AGNWSNWSNG AYCCNARGG NGTNACNTGY GGNGCNGCNA CNYTNWSNGC NGARMNGNTN 540
 MGNGGNGAYA AYAARGARTA YGARTAYWSN GTNGARTGYC ARGARGAYWS NGCNTGYCCN 600
 CGNGCNGARG ARWSNYTNC NATHGARGTN ATGGTNGAYG CNGTNCAYAA RYTNAAARTAY 660
 50 GARAAYTAYA CNWSNWSNTT YTTYATHMGN GAYATHATHA ARCCNGAYCC NCCNAARAAY 720
 YTNCARYTNA ARCCNYTNA RAAWWSNMGN CARGTNGARG TNWSNTGGGA RTAYCCNGAY 780
 ACNTGGWSNA CNCCNCAYWS NTAYTTYWSN YTNACNTTYT GYGTNCARGT NCARGGNAAR 840

WSNAARMGNG	AAAAAARGA	YMGNTNTTY	ACNGAYAARA	CNWSNGCNAC	NGTNATHGTG	900
MGNAARAAYG	CNWSNATHWS	NGTNMGNGCN	CARGAYMGNT	AYTAYWSNWS	NWSNTGGWSN	960
GARTGGGCNW	SNGTNCCNTG	YWSNTRR				987

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/05394

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/21 C07K14/56 C12N15/88 C12N15/24 C07K14/54
 C12N15/85 A61K48/00 C12N5/10 //A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and where practical search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 96 17063 A (VICAL INC) 6 June 1996 (1996-06-06)</p> <p>the whole document especially page 46, line 1 - line 37; claims; figure 1</p> <p style="text-align: center;">--- -/--</p>	<p>1-10, 22-30, 33-36, 42-45, 49-66,68</p>

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *S* document member of the same patent family

Date of the actual completion of the international search

12 October 1999

Date of mailing of the international search report

21/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel: (+31-70) 340-2040, Tx: 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Le Cornec, N

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/05394

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
Y	BELLDEGRUN A ET AL: "HUMAN RENAL CARCINOMA LINE TRANSFECTED WITH INTERLEUKIN-2 AND/OR INTERFERON ALPHA GENE(S): IMPLICATIONS FOR LIVE CANCER VACCINES" JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 85, no. 3, 3 February 1993 (1993-02-03), pages 207-216, XP002057839 ISSN: 0027-8874 cited in the application the whole document	1-10, 22-30, 33-36, 42-45, 49-66,68
Y	--- RUSSELL J. MUMPER ET AL: "Polyvinyl derivatives as novel interactive polymers for controlled Gene delivery to muscle" PHARMACEUTICAL RESEARCH, vol. 13, no. 5, May 1996 (1996-05), pages 701-709, XP002118167 the whole document	1-10, 22-30, 33-36, 42-45, 49-66,68
Y	--- H. ALILA ET AL: "Expression of biologically active human Insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats" HUMAN GENE THERAPY, vol. 8, no. 15, 10 October 1997 (1997-10-10), pages 1785-1795, XP002118452 cited in the application the whole document	1-10, 22-30, 33-36, 42-45, 49-66,68
Y	--- WO 97 33998 A (CHIOU HENRY C ;CARLO DENNIS J (US); IMMUNE RESPONSE CORP INC (US)) 18 September 1997 (1997-09-18) page 16, line 30 - line 35; example 1	1-10, 22-30, 42-45, 49-66,68
Y	--- R.J. MUMPER ET AL: "protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle" JOURNAL OF CONTROLLED RELEASE, vol. 52, 2 March 1998 (1998-03-02), pages 191-203, XP004113667 the whole document	1-10, 22-30, 33-36, 42-45, 49-66,68
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/05394

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FERRANTINI M ET AL: "ALPHA1-INTERFERON GENE TRANSFER INTO METASTATIC FRIEND LEUKEMIA CELLS ABROGATED TUMORIGENICITY IN IMMUNOCOMPETENT MICE: ANTITUMOR THERAPY BY MEANS OF INTERFERON-PRODUCING CELLS" CANCER RESEARCH, vol. 53, 1 March 1993 (1993-03-01), pages 1107-1112, XP002015124 ISSN: 0008-5472 cited in the application the whole document ---	1-10, 22-30, 33-36, 42-45, 49-66,68
Y	WO 97 00085 A (UNIV MEDICINE & DENTISTRY OF N) 3 January 1997 (1997-01-03) cited in the application page 41 -page 52; claims; example 2 ---	1-10, 22-30, 33-36, 42-45, 49-66,68
Y	WO 96 21470 A (ROLLAND ALAIN ; GENEMEDICINE INC (US); MUMPER RUSSELL J (US)) 18 July 1996 (1996-07-18) cited in the application page 14 -page 15, line 10; claims; examples 1,4 ---	1-10, 22-30, 33-36, 42-45, 49-66,68
A	WO 97 00321 A (WOOD PAUL ; SEOW HENG FONG (AU); COMMW SCIENT IND RES ORG (AU)) 3 January 1997 (1997-01-03) page 31, line 11 -page 32, line 7; claims ---	11-21
A	M. FERRANTINI ET AL: "IFN-alpha1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity" JOURNAL OF IMMUNOLOGY, vol. 153, 1994, pages 4604-4615, XP002118168 the whole document ---	1-69
A	GAO X ET AL: "CATIONIC LIPOSOME-MEDIATED GENE TRANSFER" GENE THERAPY, vol. 2, no. 10, 1 December 1995 (1995-12-01), pages 710-722, XP000749400 ISSN: 0969-7128 ---	

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/05394

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	M. COLEMAN ET AL: "Nonviral Interferon alpha Gene therapy inhibits growth of established tumors by eliciting a systemic immune response" HUMAN GENE THERAPY, vol. 9, 10 October 1998 (1998-10-10), pages 2223-2230, XP002118169 the whole document	1-8, 22-30, 43-45, 50-65
P,A	---	40, 42, 46, 47, 49, 66-69
P,X	WO 98 34952 A (GENEMEDICINE INC) 13 August 1998 (1998-08-13) The whole document especially page 11, line 8 - line 33; claims; figure 2 page 47, line 1 -page 49, line 23 ---	1-8, 22-40, 42-46, 49-65, 68, 69
P,X	WO 98 17689 A (DESHPANDE DEEPA ;FREIMARK BRUCE (US); NORDSTROM JEFF (US); GENEMED) 30 April 1998 (1998-04-30) cited in the application	1-8, 30-39, 42, 43, 46, 49-62, 65, 68, 69
P,A	the whole document	11-21, 40, 41, 44, 45, 47, 48, 63, 66, 67
T	SK MENDIRATTA ET AL: "Intratumoral delivery of iL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity" GENE THERAPY, vol. 6, no. 5, May 1999 (1999-05), pages 83-839, XP002118170 -----	

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/ 05394

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 50-55, 59-61, 63-69
are directed to a method of treatment of the human/animal
body, (rule 39.1 (IV) PCT, the search has been carried out and
based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PC./US 99/05394

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9617063 A	06-06-1996	US 5641665 A EP 0795015 A JP 10509877 T	24-06-1997 17-09-1997 29-09-1998
WO 9733998 A	18-09-1997	AU 2322397 A CA 2248538 A EP 0904373 A	01-10-1997 18-09-1997 31-03-1999
WO 9700085 A	03-01-1997	AU 6282896 A EP 0835130 A	15-01-1997 15-04-1998
WO 9621470 A	18-07-1996	AU 703419 B AU 4611096 A CA 2210132 A EP 0794798 A JP 11502507 T	25-03-1999 31-07-1996 18-07-1996 17-09-1997 02-03-1999
WO 9700321 A	03-01-1997	AU 5991796 A	15-01-1997
WO 9834952 A	13-08-1998	AU 6269298 A	26-08-1998
WO 9817689 A	30-04-1998	AU 5146898 A	15-05-1998